Gene "Gene synonym" Ensembl "Gene description" Uniprot Chromosome Position "Protein class" "Biological process" "Molecular function" "Disease involvement" Evidence "HPA evidence" "UniProt evidence" "NeXtProt evidence" "MS evidence" "RNA tissue specificity" "RNA tissue distribution" "RNA tissue specificity score" "RNA tissue specific NX" "RNA cell line specificity" "RNA cell line distribution" "RNA cell line specificity score" "RNA cell line specific NX" "RNA cancer specificity" "RNA cancer distribution" "RNA cancer specificity score" "RNA cancer specific FPKM" "RNA brain regional specificity" "RNA brain regional distribution" "RNA brain regional specificity score" "RNA brain regional specific NX" "RNA blood cell specificity" "RNA blood cell distribution" "RNA blood cell specificity score" "RNA blood cell specific NX" "RNA blood lineage specificity" "RNA blood lineage distribution" "RNA blood lineage specificity score" "RNA blood lineage specific NX" "RNA mouse brain regional specificity" "RNA mouse brain regional distribution" "RNA mouse brain regional specificity score" "RNA mouse brain regional specific pTPM" "RNA pig brain regional specificity" "RNA pig brain regional distribution" "RNA pig brain regional specificity score" "RNA pig brain regional specific pTPM" Antibody "Reliability (IH)" "Reliability (Mouse Brain)" "Reliability (IF)" "Subcellular location" "Secretome location" "Blood concentration - Conc. blood IM [pg/L]" "Blood concentration - Conc. blood MS [pg/L]" "Subcellular main location" "Subcellular additional location" "Antibody RRID" "Pathology prognostics - Breast cancer" "Pathology prognostics - Cervical cancer" "Pathology prognostics - Colorectal cancer" "Pathology prognostics - Endometrial cancer" "Pathology prognostics - Glioma" "Pathology prognostics - Head and neck cancer" "Pathology prognostics - Liver cancer" "Pathology prognostics - Lung cancer" "Pathology prognostics - Melanoma" "Pathology prognostics - Ovarian cancer" "Pathology prognostics - Pancreatic cancer" "Pathology prognostics - Prostate cancer" "Pathology prognostics - Renal cancer" "Pathology prognostics - Stomach cancer" "Pathology prognostics - Testis cancer" "Pathology prognostics - Thyroid cancer" "Pathology prognostics - Urothelial cancer" "Tissue RNA - adipose tissue [NX]" "Tissue RNA - adrenal gland [NX]" "Tissue RNA - amygdala [NX]" "Tissue RNA - appendix [NX]" "Tissue RNA - basal ganglia [NX]" "Tissue RNA - bone marrow [NX]" "Tissue RNA - breast [NX]" "Tissue RNA - cerebellum [NX]" "Tissue RNA - cerebral cortex [NX]" "Tissue RNA - cervix, uterine [NX]" "Tissue RNA - colon [NX]" "Tissue RNA - corpus callosum [NX]" "Tissue RNA - ductus deferens [NX]" "Tissue RNA - duodenum [NX]" "Tissue RNA - endometrium 1 [NX]" "Tissue RNA - epididymis [NX]" "Tissue RNA - esophagus [NX]" "Tissue RNA - fallopian tube [NX]" "Tissue RNA - gallbladder [NX]" "Tissue RNA - heart muscle [NX]" "Tissue RNA - hippocampal formation [NX]" "Tissue RNA - hypothalamus [NX]" "Tissue RNA - kidney [NX]" "Tissue RNA - liver [NX]" "Tissue RNA - lung [NX]" "Tissue RNA - lymph node [NX]" "Tissue RNA - midbrain [NX]" "Tissue RNA - olfactory region [NX]" "Tissue RNA - ovary [NX]" "Tissue RNA - pancreas [NX]" "Tissue RNA - parathyroid gland [NX]" "Tissue RNA - pituitary gland [NX]" "Tissue RNA - placenta [NX]" "Tissue RNA - pons and medulla [NX]" "Tissue RNA - prostate [NX]" "Tissue RNA - rectum [NX]" "Tissue RNA - retina [NX]" "Tissue RNA - salivary gland [NX]" "Tissue RNA - seminal vesicle [NX]" "Tissue RNA - skeletal muscle [NX]" "Tissue RNA - skin 1 [NX]" "Tissue RNA - small intestine [NX]" "Tissue RNA - smooth muscle [NX]" "Tissue RNA - spinal cord [NX]" "Tissue RNA - spleen [NX]" "Tissue RNA - stomach 1 [NX]" "Tissue RNA - testis [NX]" "Tissue RNA - thalamus [NX]" "Tissue RNA - thymus [NX]" "Tissue RNA - thyroid gland [NX]" "Tissue RNA - tongue [NX]" "Tissue RNA - tonsil [NX]" "Tissue RNA - urinary bladder [NX]" "Tissue RNA - vagina [NX]" "Tissue RNA - B-cells [NX]" "Tissue RNA - dendritic cells [NX]" "Tissue RNA - granulocytes [NX]" "Tissue RNA - monocytes [NX]" "Tissue RNA - NK-cells [NX]" "Tissue RNA - T-cells [NX]" "Tissue RNA - total PBMC [NX]" "Cell RNA - A-431 [NX]" "Cell RNA - A549 [NX]" "Cell RNA - AF22 [NX]" "Cell RNA - AN3-CA [NX]" "Cell RNA - ASC diff [NX]" "Cell RNA - ASC TERT1 [NX]" "Cell RNA - BEWO [NX]" "Cell RNA - BJ [NX]" "Cell RNA - BJ hTERT+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [NX]" "Cell RNA - CACO-2 [NX]" "Cell RNA - CAPAN-2 [NX]" "Cell RNA - Daudi [NX]" "Cell RNA - EFO-21 [NX]" "Cell RNA - fHDF/TERT166 [NX]" "Cell RNA - HaCaT [NX]" "Cell RNA - HAP1 [NX]" "Cell RNA - HBEC3-KT [NX]" "Cell RNA - HBF TERT88 [NX]" "Cell RNA - HDLM-2 [NX]" "Cell RNA - HEK 293 [NX]" "Cell RNA - HEL [NX]" "Cell RNA - HeLa [NX]" "Cell RNA - Hep G2 [NX]" "Cell RNA - HHSteC [NX]" "Cell RNA - HL-60 [NX]" "Cell RNA - HMC-1 [NX]" "Cell RNA - HSkMC [NX]" "Cell RNA - hTCEpi [NX]" "Cell RNA - hTEC/SVTERT24-B [NX]" "Cell RNA - hTERT-HME1 [NX]" "Cell RNA - HUVEC TERT2 [NX]" "Cell RNA - K-562 [NX]" "Cell RNA - Karpas-707 [NX]" "Cell RNA - LHCN-M2 [NX]" "Cell RNA - MCF7 [NX]" "Cell RNA - MOLT-4 [NX]" "Cell RNA - NB-4 [NX]" "Cell RNA - NTERA-2 [NX]" "Cell RNA - PC-3 [NX]" "Cell RNA - REH [NX]" "Cell RNA - RH-30 [NX]" "Cell RNA - RPMI-8226 [NX]" "Cell RNA - RPTEC TERT1 [NX]" "Cell RNA - RT4 [NX]" "Cell RNA - SCLC-21H [NX]" "Cell RNA - SH-SY5Y [NX]" "Cell RNA - SiHa [NX]" "Cell RNA - SK-BR-3 [NX]" "Cell RNA - SK-MEL-30 [NX]" "Cell RNA - T-47d [NX]" "Cell RNA - THP-1 [NX]" "Cell RNA - TIME [NX]" "Cell RNA - U-138 MG [NX]" "Cell RNA - U-2 OS [NX]" "Cell RNA - U-2197 [NX]" "Cell RNA - U-251 MG [NX]" "Cell RNA - U-266/70 [NX]" "Cell RNA - U-266/84 [NX]" "Cell RNA - U-698 [NX]" "Cell RNA - U-87 MG [NX]" "Cell RNA - U-937 [NX]" "Cell RNA - WM-115 [NX]" "Blood RNA - basophil [NX]" "Blood RNA - classical monocyte [NX]" "Blood RNA - eosinophil [NX]" "Blood RNA - gdT-cell [NX]" "Blood RNA - intermediate monocyte [NX]" "Blood RNA - MAIT T-cell [NX]" "Blood RNA - memory B-cell [NX]" "Blood RNA - memory CD4 T-cell [NX]" "Blood RNA - memory CD8 T-cell [NX]" "Blood RNA - myeloid DC [NX]" "Blood RNA - naive B-cell [NX]" "Blood RNA - naive CD4 T-cell [NX]" "Blood RNA - naive CD8 T-cell [NX]" "Blood RNA - neutrophil [NX]" "Blood RNA - NK-cell [NX]" "Blood RNA - non-classical monocyte [NX]" "Blood RNA - plasmacytoid DC [NX]" "Blood RNA - T-reg [NX]" "Blood RNA - total PBMC [NX]" "Brain RNA - amygdala [NX]" "Brain RNA - basal ganglia [NX]" "Brain RNA - cerebellum [NX]" "Brain RNA - cerebral cortex [NX]" "Brain RNA - hippocampal formation [NX]" "Brain RNA - hypothalamus [NX]" "Brain RNA - midbrain [NX]" "Brain RNA - olfactory region [NX]" "Brain RNA - pons and medulla [NX]" "Brain RNA - thalamus [NX]" ABI1 "ABI-1, E3B1, SSH3BP1" ENSG00000136754 "Abl interactor 1" Q8IZP0 10 26746593-26861087 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Host-virus interaction" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008375, HPA029973, HPA068407" Approved Enhanced "Plasma membrane,Cell Junctions,Cytosol" 400000 "Plasma membrane, Cell Junctions" Cytosol "CAB008375: AB_592744, HPA029973: , HPA068407: " "unprognostic (2.83e-3)" "unprognostic (8.69e-2)" "unprognostic (1.12e-1)" "unprognostic (3.96e-1)" "unprognostic (2.51e-2)" "unprognostic (9.24e-3)" "unprognostic (1.88e-3)" "unprognostic (2.03e-1)" "unprognostic (6.04e-2)" "unprognostic (4.38e-1)" "unprognostic (2.40e-2)" "unprognostic (5.48e-2)" "unprognostic (1.98e-1)" "unprognostic (1.07e-1)" "unprognostic (1.79e-1)" "unprognostic (1.37e-1)" "unprognostic (1.18e-1)" 24.0 14.0 32.0 28.1 32.6 54.1 21.4 28.2 35.5 22.5 22.7 19.8 14.8 24.8 23.9 15.4 45.1 20.3 21.6 14.1 47.3 23.1 21.9 17.8 22.5 32.1 25.0 26.4 25.3 17.0 19.1 14.4 22.7 20.9 19.1 24.8 26.7 30.9 17.0 16.6 33.0 26.0 21.6 27.5 25.5 23.9 12.4 20.5 43.5 18.8 27.3 40.9 25.2 30.3 36.1 26.8 51.5 28.0 20.5 44.5 31.5 23.2 13.1 10.7 10.5 16.2 20.0 16.0 23.6 16.1 17.5 20.4 15.3 27.6 42.8 12.1 25.0 26.1 12.9 15.3 19.5 28.5 11.5 18.8 8.9 10.8 11.1 9.1 19.0 13.6 19.5 17.1 10.2 21.1 13.8 27.4 17.8 10.0 21.3 8.7 8.8 6.3 23.1 19.9 27.5 18.6 10.8 8.9 9.5 19.6 19.2 19.7 12.4 14.5 26.2 13.4 16.5 16.9 12.0 6.1 9.8 50.9 19.3 23.3 9.6 35.5 23.8 51.5 27.0 28.0 25.8 36.1 25.9 30.0 26.8 28.6 24.4 26.5 37.9 20.5 26.7 22.3 44.5 31.5 32.0 32.6 28.2 31.9 47.3 23.1 25.0 26.4 20.9 20.5 ABL1 "ABL, c-ABL, JTK7, p150" ENSG00000097007 "ABL proto-oncogene 1, non-receptor tyrosine kinase" P00519 9 130713946-130887675 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Apoptosis, Autophagy, Cell adhesion, DNA damage, DNA repair, Endocytosis" "DNA-binding, Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002686, HPA027251, HPA027280, HPA028409" Supported Enhanced "Nucleoplasm,Nuclear bodies" Nucleoplasm "Nuclear bodies" "CAB002686: , HPA027251: AB_1844453, HPA027280: AB_1844454, HPA028409: AB_10601011" "unprognostic (4.82e-2)" "unprognostic (3.99e-2)" "unprognostic (5.55e-2)" "unprognostic (4.72e-2)" "unprognostic (1.16e-1)" "unprognostic (1.46e-1)" "unprognostic (3.75e-3)" "unprognostic (1.89e-3)" "unprognostic (2.34e-1)" "unprognostic (2.54e-2)" "unprognostic (1.09e-2)" "unprognostic (1.48e-1)" "unprognostic (3.96e-3)" "unprognostic (1.10e-2)" "unprognostic (1.47e-1)" "unprognostic (1.22e-1)" "unprognostic (1.06e-1)" 20.1 11.6 12.4 15.0 18.1 10.7 22.0 6.7 16.0 28.9 34.3 29.1 12.1 11.9 26.6 16.9 21.4 20.8 30.9 14.2 10.3 8.4 9.9 6.7 13.8 8.7 24.1 9.4 24.2 12.2 27.7 14.5 13.6 17.1 27.3 15.8 19.4 14.6 18.0 10.8 14.2 17.0 66.6 14.3 10.8 21.9 9.8 21.2 5.8 19.5 11.4 9.1 35.8 31.9 3.1 3.1 1.1 5.0 2.4 2.6 1.6 7.0 15.7 16.9 20.4 24.8 30.3 6.2 12.4 19.5 14.6 12.4 12.3 9.2 11.6 7.2 16.5 13.7 8.5 11.5 10.8 7.3 5.3 7.6 26.9 10.5 16.9 11.7 10.7 22.1 12.7 26.1 16.2 20.2 42.6 9.3 17.8 13.4 14.8 9.6 18.7 11.6 17.2 21.9 12.6 14.7 8.3 15.8 19.7 20.8 8.1 10.0 15.9 10.8 23.1 56.0 14.5 21.4 19.5 2.8 6.6 15.6 23.1 9.7 17.7 0.2 2.1 1.1 2.0 1.2 2.6 3.1 2.0 1.9 2.0 1.4 1.9 1.7 0.2 2.4 5.0 3.1 0.9 1.6 12.4 18.1 6.7 16.0 10.3 8.4 24.1 9.4 17.1 21.2 ABL2 "ABLL, ARG" ENSG00000143322 "ABL proto-oncogene 2, non-receptor tyrosine kinase" P42684 1 179099327-179229684 "Cancer-related genes, Enzymes, Predicted intracellular proteins, RAS pathway related proteins" "Cell adhesion" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "hTERT-HME1: 31.7;TIME: 29.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001866, CAB017106, HPA072754" Uncertain Supported Nucleoplasm Nucleoplasm "CAB017106: , HPA001866: AB_1078082, HPA072754: " "unprognostic (3.05e-1)" "prognostic unfavourable (3.50e-4)" "unprognostic (1.07e-1)" "unprognostic (4.71e-2)" "unprognostic (9.45e-2)" "unprognostic (8.23e-3)" "unprognostic (1.91e-2)" "unprognostic (4.81e-3)" "unprognostic (1.26e-1)" "unprognostic (6.98e-2)" "unprognostic (1.12e-1)" "unprognostic (3.73e-1)" "prognostic unfavourable (1.78e-7)" "unprognostic (4.76e-2)" "unprognostic (4.14e-2)" "unprognostic (6.08e-2)" "prognostic unfavourable (8.40e-4)" 14.3 5.2 8.6 7.4 13.7 3.7 8.3 14.9 10.6 9.2 6.6 5.8 4.5 4.0 5.4 4.7 3.9 4.3 18.8 6.8 9.7 3.9 4.9 4.3 11.5 3.7 6.5 6.1 5.6 8.4 9.2 8.4 6.1 8.1 5.1 5.2 5.8 4.5 4.4 5.2 6.6 3.7 6.9 6.2 3.9 4.7 9.2 8.6 3.6 5.8 3.1 3.6 6.7 11.2 2.8 2.0 3.8 1.2 1.8 2.2 0.6 10.0 5.5 3.7 2.5 3.2 7.3 2.3 11.1 9.1 13.7 9.9 4.0 3.1 5.8 8.2 7.9 5.0 5.2 3.7 19.4 3.6 4.8 2.8 5.0 2.0 5.8 3.1 0.9 6.7 4.9 19.4 31.7 15.1 6.6 1.7 17.7 2.6 2.4 1.6 3.6 1.8 3.7 6.2 2.8 4.6 1.6 2.3 5.1 9.2 2.9 22.8 2.6 2.6 29.5 14.2 10.6 6.8 17.8 3.1 3.8 6.0 6.7 1.7 13.7 3.8 1.2 0.4 2.2 0.4 1.0 1.8 1.4 1.4 0.9 2.8 1.9 2.0 2.6 1.8 0.5 2.0 0.8 0.6 8.6 13.7 14.9 10.6 9.7 3.9 6.5 6.1 8.1 8.6 ACKR3 "CMKOR1, CXCR7, GPR159, RDC1" ENSG00000144476 "Atypical chemokine receptor 3" P25106 2 236567787-236582358 "Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins" "Cell adhesion, Host-virus interaction" "Developmental protein, G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in some" "HeLa: 22.8;MCF7: 16.8;RT4: 66.7;SiHa: 20.4;U-2197: 70.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 6 "NK-cells: 6.1;T-cells: 6.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA032003, HPA049718" Approved Supported "Vesicles,Plasma membrane" "Vesicles, Plasma membrane" "HPA032003: , HPA049718: " "unprognostic (1.65e-2)" "prognostic unfavourable (4.64e-4)" "unprognostic (2.50e-1)" "unprognostic (1.92e-3)" "unprognostic (2.10e-1)" "unprognostic (1.23e-1)" "unprognostic (7.34e-3)" "unprognostic (1.55e-2)" "unprognostic (1.85e-2)" "unprognostic (1.35e-1)" "unprognostic (9.70e-3)" "unprognostic (6.69e-2)" "prognostic unfavourable (1.76e-6)" "prognostic unfavourable (2.01e-4)" "unprognostic (9.71e-2)" "unprognostic (8.57e-3)" "prognostic unfavourable (2.93e-4)" 56.1 2.9 5.4 6.9 5.6 1.7 28.5 2.2 6.4 10.7 15.2 8.9 9.1 5.7 9.9 20.4 23.6 14.6 15.3 30.2 8.4 3.0 3.8 29.6 10.9 7.2 3.8 6.5 19.3 25.7 2.2 10.7 59.6 8.4 14.2 12.8 25.2 8.9 8.9 36.4 16.0 15.7 32.6 7.2 70.9 12.6 9.4 5.5 0.2 34.3 22.3 8.6 59.2 17.8 1.0 0.2 0.1 0.5 6.1 6.1 0.6 0.0 0.0 1.3 0.0 2.3 0.0 9.8 0.5 0.3 0.4 1.0 0.1 0.0 0.0 1.1 0.0 14.3 0.0 5.1 0.0 0.0 0.0 0.0 22.8 0.0 0.0 0.0 0.0 0.6 13.1 0.0 0.0 2.3 0.2 0.0 0.0 16.8 0.0 0.0 2.3 0.1 0.0 1.6 0.1 0.0 66.7 0.0 0.0 20.4 0.1 0.0 0.0 0.0 0.0 0.1 5.3 70.1 0.0 0.2 0.0 0.0 0.2 1.4 0.1 0.0 0.1 0.0 4.1 0.3 6.1 0.6 2.1 5.0 0.2 1.0 1.8 2.3 0.1 6.1 0.5 0.0 3.1 0.6 5.4 5.6 2.2 6.4 8.4 3.0 3.8 6.5 8.4 5.5 ACSL3 "ACS3, FACL3, PRO2194" ENSG00000123983 "Acyl-CoA synthetase long chain family member 3" O95573 2 222860934-222944639 "Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins" "Fatty acid metabolism, Lipid metabolism" Ligase "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 4 "parathyroid gland: 206.1" "Cell line enhanced" "Detected in all" "SK-MEL-30: 92.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA011315, HPA071021" Approved Approved "Nucleoli,Lipid droplets" Nucleoli "Lipid droplets" "HPA011315: AB_1848344, HPA071021: " "unprognostic (1.87e-1)" "unprognostic (5.64e-2)" "unprognostic (2.36e-1)" "unprognostic (9.35e-3)" "unprognostic (7.53e-2)" "unprognostic (2.07e-2)" "prognostic unfavourable (2.75e-4)" "prognostic unfavourable (8.78e-4)" "unprognostic (3.90e-2)" "unprognostic (2.50e-1)" "unprognostic (2.64e-1)" "unprognostic (4.26e-2)" "unprognostic (1.17e-3)" "unprognostic (1.36e-1)" "unprognostic (2.72e-1)" "unprognostic (2.65e-1)" "unprognostic (1.60e-1)" 14.7 17.0 22.8 9.9 26.0 16.3 51.5 19.4 45.9 15.3 16.5 16.1 11.6 12.7 10.9 18.4 28.3 9.0 11.8 22.7 20.9 22.8 17.9 22.3 15.6 10.5 19.6 21.2 11.7 10.3 206.1 8.8 19.1 24.4 44.4 16.7 14.4 34.2 15.5 19.1 11.4 12.7 12.2 22.2 9.7 28.3 13.7 14.2 13.5 17.3 11.2 8.7 14.6 15.4 15.0 22.5 21.8 16.8 16.6 20.1 16.5 9.9 17.6 27.0 29.3 11.8 29.3 7.5 12.7 33.0 15.2 32.2 15.8 25.7 4.8 7.4 12.1 29.4 5.8 28.3 19.8 8.6 11.1 11.2 14.3 17.7 26.0 7.4 5.5 15.1 40.1 25.2 44.0 16.6 21.2 18.3 21.5 21.2 14.4 8.7 13.7 9.2 7.9 22.9 8.1 21.9 40.9 14.2 10.6 7.5 20.3 92.7 10.2 18.1 11.4 10.2 16.3 8.8 9.3 6.5 3.1 16.5 11.0 6.9 30.9 16.6 14.6 21.8 20.1 16.8 19.3 11.6 12.8 14.6 15.7 15.0 18.7 16.7 21.8 16.6 15.9 22.5 9.5 16.5 22.8 26.0 19.4 45.9 20.9 22.8 19.6 21.2 24.4 14.2 AFDN "AF-6, AF6, MLLT4" ENSG00000130396 "Afadin, adherens junction formation factor" P55196 6 167826922-167972023 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Cell adhesion" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013496, HPA030212, HPA030213, HPA030214, HPA030215, HPA049868" Approved Enhanced "Nucleoplasm,Plasma membrane,Cell Junctions" "Plasma membrane, Cell Junctions" Nucleoplasm "CAB013496: , HPA030212: AB_10599291, HPA030213: AB_10601340, HPA030214: AB_10601005, HPA030215: AB_10601556, HPA049868: " "prognostic unfavourable (7.43e-5)" "unprognostic (2.66e-3)" "unprognostic (2.07e-2)" "unprognostic (2.61e-1)" "unprognostic (1.13e-1)" "unprognostic (9.06e-2)" "unprognostic (4.12e-1)" "unprognostic (3.12e-2)" "unprognostic (4.12e-1)" "unprognostic (1.09e-3)" "unprognostic (1.75e-1)" "unprognostic (1.73e-2)" "unprognostic (5.56e-2)" "unprognostic (5.43e-3)" "unprognostic (1.59e-1)" "unprognostic (4.72e-2)" "unprognostic (5.68e-2)" 17.0 7.4 14.9 13.0 17.2 1.8 23.5 17.8 19.3 19.6 26.3 16.1 25.5 22.2 15.8 17.7 59.5 27.9 18.2 13.9 15.6 7.2 20.6 29.3 26.3 5.1 17.1 12.5 16.2 29.7 16.4 27.4 18.7 16.1 20.9 27.2 15.3 38.6 18.6 12.7 24.8 42.3 17.4 13.0 13.5 21.1 16.3 15.2 2.1 25.7 13.7 24.5 16.3 27.9 3.5 0.6 2.9 0.5 0.0 1.2 0.0 19.4 6.1 42.4 15.1 4.1 3.5 31.6 7.9 4.0 6.8 8.5 25.9 12.1 3.4 14.7 4.7 9.4 17.6 16.2 12.3 21.9 18.2 0.1 2.6 19.6 6.2 2.1 9.3 2.4 10.9 11.5 27.1 12.6 38.9 13.6 4.4 8.3 0.2 0.1 10.4 2.8 12.5 11.1 14.7 12.5 9.5 19.7 12.0 8.0 30.5 12.0 3.6 0.8 18.5 3.2 15.4 13.7 13.0 0.2 16.5 7.1 9.5 4.5 27.8 0.0 0.5 0.0 1.0 0.5 0.6 3.5 1.2 0.4 0.6 2.7 0.0 0.5 2.9 0.0 0.3 0.0 0.6 0.0 14.9 17.2 17.8 19.3 15.6 7.2 17.1 12.5 16.1 15.2 AFF1 "AF-4, AF4, MLLT2, PBM1" ENSG00000172493 "AF4/FMR2 family member 1" P51825 4 86935002-87141054 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 121.7" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA069947 Approved Nucleoplasm,Mitochondria "Nucleoplasm, Mitochondria" "HPA069947: " "unprognostic (1.01e-1)" "unprognostic (7.56e-2)" "unprognostic (2.57e-3)" "unprognostic (1.53e-1)" "unprognostic (1.33e-1)" "unprognostic (1.55e-2)" "unprognostic (1.79e-1)" "unprognostic (6.23e-2)" "unprognostic (6.09e-2)" "unprognostic (7.13e-2)" "unprognostic (1.24e-1)" "unprognostic (8.32e-3)" "unprognostic (5.86e-2)" "unprognostic (1.33e-2)" "unprognostic (4.41e-1)" "unprognostic (2.55e-1)" "unprognostic (2.71e-2)" 33.7 16.6 8.0 11.8 9.5 19.5 26.5 6.5 12.2 20.2 21.0 10.5 18.9 11.1 27.4 16.6 15.8 18.6 15.3 22.4 10.3 5.3 27.6 15.5 18.4 12.9 9.3 5.5 24.7 19.0 28.6 18.5 121.7 9.5 16.8 14.3 27.0 16.0 25.6 58.8 18.6 16.2 20.3 11.5 13.9 15.0 6.7 10.3 17.0 38.8 21.1 13.9 19.5 26.5 11.3 14.6 21.1 5.4 5.1 8.8 2.8 7.8 7.2 6.0 6.3 9.9 11.8 8.5 7.9 11.6 6.0 9.0 7.6 14.5 8.9 10.8 9.6 3.6 9.4 11.9 8.4 15.1 3.7 18.4 18.7 6.3 7.7 17.6 14.6 9.6 8.6 10.3 9.1 22.1 11.3 25.1 2.5 2.1 15.9 5.1 7.9 2.5 12.6 3.5 11.3 17.7 7.5 13.6 2.5 12.0 7.9 3.8 4.7 14.8 11.0 11.2 10.2 6.8 4.3 21.8 12.1 15.3 9.2 20.4 4.0 3.5 5.4 11.7 6.7 4.1 7.4 8.0 8.8 6.6 6.0 11.3 4.7 4.4 21.1 5.1 2.2 14.6 7.5 2.8 8.0 9.5 6.5 12.2 10.3 5.3 9.3 5.5 9.5 10.3 AFF3 "LAF4, MLLT2-like" ENSG00000144218 "AF4/FMR2 family member 3" P51826 2 99545419-100142739 "Cancer-related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 43.6" "Cell line enhanced" "Detected in many" "Daudi: 23.3;T-47d: 11.7;U-698: 34.5" "Cancer enhanced" "Detected in many" "breast cancer: 11.4" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "memory B-cell: 16.2;naive B-cell: 27.5;plasmacytoid DC: 12.8" "Group enriched" "Detected in many" 16 "B-cells: 27.5;dendritic cells: 12.8" "Low region specificity" "Detected in all" "HPA044512, HPA053379" Approved Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA044512: AB_10795984, HPA053379: " "unprognostic (1.05e-2)" "unprognostic (3.01e-2)" "unprognostic (2.30e-1)" "unprognostic (4.88e-3)" "unprognostic (1.02e-1)" "unprognostic (4.98e-5)" "unprognostic (1.11e-3)" "unprognostic (3.04e-2)" "unprognostic (8.75e-2)" "unprognostic (3.07e-1)" "unprognostic (1.95e-3)" "unprognostic (7.57e-2)" "prognostic unfavourable (5.64e-4)" "unprognostic (6.40e-3)" "unprognostic (6.79e-2)" "unprognostic (3.69e-2)" "unprognostic (7.87e-3)" 3.2 2.4 6.0 40.2 6.1 10.3 16.6 20.5 9.9 4.2 4.2 1.8 0.8 1.2 8.9 1.7 4.1 4.1 2.3 4.9 6.3 6.2 1.8 2.4 7.6 23.3 5.4 6.8 7.5 1.1 0.3 5.2 6.9 4.4 18.9 2.3 5.5 6.6 3.3 1.0 1.0 5.9 8.6 6.6 43.6 4.8 6.0 2.5 34.7 1.7 0.7 42.0 7.4 2.7 27.5 12.8 0.2 0.2 0.9 1.2 0.4 0.1 0.0 9.8 3.4 0.0 0.4 0.0 1.3 0.3 2.9 1.0 0.0 0.0 23.3 0.1 1.5 0.1 0.2 0.0 1.7 5.9 2.8 0.0 0.1 0.0 0.2 0.1 6.7 0.6 0.0 6.1 0.1 0.0 0.1 0.0 0.0 0.1 1.9 0.3 1.3 1.6 3.2 0.0 0.1 0.0 0.0 9.7 3.4 0.1 0.1 6.3 11.7 10.7 3.9 9.3 2.5 0.3 1.5 0.2 0.0 34.5 8.7 0.8 0.7 0.2 0.2 0.0 0.0 0.2 0.2 16.2 0.1 0.0 2.9 27.5 1.2 0.0 0.1 0.9 0.2 12.8 0.0 0.4 6.0 6.1 20.5 9.9 6.3 6.2 5.4 6.8 4.4 2.5 AFF4 "AF5Q31, MCEF" ENSG00000072364 "AF4/FMR2 family member 4" Q9UHB7 5 132875379-132963634 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Cancer-related genes, Disease mutation, Dwarfism, Obesity, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA023690, HPA029634" Approved Supported "Nucleoplasm,Nucleoli fibrillar center" "Nucleoplasm, Nucleoli fibrillar center" "HPA023690: AB_1844633, HPA029634: " "unprognostic (3.24e-2)" "unprognostic (1.86e-2)" "unprognostic (6.17e-3)" "unprognostic (1.45e-1)" "unprognostic (1.99e-1)" "unprognostic (1.10e-1)" "unprognostic (2.56e-2)" "unprognostic (7.37e-2)" "unprognostic (1.18e-1)" "unprognostic (6.13e-2)" "unprognostic (4.94e-2)" "unprognostic (3.52e-1)" "unprognostic (1.16e-2)" "unprognostic (2.77e-2)" "unprognostic (3.25e-2)" "prognostic unfavourable (6.44e-4)" "unprognostic (1.69e-1)" 22.9 29.6 22.8 19.1 38.7 38.3 23.6 37.8 25.6 26.2 21.8 25.2 22.1 14.6 27.6 19.5 29.8 20.8 26.8 21.3 18.7 18.7 25.7 24.2 24.8 19.6 19.0 19.7 34.0 24.9 48.8 40.1 20.4 18.3 26.7 18.5 27.5 25.2 25.1 32.1 22.2 17.8 24.4 18.8 17.3 24.8 17.6 24.4 26.6 33.9 15.7 19.2 26.3 24.7 8.7 5.2 12.2 4.9 3.8 5.5 1.5 16.8 13.6 18.8 20.8 14.5 17.5 14.7 18.3 19.7 16.9 21.6 20.1 11.1 8.6 21.8 23.9 8.5 15.1 22.6 28.3 6.1 9.7 10.6 18.6 7.1 18.6 3.7 11.1 20.5 15.1 29.2 29.8 16.1 7.6 7.3 21.0 6.4 10.2 4.0 7.2 5.6 6.9 18.3 3.2 14.7 23.8 14.7 15.5 20.8 5.1 20.7 10.8 6.0 22.7 20.3 17.3 17.8 19.4 10.1 17.2 7.8 19.1 6.9 13.8 12.2 2.4 3.8 5.5 2.0 4.1 7.7 5.1 3.7 2.9 8.7 5.3 4.6 5.2 3.8 4.9 5.2 2.5 1.5 22.8 38.7 37.8 25.6 18.7 18.7 19.0 19.7 18.3 24.4 AL035425.2 ENSG00000260548 X 108722070-108732687 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in some" "ovary: 13.0;pituitary gland: 7.4;thyroid gland: 8.9" "Cell line enhanced" "Detected in some" "HEK 293: 18.6;NTERA-2: 2.6;RT4: 4.8;WM-115: 4.9" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.6 2.9 0.0 0.0 3.9 0.9 0.0 0.5 0.0 0.0 0.1 5.1 0.0 0.0 0.0 0.0 0.5 13.0 0.9 0.0 7.4 0.0 0.1 0.0 0.0 0.7 0.0 1.1 0.0 1.5 0.1 0.0 0.4 0.0 8.9 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 18.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 0.0 0.0 0.0 0.0 0.0 4.8 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 4.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 ALK CD246 ENSG00000171094 "ALK receptor tyrosine kinase" Q9UM73 2 29192774-29921566 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 8.1;pituitary gland: 17.9" "Cell line enriched" "Detected in some" 6 "SH-SY5Y: 26.4" "Group enriched" "Detected in some" 5 "glioma: 1.0;melanoma: 1.5;ovarian cancer: 0.7;thyroid cancer: 1.3" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA010694 Approved Supported "Plasma membrane" "Plasma membrane" "HPA010694: AB_1078133" "unprognostic (4.96e-2)" "unprognostic (1.11e-2)" "unprognostic (1.45e-1)" "unprognostic (4.56e-7)" "unprognostic (7.17e-2)" "unprognostic (1.71e-1)" "unprognostic (9.07e-3)" "unprognostic (6.29e-3)" "unprognostic (1.18e-1)" "unprognostic (1.01e-1)" "unprognostic (2.67e-4)" "unprognostic (3.70e-2)" "unprognostic (2.06e-2)" "unprognostic (7.15e-2)" "unprognostic (1.98e-1)" "unprognostic (1.38e-1)" "unprognostic (3.61e-2)" 1.8 3.1 3.6 1.2 4.4 0.3 1.1 0.5 8.1 0.7 2.1 2.0 0.0 0.7 0.5 0.5 0.6 0.5 1.2 0.4 3.4 4.9 0.4 0.5 1.1 0.5 2.7 4.2 0.6 0.4 0.4 17.9 0.5 5.5 0.5 1.2 2.4 0.9 0.8 0.3 0.9 1.5 0.9 2.1 0.5 0.8 4.9 0.9 0.0 1.6 0.0 0.3 0.6 1.2 0.0 0.0 0.0 0.2 0.0 0.7 0.0 0.0 0.0 0.4 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.0 3.5 0.0 0.0 0.1 0.3 26.4 0.0 0.0 0.6 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 3.1 0.0 4.0 0.0 0.1 0.0 0.7 0.0 0.2 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 3.6 4.4 0.5 5.9 3.4 4.9 2.7 4.2 5.5 0.9 ARHGAP26 "GRAF, KIAA0621, OPHN1L, OPHN1L1" ENSG00000145819 "Rho GTPase activating protein 26" Q9UNA1 5 142770377-143229011 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "GTPase activation" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Karpas-707: 39.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "neutrophil: 19.6;NK-cell: 5.8" "Group enriched" "Detected in many" 4 "granulocytes: 19.6;NK-cells: 5.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA035106, HPA035107" Enhanced Approved Cytosol Cytosol "HPA035106: , HPA035107: AB_10669855" "prognostic favourable (2.05e-4)" "prognostic favourable (1.36e-4)" "prognostic favourable (6.95e-4)" "prognostic favourable (5.93e-6)" "unprognostic (1.19e-1)" "unprognostic (1.93e-2)" "unprognostic (4.19e-3)" "unprognostic (5.93e-2)" "unprognostic (2.22e-1)" "unprognostic (9.43e-3)" "unprognostic (7.19e-3)" "unprognostic (8.65e-2)" "unprognostic (3.21e-3)" "unprognostic (5.67e-2)" "unprognostic (2.70e-2)" "unprognostic (2.95e-2)" "prognostic favourable (2.88e-6)" 13.3 5.7 18.4 18.6 22.7 33.9 13.0 29.2 23.9 15.9 14.2 7.5 9.9 13.2 9.4 10.9 7.6 18.5 16.4 17.0 12.8 10.5 8.0 7.7 20.0 8.8 12.9 15.4 4.8 5.5 4.8 15.1 22.4 11.9 8.5 14.8 8.8 14.6 11.2 14.0 8.5 12.6 11.1 12.6 18.9 17.0 16.1 12.2 10.3 10.0 5.4 13.6 9.4 10.6 0.3 2.0 19.6 2.8 5.8 3.0 1.0 6.8 13.7 3.8 3.5 5.7 6.3 5.9 0.8 1.1 3.3 5.8 18.8 15.5 0.9 6.8 2.2 3.3 1.9 6.4 4.1 14.1 2.2 0.0 1.7 11.9 3.6 10.1 1.3 2.3 11.4 6.1 14.1 4.9 0.2 39.0 1.0 1.0 5.7 4.2 1.8 3.5 2.2 5.7 16.3 9.7 10.5 1.5 2.4 1.7 1.9 3.2 1.0 3.1 9.4 1.8 2.6 0.2 3.6 1.7 5.5 0.2 4.7 9.5 2.5 2.9 2.8 1.6 3.0 1.7 1.3 0.2 0.6 1.8 2.0 0.3 0.2 0.8 19.6 5.8 1.0 0.5 0.2 1.0 18.4 22.7 29.2 23.9 12.8 10.5 12.9 15.4 11.9 12.2 ARHGEF12 "KIAA0382, LARG" ENSG00000196914 "Rho guanine nucleotide exchange factor 12" Q9NZN5 11 120336914-120489936 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "GTPase activation, Guanine-nucleotide releasing factor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "basophil: 2.2" "Group enriched" "Detected in many" 5 "granulocytes: 2.2;NK-cells: 1.5;T-cells: 1.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA018911, CAB025581" Approved Approved "Nucleoplasm,Plasma membrane,Cytosol" "Plasma membrane, Cytosol" Nucleoplasm "CAB025581: , HPA018911: AB_1845003" "unprognostic (1.55e-1)" "unprognostic (1.29e-1)" "unprognostic (6.91e-3)" "unprognostic (1.28e-1)" "unprognostic (7.28e-2)" "unprognostic (5.39e-2)" "unprognostic (1.56e-1)" "unprognostic (5.55e-2)" "unprognostic (4.79e-2)" "unprognostic (7.77e-2)" "unprognostic (4.34e-3)" "unprognostic (4.78e-2)" "prognostic favourable (5.43e-6)" "unprognostic (1.29e-1)" "unprognostic (4.38e-2)" "unprognostic (2.13e-1)" "unprognostic (1.48e-1)" 17.6 19.2 27.6 8.3 32.5 5.9 19.6 40.4 41.5 21.7 16.4 12.4 15.7 14.9 17.5 15.9 17.8 18.6 17.3 23.4 21.8 17.7 41.2 38.8 24.1 6.5 15.8 26.3 16.3 16.9 55.8 17.2 25.4 21.1 16.8 17.8 20.7 16.7 20.0 24.1 29.0 14.8 18.6 10.8 12.4 19.0 6.7 13.0 3.0 31.3 15.0 10.9 19.4 22.9 0.3 0.3 2.2 0.1 1.5 1.0 0.4 12.9 10.9 14.7 14.0 19.9 19.9 6.1 15.3 17.3 9.3 11.9 12.7 9.5 1.1 18.8 27.3 9.8 18.8 19.4 18.2 10.7 9.2 21.1 11.7 9.8 17.8 0.0 15.7 18.9 14.1 20.4 22.7 28.2 17.8 43.3 23.5 9.0 0.0 0.0 4.0 9.4 4.6 16.8 4.1 22.9 22.6 10.8 13.3 21.4 18.0 5.6 15.3 1.7 27.8 20.7 8.9 13.4 11.1 12.7 5.1 7.2 8.5 2.7 15.6 2.2 0.0 0.0 1.0 0.1 0.2 0.3 0.6 0.6 0.0 0.3 0.0 0.5 0.0 1.5 0.1 0.3 0.7 0.4 27.6 32.5 40.4 41.5 21.8 17.7 15.8 26.3 21.1 13.0 ARID1A "B120, BAF250, BAF250a, C10rf4, C1orf4, P270, SMARCF1" ENSG00000117713 "AT-rich interaction domain 1A" O14497 1 26693236-26782110 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Neurogenesis, Transcription, Transcription regulation" "Chromatin regulator, DNA-binding" "Cancer-related genes, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA005456, CAB016334" Supported Enhanced Nucleoplasm Nucleoplasm "CAB016334: AB_673396, HPA005456: AB_1078205" "unprognostic (2.83e-1)" "unprognostic (1.81e-1)" "unprognostic (7.48e-2)" "unprognostic (1.41e-1)" "unprognostic (2.44e-1)" "unprognostic (1.89e-2)" "prognostic unfavourable (4.18e-4)" "unprognostic (3.02e-1)" "unprognostic (3.66e-2)" "unprognostic (1.34e-1)" "unprognostic (9.69e-2)" "unprognostic (7.76e-2)" "unprognostic (1.01e-2)" "unprognostic (1.62e-2)" "unprognostic (6.05e-2)" "unprognostic (2.66e-1)" "unprognostic (6.54e-2)" 18.6 18.4 17.4 24.9 17.0 33.8 27.8 23.6 19.1 20.3 23.7 21.7 23.9 15.8 24.1 17.3 23.2 20.6 21.9 15.5 14.8 12.8 13.7 15.9 18.8 35.6 20.3 19.2 24.1 23.9 27.5 15.8 19.3 17.2 16.5 16.4 18.9 21.4 23.1 22.6 20.6 20.7 18.4 15.4 25.9 19.5 16.5 19.8 57.3 24.8 14.2 24.5 24.4 20.4 4.3 5.3 7.4 3.3 4.7 5.1 3.5 18.9 18.0 25.6 26.6 7.4 7.1 12.0 8.9 7.7 12.2 8.7 13.2 12.8 26.8 7.8 11.5 11.5 22.2 9.8 14.3 33.2 8.7 22.8 11.7 8.8 6.1 33.7 7.3 8.2 7.0 14.4 10.3 10.5 27.2 30.0 7.9 9.0 28.4 13.1 27.0 8.4 29.7 16.9 15.2 7.6 12.8 23.9 19.7 15.6 13.2 10.7 3.9 19.2 18.4 13.1 12.7 12.2 14.4 14.3 18.8 12.3 8.0 21.6 11.6 0.4 3.3 2.9 4.0 2.9 5.1 4.3 3.2 4.9 3.1 4.3 4.0 4.4 7.4 4.7 2.8 5.3 1.5 3.5 17.4 17.0 23.6 19.1 14.8 12.8 20.3 19.2 17.2 19.8 ARNT "bHLHe2, HIF-1beta" ENSG00000143437 "Aryl hydrocarbon receptor nuclear translocator" P27540 1 150809705-150876768 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enriched" "Detected in many" 7 "U-698: 94.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001759, CAB004318" Supported Supported "Nucleoplasm,Nuclear bodies" "Nucleoplasm, Nuclear bodies" "CAB004318: AB_626698, HPA001759: AB_1078213" "unprognostic (1.81e-1)" "unprognostic (8.14e-2)" "unprognostic (6.87e-2)" "unprognostic (5.76e-2)" "unprognostic (1.86e-1)" "unprognostic (4.10e-2)" "unprognostic (9.43e-2)" "unprognostic (5.27e-3)" "unprognostic (5.05e-1)" "unprognostic (3.42e-2)" "unprognostic (1.22e-1)" "unprognostic (9.52e-2)" "unprognostic (1.85e-3)" "unprognostic (2.68e-1)" "unprognostic (4.67e-1)" "unprognostic (6.45e-2)" "unprognostic (6.92e-2)" 23.5 20.8 12.1 14.5 12.6 11.3 25.1 25.4 14.4 28.0 17.2 18.7 12.8 10.9 26.1 14.4 16.6 20.4 17.9 20.0 10.2 8.2 14.4 32.2 21.6 12.0 11.6 9.5 31.8 22.4 16.5 22.9 31.7 12.3 18.2 16.4 28.3 15.2 16.3 25.5 21.9 15.2 22.6 14.0 19.2 16.5 14.9 12.3 18.8 16.1 13.9 18.0 23.0 24.4 6.6 12.7 23.9 15.6 8.0 8.8 9.7 4.0 4.1 6.2 4.7 13.4 12.9 8.4 4.5 9.0 6.2 5.7 3.5 4.1 4.2 4.1 8.1 4.6 5.6 5.1 5.4 6.7 3.4 5.0 7.0 4.1 7.7 6.0 5.9 10.0 4.8 7.5 6.7 7.6 6.5 8.5 6.4 7.8 4.8 3.3 5.1 3.2 6.0 7.5 6.0 4.9 4.1 4.1 6.1 8.8 6.0 3.5 7.7 13.1 5.4 5.2 4.6 4.1 3.9 9.7 7.0 94.7 6.3 0.2 3.5 23.9 15.6 13.9 8.8 14.7 7.9 6.2 7.2 8.4 12.7 6.6 7.0 7.1 8.1 8.0 14.7 5.2 7.2 9.7 12.1 12.6 25.4 14.4 10.2 8.2 11.6 9.5 12.3 12.3 ASPSCR1 "ASPL, ASPS, TUG, UBXD9, UBXN9" ENSG00000169696 "ASPSCR1, UBX domain containing tether for SLC2A4" Q9BZE9 17 81976807-82017406 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enriched" "Detected in all" 5 "Hep G2: 80.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA026749 Approved Supported "Nucleoplasm,Vesicles,Plasma membrane" Nucleoplasm "Vesicles, Plasma membrane" "HPA026749: AB_1845114" "unprognostic (5.01e-2)" "unprognostic (1.19e-3)" "unprognostic (7.61e-2)" "unprognostic (1.34e-1)" "unprognostic (1.36e-1)" "prognostic favourable (8.55e-4)" "unprognostic (2.02e-1)" "unprognostic (2.07e-2)" "unprognostic (3.43e-1)" "unprognostic (1.71e-3)" "prognostic favourable (2.67e-4)" "unprognostic (1.13e-1)" "prognostic unfavourable (1.26e-4)" "unprognostic (3.16e-2)" "unprognostic (1.13e-1)" "unprognostic (2.27e-1)" "unprognostic (1.01e-2)" 10.3 12.6 14.3 12.6 14.5 16.8 10.6 16.5 20.8 9.9 12.9 16.7 11.8 17.5 10.1 15.8 11.9 9.3 15.1 11.5 13.1 12.6 15.8 31.9 14.1 14.8 18.9 12.9 8.8 17.8 17.0 19.7 21.8 14.8 13.2 7.1 14.4 22.6 9.9 25.1 15.5 14.4 9.1 12.6 13.2 13.0 16.9 14.6 9.8 16.4 12.9 13.0 9.7 8.3 8.1 14.6 15.7 11.3 7.2 10.5 5.2 4.9 8.8 3.4 5.0 2.2 2.7 14.9 4.7 3.6 5.7 5.6 5.1 5.8 5.1 4.9 3.4 2.4 3.7 3.6 1.8 3.5 11.2 5.7 7.2 80.8 7.1 5.0 8.3 3.1 3.9 2.9 2.0 5.5 5.7 7.3 3.2 17.0 4.6 10.9 4.3 6.4 5.1 5.0 10.4 5.6 4.6 9.2 9.4 3.9 12.3 8.8 7.4 12.0 4.5 9.9 6.8 7.2 5.9 5.3 3.2 5.7 5.3 5.1 5.9 15.7 11.3 8.0 6.7 7.6 4.0 7.9 10.5 9.0 14.6 8.1 8.0 6.0 2.9 7.2 9.3 9.1 4.9 5.2 14.3 14.5 16.5 20.8 13.1 12.6 18.9 12.9 14.8 14.6 ATF1 TREB36 ENSG00000123268 "Activating transcription factor 1" P18846 12 50763710-50821122 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB016222, HPA055069, HPA055406" Supported Enhanced Nucleoplasm Nucleoplasm "CAB016222: AB_2290030, HPA055069: , HPA055406: " "unprognostic (1.71e-1)" "unprognostic (1.50e-3)" "unprognostic (1.50e-1)" "unprognostic (9.05e-2)" "unprognostic (6.68e-2)" "unprognostic (1.58e-1)" "prognostic unfavourable (1.53e-5)" "unprognostic (3.65e-1)" "unprognostic (8.17e-3)" "unprognostic (5.94e-2)" "unprognostic (4.31e-3)" "unprognostic (5.52e-2)" "unprognostic (1.73e-1)" "unprognostic (2.74e-2)" "unprognostic (2.46e-1)" "unprognostic (2.27e-1)" "unprognostic (8.75e-2)" 24.4 20.7 9.8 13.7 9.5 10.2 16.2 28.1 10.6 22.4 19.7 8.1 14.6 12.3 19.2 14.2 16.2 15.5 13.4 20.0 10.8 8.0 17.7 19.8 15.1 15.8 12.2 6.0 24.7 11.8 18.1 15.2 36.1 11.9 20.7 15.1 12.5 16.3 14.2 37.9 12.9 18.8 13.4 12.3 22.9 12.7 9.3 13.9 34.4 30.8 16.3 16.2 21.6 20.0 13.3 13.6 26.3 12.3 12.2 18.8 11.6 13.4 9.7 10.3 10.5 14.9 15.8 25.6 14.3 24.6 22.6 17.8 19.9 21.3 18.5 23.6 16.5 11.2 12.1 14.7 24.2 18.2 12.6 20.4 22.0 10.6 28.5 29.3 19.6 16.9 23.3 16.1 26.6 10.9 24.8 17.9 16.7 19.9 18.4 18.6 15.0 15.6 17.7 16.0 21.9 17.2 9.3 13.9 7.5 30.2 13.2 21.5 18.3 17.9 7.5 15.9 19.3 13.4 11.3 9.9 11.7 29.7 15.4 16.5 7.5 4.2 11.5 26.3 13.9 12.3 15.8 13.0 15.1 16.4 13.6 13.3 18.8 14.3 7.3 12.2 7.7 6.2 17.9 11.6 9.8 9.5 28.1 10.6 10.8 8.0 12.2 6.0 11.9 13.9 ATIC "AICARFT, IMPCHASE, PURH" ENSG00000138363 "5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase" P31939 2 215311817-215349773 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Purine biosynthesis" "Hydrolase, Multifunctional enzyme, Transferase" "Cancer-related genes, Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013462, HPA021012" Supported Enhanced "Plasma membrane,Cytosol" 3400000 "Plasma membrane, Cytosol" "CAB013462: , HPA021012: AB_1845169" "unprognostic (1.41e-2)" "unprognostic (2.18e-1)" "unprognostic (1.13e-2)" "unprognostic (8.46e-2)" "unprognostic (2.90e-1)" "unprognostic (3.81e-2)" "prognostic unfavourable (1.99e-7)" "unprognostic (1.86e-2)" "unprognostic (5.07e-2)" "unprognostic (1.83e-1)" "unprognostic (6.31e-3)" "unprognostic (9.21e-2)" "prognostic unfavourable (8.77e-4)" "unprognostic (1.00e-1)" "unprognostic (1.30e-1)" "unprognostic (4.18e-2)" "unprognostic (4.39e-3)" 19.4 27.4 21.1 23.0 28.4 16.9 24.8 12.1 32.3 20.6 26.7 29.1 18.1 23.4 27.9 15.6 19.1 21.9 19.1 18.2 20.3 21.1 23.1 35.6 17.3 36.1 29.7 19.9 23.4 32.9 25.1 21.1 31.1 24.4 21.9 35.9 19.5 14.4 29.4 35.5 17.0 20.6 26.7 21.7 29.0 20.4 15.0 28.0 46.3 16.1 13.5 35.3 27.6 18.0 21.7 13.4 2.9 8.9 19.6 22.8 10.0 20.2 30.7 17.1 29.1 23.0 23.3 8.6 20.7 18.0 23.7 27.2 59.1 31.8 29.5 25.7 21.6 21.3 37.6 31.2 34.0 21.9 36.4 35.9 26.3 53.0 29.8 44.9 18.4 19.7 24.0 31.6 38.2 15.8 46.3 24.6 32.5 29.9 39.1 21.8 65.9 17.2 36.4 24.7 26.4 25.1 32.7 26.9 18.6 16.6 20.5 23.4 33.6 16.0 13.9 20.1 20.8 25.9 13.0 31.1 40.6 61.2 17.5 25.1 29.0 2.9 6.0 0.1 13.2 8.9 22.8 21.7 18.6 20.0 13.4 13.2 18.9 17.5 0.7 19.6 7.4 11.7 17.7 10.0 21.1 28.4 12.1 32.3 20.3 21.1 29.7 19.9 24.4 28.0 BCL10 "c-E10, CARMEN, CIPER, CLAP, mE10" ENSG00000142867 "B cell CLL/lymphoma 10" O95999 1 85266248-85277090 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Apoptosis, Immunity" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HUVEC TERT2: 40.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB001944, HPA017925" Approved Approved Nucleoplasm Nucleoplasm "CAB001944: , HPA017925: AB_1845312" "unprognostic (3.78e-3)" "unprognostic (2.53e-1)" "prognostic favourable (2.51e-4)" "unprognostic (1.61e-1)" "unprognostic (3.47e-1)" "unprognostic (2.61e-2)" "prognostic unfavourable (7.21e-7)" "unprognostic (7.06e-2)" "unprognostic (2.36e-1)" "unprognostic (9.46e-2)" "unprognostic (1.27e-2)" "unprognostic (1.73e-1)" "unprognostic (4.92e-3)" "unprognostic (3.18e-2)" "unprognostic (1.06e-1)" "unprognostic (1.63e-1)" "unprognostic (1.07e-1)" 17.2 10.7 5.8 16.4 6.0 19.6 20.7 5.8 8.6 14.7 21.5 7.5 9.5 12.2 14.8 10.0 29.0 8.5 16.7 7.5 5.9 5.4 11.9 11.4 20.4 21.5 6.5 5.2 11.6 9.1 5.4 6.3 11.8 5.9 11.6 20.4 6.4 11.8 12.4 5.0 14.6 27.6 9.9 6.1 18.5 13.0 8.5 5.1 18.3 11.3 12.7 22.1 14.3 17.6 22.4 14.2 37.5 18.2 10.4 13.3 9.0 15.7 3.3 4.6 4.9 6.6 9.8 7.8 12.1 11.0 8.8 12.2 4.0 6.4 7.1 8.6 9.5 8.6 5.2 12.9 12.8 6.0 4.0 7.4 3.3 5.5 10.3 7.3 7.0 7.8 14.3 13.1 11.7 40.0 5.3 6.4 14.7 3.0 7.0 6.0 8.0 11.2 5.0 10.5 4.5 30.6 12.2 3.1 4.1 3.7 12.5 11.5 4.2 5.0 19.9 9.1 6.4 11.1 12.0 5.2 2.8 6.9 4.5 6.4 6.2 25.2 15.1 20.1 10.0 18.2 11.1 22.4 13.1 11.3 14.2 20.3 12.4 11.4 37.5 10.4 13.5 12.0 13.3 9.0 5.8 6.0 5.8 8.6 5.9 5.4 6.5 5.2 5.9 5.1 BCL11A "BCL11A-L, BCL11A-S, BCL11A-XL, CTIP1, EVI9, HBFQTL5, ZNF856" ENSG00000119866 "B cell CLL/lymphoma 11A" Q9H165 2 60450520-60555154 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" Repressor "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 107.1" "Cell line enhanced" "Detected in some" "Daudi: 20.3;MOLT-4: 18.7;REH: 19.1;U-698: 41.8;U-937: 13.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 6 "memory B-cell: 39.6;naive B-cell: 53.7;plasmacytoid DC: 107.1" "Group enriched" "Detected in many" 16 "B-cells: 53.7;dendritic cells: 107.1" "Group enriched" "Detected in all" 5 "amygdala: 42.3;basal ganglia: 57.1;cerebral cortex: 62.7;hippocampal formation: 65.3;olfactory region: 101.8" "Group enriched" "Detected in all" 4 "basal ganglia: 58.3;cerebral cortex: 93.2;hippocampal formation: 97.2;olfactory region: 128.9" "CAB014891, HPA029003" Enhanced Supported "Nucleoplasm,Nuclear bodies" Nucleoplasm "Nuclear bodies" "CAB014891: , HPA029003: " "unprognostic (4.10e-3)" "unprognostic (6.72e-2)" "unprognostic (4.50e-2)" "unprognostic (9.41e-3)" "unprognostic (2.37e-1)" "unprognostic (4.47e-3)" "unprognostic (2.53e-2)" "unprognostic (1.68e-2)" "unprognostic (1.02e-1)" "unprognostic (2.45e-1)" "unprognostic (4.27e-4)" "unprognostic (1.23e-2)" "unprognostic (2.35e-2)" "unprognostic (3.59e-2)" "unprognostic (2.26e-1)" "unprognostic (4.40e-2)" "unprognostic (2.99e-2)" 1.5 2.4 6.6 13.9 14.6 17.0 5.5 1.8 34.5 3.9 8.6 0.2 0.1 7.6 1.8 1.4 13.6 4.8 2.2 4.7 14.5 3.4 1.7 1.5 3.0 21.2 3.5 14.4 1.6 11.3 1.2 3.9 0.9 9.6 4.8 5.1 0.0 11.4 2.0 1.4 24.9 11.4 2.9 2.0 13.5 3.3 2.0 2.6 20.9 2.4 4.0 30.4 3.6 7.8 53.7 107.1 1.3 5.1 1.0 0.1 1.2 0.2 0.0 1.7 0.0 0.3 0.3 0.1 0.6 0.0 0.0 0.0 0.0 0.0 20.3 0.1 0.0 4.1 6.3 3.0 0.0 0.3 6.0 0.0 0.2 0.1 0.0 7.3 0.0 0.7 1.6 0.0 1.0 1.0 0.3 0.1 0.0 0.0 18.7 7.4 11.5 0.1 19.1 0.5 7.7 0.0 0.3 8.2 2.0 0.1 0.1 0.1 0.1 3.5 0.5 0.1 4.8 0.1 0.0 0.3 0.0 41.8 0.0 13.4 0.6 0.4 2.9 0.5 0.0 5.1 0.1 39.6 0.0 0.0 10.7 53.7 0.1 0.1 1.3 1.0 3.7 107.1 0.1 1.2 6.6 14.6 1.8 34.5 14.5 3.4 3.5 14.4 9.6 2.6 BCL11B "CTIP-2, CTIP2, hRIT1-alpha, ZNF856B" ENSG00000127152 "B cell CLL/lymphoma 11B" Q9C0K0 14 99169287-99271524 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" Repressor "Cancer-related genes, Disease mutation, Mental retardation, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 13.7;lymphoid tissue: 25.4;skin 1: 17.6" "Cell line enriched" "Detected in some" 6 "MOLT-4: 32.6" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in many" "basal ganglia: 13.7" "Group enriched" "Detected in many" 8 "gdT-cell: 3.3;MAIT T-cell: 3.0;memory CD4 T-cell: 4.5;memory CD8 T-cell: 3.7;naive CD4 T-cell: 7.4;naive CD8 T-cell: 4.9;T-reg: 3.0" "Lineage enriched" "Detected in single" 14 "T-cells: 7.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA049117 Enhanced Supported Approved "Nucleoplasm,Nucleoli fibrillar center" Nucleoplasm "Nucleoli fibrillar center" "HPA049117: AB_2680639" "unprognostic (1.64e-5)" "unprognostic (4.66e-2)" "unprognostic (2.35e-2)" "unprognostic (1.87e-2)" "unprognostic (9.37e-2)" "unprognostic (5.97e-2)" "unprognostic (4.75e-2)" "unprognostic (6.07e-2)" "unprognostic (1.74e-1)" "unprognostic (1.40e-2)" "unprognostic (1.90e-1)" "unprognostic (1.12e-1)" "unprognostic (1.60e-6)" "unprognostic (1.07e-3)" "unprognostic (1.61e-1)" "unprognostic (3.31e-3)" "prognostic favourable (7.48e-4)" 0.3 0.4 4.4 6.6 13.7 5.2 1.3 0.3 3.8 0.8 1.3 0.1 0.0 2.3 1.9 0.8 3.9 0.3 3.0 0.8 4.8 1.0 0.3 0.5 1.1 10.8 0.8 2.6 0.2 0.1 0.0 0.1 0.0 0.6 0.6 1.7 0.3 5.0 0.7 0.1 17.6 3.0 0.2 0.7 4.9 2.1 0.4 1.6 25.4 0.9 1.5 8.8 2.0 2.3 0.0 0.0 0.1 0.0 0.5 7.4 1.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.3 1.2 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 1.3 0.0 0.1 0.0 0.0 3.0 0.0 1.8 32.6 0.5 0.3 0.0 5.1 0.0 0.0 0.0 1.8 2.6 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.1 0.0 2.0 0.0 0.0 1.4 0.4 0.0 0.0 0.0 0.1 3.3 0.0 3.0 0.0 4.5 3.7 0.0 0.0 7.4 4.9 0.0 0.5 0.0 0.0 3.0 1.1 4.4 13.7 0.3 3.8 4.8 1.0 0.8 2.6 0.6 1.6 BCL2 "Bcl-2, PPP1R50" ENSG00000171791 "BCL2, apoptosis regulator" P10415 18 63123346-63320128 "Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Apoptosis "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Karpas-707: 22.3;U-266/70: 77.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 6 "gdT-cell: 2.3;MAIT T-cell: 7.6;memory B-cell: 5.2;memory CD4 T-cell: 6.3;memory CD8 T-cell: 3.8;naive B-cell: 4.1;naive CD4 T-cell: 5.1;naive CD8 T-cell: 4.5;T-reg: 6.7" "Group enriched" "Detected in many" 8 "B-cells: 5.2;T-cells: 7.6" "Low region specificity" "Detected in all" "CAB000003, HPA055295" Enhanced Supported "Nucleoplasm,Nuclear membrane" "Nuclear membrane" Nucleoplasm "CAB000003: AB_2064429, HPA055295: " "unprognostic (1.11e-3)" "prognostic favourable (5.13e-5)" "unprognostic (5.49e-2)" "unprognostic (1.19e-1)" "unprognostic (1.89e-1)" "unprognostic (3.05e-3)" "unprognostic (2.88e-1)" "unprognostic (1.93e-3)" "unprognostic (4.78e-2)" "unprognostic (2.08e-1)" "unprognostic (2.23e-2)" "unprognostic (8.51e-2)" "prognostic favourable (1.29e-8)" "unprognostic (6.67e-2)" "unprognostic (1.19e-1)" "prognostic unfavourable (2.47e-4)" "unprognostic (2.63e-1)" 12.9 3.0 10.1 15.7 9.4 5.3 24.6 4.7 8.4 14.8 7.8 7.4 9.1 5.0 17.1 9.3 4.7 12.2 9.2 6.5 10.0 8.1 8.5 2.3 5.0 14.6 10.8 5.6 18.2 2.9 19.6 7.0 22.4 9.2 8.4 5.9 10.8 5.4 15.7 20.0 6.3 10.5 8.6 9.3 17.8 5.4 3.5 10.5 21.0 35.6 2.9 13.4 7.9 16.4 5.2 0.3 0.7 0.2 0.7 7.6 1.9 0.4 0.1 2.3 1.8 2.7 0.4 0.8 0.2 0.2 0.7 0.5 1.1 0.1 0.0 0.4 0.2 0.1 2.0 0.3 0.4 13.3 0.4 0.0 0.6 0.2 0.5 12.1 1.8 0.5 0.2 0.9 1.9 0.2 0.2 22.3 0.4 0.4 2.5 5.2 0.5 0.4 11.4 0.5 8.6 3.8 1.8 1.9 1.8 0.0 0.0 2.7 0.1 10.2 0.1 3.0 1.0 0.3 1.5 77.6 10.2 0.8 0.5 8.6 1.7 0.7 0.0 0.0 2.3 0.0 7.6 5.2 6.3 3.8 0.1 4.1 5.1 4.5 0.1 0.7 0.2 0.3 6.7 1.9 10.1 9.4 4.7 8.4 10.0 8.1 10.8 5.6 9.2 10.5 BCL3 "BCL4, D19S37" ENSG00000069399 "B cell CLL/lymphoma 3" P20749 19 44747705-44760044 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" Activator "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HDLM-2: 26.5;Karpas-707: 22.0;SiHa: 28.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "neutrophil: 16.5" "Lineage enriched" "Detected in all" 6 "granulocytes: 16.5" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB002051, HPA047514" Approved Supported Nucleoplasm,Vesicles,Midbody Nucleoplasm "Vesicles, Midbody" "CAB002051: AB_563428, HPA047514: " "prognostic favourable (9.67e-4)" "unprognostic (8.82e-2)" "unprognostic (2.81e-1)" "unprognostic (7.54e-2)" "prognostic unfavourable (4.01e-4)" "unprognostic (3.49e-2)" "unprognostic (2.34e-3)" "unprognostic (2.79e-1)" "prognostic favourable (3.74e-4)" "unprognostic (2.09e-2)" "unprognostic (9.23e-2)" "unprognostic (1.81e-1)" "prognostic unfavourable (3.13e-14)" "unprognostic (8.24e-2)" "unprognostic (1.36e-1)" "unprognostic (3.77e-2)" "unprognostic (3.04e-2)" 17.7 13.0 4.0 21.1 5.6 35.2 18.7 1.4 4.7 11.7 14.9 2.4 5.9 24.5 10.4 9.7 27.1 12.5 22.7 20.1 3.9 2.0 17.8 52.1 36.4 20.5 4.3 0.5 26.5 13.2 2.4 9.2 9.5 5.6 16.0 8.0 8.8 13.7 13.7 20.2 9.0 35.5 11.5 6.5 41.6 15.0 8.3 4.0 6.5 13.9 22.9 37.0 18.7 11.9 1.3 2.6 16.5 2.4 1.8 1.5 0.7 3.8 13.4 0.3 7.1 2.6 5.4 0.6 2.4 2.6 1.5 2.2 2.8 7.1 3.8 5.5 4.7 4.3 0.9 4.0 0.9 26.5 0.2 0.4 7.0 3.6 6.2 0.3 11.4 9.4 3.2 3.3 4.2 4.0 0.5 22.0 0.9 3.2 0.0 2.9 0.3 5.6 1.7 2.7 1.4 6.8 8.1 0.0 0.4 28.2 14.4 0.7 5.0 2.9 6.7 4.8 5.0 7.5 0.9 20.9 8.2 3.9 8.9 0.5 3.6 0.2 2.4 4.2 0.7 1.6 1.0 1.3 0.9 1.1 2.1 1.1 0.5 0.6 16.5 1.8 0.9 2.6 1.5 0.7 4.0 5.6 1.4 4.7 3.9 2.0 4.3 0.5 5.6 4.0 BCL6 "BCL5, BCL6A, LAZ3, ZBTB27, ZNF51" ENSG00000113916 "B cell CLL/lymphoma 6" P41182 3 187721377-187745727 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Immunity, Inflammatory response, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 114.3" "Cell line enhanced" "Detected in many" "ASC diff: 26.8;Daudi: 42.1;HSkMC: 30.6;U-698: 58.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 4 "neutrophil: 63.4" "Lineage enriched" "Detected in many" 4 "granulocytes: 63.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000307, HPA004899, HPA050645" Enhanced Supported "Nucleoplasm,Golgi apparatus" Nucleoplasm "Golgi apparatus" "CAB000307: AB_2063451, HPA004899: AB_1078273, HPA050645: " "unprognostic (5.36e-2)" "unprognostic (3.29e-2)" "unprognostic (1.63e-3)" "unprognostic (2.49e-1)" "unprognostic (2.85e-1)" "unprognostic (6.34e-3)" "unprognostic (2.62e-2)" "unprognostic (3.33e-3)" "unprognostic (8.75e-2)" "unprognostic (2.04e-2)" "unprognostic (1.63e-3)" "unprognostic (1.29e-1)" "prognostic unfavourable (1.27e-9)" "unprognostic (5.22e-2)" "unprognostic (7.82e-2)" "unprognostic (5.67e-2)" "unprognostic (2.58e-2)" 47.1 14.3 21.8 23.2 25.9 50.6 48.0 58.7 23.7 21.2 21.2 19.2 11.5 4.1 17.7 8.8 20.9 28.3 22.3 18.6 21.5 8.0 10.1 20.1 26.3 24.5 31.6 9.3 20.2 15.6 9.1 23.3 7.5 28.5 17.3 5.8 15.9 19.1 11.8 114.3 36.4 8.1 24.4 50.1 27.2 16.1 10.2 26.6 18.9 14.8 10.4 22.4 24.9 20.0 3.9 5.6 63.4 15.4 0.9 1.3 5.2 1.2 3.6 3.5 0.8 26.8 21.4 3.9 4.2 10.4 4.9 5.2 2.5 2.0 42.1 3.1 5.3 2.0 1.1 2.8 4.2 8.9 1.4 0.0 1.7 6.0 13.9 0.5 0.2 30.6 17.9 6.0 9.2 2.7 0.4 7.3 4.7 1.4 1.4 0.3 0.3 2.7 11.7 1.8 0.2 3.4 6.2 0.8 0.0 4.9 2.1 2.7 9.2 1.5 5.5 11.9 1.9 4.3 1.9 5.4 1.7 58.5 6.5 1.5 8.4 1.6 6.9 4.1 1.3 8.7 1.3 1.4 0.8 1.2 5.6 3.9 0.5 0.6 63.4 0.9 15.4 0.9 0.6 5.2 21.8 25.9 58.7 23.7 21.5 8.0 31.6 9.3 28.5 26.6 BCL7A BCL7 ENSG00000110987 "BCL tumor suppressor 7A" Q4VC05 12 122019422-122062044 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Daudi: 25.9;MOLT-4: 19.0;U-698: 29.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "naive B-cell: 8.4;plasmacytoid DC: 9.7" "Group enriched" "Detected in many" 10 "B-cells: 8.4;dendritic cells: 9.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA019762 Approved Approved Nucleoplasm,Vesicles "Nucleoplasm, Vesicles" "HPA019762: AB_10962489" "unprognostic (3.27e-1)" "unprognostic (2.97e-2)" "prognostic unfavourable (6.81e-4)" "unprognostic (1.35e-1)" "unprognostic (1.46e-1)" "unprognostic (1.23e-1)" "prognostic unfavourable (2.04e-4)" "unprognostic (5.18e-1)" "unprognostic (5.13e-2)" "unprognostic (1.06e-2)" "unprognostic (3.13e-1)" "unprognostic (3.11e-1)" "prognostic favourable (1.54e-6)" "unprognostic (4.86e-2)" "unprognostic (8.56e-2)" "unprognostic (6.16e-3)" "unprognostic (1.51e-2)" 3.8 3.7 13.0 9.8 14.5 9.9 6.5 19.8 18.2 6.7 4.2 6.8 3.3 3.6 6.0 7.4 3.3 10.3 4.3 9.4 9.5 7.5 10.7 5.3 5.1 19.4 6.6 15.9 4.9 11.7 8.3 6.1 2.8 6.8 6.3 3.8 3.8 8.2 7.2 12.8 8.2 3.4 4.1 5.1 6.5 4.4 3.1 7.9 26.4 11.1 3.5 15.8 6.9 5.4 8.4 9.7 0.1 0.1 0.5 0.9 0.6 1.7 2.4 7.9 5.6 0.5 0.3 1.7 1.0 1.0 1.7 1.5 1.0 0.7 25.9 2.9 0.8 2.3 5.7 5.5 1.4 0.0 9.4 1.3 0.2 1.4 1.7 4.0 2.3 1.2 5.2 1.2 7.1 2.1 5.8 0.0 1.0 3.6 19.0 0.3 2.8 4.0 10.5 2.7 0.3 3.1 4.4 7.9 8.9 1.3 0.3 3.3 5.3 3.3 1.9 0.3 1.7 2.9 1.7 2.7 1.8 29.9 0.5 2.5 1.8 0.1 0.0 0.0 0.1 0.0 0.0 2.9 0.2 0.2 2.2 8.4 0.9 0.6 0.1 0.5 0.1 9.7 0.0 0.6 13.0 14.5 19.8 18.0 9.5 7.5 6.6 15.9 6.8 7.9 BCL9 ENSG00000116128 "B cell CLL/lymphoma 9" O00512 1 147541412-147626216 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Wnt signaling pathway" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "NTERA-2: 24.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA020274 Approved Approved "Nucleoplasm,Nuclear bodies" "Nucleoplasm, Nuclear bodies" "HPA020274: " "unprognostic (2.31e-1)" "unprognostic (1.52e-2)" "unprognostic (5.32e-2)" "unprognostic (1.38e-1)" "unprognostic (1.04e-1)" "unprognostic (1.65e-1)" "prognostic unfavourable (6.74e-4)" "unprognostic (1.03e-1)" "unprognostic (2.78e-1)" "unprognostic (2.29e-1)" "unprognostic (4.78e-3)" "unprognostic (3.92e-2)" "unprognostic (1.64e-3)" "unprognostic (2.58e-1)" "unprognostic (2.20e-1)" "unprognostic (1.37e-1)" "unprognostic (1.60e-2)" 4.5 7.8 10.2 5.9 9.2 3.1 4.8 22.3 12.6 18.2 9.4 8.1 10.9 5.3 23.9 15.9 6.8 18.9 5.2 8.3 8.0 7.4 9.6 4.3 5.0 4.0 5.9 8.7 17.0 6.1 14.6 10.6 4.5 6.8 10.5 7.9 11.8 8.1 13.2 7.9 7.8 5.5 15.7 5.4 3.8 7.6 6.1 6.5 22.4 7.8 8.0 6.0 9.6 8.0 0.4 0.0 0.6 0.3 0.1 2.6 1.0 3.0 2.9 20.9 15.5 2.4 2.8 4.1 2.5 3.9 2.7 2.6 3.8 4.5 2.9 5.5 2.3 2.4 13.2 4.5 2.6 6.8 3.7 1.4 3.2 2.5 2.0 0.8 4.1 2.8 3.8 3.2 2.3 4.2 2.7 4.7 2.4 6.8 7.1 0.7 24.6 6.5 7.6 5.2 5.5 10.6 3.4 5.7 12.3 2.8 5.1 4.8 6.5 1.4 3.0 1.9 9.1 5.4 3.9 21.1 5.3 5.4 4.8 0.8 9.2 0.0 0.3 0.6 1.0 0.0 0.9 0.2 1.2 1.2 0.0 0.4 2.6 1.6 0.2 0.1 0.1 0.0 0.9 1.0 10.2 9.2 22.3 12.6 8.0 7.4 5.9 8.7 6.8 6.5 BCOR "FLJ20285, KIAA1575" ENSG00000183337 "BCL6 corepressor" Q6W2J9 X 40049815-40177329 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Repressor" "Cancer-related genes, Disease mutation, Microphthalmia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA056308, HPA073591" Enhanced Nucleoplasm Nucleoplasm "HPA056308: , HPA073591: " "unprognostic (2.75e-2)" "unprognostic (2.83e-1)" "unprognostic (2.45e-1)" "unprognostic (9.26e-2)" "unprognostic (1.55e-1)" "unprognostic (9.80e-3)" "prognostic unfavourable (1.30e-5)" "unprognostic (3.82e-3)" "unprognostic (6.86e-2)" "unprognostic (1.86e-1)" "unprognostic (4.08e-2)" "unprognostic (1.18e-1)" "unprognostic (3.91e-3)" "unprognostic (6.83e-2)" "unprognostic (9.57e-2)" "unprognostic (2.63e-1)" "unprognostic (1.55e-1)" 9.1 12.8 8.7 8.7 10.5 20.6 13.3 11.5 12.0 10.0 12.6 22.7 11.9 7.8 11.1 13.9 13.6 10.4 8.6 13.0 7.1 5.4 11.2 13.3 11.4 15.2 12.9 8.4 19.8 13.6 19.7 11.9 12.5 10.7 13.2 8.2 13.7 11.1 16.5 28.8 13.6 10.3 12.9 8.6 11.4 11.5 9.8 15.8 18.4 16.0 11.4 13.5 13.8 25.5 6.5 7.3 7.6 7.1 8.2 6.8 11.8 12.9 8.6 17.5 21.4 2.0 1.5 3.0 4.4 7.0 5.6 4.6 3.6 5.2 11.8 5.2 8.2 12.1 28.5 3.7 5.0 20.6 25.9 13.1 13.2 14.1 3.4 10.6 7.6 2.6 5.5 6.2 3.6 7.6 33.7 28.5 6.9 8.3 24.0 22.2 17.2 13.4 11.7 18.1 13.3 10.3 8.2 12.5 22.7 9.2 8.2 6.9 8.8 23.4 6.2 6.1 7.7 8.9 4.9 16.9 13.1 12.3 5.3 9.7 9.3 7.6 5.0 4.5 6.8 6.1 4.3 6.5 4.7 3.9 7.3 5.5 4.7 4.8 1.1 8.2 7.1 3.1 5.5 11.8 8.7 10.5 11.5 12.0 7.1 5.4 12.9 8.4 10.7 15.8 BCR "ALL, BCR1, CML, D22S11, D22S662, PHL" ENSG00000186716 "BCR, RhoGEF and GTPase activating protein" P11274 22 23179704-23318037 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "GTPase activation, Guanine-nucleotide releasing factor, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "K-562: 43.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010421, CAB018545, HPA038337" Approved Approved Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB010421: AB_2274682, CAB018545: AB_2063918, HPA038337: AB_10675795" "unprognostic (7.46e-3)" "unprognostic (2.43e-2)" "unprognostic (2.15e-3)" "unprognostic (1.16e-1)" "unprognostic (5.35e-2)" "unprognostic (1.45e-1)" "unprognostic (5.08e-2)" "unprognostic (1.44e-1)" "unprognostic (7.55e-2)" "unprognostic (1.81e-1)" "unprognostic (9.46e-2)" "unprognostic (2.39e-2)" "prognostic favourable (9.15e-10)" "unprognostic (1.47e-1)" "unprognostic (7.10e-2)" "unprognostic (4.10e-2)" "unprognostic (7.43e-2)" 14.5 8.4 24.0 9.1 41.2 26.7 10.5 14.2 26.5 13.6 9.7 10.3 10.6 8.7 9.2 13.9 19.3 10.8 8.3 7.8 20.9 13.0 16.3 8.3 11.3 10.9 16.0 15.6 8.8 12.9 14.5 14.9 15.7 14.2 7.0 6.8 8.3 15.5 9.7 3.4 12.8 8.7 9.0 9.5 9.1 14.0 9.6 15.4 11.8 16.6 5.5 9.2 9.2 8.8 1.5 0.8 1.2 1.0 2.8 6.6 2.5 18.6 8.1 12.4 12.7 7.4 5.1 18.8 6.8 6.3 6.3 5.1 14.1 7.5 13.0 12.6 5.7 19.2 1.3 18.8 1.8 24.9 12.9 11.4 11.1 11.2 9.7 10.5 6.0 4.3 12.7 9.4 8.2 21.8 43.5 6.1 2.8 12.3 9.8 8.2 10.5 7.9 12.9 5.0 8.6 9.7 11.8 11.4 10.8 12.4 10.7 5.1 6.7 8.6 24.6 3.8 0.4 6.1 5.5 1.4 5.6 4.6 9.7 8.0 5.8 0.0 1.0 0.0 6.6 0.4 2.3 1.4 3.3 3.3 0.8 1.5 2.6 3.6 1.2 2.8 1.0 0.8 1.6 2.5 24.0 41.2 14.2 24.9 20.9 13.0 16.0 15.6 14.2 15.4 BIRC3 "API2, c-IAP2, cIAP2, hiap-1, MALT2, MIHC, RNF49" ENSG00000023445 "Baculoviral IAP repeat containing 3" Q13489 11 102317450-102339403 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Apoptosis, Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 46.0;lymphoid tissue: 46.3" "Cell line enhanced" "Detected in many" "CAPAN-2: 37.5;Daudi: 33.0;HDLM-2: 31.2;hTERT-HME1: 32.8;U-266/70: 22.0;U-266/84: 18.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "memory B-cell: 32.9;naive B-cell: 32.9" "Group enriched" "Detected in many" 10 "B-cells: 32.9;T-cells: 17.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA002317 Enhanced Approved Supported Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "HPA002317: AB_1846748" "prognostic favourable (3.60e-4)" "unprognostic (2.89e-1)" "prognostic favourable (9.35e-4)" "unprognostic (3.28e-2)" "prognostic unfavourable (7.28e-4)" "unprognostic (5.83e-3)" "unprognostic (2.23e-1)" "unprognostic (3.88e-3)" "unprognostic (9.62e-2)" "unprognostic (1.29e-1)" "prognostic unfavourable (3.03e-4)" "unprognostic (3.21e-1)" "prognostic unfavourable (6.66e-6)" "unprognostic (6.42e-2)" "unprognostic (6.23e-3)" "unprognostic (1.00e-1)" "unprognostic (3.85e-2)" 6.9 3.3 1.4 43.9 2.3 5.1 5.4 0.5 2.0 5.3 13.1 0.5 2.8 6.8 2.9 3.7 8.4 3.9 13.9 6.0 2.2 1.3 10.8 12.5 21.8 46.3 2.8 1.2 3.4 7.0 1.1 14.5 0.9 2.2 8.7 6.2 1.1 9.2 4.7 2.2 5.5 46.0 7.3 3.0 34.9 15.9 3.2 2.7 34.2 3.0 4.1 34.0 12.6 6.2 32.9 0.8 2.0 2.6 2.5 17.1 2.8 6.3 5.1 0.0 0.1 0.1 0.7 0.6 0.5 4.3 0.6 0.7 0.9 37.5 33.0 17.0 0.3 3.6 0.0 0.9 2.1 31.2 0.1 0.1 1.5 0.2 6.5 0.5 0.7 0.7 4.6 2.1 32.8 0.1 0.1 0.0 0.8 0.0 2.2 0.3 0.1 0.2 0.0 0.3 1.6 8.5 3.3 0.0 0.1 0.5 0.5 0.3 1.6 0.3 1.7 7.2 0.7 0.4 6.5 22.0 18.8 11.6 1.3 1.8 0.8 2.0 0.9 0.4 1.4 2.2 2.5 32.9 10.7 3.5 0.8 32.9 7.5 2.2 0.5 2.5 2.6 0.3 17.1 2.8 1.4 2.3 0.5 2.0 2.2 1.3 2.8 1.2 2.2 2.7 BRAF BRAF1 ENSG00000157764 "B-Raf proto-oncogene, serine/threonine kinase" P15056 7 140719327-140924928 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Allosteric enzyme, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Cardiomyopathy, Deafness, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Mental retardation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001328, CAB004552, HPA071048" Approved Approved Vesicles,Cytosol Vesicles Cytosol "CAB004552: AB_626760, HPA001328: AB_1078296, HPA071048: " "unprognostic (2.98e-3)" "unprognostic (5.66e-2)" "unprognostic (2.20e-2)" "unprognostic (2.66e-3)" "unprognostic (2.44e-1)" "unprognostic (1.48e-2)" "unprognostic (2.07e-2)" "unprognostic (4.23e-2)" "unprognostic (4.07e-2)" "unprognostic (1.58e-2)" "unprognostic (6.53e-2)" "unprognostic (1.91e-2)" "unprognostic (3.79e-3)" "unprognostic (2.08e-1)" "unprognostic (1.76e-1)" "unprognostic (8.01e-2)" "unprognostic (5.46e-2)" 13.1 12.1 20.1 16.5 20.4 27.8 14.2 29.9 21.5 12.4 12.3 9.5 12.5 9.3 15.3 17.0 11.8 11.5 12.0 13.6 13.2 12.2 13.7 12.8 15.9 13.3 9.9 17.8 16.8 13.2 28.9 24.8 13.7 15.3 14.5 11.0 10.7 11.6 16.6 12.9 15.6 10.5 13.0 10.9 12.3 12.0 24.9 12.2 13.5 16.6 7.5 12.1 18.6 18.1 2.6 1.9 7.5 2.4 7.0 5.6 1.1 5.4 4.6 6.8 8.1 8.3 10.7 10.9 6.1 6.5 4.9 7.1 5.0 5.9 9.3 4.7 6.2 3.0 6.0 4.8 9.0 8.6 4.9 6.0 4.5 4.6 7.0 9.8 6.1 7.1 5.4 5.2 10.8 5.7 9.5 16.7 8.7 2.9 13.0 10.3 6.3 2.9 8.5 5.8 7.6 4.8 10.4 7.9 6.6 7.0 4.3 6.3 4.0 6.7 8.4 5.3 4.1 11.5 4.9 19.4 11.0 14.8 8.7 9.9 5.7 3.3 2.0 7.5 3.1 1.7 2.1 2.6 3.0 2.4 1.6 2.6 5.6 2.8 4.1 7.0 2.4 1.9 2.7 1.1 20.1 20.4 29.9 21.5 13.2 12.2 9.9 17.8 15.3 12.2 BRD3 "KIAA0043, ORFX, RING3L" ENSG00000169925 "Bromodomain containing 3" Q15059 9 134030305-134068535 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA051830 Approved Approved "Nuclear bodies" "Nuclear bodies" "HPA051830: " "unprognostic (3.53e-2)" "unprognostic (2.17e-1)" "unprognostic (1.55e-2)" "unprognostic (1.90e-1)" "unprognostic (6.20e-2)" "unprognostic (2.60e-2)" "unprognostic (2.98e-2)" "unprognostic (3.48e-2)" "unprognostic (1.11e-2)" "unprognostic (6.75e-2)" "unprognostic (2.79e-1)" "unprognostic (1.98e-1)" "prognostic favourable (2.71e-7)" "unprognostic (1.00e-1)" "unprognostic (4.71e-2)" "unprognostic (2.57e-2)" "unprognostic (1.42e-1)" 16.3 15.7 18.0 12.0 20.0 12.3 14.2 21.8 21.8 21.0 20.3 26.7 17.3 13.8 21.7 17.4 14.6 17.7 12.6 17.1 19.9 14.8 11.3 14.5 14.6 11.9 15.8 15.8 19.1 18.7 21.8 15.8 15.7 15.6 19.9 10.3 16.6 16.5 22.5 29.2 19.6 12.9 16.3 17.8 20.1 14.8 17.8 18.2 35.4 18.7 9.2 10.3 17.9 14.1 7.3 16.6 14.6 12.9 15.4 11.9 7.8 4.0 12.4 15.8 12.3 8.8 7.2 14.5 4.2 4.7 4.6 4.7 10.3 6.8 1.5 4.4 3.8 14.2 14.6 5.7 3.7 9.6 8.2 8.8 14.0 11.6 7.9 11.5 7.9 7.6 7.1 5.3 6.1 7.5 7.9 4.6 4.7 13.7 21.3 15.5 21.1 9.6 15.8 22.8 7.7 6.5 4.3 23.2 21.4 18.6 7.0 4.9 10.1 19.2 9.6 11.3 6.3 7.3 3.7 2.5 2.6 1.4 5.7 8.0 7.5 5.9 12.9 14.5 11.9 9.8 10.0 7.1 9.6 10.6 12.5 7.3 9.1 9.7 14.6 15.4 7.9 16.6 4.4 7.8 18.0 20.0 21.8 21.8 19.9 14.8 15.8 15.8 15.6 18.2 BRD4 "CAP, HUNK1, HUNKI, MCAP" ENSG00000141867 "Bromodomain containing 4" O60885 19 15235519-15332545 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "DNA damage, Host-virus interaction, Transcription, Transcription regulation" "Chromatin regulator" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA015055, HPA061646, CAB068177, CAB068178" Supported Enhanced Nucleoplasm Nucleoplasm "CAB068177: , CAB068178: , HPA015055: AB_1845435, HPA061646: " "unprognostic (2.83e-3)" "unprognostic (2.39e-2)" "unprognostic (6.37e-3)" "unprognostic (3.38e-2)" "unprognostic (2.15e-1)" "unprognostic (9.53e-3)" "unprognostic (3.03e-3)" "unprognostic (6.13e-2)" "unprognostic (7.63e-2)" "unprognostic (2.72e-2)" "unprognostic (3.98e-2)" "unprognostic (5.26e-2)" "unprognostic (1.83e-3)" "unprognostic (2.43e-1)" "unprognostic (2.73e-1)" "unprognostic (1.28e-1)" "unprognostic (1.22e-1)" 23.0 20.7 27.8 25.6 30.1 25.2 20.4 32.1 29.9 20.8 19.6 17.2 18.9 17.6 23.4 12.5 22.9 18.6 15.8 21.3 20.3 12.4 18.1 25.3 22.5 22.7 14.8 17.6 27.3 31.3 19.1 18.8 34.0 17.6 20.8 10.7 18.9 22.0 19.3 47.7 27.3 21.0 20.3 13.9 26.8 20.2 20.1 16.8 34.2 21.5 11.6 23.7 20.9 24.8 6.9 4.3 11.6 4.4 4.9 3.5 2.0 20.5 20.7 12.9 24.4 12.4 8.8 15.6 15.1 12.4 12.0 12.6 21.9 31.0 25.8 25.1 16.5 20.6 15.0 14.3 10.4 25.8 9.9 24.4 18.2 19.0 18.9 24.0 27.2 12.9 14.8 14.8 29.3 11.6 41.3 26.2 7.6 26.6 22.6 17.4 26.4 24.4 28.4 13.6 16.1 9.5 22.2 15.6 14.2 20.0 14.7 17.1 14.7 16.5 18.4 31.3 15.0 27.8 23.8 21.4 18.8 13.1 17.3 19.6 24.2 5.2 3.6 3.9 3.5 4.4 2.7 5.4 3.1 2.9 2.1 6.9 3.1 2.9 11.6 4.9 3.9 4.3 2.2 2.0 27.8 30.1 32.1 29.9 20.3 12.4 14.8 17.6 17.6 16.8 BTG1 APRO2 ENSG00000133639 "BTG anti-proliferation factor 1" P62324 12 92140278-92145897 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 190.7" "Cell line enhanced" "Detected in all" "ASC TERT1: 49.6" "Low cancer specificity" "Detected in all" "Region enriched" "Detected in all" 5 "cerebellum: 66.8" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA005972 Approved Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA005972: AB_1078303" "prognostic favourable (4.36e-5)" "unprognostic (1.43e-1)" "unprognostic (2.32e-1)" "unprognostic (1.37e-2)" "unprognostic (1.07e-1)" "unprognostic (3.61e-3)" "unprognostic (1.10e-1)" "unprognostic (5.51e-2)" "unprognostic (1.46e-1)" "unprognostic (1.34e-2)" "unprognostic (2.50e-1)" "unprognostic (4.94e-2)" "prognostic unfavourable (1.95e-7)" "unprognostic (1.14e-1)" "unprognostic (1.56e-1)" "unprognostic (5.79e-2)" "unprognostic (9.81e-2)" 52.0 22.1 11.5 58.3 13.4 126.9 114.4 66.8 10.4 41.7 40.1 5.5 21.9 15.5 30.1 22.0 28.7 27.9 39.9 49.2 11.9 8.1 22.2 58.1 85.6 190.7 10.4 8.2 29.1 64.2 17.6 17.1 23.4 13.3 28.7 18.1 21.0 19.0 25.9 31.6 70.6 34.3 26.0 24.6 77.1 26.4 19.0 8.9 148.9 15.7 14.3 58.2 54.2 35.2 58.3 6.6 94.3 14.0 47.1 95.2 26.1 6.8 8.6 9.5 1.1 35.7 49.6 4.1 7.7 17.1 5.2 5.2 5.1 2.4 7.4 1.6 8.2 4.7 3.1 8.7 9.7 8.9 6.7 1.4 6.0 2.6 36.2 5.4 2.5 42.3 26.2 11.9 36.9 10.4 5.1 9.8 5.9 7.1 3.8 17.4 2.3 9.9 13.1 5.3 2.3 16.0 14.3 5.3 10.6 9.7 7.5 25.0 31.4 12.6 3.3 5.9 1.8 4.5 4.7 13.6 7.2 12.3 4.6 4.3 6.6 22.3 13.6 94.3 17.0 10.6 20.1 44.5 34.3 29.8 6.6 58.3 95.2 39.1 52.3 47.1 14.0 6.2 39.2 26.1 11.5 13.4 66.8 10.4 11.9 8.1 10.4 8.2 13.3 8.9 CAMTA1 KIAA0833 ENSG00000171735 "Calmodulin binding transcription activator 1" Q9Y6Y1 1 6785324-7769706 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" Activator "Cancer-related genes, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA036342, HPA036343" Approved Supported Cytosol Cytosol "HPA036342: , HPA036343: AB_10671839" "unprognostic (1.11e-1)" "unprognostic (6.31e-2)" "unprognostic (5.80e-2)" "unprognostic (4.14e-3)" "unprognostic (3.10e-2)" "unprognostic (1.47e-2)" "prognostic unfavourable (5.25e-4)" "unprognostic (1.08e-2)" "unprognostic (3.59e-1)" "prognostic favourable (4.10e-4)" "unprognostic (3.90e-3)" "unprognostic (8.84e-2)" "unprognostic (1.35e-3)" "unprognostic (2.17e-2)" "unprognostic (9.19e-3)" "unprognostic (1.42e-1)" "unprognostic (9.03e-3)" 18.4 24.3 31.6 12.2 30.7 12.1 21.7 24.4 37.1 16.5 30.2 19.9 13.2 28.3 20.0 46.7 22.7 16.8 17.7 58.1 26.4 27.6 36.7 37.2 16.5 13.3 31.2 26.5 17.1 18.6 22.0 17.6 14.3 47.5 22.2 27.1 25.0 27.1 29.6 48.0 12.9 30.4 38.4 23.9 15.7 21.5 23.0 19.4 14.7 30.8 20.5 17.5 31.3 18.7 19.8 32.3 28.3 32.4 10.3 18.1 18.9 21.5 12.2 33.9 17.2 17.5 26.8 9.5 23.5 18.1 25.3 21.4 14.7 27.5 18.0 18.5 24.5 13.4 17.7 24.2 36.2 13.4 19.2 20.2 28.8 28.7 28.5 15.3 14.7 18.0 16.9 18.2 28.1 28.1 14.2 24.4 29.1 20.9 20.3 42.0 23.4 14.3 13.6 30.2 39.7 34.1 12.6 35.1 28.3 16.6 24.7 36.0 13.4 19.2 16.4 18.0 15.2 18.5 14.6 18.7 23.0 48.2 26.9 34.5 10.1 27.5 32.4 28.3 11.5 19.4 12.5 19.8 18.0 14.2 30.6 16.2 14.7 12.8 6.6 10.3 14.7 32.3 18.1 18.9 31.6 30.7 24.4 37.1 26.4 27.6 31.2 26.5 47.5 19.4 CANT1 "SCAN-1, SHAPY" ENSG00000171302 "Calcium activated nucleotidase 1" Q8WVQ1 17 78991717-79009867 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" Hydrolase "Cancer-related genes, Disease mutation, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "T-47d: 71.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019627, HPA019639, HPA022818" Enhanced 2300000 "HPA019627: AB_1845969, HPA019639: AB_1845970, HPA022818: AB_1845971" "unprognostic (1.98e-2)" "unprognostic (2.49e-2)" "unprognostic (1.50e-2)" "unprognostic (5.36e-2)" "unprognostic (2.13e-2)" "unprognostic (2.21e-2)" "prognostic unfavourable (1.41e-4)" "prognostic unfavourable (2.90e-4)" "unprognostic (1.76e-1)" "unprognostic (9.00e-2)" "unprognostic (3.30e-1)" "unprognostic (2.49e-1)" "prognostic unfavourable (6.21e-4)" "unprognostic (7.04e-2)" "unprognostic (5.06e-2)" "unprognostic (1.16e-1)" "unprognostic (7.23e-2)" 13.8 15.3 9.6 13.1 10.2 8.1 13.0 12.2 10.8 17.7 43.8 12.3 25.4 25.5 12.0 14.3 27.5 10.0 19.5 10.8 9.0 6.9 10.3 17.7 11.1 11.5 12.5 7.7 10.4 14.7 13.1 11.8 33.0 12.0 36.7 41.5 7.9 30.3 41.4 9.0 8.9 27.2 8.0 12.4 18.1 25.8 19.0 10.3 14.1 12.4 8.9 14.4 10.3 13.7 4.1 3.8 17.5 4.4 3.1 6.2 4.4 26.4 29.0 8.1 11.7 7.7 9.2 10.4 16.3 14.3 17.6 14.9 13.7 25.0 6.4 9.6 11.4 13.4 6.9 12.9 17.6 10.6 12.6 8.3 8.8 11.4 6.6 7.9 13.1 9.5 8.3 16.2 8.8 30.3 10.4 10.9 11.7 14.3 12.0 4.7 5.5 30.9 6.7 13.3 7.2 7.7 13.3 11.7 11.7 8.7 57.8 12.3 71.4 9.5 15.1 26.3 23.8 11.8 20.4 12.9 10.7 6.2 16.8 6.1 16.4 6.1 3.8 8.1 6.2 4.4 6.1 4.1 4.6 5.2 3.8 2.9 4.5 4.4 17.5 3.1 2.9 2.7 3.8 4.4 9.6 10.2 12.2 10.8 9.0 6.9 12.5 7.7 12.0 10.3 CARS CARS1 ENSG00000110619 "Cysteinyl-tRNA synthetase" P49589 11 3000922-3057613 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Protein biosynthesis" "Aminoacyl-tRNA synthetase, Ligase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002383, HPA002384, CAB075734, CAB075735, CAB075736, CAB075737" Enhanced Enhanced Cytosol 110000 Cytosol "CAB075734: , CAB075735: , CAB075736: , CAB075737: , HPA002383: AB_1078399, HPA002384: AB_1846033" "unprognostic (9.10e-3)" "unprognostic (1.83e-1)" "unprognostic (4.16e-3)" "unprognostic (1.43e-1)" "unprognostic (1.00e-2)" "unprognostic (7.97e-2)" "prognostic unfavourable (5.16e-4)" "unprognostic (1.41e-2)" "unprognostic (1.05e-1)" "unprognostic (8.00e-2)" "unprognostic (5.51e-2)" "unprognostic (2.45e-1)" "prognostic unfavourable (0.00e+0)" "unprognostic (5.37e-2)" "unprognostic (1.71e-1)" "unprognostic (1.48e-1)" "unprognostic (3.46e-1)" 24.9 15.9 15.8 15.8 17.7 9.0 15.9 9.5 29.1 13.4 16.3 19.1 11.1 15.9 14.0 10.7 16.0 10.8 14.2 12.5 15.3 18.7 10.7 22.1 15.1 17.2 23.3 15.9 14.5 42.5 14.9 15.9 14.0 23.0 10.8 17.6 7.4 20.3 14.8 24.6 18.8 17.8 21.0 16.1 14.8 22.8 13.4 17.3 9.8 23.0 14.5 22.7 14.4 19.4 8.3 13.3 18.0 23.9 16.4 18.1 11.6 7.5 3.8 5.0 15.0 19.5 18.0 4.5 19.3 22.0 13.3 24.1 9.4 18.0 11.7 5.7 24.3 19.4 16.3 21.9 18.4 34.1 3.7 6.6 6.6 7.2 46.8 13.7 14.5 29.6 17.3 11.5 12.9 17.5 11.0 41.5 13.1 11.5 9.6 0.0 18.7 6.9 4.6 8.3 14.6 0.0 12.6 10.7 14.2 4.7 13.6 21.1 0.0 0.0 6.0 5.5 5.1 13.6 0.2 30.9 28.1 7.4 0.0 7.2 10.8 7.7 12.0 8.8 15.2 10.5 13.0 8.3 13.6 13.6 13.3 6.0 7.5 12.1 18.0 16.4 23.9 5.2 18.1 11.6 15.8 17.7 9.5 29.1 15.3 18.7 23.3 15.9 23.0 17.3 CBFA2T3 "ETO2, MTG16, MTGR2, RUNX1T3, ZMYND4" ENSG00000129993 "CBFA2/RUNX1 translocation partner 3" O75081 16 88874858-88977204 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Differentiation, Transcription, Transcription regulation" Repressor "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 75.9" "Cell line enhanced" "Detected in some" "HEL: 21.0;K-562: 36.7;MCF7: 17.0;MOLT-4: 18.6;NB-4: 22.7;REH: 36.9;T-47d: 16.8" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in all" "cerebellum: 26.0" "Cell type enhanced" "Detected in many" "plasmacytoid DC: 11.6" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA059931, HPA062423, HPA065890" Approved Enhanced Nucleoplasm Nucleoplasm "HPA059931: , HPA062423: , HPA065890: " "unprognostic (2.47e-1)" "unprognostic (2.03e-2)" "unprognostic (9.24e-3)" "unprognostic (2.62e-1)" "unprognostic (1.98e-1)" "prognostic favourable (3.95e-4)" "unprognostic (1.13e-3)" "unprognostic (1.69e-2)" "unprognostic (1.25e-1)" "unprognostic (2.10e-1)" "unprognostic (7.30e-3)" "unprognostic (2.38e-1)" "unprognostic (7.04e-5)" "unprognostic (2.18e-1)" "unprognostic (4.08e-2)" "unprognostic (4.62e-2)" "unprognostic (9.35e-3)" 10.0 1.7 3.6 11.3 7.4 8.2 6.1 26.0 5.4 2.3 3.9 1.3 1.4 3.9 3.2 2.1 2.1 1.9 2.5 6.2 3.0 3.0 0.7 2.0 6.4 9.5 2.0 3.8 0.9 24.9 0.7 2.7 3.8 2.3 3.7 1.5 3.1 4.5 2.9 14.2 2.6 5.5 1.5 1.2 14.7 3.5 3.2 2.2 75.9 2.4 2.0 10.3 3.6 4.8 3.7 11.6 3.6 4.9 0.1 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 1.0 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 21.0 0.0 0.0 0.0 5.5 10.4 0.0 0.0 0.0 0.0 0.0 36.7 0.1 0.0 17.0 18.6 22.7 0.4 0.0 36.9 0.2 3.7 0.0 0.0 7.2 1.6 0.8 0.1 0.1 16.8 5.8 0.1 0.0 0.1 0.1 0.0 0.1 0.1 12.2 0.0 6.4 0.0 1.1 2.7 2.7 0.0 3.2 0.0 3.7 0.0 0.0 7.1 2.1 0.0 0.0 3.6 0.1 4.9 11.6 0.0 1.7 3.6 7.4 26.0 5.4 3.0 3.0 2.0 3.8 2.3 2.2 CBFB PEBP2B ENSG00000067955 "Core-binding factor beta subunit" Q13951 16 67029116-67101058 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-698: 99.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA038852 Uncertain Approved Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "HPA038852: AB_10795358" "unprognostic (1.05e-1)" "unprognostic (1.18e-2)" "unprognostic (1.30e-1)" "unprognostic (3.22e-2)" "unprognostic (4.66e-2)" "unprognostic (3.80e-3)" "prognostic unfavourable (2.83e-4)" "unprognostic (1.63e-2)" "unprognostic (1.47e-1)" "unprognostic (1.11e-1)" "unprognostic (4.46e-3)" "unprognostic (1.88e-2)" "prognostic unfavourable (2.89e-8)" "unprognostic (1.03e-1)" "unprognostic (4.31e-2)" "unprognostic (1.37e-1)" "unprognostic (1.20e-1)" 15.9 10.9 15.9 26.4 25.1 20.5 15.0 9.5 14.3 15.4 10.6 23.3 11.8 8.8 15.3 10.2 20.5 14.3 16.3 21.5 16.2 13.2 12.1 14.4 16.1 32.6 23.6 12.4 17.3 13.6 40.4 18.8 13.2 17.5 14.6 11.1 13.7 19.6 10.3 33.3 14.8 12.2 11.7 22.4 18.2 17.1 7.3 24.2 42.2 17.0 14.8 31.0 15.9 18.8 6.5 9.1 20.5 9.2 14.8 7.0 5.1 15.4 10.3 9.0 14.7 6.6 8.5 14.5 17.9 10.7 16.9 15.0 20.7 17.7 34.2 17.1 15.2 15.4 16.1 10.1 22.8 11.7 9.2 23.7 8.8 16.4 9.4 30.9 51.1 8.5 6.9 18.9 14.6 13.7 25.2 12.2 17.5 11.7 31.8 16.6 8.8 14.6 64.5 39.1 29.0 11.9 13.8 13.3 11.9 45.9 7.0 18.3 6.3 22.2 18.9 26.3 18.0 14.9 24.0 16.7 29.7 99.9 20.0 21.2 23.6 20.5 7.4 7.4 6.7 9.2 7.0 6.5 6.6 7.0 9.1 6.4 6.3 5.3 4.6 14.8 6.1 3.3 7.0 5.1 15.9 25.1 9.5 14.3 16.2 13.2 23.6 12.4 17.5 24.2 CBL "c-Cbl, CBL2, RNF55" ENSG00000110395 "Cbl proto-oncogene" P22681 11 119206276-119313926 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Ubl conjugation pathway" Transferase "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 40.9" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 11.8" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004350, HPA027956" Enhanced Supported Cytosol Cytosol "CAB004350: AB_2244054, HPA027956: AB_10601094" "unprognostic (2.52e-1)" "unprognostic (1.32e-3)" "unprognostic (1.60e-1)" "unprognostic (1.15e-1)" "unprognostic (1.50e-2)" "unprognostic (2.92e-1)" "unprognostic (4.10e-3)" "unprognostic (9.75e-2)" "unprognostic (1.72e-1)" "unprognostic (1.52e-1)" "unprognostic (1.03e-2)" "unprognostic (5.23e-2)" "unprognostic (5.21e-2)" "unprognostic (5.27e-2)" "unprognostic (1.52e-1)" "unprognostic (1.12e-1)" "unprognostic (5.85e-2)" 9.9 5.5 9.1 17.0 11.1 11.1 8.8 10.7 12.0 6.2 7.5 8.7 3.0 5.7 9.9 5.3 7.5 7.4 6.3 5.9 8.0 9.6 5.5 4.0 10.3 16.3 8.1 6.9 6.3 5.6 16.6 4.1 9.1 9.3 5.3 7.5 6.4 5.4 7.1 3.9 7.4 8.6 10.6 8.9 13.3 7.3 32.3 5.1 40.9 6.0 5.5 15.6 7.6 7.7 1.8 3.3 11.8 3.7 0.6 1.9 1.0 6.3 4.8 16.8 10.5 5.0 6.0 9.9 6.8 7.1 6.6 6.6 10.2 7.8 15.0 6.2 8.6 9.3 11.5 5.8 14.5 8.5 2.7 15.4 3.6 3.1 6.2 17.9 17.6 5.2 6.5 16.9 18.2 16.3 12.4 6.3 11.9 6.8 9.5 10.0 8.7 5.3 10.3 8.4 2.8 5.9 5.1 2.3 7.0 12.7 5.5 4.5 5.8 15.1 13.6 10.3 7.3 7.2 8.9 2.1 3.1 12.2 4.2 15.5 7.3 0.8 3.2 2.4 1.3 3.7 1.1 1.8 1.6 1.3 3.3 1.8 1.8 1.9 11.8 0.6 3.1 1.8 1.4 1.0 9.1 11.1 10.7 12.0 8.0 9.6 8.1 6.9 9.3 5.1 CCDC6 "D10S170, H4, PTC, TPC, TST1" ENSG00000108091 "Coiled-coil domain containing 6" Q16204 10 59788763-59906656 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019049, HPA019051" Enhanced Supported Cytosol Cytosol "HPA019049: AB_1846163, HPA019051: AB_1846164" "unprognostic (1.88e-2)" "unprognostic (1.72e-2)" "unprognostic (4.41e-2)" "unprognostic (1.25e-3)" "unprognostic (5.98e-3)" "prognostic favourable (5.48e-4)" "prognostic unfavourable (1.11e-4)" "unprognostic (7.39e-2)" "unprognostic (2.45e-1)" "unprognostic (2.28e-1)" "prognostic unfavourable (3.95e-4)" "unprognostic (4.08e-1)" "unprognostic (4.69e-2)" "unprognostic (2.23e-1)" "unprognostic (2.56e-1)" "unprognostic (9.95e-2)" "unprognostic (4.19e-2)" 13.7 13.3 22.8 11.7 41.8 12.8 20.7 13.8 27.1 23.0 23.9 11.3 10.7 20.4 28.4 16.6 33.2 23.6 16.2 11.2 17.0 18.1 19.4 10.9 15.5 18.7 13.8 17.6 19.8 22.5 16.8 13.7 13.3 14.5 18.7 18.4 9.6 25.5 14.0 18.2 26.0 20.4 28.1 11.8 14.5 16.6 12.6 12.3 10.6 19.1 14.8 20.7 21.7 23.8 7.1 7.3 0.2 3.4 1.2 2.3 1.4 15.8 14.3 7.2 16.1 11.0 16.6 14.7 7.8 10.4 7.8 9.2 27.8 31.1 13.6 11.8 13.0 23.5 14.4 14.2 11.7 20.3 7.2 11.1 11.6 16.9 13.3 12.6 10.4 12.0 18.9 13.0 32.0 11.5 8.3 8.7 10.1 21.3 5.2 7.3 11.5 9.8 7.1 11.8 8.5 13.1 13.6 7.4 6.4 9.8 41.5 8.7 26.3 6.8 11.7 7.3 13.4 11.3 13.0 4.6 5.3 6.2 11.6 24.2 4.5 0.0 2.9 0.0 1.5 3.4 1.8 6.7 2.3 2.1 7.3 7.1 2.2 1.6 0.2 1.2 1.9 1.9 2.1 1.4 22.8 41.8 13.8 27.1 17.0 18.1 13.8 17.6 14.5 12.3 CCNB1IP1 "C14orf18, HEI10" ENSG00000100814 "Cyclin B1 interacting protein 1" Q9NPC3 14 20311368-20333312 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Meiosis, Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "hTERT-HME1: 86.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "unprognostic (4.79e-2)" "unprognostic (1.35e-1)" "unprognostic (1.29e-1)" "unprognostic (9.37e-2)" "unprognostic (5.46e-3)" "unprognostic (2.79e-2)" "unprognostic (8.43e-2)" "unprognostic (5.88e-2)" "unprognostic (1.56e-1)" "unprognostic (1.88e-2)" "unprognostic (4.87e-2)" "unprognostic (4.77e-2)" "prognostic favourable (5.18e-6)" "unprognostic (2.12e-1)" "unprognostic (1.54e-2)" "unprognostic (4.43e-1)" "unprognostic (1.52e-1)" 12.6 9.7 10.9 9.8 13.7 14.2 27.2 14.5 16.4 20.3 13.4 13.2 17.2 9.9 20.4 24.2 17.4 18.8 12.4 33.8 11.1 11.2 31.2 34.4 15.4 11.2 13.4 11.1 49.1 20.6 14.5 12.1 14.4 15.9 18.0 14.5 15.8 14.0 12.3 20.6 14.6 10.0 27.6 15.8 11.3 13.0 9.7 13.9 11.2 35.8 15.3 16.1 33.6 17.7 9.3 13.7 3.5 3.1 4.4 10.7 3.0 6.5 5.4 30.8 29.6 15.8 21.8 24.9 8.1 16.3 12.5 16.5 18.3 7.3 23.0 5.4 5.9 11.9 21.4 15.3 16.9 6.6 18.1 13.5 5.1 17.2 46.5 24.9 12.7 29.6 25.8 8.9 86.7 9.4 16.5 18.2 8.2 10.5 14.4 17.0 18.5 10.3 17.8 15.2 9.6 13.0 9.7 24.6 25.6 5.6 13.0 36.3 4.1 18.3 4.0 7.1 9.1 8.6 10.5 8.6 10.7 15.7 2.4 21.1 8.2 3.5 3.1 0.0 6.7 1.1 9.1 9.3 7.4 8.3 13.7 8.4 7.7 10.7 0.5 4.4 1.1 13.7 9.9 3.0 10.9 13.7 14.5 16.4 11.1 11.2 13.4 11.1 15.9 13.9 CCND1 "BCL1, D11S287E, PRAD1, U21B31" ENSG00000110092 "Cyclin D1" P24385 11 69641087-69654474 "Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins" "Cell cycle, Cell division, DNA damage, Transcription, Transcription regulation" "Cyclin, Repressor" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "U-266/70: 94.3;WM-115: 131.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "memory B-cell: 3.0;myeloid DC: 3.4" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000024, HPA027802" Uncertain Supported Nucleoplasm Nucleoplasm "CAB000024: AB_563678, HPA027802: " "unprognostic (4.90e-2)" "unprognostic (1.54e-1)" "unprognostic (7.62e-2)" "unprognostic (1.39e-2)" "unprognostic (2.18e-1)" "prognostic unfavourable (5.51e-4)" "unprognostic (1.38e-1)" "unprognostic (2.53e-2)" "unprognostic (9.46e-2)" "unprognostic (4.84e-3)" "prognostic unfavourable (1.96e-4)" "unprognostic (4.39e-2)" "unprognostic (2.61e-3)" "unprognostic (4.38e-3)" "unprognostic (1.16e-1)" "unprognostic (6.40e-3)" "unprognostic (2.57e-1)" 52.0 11.6 9.7 6.0 9.7 0.7 22.8 3.4 7.7 15.4 8.9 15.4 19.9 8.4 18.8 23.1 37.7 11.8 31.0 23.9 10.8 8.8 14.5 68.1 22.2 3.7 12.4 5.6 6.5 31.5 83.2 16.6 38.1 10.0 30.7 6.8 24.8 25.6 21.7 2.0 43.6 10.4 16.5 12.6 12.9 19.2 4.0 7.5 9.0 17.1 23.1 23.6 21.4 22.1 3.0 3.4 0.8 0.0 0.0 0.9 0.3 47.6 19.1 6.3 0.1 19.6 20.7 13.7 75.6 28.1 8.8 5.2 21.4 37.0 0.0 34.3 39.3 34.9 0.6 20.5 15.9 0.1 3.8 0.0 4.7 21.7 4.7 0.3 0.7 11.7 4.0 12.4 4.8 15.1 0.0 0.1 69.5 20.2 0.0 2.7 11.6 21.1 0.1 20.2 1.1 41.0 29.5 1.0 25.0 0.9 17.9 47.0 10.9 0.9 63.0 43.4 12.1 18.8 51.3 94.3 56.3 0.1 37.1 0.6 131.3 0.8 0.0 0.0 0.9 0.0 0.1 3.0 0.4 0.2 3.4 2.5 0.8 0.2 0.2 0.0 0.0 0.0 0.0 0.3 9.7 9.7 3.4 7.7 10.8 8.8 12.4 5.6 10.0 7.5 CCND2 ENSG00000118971 "Cyclin D2" P30279 12 4273772-4305350 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cell cycle, Cell division" Cyclin "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "AF22: 32.3;HBEC3-KT: 29.5;HDLM-2: 49.7;Karpas-707: 71.7;RH-30: 46.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA049138, HPA054196" Approved Enhanced Nucleoplasm Nucleoplasm "HPA049138: , HPA054196: " "unprognostic (2.98e-3)" "unprognostic (1.15e-1)" "unprognostic (7.21e-2)" "unprognostic (1.65e-2)" "unprognostic (1.70e-2)" "unprognostic (4.82e-2)" "unprognostic (4.94e-2)" "unprognostic (2.01e-3)" "unprognostic (3.16e-2)" "unprognostic (1.66e-2)" "prognostic favourable (2.52e-4)" "unprognostic (1.75e-1)" "unprognostic (1.25e-1)" "unprognostic (8.23e-2)" "unprognostic (4.52e-1)" "prognostic favourable (9.76e-5)" "unprognostic (7.06e-2)" 13.7 39.3 20.8 12.0 15.9 23.6 10.4 6.1 22.3 14.4 28.3 8.1 24.3 18.5 21.9 41.9 12.2 16.5 9.1 36.9 17.5 7.3 6.0 5.7 12.8 24.5 7.9 17.0 11.6 18.4 8.3 19.2 23.5 9.3 16.4 24.2 14.1 8.3 22.4 2.0 9.2 19.6 45.5 14.0 16.5 11.1 5.2 8.6 6.2 18.5 6.9 13.6 22.3 16.3 3.9 2.1 4.6 1.0 9.1 14.8 5.4 0.0 0.0 32.3 0.0 5.6 0.8 0.0 0.0 0.0 0.0 0.0 13.8 0.0 0.0 0.2 0.0 4.1 0.9 29.5 0.0 49.7 0.8 0.3 0.0 0.2 0.1 12.6 2.7 10.8 4.9 0.0 22.3 0.0 3.4 71.7 6.2 0.0 0.0 16.6 13.3 0.0 0.0 46.9 23.4 0.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.3 0.0 9.4 0.0 0.0 1.2 12.1 0.0 0.1 9.1 0.0 4.1 1.0 4.6 9.1 0.2 13.7 3.9 13.0 11.0 2.1 1.5 8.2 9.8 1.5 9.1 0.1 1.0 14.8 5.4 20.8 15.9 6.1 22.3 17.5 7.3 7.9 17.0 9.3 8.6 CCND3 ENSG00000112576 "Cyclin D3" P30281 6 41934933-42050357 "Cancer-related genes, Predicted intracellular proteins" "Cell cycle, Cell division" Cyclin "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 129.2;lymphoid tissue: 142.5" "Cell line enhanced" "Detected in all" "MOLT-4: 92.5;REH: 87.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000116, HPA071369" Approved Supported "Nucleoplasm,Nuclear bodies,Cytosol" "Nucleoplasm, Nuclear bodies" Cytosol "CAB000116: , HPA071369: " "unprognostic (4.53e-2)" "unprognostic (4.45e-2)" "unprognostic (2.45e-1)" "unprognostic (4.40e-3)" "unprognostic (1.01e-1)" "unprognostic (9.80e-2)" "unprognostic (3.40e-2)" "unprognostic (5.25e-2)" "unprognostic (7.76e-2)" "unprognostic (3.45e-1)" "unprognostic (9.17e-2)" "unprognostic (6.39e-2)" "unprognostic (2.45e-3)" "unprognostic (9.12e-2)" "unprognostic (1.71e-1)" "prognostic favourable (8.08e-6)" "unprognostic (2.11e-1)" 20.2 39.8 16.1 28.9 17.5 74.7 36.0 13.3 19.8 13.3 17.3 11.3 14.1 16.0 10.8 10.4 13.5 13.4 19.0 16.3 15.4 14.5 13.7 8.0 32.1 83.8 14.1 15.5 11.1 10.9 5.0 10.1 21.9 9.3 14.2 11.4 10.2 18.1 14.4 6.5 14.6 22.0 11.7 11.5 51.2 18.0 7.4 10.0 142.5 26.8 9.3 32.8 13.0 16.6 24.1 42.4 129.2 45.8 39.0 52.8 66.2 9.0 33.1 3.5 7.7 6.3 12.9 40.2 10.6 6.1 11.0 8.1 6.2 4.1 39.0 18.0 7.1 5.6 9.2 13.0 5.7 6.6 6.0 61.8 14.8 5.0 13.9 10.1 54.6 12.3 8.5 10.6 4.0 13.5 31.1 3.8 15.7 12.2 92.5 48.5 1.5 7.1 87.9 13.5 4.3 25.4 6.1 11.8 3.1 9.0 11.6 5.2 7.1 39.5 22.5 12.2 6.7 10.6 11.9 2.5 1.9 60.9 7.1 21.3 7.4 129.2 30.5 87.7 52.8 35.1 37.0 16.4 36.4 42.5 42.4 24.1 42.8 45.0 42.8 39.0 45.8 27.8 23.2 66.2 16.1 17.5 13.3 19.8 15.4 14.5 14.1 15.5 9.3 10.0 CD274 "B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1" ENSG00000120217 "CD274 molecule" Q9NZQ7 9 5450503-5470566 "Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lung: 23.9;placenta: 56.0" "Cell line enhanced" "Detected in many" "HDLM-2: 33.4;HHSteC: 22.3;U-251 MG: 37.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "basophil: 8.4" "Group enriched" "Detected in many" 6 "granulocytes: 8.4;T-cells: 2.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" CAB076385 Enhanced "CAB076385: AB_2687655" "prognostic favourable (8.89e-4)" "unprognostic (4.54e-2)" "prognostic favourable (1.64e-5)" "unprognostic (1.27e-2)" "unprognostic (2.96e-2)" "unprognostic (1.08e-1)" "unprognostic (4.61e-2)" "unprognostic (1.44e-1)" "unprognostic (1.68e-2)" "unprognostic (5.67e-4)" "unprognostic (7.39e-3)" "unprognostic (1.69e-2)" "unprognostic (1.24e-2)" "unprognostic (1.35e-1)" "unprognostic (1.49e-2)" "unprognostic (2.67e-1)" "unprognostic (9.02e-2)" 3.4 2.1 1.7 10.8 3.2 1.4 2.2 2.5 3.3 2.0 2.3 2.5 2.8 2.6 1.7 2.4 3.0 1.9 4.3 9.5 1.4 3.7 3.0 3.6 23.9 6.4 2.3 0.7 1.7 2.7 3.8 7.4 56.0 3.2 2.9 2.2 3.3 1.7 1.6 4.3 1.3 2.7 2.3 2.4 12.8 1.9 1.2 1.0 11.6 3.7 2.1 5.8 3.1 1.9 0.9 0.0 8.4 0.1 0.4 2.4 0.7 5.8 0.1 0.0 0.2 0.0 0.0 0.0 11.7 9.9 3.0 4.1 0.0 1.9 0.0 0.2 0.3 0.2 0.0 5.0 9.7 33.4 0.0 3.3 0.1 0.0 22.3 0.0 0.0 0.2 0.0 6.1 9.1 5.7 0.0 1.1 9.0 0.0 0.1 0.0 0.0 0.1 0.0 1.6 0.3 0.6 0.1 0.0 0.1 0.1 0.9 0.7 0.0 0.1 10.7 6.3 2.0 0.1 37.0 0.2 0.1 0.1 2.1 0.1 0.0 8.4 0.1 0.3 1.2 0.1 2.1 0.9 2.4 1.8 0.0 0.2 1.3 0.7 5.7 0.4 0.0 0.0 1.1 0.7 1.7 3.2 2.5 3.3 1.4 3.7 2.3 0.7 3.2 1.0 CD74 DHLAG ENSG00000019582 "CD74 molecule" P04233 5 150401637-150412929 "Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins" "Adaptive immunity, Immunity" Chaperone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 504.7" "Cell line enhanced" "Detected in many" "CAPAN-2: 115.7;Daudi: 178.0;HDLM-2: 255.6;REH: 154.1;RPMI-8226: 104.9;U-266/70: 85.9;U-698: 98.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 4 "classical monocyte: 191.6;intermediate monocyte: 303.5;memory B-cell: 467.7;myeloid DC: 437.9;naive B-cell: 504.7;non-classical monocyte: 140.0;plasmacytoid DC: 303.2" "Group enriched" "Detected in all" 5 "B-cells: 504.7;dendritic cells: 437.9;monocytes: 303.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB002506, HPA010592" Enhanced Supported "Golgi apparatus" 90000 "Golgi apparatus" "CAB002506: AB_563630, HPA010592: AB_1078482" "prognostic favourable (1.06e-4)" "unprognostic (1.48e-2)" "unprognostic (4.80e-3)" "prognostic favourable (6.53e-6)" "unprognostic (1.41e-1)" "unprognostic (4.53e-2)" "unprognostic (2.05e-1)" "unprognostic (3.69e-3)" "unprognostic (1.54e-2)" "unprognostic (3.48e-2)" "unprognostic (2.20e-2)" "unprognostic (2.64e-1)" "unprognostic (5.44e-3)" "unprognostic (1.73e-1)" "unprognostic (4.95e-2)" "unprognostic (2.05e-1)" "unprognostic (4.24e-2)" 137.8 95.7 53.2 177.0 81.4 40.7 104.2 8.4 43.5 89.6 68.2 79.0 30.0 98.3 60.0 73.9 43.6 68.1 81.3 104.1 46.9 43.5 168.3 60.1 222.5 310.1 78.3 23.1 53.4 34.1 15.1 51.0 27.9 79.8 72.6 63.6 72.9 123.0 55.4 40.5 56.6 182.8 55.1 123.1 372.1 77.3 23.7 68.1 201.1 83.4 45.6 288.2 91.7 47.0 504.7 437.9 76.1 303.5 42.2 41.2 238.1 1.9 0.0 0.0 0.1 0.1 0.1 0.6 0.0 0.0 0.0 0.0 23.1 115.7 178.0 7.2 0.0 0.5 0.0 0.0 0.0 255.6 0.0 5.8 0.1 14.1 0.3 0.4 0.3 1.4 0.0 0.0 0.0 0.0 0.4 70.9 0.0 0.0 0.2 0.8 0.3 0.0 154.1 0.2 104.9 0.5 7.5 0.2 0.5 0.3 0.2 5.1 4.7 21.3 0.2 0.6 0.5 0.5 0.2 85.9 9.2 98.6 41.3 8.0 37.7 6.3 191.6 76.1 16.8 303.5 18.7 467.7 14.8 24.8 437.9 504.7 7.8 13.5 16.8 42.2 140.0 303.2 41.2 238.1 53.2 81.4 8.4 43.5 46.9 43.5 78.3 23.1 79.8 68.1 CDH11 "CAD11, OB" ENSG00000140937 "Cadherin 11" P55287 16 64943753-65126112 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes, Deafness, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ovary: 71.0" "Cell line enhanced" "Detected in many" "BJ: 47.1;fHDF/TERT166: 64.3;HSkMC: 44.3;PC-3: 55.3;U-2197: 37.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB013072 Enhanced 70000 "CAB013072: AB_2533068" "unprognostic (1.77e-1)" "unprognostic (1.51e-1)" "unprognostic (1.50e-1)" "unprognostic (6.93e-2)" "unprognostic (6.00e-2)" "unprognostic (1.02e-1)" "unprognostic (6.96e-2)" "unprognostic (1.28e-1)" "unprognostic (2.09e-1)" "unprognostic (2.30e-2)" "unprognostic (3.74e-2)" "unprognostic (6.75e-2)" "prognostic unfavourable (2.48e-9)" "unprognostic (1.43e-3)" "unprognostic (3.20e-2)" "unprognostic (1.26e-1)" "unprognostic (5.07e-3)" 8.1 3.6 5.5 9.2 12.1 0.3 6.1 5.5 8.8 24.1 4.3 7.5 2.4 2.7 25.9 5.9 3.0 6.8 22.4 4.6 7.3 5.1 4.8 1.0 20.8 5.9 7.8 8.5 71.0 1.7 1.2 6.0 44.2 8.3 8.0 4.9 22.2 7.3 9.7 2.5 5.7 3.4 20.5 10.6 35.1 5.1 4.0 5.4 0.1 4.8 1.9 4.9 18.4 11.7 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 10.2 0.0 7.3 15.9 0.0 47.1 27.3 12.1 6.9 0.8 0.0 0.0 0.0 64.3 0.0 0.0 0.3 8.7 0.0 0.4 0.0 0.2 0.0 6.0 0.0 2.8 44.3 0.0 14.8 3.0 3.4 0.0 0.0 6.4 0.0 0.0 0.0 3.7 55.3 0.1 7.3 0.0 0.0 0.0 0.1 7.0 0.0 0.0 0.0 0.0 0.0 0.0 25.0 3.4 37.8 13.3 0.0 0.0 0.0 4.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.5 12.1 5.5 8.8 7.3 5.1 7.8 8.5 8.3 5.4 CDK6 PLSTIRE ENSG00000105810 "Cyclin dependent kinase 6" Q00534 7 92604921-92836594 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Differentiation" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Primary microcephaly" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 74.6" "Cell line enhanced" "Detected in many" "MOLT-4: 91.7;REH: 44.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002637, CAB004363" Enhanced Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB004363: AB_627242, HPA002637: AB_1846432" "unprognostic (1.29e-1)" "unprognostic (5.98e-3)" "unprognostic (9.07e-2)" "unprognostic (2.78e-3)" "unprognostic (2.56e-2)" "unprognostic (3.24e-2)" "unprognostic (3.39e-1)" "unprognostic (2.42e-3)" "unprognostic (7.19e-2)" "unprognostic (7.78e-3)" "prognostic unfavourable (3.86e-6)" "unprognostic (4.06e-2)" "unprognostic (4.09e-3)" "unprognostic (1.09e-1)" "unprognostic (7.88e-2)" "unprognostic (1.93e-1)" "prognostic unfavourable (2.33e-5)" 6.6 11.3 6.0 9.1 7.5 22.5 5.9 2.4 6.0 7.8 10.0 9.6 5.7 7.5 6.0 5.9 8.5 4.6 7.8 6.6 6.9 4.2 6.5 7.5 7.3 7.4 7.0 5.2 5.0 10.0 25.7 4.2 20.5 7.5 6.1 9.2 4.4 10.9 6.1 2.0 11.6 9.4 9.8 7.5 6.3 10.8 5.4 8.0 74.6 4.3 9.2 10.3 6.7 9.0 3.6 5.6 6.5 4.8 3.9 7.1 2.3 6.0 2.8 7.8 5.0 2.3 2.6 1.6 6.3 3.9 3.1 3.0 7.7 4.7 4.7 3.6 4.2 3.8 4.3 9.0 7.4 10.3 3.0 11.8 5.4 7.4 1.4 7.3 0.5 2.5 4.9 4.2 20.0 1.2 11.2 13.0 5.6 1.2 91.7 0.7 2.4 2.6 44.8 27.6 7.9 4.3 0.1 4.1 26.8 0.7 2.1 3.7 0.1 12.0 4.6 10.3 16.1 4.0 12.6 7.0 0.1 6.3 1.5 25.0 13.6 4.9 1.9 6.5 5.2 3.9 5.9 2.0 5.5 5.6 4.0 3.6 7.1 4.0 1.1 3.9 4.8 5.6 2.8 2.3 6.0 7.5 2.4 6.0 6.9 4.2 7.0 5.2 7.5 8.0 CDX2 CDX3 ENSG00000165556 "Caudal type homeobox 2" Q99626 13 27962137-27971139 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 12 "intestine: 21.2" "Group enriched" "Detected in some" 6 "CACO-2: 14.4;CAPAN-2: 4.8;HEK 293: 8.0" "Cancer enriched" "Detected in many" 6 "colorectal cancer: 63.7" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "CAB002221, HPA045669, HPA049580" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB002221: AB_563649, HPA045669: , HPA049580: " "unprognostic (1.42e-1)" "unprognostic (2.41e-1)" "unprognostic (2.92e-1)" "unprognostic (8.11e-3)" "unprognostic (4.19e-6)" "unprognostic (1.73e-4)" "unprognostic (1.71e-1)" "unprognostic (1.58e-1)" "unprognostic (5.51e-2)" "unprognostic (6.07e-3)" "unprognostic (1.13e-1)" "unprognostic (1.09e-1)" 0.0 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 21.2 13.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.1 14.3 0.0 0.0 0.0 0.0 16.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 14.4 4.8 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 8.0 0.0 0.2 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 CHCHD7 "COX23, MGC2217" ENSG00000170791 "Coiled-coil-helix-coiled-coil-helix domain containing 7" Q9BUK0 8 56211686-56218798 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA050783 Approved Approved "Cell Junctions,Aggresome" "Cell Junctions" Aggresome "HPA050783: " "unprognostic (1.64e-2)" "unprognostic (3.23e-2)" "unprognostic (3.18e-2)" "prognostic unfavourable (1.39e-6)" "unprognostic (4.46e-2)" "unprognostic (2.43e-1)" "unprognostic (5.04e-2)" "unprognostic (8.38e-3)" "unprognostic (1.62e-1)" "unprognostic (9.03e-2)" "unprognostic (2.24e-1)" "unprognostic (1.15e-1)" "prognostic favourable (9.47e-5)" "unprognostic (1.94e-1)" "unprognostic (5.07e-1)" "unprognostic (1.77e-2)" "unprognostic (2.50e-1)" 16.6 14.8 24.1 19.6 29.4 17.6 18.9 27.1 23.3 17.6 20.7 18.3 22.8 22.5 13.1 34.3 15.7 17.6 12.3 27.0 21.0 19.5 23.4 18.0 19.4 24.4 27.0 16.0 36.3 20.0 22.5 48.3 13.3 26.7 19.2 21.3 19.2 34.5 18.0 23.2 14.6 26.2 14.8 32.0 33.0 17.7 7.6 24.8 27.4 19.8 18.3 24.9 15.5 16.4 31.0 33.6 26.2 20.6 24.2 31.1 17.3 18.8 6.0 13.5 4.4 36.0 25.6 14.0 13.5 12.7 10.8 8.1 15.4 23.1 17.8 11.9 7.9 10.6 14.0 20.7 13.4 7.7 26.9 27.2 14.4 21.3 18.3 23.2 17.5 30.5 19.1 7.6 34.2 11.2 13.3 11.7 25.3 9.4 23.1 34.4 11.9 8.7 26.6 4.1 14.8 19.8 20.4 3.5 2.3 7.1 11.0 10.0 11.5 13.0 16.2 5.7 12.1 18.3 12.6 12.4 12.6 29.7 16.0 34.5 9.7 21.5 20.6 26.2 23.2 19.0 22.5 31.0 26.0 23.6 22.8 26.4 31.1 27.8 7.9 24.2 16.6 33.6 29.7 17.3 24.1 29.4 27.1 23.3 21.0 19.5 27.0 16.0 26.7 24.8 CIC KIAA0306 ENSG00000079432 "Capicua transcriptional repressor" Q96RK0 19 42268537-42295797 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB026388, HPA044341, HPA064725" Approved Supported Nucleoplasm,Vesicles Nucleoplasm Vesicles "CAB026388: , HPA044341: , HPA064725: " "unprognostic (2.02e-2)" "unprognostic (4.08e-1)" "unprognostic (1.41e-2)" "unprognostic (3.54e-3)" "unprognostic (3.67e-1)" "unprognostic (4.17e-3)" "unprognostic (1.49e-1)" "unprognostic (2.06e-1)" "unprognostic (4.87e-1)" "unprognostic (1.85e-2)" "unprognostic (1.72e-3)" "unprognostic (3.10e-1)" "unprognostic (4.23e-2)" "unprognostic (1.00e-1)" "unprognostic (2.38e-1)" "unprognostic (1.88e-2)" "unprognostic (1.56e-1)" 18.6 15.7 30.5 22.8 29.9 28.1 20.3 46.8 31.6 17.5 14.7 24.7 13.0 16.5 28.6 12.3 12.3 22.1 17.4 12.1 25.5 15.2 14.9 15.1 15.8 21.5 25.2 20.1 31.5 22.6 16.6 22.6 13.2 20.4 14.4 6.2 19.0 23.8 20.8 21.0 34.1 16.1 16.3 16.5 24.7 14.5 31.5 25.6 13.6 16.8 10.6 13.4 13.6 17.4 2.3 2.0 5.0 2.6 0.6 2.5 1.6 17.6 32.0 12.3 16.9 8.0 15.1 6.0 13.5 11.3 11.4 10.6 9.0 10.9 12.3 12.9 10.6 8.6 6.8 20.4 3.7 29.8 9.2 10.3 20.2 10.7 10.1 5.8 29.4 18.0 12.0 12.9 7.6 10.4 10.1 25.9 6.4 16.8 11.4 11.1 7.7 18.2 9.8 10.5 7.3 9.5 16.6 15.9 13.1 12.8 8.0 10.1 9.5 12.5 19.9 27.3 22.2 9.3 16.4 21.5 14.8 8.4 21.2 9.2 16.1 3.4 1.8 1.0 2.5 2.6 1.9 1.7 1.3 1.6 1.7 2.3 0.9 1.5 5.0 0.6 1.9 2.0 0.5 1.6 30.5 29.9 46.8 31.6 25.5 15.2 25.2 20.1 20.4 25.6 CIITA "C2TA, MHC2TA, NLRA" ENSG00000179583 "Class II major histocompatibility complex transactivator" P33076 16 10866222-10943021 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, Acyltransferase, Kinase, Transferase" "Cancer-related genes, Disease mutation, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 67.2" "Cell line enhanced" "Detected in some" "HDLM-2: 22.8;REH: 40.0;U-698: 11.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB016084, HPA054757" Enhanced Supported Nucleoplasm Nucleoplasm "CAB016084: AB_627261, HPA054757: " "unprognostic (1.45e-3)" "unprognostic (1.38e-2)" "unprognostic (8.22e-3)" "unprognostic (1.12e-2)" "unprognostic (5.66e-2)" "unprognostic (2.88e-3)" "unprognostic (2.92e-2)" "unprognostic (1.55e-2)" "unprognostic (1.15e-2)" "unprognostic (1.85e-1)" "unprognostic (1.23e-1)" "unprognostic (3.72e-1)" "unprognostic (1.64e-2)" "unprognostic (2.72e-2)" "unprognostic (6.33e-3)" "unprognostic (2.74e-1)" "unprognostic (1.05e-2)" 8.0 5.9 4.6 47.7 7.1 4.3 6.8 1.5 5.5 6.3 3.7 10.6 4.2 10.4 8.1 10.4 4.8 5.2 8.1 4.9 4.7 3.5 8.8 2.9 15.0 27.0 9.4 1.1 2.5 3.5 1.9 4.0 1.2 6.6 5.5 4.3 5.5 13.3 4.3 2.9 4.4 17.4 3.7 15.6 25.9 6.2 1.5 7.4 12.6 6.1 5.2 67.2 6.3 6.8 27.3 19.0 6.5 11.9 0.7 0.5 1.7 0.1 0.2 0.3 0.3 0.1 0.0 0.2 0.1 0.0 0.1 0.1 0.3 5.5 5.0 0.8 0.0 0.9 0.0 0.0 0.1 22.8 0.2 2.9 1.0 0.6 0.0 0.4 0.4 1.0 0.0 0.1 0.0 0.0 0.3 2.0 0.1 0.3 0.2 0.4 0.1 0.1 40.0 0.3 3.5 0.0 1.6 0.9 0.1 0.9 0.3 0.9 0.5 1.6 0.3 2.1 0.3 0.6 0.2 8.4 0.6 11.8 7.5 0.5 6.8 0.2 11.9 6.5 0.3 9.5 0.1 17.9 0.1 0.5 17.7 27.3 0.1 0.2 2.8 0.7 10.0 19.0 0.4 1.7 4.6 7.1 1.5 5.5 4.7 3.5 9.4 1.1 6.6 7.4 CLIP1 "CLIP, CLIP-170, CLIP170, CYLN1, RSN" ENSG00000130779 "CAP-Gly domain containing linker protein 1" P30622 12 122271432-122422632 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" Transport "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 96.5" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004399, HPA026678" Approved Supported "Microtubule ends,Cytosol" 7700 "Microtubule ends, Cytosol" "CAB004399: AB_671001, HPA026678: AB_1846954" "unprognostic (1.18e-1)" "unprognostic (2.01e-1)" "unprognostic (1.72e-1)" "unprognostic (4.91e-2)" "unprognostic (6.28e-2)" "unprognostic (2.28e-1)" "unprognostic (1.20e-1)" "unprognostic (4.73e-2)" "unprognostic (2.51e-1)" "unprognostic (7.62e-2)" "unprognostic (2.31e-2)" "unprognostic (8.97e-2)" "unprognostic (3.26e-2)" "unprognostic (5.50e-2)" "unprognostic (2.63e-1)" "unprognostic (3.37e-1)" "unprognostic (2.52e-3)" 14.4 12.6 9.8 9.1 10.9 6.4 11.7 44.5 11.5 11.6 19.5 4.3 13.9 5.7 14.3 10.1 24.8 7.5 7.7 11.8 9.3 7.5 10.0 15.2 10.0 5.8 6.5 9.5 6.3 9.1 37.8 10.9 36.5 8.7 13.2 7.1 6.7 11.8 15.1 96.5 16.8 9.1 31.1 7.2 5.9 9.6 6.1 6.9 3.7 24.1 25.9 10.1 22.2 16.6 5.3 5.4 18.2 10.6 3.9 7.2 3.7 15.3 19.4 12.0 12.1 10.3 15.9 20.9 21.9 20.9 14.9 9.3 9.0 7.6 6.9 14.8 28.4 19.7 7.6 9.0 16.9 28.9 5.5 2.3 12.9 9.5 20.5 7.9 12.7 10.5 31.0 17.1 25.9 14.9 8.6 4.7 14.9 8.9 4.9 2.8 4.5 17.2 4.6 9.3 3.4 13.4 17.6 4.6 2.9 47.0 11.5 19.2 9.9 4.7 28.8 11.3 12.2 26.5 14.3 5.3 4.1 4.1 19.4 4.0 7.8 3.6 6.5 5.2 7.2 10.6 5.4 5.3 6.7 6.5 5.4 3.6 5.0 3.7 18.2 3.9 8.6 3.5 5.8 3.7 9.8 10.9 44.5 11.5 9.3 7.5 6.5 9.5 8.7 6.9 CLTC "CLTCL2, Hc" ENSG00000141367 "Clathrin heavy chain" Q00610 17 59619689-59696956 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Autophagy, Cell cycle, Cell division, Mitosis" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "CAB010389, CAB011571, CAB017155, HPA059143" Approved Enhanced "Vesicles,Endosomes,Lysosomes,Mitotic spindle,Cytosol" 51000000 "Vesicles, Endosomes, Lysosomes" "Mitotic spindle, Cytosol" "CAB010389: AB_2083184, CAB011571: AB_2083165, CAB017155: , HPA059143: " "unprognostic (1.56e-1)" "prognostic unfavourable (7.35e-4)" "prognostic favourable (7.65e-4)" "unprognostic (1.03e-1)" "unprognostic (2.62e-1)" "unprognostic (5.23e-3)" "prognostic unfavourable (5.54e-4)" "unprognostic (1.11e-1)" "unprognostic (6.43e-2)" "unprognostic (1.09e-1)" "unprognostic (3.34e-2)" "unprognostic (2.69e-1)" "unprognostic (1.49e-1)" "unprognostic (1.18e-1)" "unprognostic (9.22e-2)" "unprognostic (1.10e-1)" "prognostic unfavourable (2.02e-4)" 39.5 45.7 47.4 35.1 57.6 30.7 57.9 59.1 83.6 38.1 45.0 25.1 47.7 27.9 38.7 52.3 32.1 30.9 34.1 39.9 47.1 53.7 48.6 46.0 46.5 60.7 53.9 59.3 29.8 23.3 96.1 30.0 51.5 57.0 38.9 48.9 22.7 28.6 54.4 44.2 30.5 27.7 45.8 47.8 28.0 34.2 29.4 28.8 28.0 43.7 26.6 31.2 37.1 40.6 10.0 24.6 13.9 24.6 12.3 15.6 13.1 46.9 71.1 35.1 34.7 59.3 48.3 40.1 50.5 53.3 45.3 47.3 43.5 28.9 32.7 58.0 71.7 31.0 52.2 42.0 60.5 35.1 28.1 53.6 45.0 67.5 45.2 36.6 31.0 45.7 25.7 68.8 44.4 50.0 53.3 46.3 70.5 83.7 21.7 10.9 30.2 41.5 19.3 58.8 39.6 50.7 66.7 31.5 37.5 31.3 20.5 29.9 48.7 23.1 63.9 83.1 49.6 39.6 51.7 36.5 51.2 30.2 60.9 24.8 50.7 10.5 20.9 13.9 12.7 24.6 15.6 10.0 11.7 13.7 24.6 9.1 10.0 11.0 13.4 12.3 20.7 16.1 14.5 13.1 47.4 57.6 59.1 83.6 47.1 53.7 53.9 59.3 57.0 28.8 CLTCL1 "CHC22, CLH22, CLTCL, CLTD" ENSG00000070371 "Clathrin heavy chain like 1" P53675 22 19179473-19291716 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skeletal muscle: 53.0" "Cell line enhanced" "Detected in many" "HMC-1: 34.3;K-562: 16.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 8 "classical monocyte: 3.3;neutrophil: 8.4" "Group enriched" "Detected in many" 15 "granulocytes: 8.4;monocytes: 3.3" "HPA075327, HPA075795" Enhanced Approved Vesicles Vesicles "HPA075327: , HPA075795: " "unprognostic (1.29e-2)" "unprognostic (3.13e-2)" "unprognostic (1.93e-2)" "unprognostic (3.16e-3)" "unprognostic (8.20e-2)" "unprognostic (6.93e-3)" "unprognostic (1.60e-1)" "unprognostic (3.28e-1)" "unprognostic (4.42e-2)" "unprognostic (2.93e-3)" "unprognostic (3.14e-1)" "unprognostic (1.02e-1)" "unprognostic (1.20e-1)" "unprognostic (8.71e-4)" "unprognostic (1.61e-1)" "unprognostic (2.10e-2)" "unprognostic (1.06e-1)" 2.9 3.3 1.1 0.9 2.0 9.7 1.6 3.4 1.8 1.3 1.0 3.7 1.2 0.4 2.3 3.1 2.2 1.4 0.9 5.6 1.3 1.7 1.0 1.7 1.2 0.6 2.7 1.4 1.4 0.9 2.1 14.9 1.1 4.1 1.8 0.8 4.2 1.5 1.1 53.0 2.1 0.9 2.4 3.6 0.9 1.0 17.2 1.2 1.3 2.7 10.4 0.7 1.2 1.3 0.2 0.3 8.4 3.3 0.0 0.3 0.6 2.2 2.3 1.5 2.5 5.8 3.2 0.7 1.6 1.7 2.3 3.4 0.8 0.7 0.9 0.2 3.6 0.8 2.4 4.5 1.8 0.1 2.4 0.1 2.2 2.7 2.9 3.2 34.3 13.7 3.7 4.1 5.8 1.4 16.0 0.9 5.2 1.8 0.4 11.4 2.0 1.9 1.2 13.1 0.0 1.7 0.9 3.7 0.6 3.4 2.1 0.2 4.6 13.8 0.4 4.0 8.6 2.2 2.6 1.8 4.2 0.4 2.4 8.8 0.8 0.0 3.3 0.3 0.1 0.7 0.0 0.0 0.1 0.3 0.3 0.2 0.3 0.0 8.4 0.0 0.0 0.1 0.0 0.6 1.1 2.0 3.4 1.8 1.3 1.7 2.7 1.4 4.1 1.2 CNBP "CNBP1, DM2, RNF163, ZCCHC22, ZNF9" ENSG00000169714 "CCHC-type zinc finger nucleic acid binding protein" P62633 3 129169484-129183922 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA063097 Supported Nucleoplasm,Cytosol 43000 "Nucleoplasm, Cytosol" "HPA063097: " "unprognostic (1.74e-1)" "unprognostic (3.11e-2)" "unprognostic (4.84e-1)" "unprognostic (3.35e-2)" "unprognostic (6.28e-2)" "unprognostic (7.38e-2)" "unprognostic (7.02e-3)" "unprognostic (1.23e-1)" "unprognostic (1.06e-3)" "unprognostic (6.39e-2)" "prognostic unfavourable (3.51e-4)" "unprognostic (4.72e-3)" "unprognostic (4.62e-3)" "unprognostic (1.89e-1)" "unprognostic (2.03e-1)" "unprognostic (2.51e-1)" "unprognostic (1.58e-1)" 54.2 52.8 36.4 33.6 33.7 35.9 46.6 43.5 35.6 58.1 47.1 34.5 40.5 32.4 54.5 49.4 55.6 40.9 48.5 78.2 33.0 32.0 38.0 71.6 47.5 40.6 39.7 30.3 67.4 65.4 39.3 33.5 41.5 33.3 62.3 37.1 41.3 48.9 50.9 182.1 46.7 40.6 71.9 38.0 43.2 43.1 32.1 33.1 39.0 67.3 81.1 41.2 76.1 63.5 74.3 60.3 120.1 84.1 61.7 83.4 172.9 61.2 36.3 53.0 42.0 53.0 45.5 41.8 48.2 76.5 52.6 60.5 53.2 43.2 81.5 41.4 44.8 46.1 69.2 55.9 71.3 54.7 50.4 78.7 37.5 57.2 52.8 84.4 45.3 43.9 65.6 36.8 133.0 46.4 58.9 56.1 55.0 73.3 78.2 62.1 64.6 61.4 68.8 49.2 97.1 54.4 59.1 72.2 57.8 38.0 37.6 102.2 43.3 58.1 48.8 39.0 38.4 53.5 48.7 52.8 48.0 128.2 40.1 57.9 51.4 93.4 84.1 96.8 64.1 63.8 80.6 74.3 77.4 68.9 60.3 62.7 83.4 72.0 120.1 61.7 48.9 35.1 73.9 172.9 36.4 33.7 43.5 35.6 33.0 32.0 39.7 30.3 33.3 33.1 CNTRL "CEP1, CEP110" ENSG00000119397 Centriolin Q7Z7A1 9 121074863-121177610 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HL-60: 34.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA020468, HPA020480, HPA051583" Approved Supported Centrosome,Cytosol Centrosome Cytosol "HPA020468: , HPA020480: , HPA051583: " "unprognostic (4.33e-3)" "unprognostic (2.89e-3)" "unprognostic (2.09e-2)" "unprognostic (7.97e-2)" "unprognostic (1.17e-2)" "prognostic favourable (9.21e-5)" "unprognostic (1.05e-2)" "unprognostic (3.22e-3)" "unprognostic (3.74e-3)" "unprognostic (2.02e-1)" "unprognostic (1.78e-2)" "unprognostic (5.47e-2)" "unprognostic (3.60e-3)" "unprognostic (9.83e-3)" "unprognostic (2.43e-1)" "unprognostic (3.57e-2)" "unprognostic (1.13e-2)" 7.7 4.7 5.5 22.2 11.7 24.0 6.8 10.9 8.7 8.4 5.5 4.9 5.9 3.8 7.3 6.4 5.6 8.4 5.1 4.4 6.6 4.3 4.0 3.8 9.3 20.3 8.1 4.1 10.6 5.2 4.0 17.3 5.8 7.0 7.2 5.5 4.4 6.3 8.6 2.8 5.2 8.8 5.7 9.7 14.8 7.1 30.2 9.8 26.7 6.2 4.2 19.2 8.6 7.1 12.7 10.5 15.0 6.9 4.8 10.4 2.5 5.3 3.6 10.0 7.2 1.5 2.3 1.7 3.7 2.8 2.9 2.5 2.1 5.9 24.6 1.4 2.7 11.3 3.3 2.2 4.8 14.9 2.6 12.8 6.5 2.5 2.1 34.8 15.6 1.4 1.7 3.1 7.5 6.4 8.3 14.1 2.8 3.4 13.6 11.9 3.4 2.9 12.9 15.1 7.0 1.4 2.5 3.8 5.7 12.7 2.3 2.9 4.9 16.7 4.7 3.1 5.4 4.8 6.8 9.8 10.7 16.7 2.6 14.4 7.1 12.2 6.9 15.0 7.5 4.5 5.7 10.8 7.7 5.5 3.4 12.7 9.3 6.6 2.7 4.8 5.8 10.5 10.4 2.5 5.5 11.7 10.9 8.7 6.6 4.3 8.1 4.1 7.0 9.8 COL1A1 OI4 ENSG00000108821 "Collagen type I alpha 1 chain" P02452 17 50183289-50201632 "Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cancer-related genes, Disease mutation, Dwarfism, Ehlers-Danlos syndrome, FDA approved drug targets, Osteogenesis imperfecta" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "cervix, uterine: 415.7" "Cell line enhanced" "Detected in some" "ASC TERT1: 89.7;BJ: 172.4;fHDF/TERT166: 260.2;HSkMC: 131.8;U-138 MG: 140.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in some" "Cell type enriched" "Detected in single" 5 "naive CD8 T-cell: 1.1" "Lineage enriched" "Detected in single" 5 "T-cells: 1.1" "Low region specificity" "Detected in many" "Low region specificity" "Detected in some" HPA011795 Approved Approved Vesicles,Cytosol "Secreted to extracellular matrix" 58000000 Cytosol Vesicles "HPA011795: AB_1847088" "unprognostic (1.61e-1)" "unprognostic (3.60e-3)" "unprognostic (8.29e-2)" "unprognostic (5.52e-2)" "unprognostic (7.74e-2)" "unprognostic (2.22e-1)" "unprognostic (6.01e-2)" "prognostic unfavourable (4.43e-4)" "unprognostic (1.23e-2)" "unprognostic (2.55e-2)" "unprognostic (8.53e-2)" "unprognostic (9.90e-2)" "prognostic unfavourable (7.19e-12)" "unprognostic (2.74e-2)" "unprognostic (4.73e-2)" "unprognostic (7.26e-2)" "unprognostic (3.87e-3)" 30.2 5.7 0.7 28.2 4.0 0.1 31.7 0.6 0.9 415.7 25.7 1.6 23.9 3.0 121.8 70.9 17.4 33.0 110.3 43.9 0.7 0.1 7.5 4.6 18.8 38.5 0.7 1.2 73.6 10.5 1.0 10.7 89.1 2.2 31.5 4.0 9.2 9.1 21.0 11.0 35.5 10.6 88.0 1.3 13.7 15.0 44.6 0.7 7.7 6.7 15.5 8.7 67.3 49.7 0.2 0.0 0.0 0.0 0.0 1.1 0.0 0.3 0.2 0.9 0.1 36.9 89.7 1.5 172.4 46.8 43.0 27.0 3.4 0.8 0.0 0.4 260.2 0.5 0.4 0.1 7.7 0.2 0.3 0.0 4.3 0.2 70.3 0.0 0.0 131.8 2.5 52.5 0.2 0.0 0.1 0.0 21.6 0.4 0.0 0.0 0.9 0.5 0.3 0.1 0.1 0.2 0.0 0.1 0.4 0.3 0.2 0.0 2.2 0.0 0.0 140.1 30.6 20.9 0.8 0.1 0.3 0.0 10.4 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.7 4.0 0.6 0.9 0.7 0.1 0.7 1.2 2.2 0.7 COL2A1 "AOM, SEDC, STL1" ENSG00000139219 "Collagen type II alpha 1 chain" P02458 12 47972965-48004554 "Cancer-related genes, Disease related genes, Predicted secreted proteins" "Cancer-related genes, Cataract, Deafness, Disease mutation, Dwarfism, Stickler syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "epididymis: 22.7;pituitary gland: 11.0;retina: 8.1;stomach 1: 11.3" "Cell line enhanced" "Detected in some" "AF22: 54.0;HAP1: 33.8;HEK 293: 12.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB002214, HPA055753" Supported Approved Nucleoplasm "Secreted to extracellular matrix" Nucleoplasm "CAB002214: AB_563666, HPA055753: " "unprognostic (7.25e-2)" "unprognostic (1.20e-1)" "unprognostic (2.58e-1)" "unprognostic (3.44e-1)" "unprognostic (2.88e-2)" "unprognostic (3.08e-2)" "unprognostic (8.63e-2)" "unprognostic (2.77e-1)" "unprognostic (1.22e-1)" "unprognostic (3.12e-2)" "unprognostic (1.31e-4)" "unprognostic (2.64e-1)" "unprognostic (3.44e-3)" "unprognostic (1.89e-1)" "unprognostic (2.93e-1)" "unprognostic (2.07e-1)" "unprognostic (1.02e-1)" 0.0 0.0 0.1 2.2 0.3 0.0 0.7 0.9 0.9 0.0 0.2 0.3 0.0 0.0 0.3 22.7 0.0 0.0 0.0 0.0 0.5 1.3 0.0 0.0 1.4 0.0 0.0 0.7 1.3 0.0 0.0 11.0 0.4 1.9 2.6 0.4 8.1 0.0 0.0 0.0 0.0 0.2 0.0 0.6 0.0 11.3 2.8 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 54.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.2 0.0 0.0 33.8 0.0 0.0 0.0 12.5 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.7 0.0 0.0 1.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.9 0.9 0.5 1.3 0.0 0.7 1.9 0.0 CREB1 ENSG00000118260 "CAMP responsive element binding protein 1" P16220 2 207529737-207603431 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Differentiation, Host-virus interaction, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003803, HPA019150" Supported Enhanced Nucleoplasm Nucleoplasm "CAB003803: AB_562092, HPA019150: AB_1847220" "unprognostic (1.20e-1)" "unprognostic (3.15e-1)" "unprognostic (3.30e-2)" "unprognostic (2.69e-2)" "unprognostic (3.16e-2)" "unprognostic (1.03e-1)" "prognostic unfavourable (2.77e-5)" "unprognostic (8.41e-2)" "unprognostic (1.04e-2)" "unprognostic (2.53e-1)" "unprognostic (9.58e-2)" "unprognostic (1.74e-2)" "unprognostic (4.82e-3)" "unprognostic (5.53e-3)" "unprognostic (1.06e-1)" "unprognostic (1.77e-1)" "unprognostic (8.45e-2)" 21.2 12.9 19.4 24.8 17.0 22.9 16.7 25.5 18.7 17.6 15.7 14.3 14.7 12.6 19.3 14.9 17.9 15.4 15.5 14.4 15.4 14.5 14.6 13.1 17.7 21.7 15.8 17.7 20.5 12.9 19.8 20.0 19.8 16.1 16.3 16.2 11.2 16.2 14.9 11.6 14.3 15.2 19.5 19.8 19.0 13.3 39.2 18.5 38.4 19.7 13.3 27.7 16.1 23.6 22.1 20.7 34.8 19.1 28.4 22.5 14.5 15.4 13.8 25.7 9.8 15.1 15.5 14.6 9.9 14.9 17.3 18.2 14.0 15.7 10.0 13.4 14.6 13.5 23.2 13.6 25.5 16.0 8.4 18.4 12.4 14.3 12.6 17.3 13.5 11.1 10.1 14.3 21.3 24.3 12.9 14.7 21.3 10.6 26.4 10.3 18.3 8.4 20.6 14.0 13.2 15.4 16.0 17.7 15.4 13.8 10.1 11.9 11.3 19.0 11.6 14.1 15.1 14.8 12.7 13.3 16.8 23.1 17.4 16.0 14.8 16.9 17.0 16.8 17.3 18.0 15.4 22.1 16.6 16.7 20.7 20.2 19.9 13.5 34.8 28.4 19.1 11.3 22.5 14.5 19.4 17.0 25.5 18.7 15.4 14.5 15.8 17.7 16.1 18.5 CREB3L1 OASIS ENSG00000157613 "CAMP responsive element binding protein 3 like 1" Q96BA8 11 46277661-46321422 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors" "Host-virus interaction, Transcription, Transcription regulation, Unfolded protein response" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Osteogenesis imperfecta" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "pancreas: 60.7" "Cell line enhanced" "Detected in many" "BJ: 30.0;BJ hTERT+: 29.5;BJ hTERT+ SV40 Large T+: 27.6;fHDF/TERT166: 71.4;HHSteC: 26.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" "HPA024069, CAB026151" Enhanced "CAB026151: , HPA024069: AB_1854750" "unprognostic (2.46e-2)" "unprognostic (2.80e-1)" "unprognostic (1.34e-1)" "prognostic favourable (3.92e-4)" "unprognostic (1.66e-3)" "unprognostic (2.93e-1)" "unprognostic (5.41e-2)" "unprognostic (2.75e-2)" "unprognostic (3.21e-2)" "unprognostic (3.13e-1)" "unprognostic (1.54e-1)" "unprognostic (1.87e-1)" "prognostic unfavourable (2.97e-4)" "unprognostic (2.62e-1)" "unprognostic (1.93e-1)" "prognostic unfavourable (8.59e-4)" "unprognostic (1.12e-2)" 2.5 3.6 3.7 3.1 2.3 0.0 3.0 1.6 2.9 17.2 13.1 0.9 9.5 8.6 9.7 9.2 2.2 1.7 37.6 4.8 3.3 3.5 1.4 1.5 10.4 0.5 3.4 1.7 9.7 60.7 0.0 3.3 8.2 0.6 17.6 14.1 1.8 28.3 14.3 1.6 2.3 12.9 12.8 1.8 2.2 22.1 3.8 0.2 0.4 1.8 2.2 13.0 15.1 3.4 0.0 0.1 0.0 0.4 0.1 0.0 0.0 0.2 0.1 0.3 5.9 19.1 18.3 0.1 30.0 29.5 27.6 19.2 3.0 0.0 0.0 0.1 71.4 0.0 0.3 0.0 15.4 0.0 0.3 0.4 0.1 0.0 26.6 0.0 0.4 17.5 0.0 15.6 0.5 0.2 2.4 0.0 23.1 0.0 0.0 0.0 3.8 3.1 0.0 4.1 0.0 0.0 0.0 0.0 0.0 0.2 0.7 0.0 0.0 1.0 0.0 14.5 4.3 11.1 18.2 0.0 0.0 0.0 17.3 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 3.7 2.3 1.6 2.9 3.3 3.5 3.4 1.7 0.6 0.2 CREB3L2 "BBF2H7, TCAG_1951439" ENSG00000182158 "CAMP responsive element binding protein 3 like 2" Q70SY1 7 137874979-138002067 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors" "Transcription, Transcription regulation, Unfolded protein response" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 81.6" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA015068, HPA015534" Uncertain Supported "Nucleoplasm,Endoplasmic reticulum" "Nucleoplasm, Endoplasmic reticulum" "HPA015068: AB_1847224, HPA015534: " "unprognostic (8.50e-2)" "unprognostic (3.70e-2)" "unprognostic (2.77e-1)" "unprognostic (1.50e-3)" "unprognostic (9.88e-2)" "unprognostic (9.09e-2)" "unprognostic (5.17e-2)" "unprognostic (4.50e-1)" "unprognostic (4.77e-1)" "unprognostic (8.93e-2)" "unprognostic (9.48e-2)" "unprognostic (9.65e-2)" "unprognostic (2.42e-1)" "unprognostic (3.08e-3)" "unprognostic (7.65e-2)" "unprognostic (2.59e-2)" "unprognostic (1.32e-2)" 14.9 19.8 4.7 17.1 9.8 10.8 15.7 1.9 6.0 25.4 16.7 11.4 18.7 11.6 28.2 25.5 12.8 16.2 16.2 20.4 5.6 4.3 17.0 11.7 14.6 15.2 11.8 3.7 25.9 16.0 38.4 28.8 81.6 9.8 15.9 9.5 24.9 26.5 23.3 5.0 6.9 17.5 17.7 6.2 12.1 14.1 9.8 9.1 7.0 35.8 10.9 18.1 21.3 15.7 4.6 12.4 7.4 5.6 6.5 11.8 3.2 4.0 6.2 11.8 0.2 20.2 20.1 8.9 20.0 32.5 14.1 14.2 8.5 3.6 0.8 5.4 21.7 2.1 6.9 14.7 27.6 5.8 3.4 25.3 8.5 20.2 13.4 7.6 36.3 8.3 9.4 17.7 20.8 18.5 13.0 11.8 16.4 7.2 2.4 9.4 4.2 4.4 5.3 6.4 6.7 11.0 4.1 3.0 7.1 6.5 16.9 8.9 2.4 5.7 19.7 18.9 2.9 22.7 7.3 14.0 4.8 5.3 22.7 21.5 41.9 7.4 5.6 5.9 8.2 2.9 10.6 4.0 6.0 8.6 5.8 4.6 2.2 3.8 2.1 6.5 1.5 12.4 11.8 3.2 4.7 9.8 1.9 6.0 5.6 4.3 11.8 3.7 9.8 9.1 CREBBP "CBP, KAT3A, RSTS, RTS" ENSG00000005339 "CREB binding protein" Q92793 16 3725054-3880726 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Biological rhythms, Host-virus interaction, Transcription, Transcription regulation" "Activator, Acyltransferase, Transferase" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004212, HPA055861" Supported Enhanced "Nucleoplasm,Nuclear bodies" Nucleoplasm "Nuclear bodies" "CAB004212: AB_626817, HPA055861: " "unprognostic (1.17e-1)" "unprognostic (8.51e-2)" "unprognostic (1.60e-1)" "unprognostic (1.63e-1)" "unprognostic (1.49e-1)" "unprognostic (5.09e-2)" "unprognostic (9.59e-3)" "unprognostic (6.98e-2)" "unprognostic (8.96e-2)" "unprognostic (1.08e-1)" "unprognostic (1.76e-1)" "unprognostic (2.84e-1)" "prognostic favourable (6.24e-5)" "unprognostic (1.47e-1)" "unprognostic (1.74e-1)" "unprognostic (3.97e-2)" "unprognostic (8.23e-2)" 18.5 10.9 17.2 22.8 17.5 37.0 17.4 42.6 18.8 20.1 17.2 16.8 17.1 9.9 25.1 15.2 14.1 18.9 21.3 14.5 17.1 8.7 11.1 12.3 16.9 14.4 20.5 12.0 31.6 23.4 24.3 13.0 13.3 15.8 18.4 11.6 14.6 14.9 16.7 28.2 20.4 16.4 17.0 13.6 17.4 14.7 29.1 20.2 29.6 19.5 13.8 16.1 19.0 29.9 4.7 2.3 10.6 3.8 2.0 2.7 1.1 5.5 14.3 18.6 8.2 11.4 11.3 9.6 8.0 13.5 13.9 13.5 12.9 10.5 15.4 9.6 15.3 10.8 21.4 6.6 15.8 26.0 8.6 12.1 13.2 8.2 12.6 12.1 17.4 10.0 6.7 15.4 18.6 10.4 13.7 21.1 7.5 19.1 8.0 5.8 15.2 5.9 37.8 14.7 11.8 5.4 7.5 15.5 10.2 13.7 13.5 8.1 12.0 11.9 16.1 17.0 16.9 8.7 7.3 9.9 10.6 29.9 3.4 7.3 11.9 2.9 1.7 1.3 2.7 2.2 1.4 4.7 1.3 2.0 1.0 3.3 1.4 1.7 10.6 2.0 3.8 2.3 1.3 1.1 17.2 17.5 42.6 18.8 17.1 8.7 20.5 12.0 15.8 20.2 CRLF2 "CRL2, TSLPR" ENSG00000205755 "Cytokine receptor like factor 2" Q9HC73 X 1187549-1212750 "Cancer-related genes, Predicted membrane proteins" Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "endometrium 1: 7.8" "Cell line enhanced" "Detected in some" "HMC-1: 18.1;RPMI-8226: 4.6;U-698: 3.9" "Cancer enhanced" "Detected in single" "thyroid cancer: 1.0" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 43 "plasmacytoid DC: 4.3" "Lineage enriched" "Detected in single" 43 "dendritic cells: 4.3" "Intracellular and membrane" "unprognostic (7.84e-2)" "unprognostic (7.99e-4)" "unprognostic (6.02e-3)" "unprognostic (2.01e-2)" "unprognostic (1.15e-3)" "unprognostic (2.31e-6)" "unprognostic (1.72e-1)" "unprognostic (5.10e-2)" "unprognostic (4.59e-3)" "unprognostic (1.09e-1)" "unprognostic (1.46e-2)" "unprognostic (9.72e-3)" "unprognostic (6.88e-5)" "unprognostic (7.09e-3)" "unprognostic (4.81e-2)" "unprognostic (2.89e-2)" "unprognostic (1.62e-1)" 0.8 0.0 0.2 4.1 0.2 4.1 0.6 0.2 0.2 3.0 0.7 0.2 0.2 0.2 7.8 0.2 0.9 0.2 3.7 0.2 0.2 0.1 0.9 0.2 1.9 0.2 0.2 0.2 0.2 0.2 0.0 0.2 1.0 0.2 0.6 0.9 0.2 0.8 0.2 0.2 0.7 1.5 0.3 0.2 0.6 1.0 0.2 0.2 0.2 0.2 0.2 1.4 1.3 0.6 0.0 4.3 0.0 0.0 0.0 0.0 0.0 0.2 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.5 0.0 0.6 1.0 0.2 0.3 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.1 0.0 0.0 0.0 18.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.5 4.6 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.4 0.0 0.0 0.2 0.0 0.0 0.7 1.0 3.9 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.3 0.0 0.0 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.2 CRTC1 "FLJ14027, KIAA0616, MECT1, TORC1" ENSG00000105662 "CREB regulated transcription coactivator 1" Q6UUV9 19 18683677-18782333 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Biological rhythms, Host-virus interaction, Transcription, Transcription regulation" Activator "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 40.7" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA022035 Enhanced Supported "Nucleoplasm,Nuclear bodies,Plasma membrane,Cytosol" "Nucleoplasm, Nuclear bodies" "Plasma membrane, Cytosol" "HPA022035: AB_1847255" "unprognostic (5.95e-3)" "unprognostic (2.57e-1)" "unprognostic (9.94e-2)" "unprognostic (8.62e-3)" "unprognostic (9.07e-2)" "unprognostic (1.57e-2)" "unprognostic (1.04e-1)" "unprognostic (5.57e-2)" "unprognostic (2.27e-1)" "unprognostic (6.68e-2)" "prognostic favourable (1.80e-5)" "unprognostic (3.37e-2)" "prognostic favourable (3.83e-5)" "unprognostic (6.83e-3)" "unprognostic (1.02e-1)" "unprognostic (2.51e-2)" "unprognostic (2.03e-2)" 8.6 7.7 26.0 7.4 38.8 3.2 3.8 40.7 30.1 5.0 4.4 6.5 4.3 6.5 6.8 5.6 3.1 10.5 5.5 5.6 17.7 7.8 6.6 4.5 5.7 6.3 6.4 18.1 6.7 10.0 8.4 11.3 6.4 6.0 7.0 2.6 5.1 8.8 9.4 12.4 5.5 6.2 4.3 4.8 8.1 8.0 7.5 10.2 1.9 7.4 1.1 3.7 4.6 3.5 4.1 3.8 1.8 3.4 1.1 3.0 1.3 4.3 8.0 5.8 9.3 5.4 4.6 16.5 4.8 3.2 4.6 4.5 5.4 5.7 6.1 10.2 4.6 4.7 1.7 3.0 1.1 2.7 13.9 5.1 7.1 8.8 5.2 7.0 14.5 7.4 2.9 4.0 1.2 2.6 4.0 5.6 2.6 16.0 4.5 8.1 7.5 11.8 7.2 2.5 6.7 2.9 7.8 10.7 9.6 5.4 5.2 5.8 5.8 4.3 4.6 5.3 8.1 9.6 5.5 3.8 3.0 4.0 6.1 7.6 4.0 1.5 3.4 1.8 1.7 1.3 1.8 2.3 2.7 3.0 3.0 4.1 2.3 1.8 1.7 1.1 1.9 3.8 1.8 1.3 26.0 38.8 40.7 30.1 17.7 7.8 6.4 18.1 6.0 10.2 CRTC3 FLJ21868 ENSG00000140577 "CREB regulated transcription coactivator 3" Q6UUV7 15 90529925-90645345 "Cancer-related genes, Predicted intracellular proteins" "Host-virus interaction, Transcription, Transcription regulation" Activator "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HeLa: 39.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 16.0" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA043735, HPA063691" Uncertain Enhanced Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA043735: AB_10794286, HPA063691: " "unprognostic (7.60e-2)" "unprognostic (6.13e-2)" "unprognostic (1.35e-1)" "unprognostic (2.31e-2)" "unprognostic (5.12e-2)" "unprognostic (3.51e-1)" "unprognostic (1.75e-2)" "unprognostic (1.69e-1)" "unprognostic (6.48e-2)" "unprognostic (3.60e-1)" "unprognostic (1.47e-1)" "unprognostic (2.23e-1)" "unprognostic (5.22e-3)" "unprognostic (4.67e-2)" "unprognostic (9.32e-2)" "unprognostic (9.51e-2)" "unprognostic (2.30e-1)" 22.3 14.0 13.7 17.0 20.9 11.4 26.6 15.0 16.2 21.2 22.2 27.5 15.3 8.9 23.9 14.5 15.1 19.4 21.5 17.2 14.0 9.7 10.7 11.7 19.2 21.7 24.1 10.9 45.9 13.9 17.1 9.6 20.2 15.7 18.2 11.7 17.4 19.9 22.0 16.1 15.8 13.7 31.8 20.3 13.1 14.2 15.3 23.6 12.8 22.7 9.2 18.1 24.0 29.6 5.3 2.1 16.0 2.5 3.3 6.6 3.0 4.7 7.9 5.4 8.8 11.7 8.7 24.7 6.1 8.9 9.6 9.1 6.5 4.8 0.1 4.4 12.6 8.0 8.6 5.3 7.6 8.2 10.0 12.1 39.3 3.0 13.3 3.1 20.7 9.7 8.5 7.9 10.7 6.9 6.4 2.8 7.1 5.5 1.3 4.5 1.9 3.7 4.1 8.6 0.2 3.4 10.1 9.9 8.8 17.8 5.9 9.9 5.9 5.9 8.5 10.7 7.9 9.9 7.0 3.7 5.0 3.6 4.4 6.3 5.1 16.0 2.5 1.4 3.7 0.8 4.2 3.1 4.5 4.0 1.6 5.3 6.6 4.1 0.5 3.3 0.3 2.1 4.2 3.0 13.7 20.9 15.0 16.2 14.0 9.7 24.1 10.9 15.7 23.6 CTNNB1 "armadillo, beta-catenin, CTNNB" ENSG00000168036 "Catenin beta 1" P35222 3 41194741-41260096 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell adhesion, Host-virus interaction, Neurogenesis, Transcription, Transcription regulation, Wnt signaling pathway" Activator "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000108, CAB001950, HPA029159, HPA029160" Supported Enhanced "Plasma membrane" 1000000 "Plasma membrane" "CAB000108: , CAB001950: , HPA029159: AB_10599619, HPA029160: AB_10600996" "unprognostic (2.47e-1)" "unprognostic (3.48e-2)" "prognostic favourable (7.54e-4)" "unprognostic (1.61e-1)" "unprognostic (9.55e-2)" "unprognostic (1.05e-2)" "unprognostic (3.20e-3)" "unprognostic (2.79e-1)" "unprognostic (1.57e-1)" "unprognostic (1.80e-2)" "unprognostic (1.88e-2)" "unprognostic (9.05e-2)" "unprognostic (1.97e-3)" "unprognostic (1.82e-2)" "unprognostic (1.17e-1)" "unprognostic (2.61e-1)" "unprognostic (9.79e-2)" 52.9 54.5 38.8 33.5 45.9 46.3 70.5 78.8 59.3 71.7 49.6 57.3 34.2 48.7 79.2 42.5 46.3 49.8 45.0 42.1 38.6 41.5 46.9 53.2 53.6 31.6 37.0 47.0 84.2 38.6 59.2 44.0 82.6 41.5 50.8 50.1 75.9 53.9 49.7 31.2 44.7 70.4 66.5 39.4 41.0 37.3 29.0 39.3 40.1 62.3 44.5 36.6 46.9 54.2 10.1 13.5 7.5 14.5 11.1 13.5 4.8 22.6 30.2 63.7 35.6 34.4 28.2 48.9 25.6 36.4 42.8 42.5 20.8 32.4 18.6 23.4 45.2 17.0 46.1 73.9 45.9 17.2 31.4 30.0 40.1 74.3 25.7 17.0 14.4 41.0 33.5 51.1 31.1 37.6 21.2 11.6 47.4 23.0 11.9 9.2 58.0 23.5 9.0 41.5 12.4 26.5 70.9 15.2 25.8 42.4 21.6 113.7 35.4 35.4 48.4 32.2 24.7 20.6 37.5 7.2 11.2 19.8 33.0 21.5 53.7 4.3 8.1 6.9 11.2 14.5 13.5 9.6 10.5 12.1 13.5 10.1 10.7 10.8 7.5 11.1 13.7 11.7 12.6 4.8 38.8 45.9 78.8 59.3 38.6 41.5 37.0 47.0 41.5 39.3 CUX1 "CASP, CDP, CDP/Cut, CDP/Cux, CDP1, Clox, CUT, CUTL1, CUX, Cux/CDP, GOLIM6" ENSG00000257923 "Cut like homeobox 1" "Q13948, P39880" 7 101815904-102283958 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors" "Transcription, Transcription regulation, Transport" "Developmental protein, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "non-classical monocyte: 21.0" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003277, HPA003317" Approved Supported "Nucleoplasm,Golgi apparatus" "Nucleoplasm, Golgi apparatus" "HPA003277: AB_10601804, HPA003317: " "unprognostic (5.86e-2)" "unprognostic (5.39e-3)" "unprognostic (9.62e-3)" "unprognostic (1.73e-1)" "prognostic unfavourable (7.51e-4)" "unprognostic (5.85e-2)" "unprognostic (1.54e-1)" "unprognostic (1.04e-1)" "unprognostic (1.50e-1)" "unprognostic (2.89e-3)" "unprognostic (2.20e-1)" "unprognostic (2.50e-1)" "prognostic favourable (5.72e-7)" "unprognostic (1.12e-1)" "unprognostic (8.85e-2)" "unprognostic (1.97e-2)" "unprognostic (2.97e-1)" 19.3 12.7 22.9 19.2 24.4 19.5 12.3 48.6 29.9 31.6 26.4 23.1 17.3 22.2 52.1 17.4 23.9 24.5 23.2 53.8 18.8 18.3 27.4 16.0 22.0 11.8 20.4 11.7 33.0 41.4 34.4 30.2 24.4 16.9 22.8 17.2 26.8 26.3 16.9 31.0 15.9 25.3 27.5 31.6 15.0 23.4 8.3 17.1 44.0 33.5 23.2 24.1 31.8 21.9 2.0 12.1 4.7 21.0 3.0 2.2 4.5 14.3 15.4 10.9 13.4 8.8 18.3 6.8 14.4 15.3 6.1 4.0 9.1 9.2 18.5 23.2 14.2 11.8 6.9 11.6 3.7 8.9 7.7 6.5 11.4 7.6 23.5 8.4 3.6 12.7 23.7 4.7 10.7 7.9 15.1 15.8 5.7 29.5 27.3 10.3 4.4 16.1 18.1 9.0 22.0 10.1 16.4 10.0 29.8 12.6 31.6 12.3 6.2 10.1 11.7 25.9 17.5 19.5 8.2 10.3 4.9 40.1 23.9 7.8 18.0 2.1 8.6 1.5 2.1 8.8 2.2 2.0 1.6 2.2 7.0 1.7 1.6 2.2 4.7 3.0 21.0 12.1 1.5 4.5 22.9 24.4 48.6 29.9 18.8 18.3 20.4 11.7 16.9 17.1 DCTN1 ENSG00000204843 "Dynactin subunit 1" Q14203 2 74361154-74392087 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Mitosis, Transport" "Amyotrophic lateral sclerosis, Cancer-related genes, Neurodegeneration, Neuropathy, Parkinsonism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009108, HPA034635, HPA071875" Approved Supported "Microtubules,Cytokinetic bridge,Mitotic spindle" 220000 Microtubules "Cytokinetic bridge, Mitotic spindle" "CAB009108: AB_2090601, HPA034635: , HPA071875: " "unprognostic (1.14e-1)" "unprognostic (7.19e-2)" "unprognostic (1.33e-3)" "unprognostic (4.08e-2)" "unprognostic (1.20e-1)" "unprognostic (2.67e-1)" "unprognostic (4.61e-3)" "unprognostic (2.11e-2)" "unprognostic (2.79e-1)" "unprognostic (3.73e-3)" "unprognostic (1.87e-1)" "unprognostic (2.26e-1)" "prognostic favourable (2.34e-7)" "unprognostic (5.41e-2)" "unprognostic (3.11e-1)" "unprognostic (7.86e-3)" "unprognostic (1.12e-3)" 20.7 21.1 36.0 13.7 54.6 11.1 14.0 45.9 70.9 23.5 17.1 37.8 8.9 11.8 18.5 9.8 22.9 19.7 15.1 37.7 39.5 35.8 13.5 10.0 18.9 10.9 37.7 40.3 21.9 15.2 70.2 21.6 17.2 54.6 16.5 14.0 13.2 23.5 21.7 39.5 19.9 13.7 26.5 32.2 12.4 16.0 25.5 26.7 9.4 17.0 9.5 12.8 17.2 18.0 11.6 12.1 12.9 15.8 9.8 16.7 15.5 18.7 22.0 20.7 21.6 38.0 28.3 16.7 30.3 31.6 38.6 27.6 29.2 14.5 25.9 12.4 62.8 18.8 25.2 38.4 29.5 32.1 25.4 26.8 17.7 24.5 29.3 14.6 33.2 34.0 18.8 41.9 25.1 33.0 11.5 18.5 29.1 16.1 26.5 15.1 22.3 23.4 23.8 36.4 18.5 21.4 11.6 25.5 22.6 16.9 20.4 18.2 13.1 10.6 24.9 35.2 25.6 15.1 22.4 11.5 9.1 23.5 32.9 23.8 24.6 7.3 11.4 12.9 16.7 14.2 13.5 11.6 9.5 12.4 12.1 8.6 6.8 7.5 9.8 9.8 15.8 9.6 8.1 15.5 36.0 54.6 45.9 70.9 39.5 35.8 37.7 40.3 54.6 26.7 DDIT3 "CHOP, CHOP10, GADD153" ENSG00000175197 "DNA damage inducible transcript 3" P35638 12 57516588-57521737 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Apoptosis, Cell cycle, Growth arrest, Stress response, Transcription, Transcription regulation, Unfolded protein response, Wnt signaling pathway" "Activator, DNA-binding, Repressor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HHSteC: 122.9;hTERT-HME1: 61.8;SK-MEL-30: 57.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 50.8" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA058416, HPA068416" Uncertain Supported Nucleoplasm Nucleoplasm "HPA058416: , HPA068416: " "unprognostic (1.12e-1)" "unprognostic (5.33e-2)" "unprognostic (2.20e-3)" "unprognostic (4.92e-2)" "unprognostic (7.86e-3)" "unprognostic (2.28e-1)" "prognostic unfavourable (6.55e-4)" "unprognostic (8.55e-2)" "unprognostic (1.26e-3)" "unprognostic (9.40e-3)" "unprognostic (4.92e-2)" "unprognostic (4.16e-2)" "unprognostic (3.52e-2)" "unprognostic (3.70e-1)" "unprognostic (1.62e-1)" "unprognostic (2.56e-1)" "unprognostic (6.76e-2)" 19.1 25.5 15.9 8.3 29.9 82.2 21.4 16.7 25.2 14.8 13.5 20.1 15.7 10.6 19.5 55.8 13.0 13.1 16.0 25.8 18.6 19.8 28.8 26.1 17.1 8.8 34.4 15.5 27.3 13.0 13.5 26.8 18.0 32.1 22.8 13.9 27.3 20.7 13.9 18.0 16.3 10.9 15.4 21.8 11.2 14.7 14.3 35.3 2.9 88.9 12.6 9.4 30.2 17.0 13.8 4.6 50.8 5.4 9.2 10.9 5.1 2.5 2.4 1.5 5.2 14.1 9.6 8.2 7.2 15.9 10.7 10.1 8.4 6.8 3.7 7.2 2.1 3.2 5.8 1.1 11.1 3.0 2.3 2.9 2.6 6.1 122.9 4.6 4.5 27.4 23.3 18.1 61.8 2.5 12.4 14.2 4.7 1.5 3.0 6.0 3.0 5.6 1.7 33.7 3.2 3.8 3.3 3.2 2.3 2.1 2.4 57.3 5.2 12.2 1.4 7.3 3.1 6.9 6.2 25.2 8.4 3.9 8.8 4.3 12.9 27.5 5.4 13.5 8.0 4.6 7.0 13.8 5.7 7.3 3.7 13.1 10.9 9.9 50.8 9.2 5.1 4.6 6.5 5.1 15.9 29.9 16.7 25.2 18.6 19.8 34.4 15.5 32.1 35.3 DDX10 "Dbp4, HRH-J8" ENSG00000178105 "DEAD-box helicase 10" Q13206 11 108665025-108940930 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Helicase, Hydrolase, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-698: 57.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA004691 Approved Approved Nucleoli Nucleoli "HPA004691: AB_1078629" "unprognostic (9.49e-2)" "unprognostic (9.32e-2)" "unprognostic (1.34e-1)" "unprognostic (2.58e-1)" "unprognostic (7.97e-2)" "unprognostic (1.48e-2)" "prognostic unfavourable (2.52e-5)" "unprognostic (2.86e-2)" "unprognostic (1.23e-2)" "unprognostic (1.06e-1)" "prognostic unfavourable (5.75e-4)" "unprognostic (1.00e-1)" "prognostic favourable (2.14e-5)" "unprognostic (5.20e-2)" "unprognostic (1.98e-1)" "unprognostic (4.64e-1)" "unprognostic (2.43e-3)" 14.0 11.9 17.3 15.0 20.3 10.4 15.5 20.5 18.3 14.3 12.2 8.1 11.7 8.8 18.4 12.8 12.6 16.8 8.8 12.1 13.5 11.5 19.6 12.5 10.6 13.1 12.2 16.3 18.6 18.0 16.7 22.2 12.9 13.1 12.4 13.3 7.9 10.6 14.7 13.6 14.8 9.1 16.8 13.3 15.0 11.3 25.1 12.6 13.8 13.4 8.8 14.2 14.3 18.8 11.6 8.4 1.4 6.7 9.4 11.3 4.3 7.2 7.1 6.8 9.5 6.7 5.5 7.1 7.8 4.2 9.5 9.4 20.3 10.7 24.7 14.8 6.0 8.2 19.4 9.5 13.7 9.4 8.7 16.8 4.2 7.6 12.0 17.1 8.0 4.9 7.5 10.8 13.5 8.6 23.5 2.7 9.3 4.7 14.3 14.4 8.8 10.9 12.2 11.1 23.1 5.8 6.3 12.6 6.7 11.0 9.7 4.1 11.7 6.0 9.1 10.0 10.2 9.5 10.6 4.2 7.3 57.2 3.4 20.6 10.1 1.4 5.0 1.0 8.6 6.7 11.3 10.4 7.5 10.1 8.4 11.6 8.1 7.8 0.7 9.4 6.4 8.2 6.3 4.3 17.3 20.3 20.5 18.3 13.5 11.5 12.2 16.3 13.1 12.6 DDX5 "G17P1, HLR1, p68" ENSG00000108654 "DEAD-box helicase 5" P17844 17 64499616-64508199 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Biological rhythms, mRNA processing, mRNA splicing, Transcription, Transcription regulation" "Helicase, Hydrolase, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005868, HPA020043" Supported Enhanced Nucleoplasm 150000 Nucleoplasm "CAB005868: AB_446484, HPA020043: AB_1847572" "unprognostic (6.64e-2)" "unprognostic (6.98e-2)" "prognostic favourable (2.12e-4)" "unprognostic (8.94e-2)" "unprognostic (5.08e-2)" "unprognostic (9.85e-2)" "unprognostic (5.80e-2)" "unprognostic (1.61e-2)" "unprognostic (3.17e-2)" "unprognostic (4.71e-2)" "unprognostic (3.03e-3)" "unprognostic (1.44e-1)" "unprognostic (4.00e-1)" "unprognostic (2.08e-1)" "unprognostic (2.37e-1)" "unprognostic (2.17e-1)" "unprognostic (9.28e-3)" 91.6 61.4 46.9 80.0 68.0 108.3 94.7 61.6 58.9 81.6 81.1 53.3 104.2 27.4 106.7 94.5 64.5 96.9 101.4 53.9 48.5 30.6 53.1 68.0 84.8 70.9 62.8 44.1 74.0 49.3 88.9 110.5 56.6 73.1 59.5 55.4 50.9 62.2 103.6 77.6 59.7 54.7 113.1 71.0 67.6 69.0 39.7 57.8 82.1 81.1 77.7 69.3 91.0 63.9 46.9 59.6 66.4 66.2 40.3 60.8 109.8 54.0 20.4 61.8 39.1 57.2 53.9 39.3 53.6 69.2 65.7 65.9 22.1 33.1 79.3 30.7 70.4 32.2 66.5 61.7 74.4 28.1 47.7 51.6 15.5 16.9 41.9 65.6 55.0 60.7 53.3 60.1 46.9 70.2 40.8 67.8 50.6 32.2 137.1 19.1 36.0 63.0 85.9 65.2 55.8 40.3 25.9 43.4 72.9 52.0 50.5 65.3 47.3 36.9 49.3 40.0 44.7 43.1 55.5 37.9 74.6 140.0 42.4 32.3 47.1 66.4 62.5 66.4 53.7 56.9 60.8 46.9 42.9 51.7 59.6 46.8 44.5 43.1 37.8 40.3 66.2 37.0 50.2 109.8 46.9 68.0 61.6 58.9 48.5 30.6 62.8 44.1 73.1 57.8 DDX6 "HLR2, RCK" ENSG00000110367 "DEAD-box helicase 6" P26196 11 118747766-118791149 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Helicase, Hydrolase, RNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004668, HPA024201, HPA026644" Approved Supported "Cytosol,Cytoplasmic bodies" "Cytoplasmic bodies" Cytosol "CAB004668: AB_436960, HPA024201: AB_10603562, HPA026644: AB_1847582" "unprognostic (1.26e-1)" "unprognostic (1.40e-1)" "unprognostic (1.89e-1)" "unprognostic (3.40e-2)" "unprognostic (4.12e-2)" "unprognostic (5.82e-2)" "prognostic unfavourable (6.56e-4)" "unprognostic (3.43e-1)" "unprognostic (1.48e-2)" "unprognostic (1.16e-1)" "unprognostic (1.00e-1)" "unprognostic (7.76e-2)" "unprognostic (1.98e-1)" "unprognostic (4.91e-3)" "unprognostic (1.88e-1)" "unprognostic (9.58e-2)" "unprognostic (4.55e-2)" 29.8 23.0 25.0 24.1 41.0 43.3 25.1 41.9 39.2 26.9 23.2 29.4 14.5 17.1 30.1 22.9 31.8 23.4 17.5 26.8 25.5 25.1 22.8 24.6 23.4 32.2 21.9 27.1 38.2 27.9 30.9 43.2 26.1 29.6 24.9 20.8 25.4 26.8 22.9 43.8 23.9 24.1 27.8 30.4 30.6 21.2 19.9 24.0 46.0 27.9 19.4 42.8 33.0 25.7 12.2 6.5 17.8 10.3 7.2 12.6 5.7 11.7 16.0 25.8 25.4 22.6 23.3 16.9 15.9 20.9 14.8 14.1 23.3 18.1 26.9 16.7 26.0 18.8 30.1 23.2 23.9 20.2 6.0 51.8 10.3 18.9 15.0 37.1 20.0 24.6 17.1 21.9 35.7 23.6 23.8 39.1 20.9 32.0 27.0 17.2 18.3 11.8 29.8 20.8 21.5 17.3 30.4 17.1 23.6 30.0 24.1 9.5 28.2 14.6 26.9 24.6 13.5 14.0 16.0 12.2 15.8 32.1 9.8 17.9 21.0 10.5 4.1 11.6 10.1 5.7 12.6 11.4 9.9 10.4 4.7 12.2 12.4 10.8 17.8 7.2 10.3 6.5 8.9 5.7 25.0 41.0 41.9 39.2 25.5 25.1 21.9 27.1 29.6 24.0 DEK D6S231E ENSG00000124795 "DEK proto-oncogene" P35659 6 18223868-18264823 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Chromatin regulator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB015226, HPA054505, HPA057799" Supported Enhanced Nucleoplasm Nucleoplasm "CAB015226: , HPA054505: , HPA057799: " "unprognostic (6.35e-2)" "unprognostic (6.11e-2)" "unprognostic (5.04e-3)" "unprognostic (1.40e-2)" "unprognostic (3.66e-1)" "unprognostic (5.02e-3)" "prognostic unfavourable (9.65e-4)" "unprognostic (1.76e-1)" "unprognostic (1.48e-2)" "unprognostic (1.61e-3)" "unprognostic (6.49e-3)" "unprognostic (1.12e-2)" "prognostic unfavourable (3.45e-4)" "unprognostic (1.59e-1)" "unprognostic (1.68e-1)" "unprognostic (2.31e-1)" "unprognostic (3.78e-1)" 30.9 20.0 22.9 41.8 29.5 50.8 28.9 41.5 30.2 31.0 35.8 11.4 24.0 28.2 32.9 19.7 31.0 23.8 19.2 33.5 26.8 14.1 19.3 23.8 29.2 42.7 30.7 17.6 28.3 19.3 20.5 27.8 24.3 27.7 33.9 29.9 11.0 26.8 21.4 40.2 23.2 35.9 51.3 28.1 29.8 24.2 12.6 32.9 58.8 44.9 33.9 38.4 45.1 43.3 40.0 40.2 57.7 49.3 34.0 46.3 35.0 59.7 17.6 46.7 38.9 9.4 16.4 27.1 55.1 30.5 49.8 67.5 28.8 22.5 68.1 58.5 24.8 35.9 34.5 27.3 83.8 45.8 33.0 42.1 31.7 33.6 9.2 64.1 34.3 8.1 13.6 34.3 27.1 23.8 51.1 0.0 31.7 21.5 46.2 28.8 28.6 19.7 61.6 62.0 39.9 24.0 34.6 28.6 26.3 49.7 43.2 30.1 38.9 26.4 24.1 58.4 32.4 32.5 68.6 4.2 10.0 71.8 13.9 32.7 54.0 51.1 49.3 21.9 41.4 39.3 46.3 40.0 42.1 42.5 40.2 33.2 33.5 32.0 57.7 34.0 43.9 31.0 40.6 35.0 22.9 29.5 41.5 30.2 26.8 14.1 30.7 17.6 27.7 32.9 DNAJB1 "Hsp40, HSPF1, RSPH16B, Sis1" ENSG00000132002 "DnaJ heat shock protein family (Hsp40) member B1" P25685 19 14514770-14529770 "Cancer-related genes, Predicted intracellular proteins" "Stress response" Chaperone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "vagina: 291.1" "Cell line enhanced" "Detected in all" "Karpas-707: 109.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017450, HPA063247" Enhanced Supported Nucleoplasm 9600 Nucleoplasm "CAB017450: AB_10631418, HPA063247: " "unprognostic (3.75e-2)" "unprognostic (2.23e-1)" "unprognostic (1.46e-1)" "unprognostic (2.12e-1)" "unprognostic (1.60e-1)" "unprognostic (1.32e-1)" "unprognostic (1.52e-1)" "unprognostic (1.74e-2)" "unprognostic (3.83e-1)" "unprognostic (1.85e-1)" "unprognostic (7.91e-3)" "unprognostic (2.17e-1)" "prognostic favourable (5.96e-4)" "unprognostic (2.20e-2)" "unprognostic (4.44e-2)" "unprognostic (2.00e-2)" "unprognostic (6.77e-2)" 29.2 76.9 28.5 13.2 30.0 36.2 67.0 41.4 29.4 19.3 15.5 21.5 14.5 10.5 20.4 11.8 72.3 21.7 56.4 23.5 28.2 31.6 23.4 37.7 35.7 10.7 53.4 12.0 32.3 22.6 18.3 25.0 33.5 45.8 29.6 13.1 12.2 18.4 40.8 16.1 25.3 9.5 24.0 40.2 9.4 19.1 37.5 37.9 15.0 28.9 18.0 31.1 19.2 291.1 19.7 15.2 28.2 31.6 23.0 61.6 56.7 36.6 39.0 14.1 15.0 26.0 20.9 8.8 24.4 18.1 38.7 29.3 23.0 20.7 10.1 28.0 20.8 27.9 28.8 17.5 27.4 10.6 14.3 16.1 25.8 48.2 17.7 11.4 15.3 11.6 42.1 14.9 13.1 12.7 23.9 109.8 21.3 23.2 18.3 10.6 15.0 42.0 14.0 19.9 22.8 17.6 12.6 13.0 9.6 22.1 43.8 24.0 12.0 11.1 13.2 31.4 18.9 36.2 51.2 48.9 30.0 13.3 22.4 19.8 28.0 11.5 18.9 22.3 36.6 31.1 38.9 19.4 52.5 45.4 15.2 19.7 61.6 47.6 28.2 23.0 31.6 9.1 51.8 56.7 28.5 30.0 41.4 29.4 28.2 31.6 53.4 12.0 45.8 37.9 EBF1 "EBF, OLF1" ENSG00000164330 "Early B cell factor 1" Q9UH73 5 158695916-159099761 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in some" "ASC diff: 19.0;HSkMC: 14.8;REH: 39.7" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in all" 5 "cerebellum: 23.6" "Group enriched" "Detected in some" 62 "memory B-cell: 11.8;naive B-cell: 10.4" "Lineage enriched" "Detected in single" 66 "B-cells: 11.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA061169 Approved Nucleoplasm,Vesicles Nucleoplasm Vesicles "HPA061169: " "unprognostic (7.86e-2)" "unprognostic (3.08e-2)" "unprognostic (7.29e-2)" "unprognostic (4.70e-2)" "unprognostic (2.63e-1)" "unprognostic (1.39e-2)" "unprognostic (1.78e-1)" "unprognostic (1.60e-1)" "unprognostic (5.75e-2)" "unprognostic (1.60e-1)" "unprognostic (4.58e-2)" "unprognostic (1.02e-1)" "prognostic unfavourable (9.62e-7)" "prognostic unfavourable (7.80e-4)" "unprognostic (5.75e-2)" "unprognostic (5.81e-2)" "unprognostic (4.37e-3)" 33.7 3.3 1.9 9.7 2.5 3.1 25.0 23.6 2.0 15.9 5.8 1.1 9.0 1.2 19.7 13.0 5.0 8.5 9.4 15.5 2.0 2.4 3.3 0.9 5.2 12.7 3.2 1.2 7.4 3.7 1.8 2.6 10.7 4.7 8.5 3.4 10.4 4.7 10.8 15.5 4.8 4.5 25.7 6.6 5.4 3.4 8.4 1.0 0.1 6.8 13.2 9.1 11.7 12.5 11.8 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.2 6.1 0.0 19.0 8.2 0.0 0.0 0.0 0.2 0.5 0.0 0.0 5.4 0.0 2.2 0.0 0.2 0.0 0.1 1.2 0.0 0.0 1.6 0.0 0.3 0.0 0.0 14.8 0.0 5.8 0.2 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.5 0.0 39.7 0.2 0.0 0.0 0.0 3.2 0.8 0.3 0.0 0.0 0.0 0.0 0.0 7.3 0.8 8.3 0.1 0.0 0.0 5.5 4.8 0.4 6.6 0.1 0.0 0.1 0.0 0.0 0.0 11.8 0.0 0.0 0.0 10.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 1.9 2.5 23.6 1.6 2.0 2.4 3.2 1.2 4.7 1.0 EIF3E "eIF3-p48, eIF3e, EIF3S6, INT6" ENSG00000104408 "Eukaryotic translation initiation factor 3 subunit E" P60228 8 108201216-108435333 "Cancer-related genes, Predicted intracellular proteins" "Protein biosynthesis" "Initiation factor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA023973 Approved Supported Cytosol Cytosol "HPA023973: AB_1848083" "unprognostic (8.18e-2)" "unprognostic (4.28e-2)" "unprognostic (6.26e-2)" "unprognostic (1.51e-1)" "unprognostic (3.52e-3)" "unprognostic (6.93e-3)" "unprognostic (2.29e-2)" "unprognostic (2.57e-2)" "unprognostic (3.47e-1)" "unprognostic (1.96e-1)" "unprognostic (1.67e-3)" "unprognostic (3.63e-1)" "prognostic unfavourable (3.06e-7)" "unprognostic (2.46e-1)" "unprognostic (1.60e-1)" "unprognostic (1.81e-1)" "unprognostic (2.77e-2)" 88.2 44.0 27.6 49.2 38.2 57.8 75.1 41.5 25.2 101.6 73.6 14.6 47.2 34.4 55.5 47.6 111.2 45.4 41.0 39.5 23.9 22.4 51.8 63.6 60.3 75.3 33.0 19.5 127.6 90.2 29.2 72.5 54.6 28.9 100.1 40.3 22.8 56.9 45.5 100.4 46.7 56.3 73.7 38.4 63.9 49.7 52.7 31.5 100.5 93.8 70.8 50.7 121.7 69.2 49.0 51.7 14.0 39.5 38.7 78.1 59.4 62.0 30.6 41.0 50.7 69.9 147.9 28.0 32.4 50.6 48.2 50.4 38.3 62.5 106.9 42.6 36.4 38.6 54.0 63.6 64.2 42.0 55.0 85.3 32.4 54.6 56.0 50.8 40.0 111.7 94.1 36.4 101.0 73.3 71.8 44.4 54.2 61.3 65.8 96.3 40.9 48.9 61.2 50.8 83.2 63.0 37.4 46.4 42.3 18.2 15.4 72.2 65.5 73.7 46.5 28.2 48.7 29.2 40.7 33.5 25.0 61.2 34.9 88.8 31.4 14.0 39.5 7.4 26.6 36.2 52.0 49.0 52.6 37.7 51.7 40.4 78.1 56.1 3.7 38.7 33.6 27.3 45.2 59.4 27.6 38.2 41.5 25.2 23.9 22.4 33.0 19.5 28.9 31.5 EIF4A2 "BM-010, DDX2B, EIF4A, EIF4F" ENSG00000156976 "Eukaryotic translation initiation factor 4A2" Q14240 3 186783205-186789900 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, Protein biosynthesis" "Helicase, Hydrolase, Initiation factor, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "EFO-21: 106.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "CAB011690, HPA068286" Uncertain Approved Cytosol 1000000 Cytosol "CAB011690: AB_732123, HPA068286: " "unprognostic (1.49e-1)" "unprognostic (9.62e-2)" "unprognostic (3.78e-2)" "unprognostic (9.50e-3)" "unprognostic (2.82e-2)" "unprognostic (1.10e-2)" "unprognostic (4.46e-2)" "unprognostic (6.27e-2)" "unprognostic (4.32e-3)" "unprognostic (1.00e-1)" "unprognostic (6.39e-2)" "unprognostic (3.99e-2)" "unprognostic (6.36e-2)" "unprognostic (3.22e-1)" "unprognostic (3.03e-1)" "unprognostic (4.67e-2)" "unprognostic (2.62e-2)" 34.6 66.1 61.2 27.7 79.9 1.9 53.5 121.1 111.5 65.1 52.1 26.5 30.1 30.3 73.1 45.5 44.5 73.9 45.1 83.7 58.4 71.9 63.9 43.5 33.7 36.1 48.9 61.7 142.0 59.0 30.9 84.1 47.3 69.6 57.9 40.1 31.8 43.7 62.8 126.7 19.8 35.6 57.1 41.9 32.5 39.0 32.9 39.5 23.9 67.8 36.4 35.4 61.1 51.7 55.1 19.3 39.4 24.8 33.0 63.4 51.3 10.5 5.3 22.3 3.6 85.9 81.0 6.8 19.0 17.2 20.2 26.6 19.6 3.8 23.6 106.5 27.3 17.8 32.7 8.0 35.6 22.0 17.2 38.0 7.1 26.3 33.7 8.0 26.7 54.2 38.5 5.8 48.6 35.8 12.8 39.8 65.6 1.8 12.7 3.9 22.1 25.5 16.3 15.8 14.3 40.0 12.9 43.9 8.8 30.9 21.3 40.4 33.2 29.3 26.1 16.0 8.0 15.4 11.6 31.7 44.8 10.8 11.0 8.4 7.5 39.4 16.0 18.5 28.5 18.2 45.3 55.1 41.9 34.8 19.3 46.1 63.4 50.2 11.0 33.0 24.8 17.4 38.6 51.3 61.2 79.9 121.1 111.5 58.4 71.9 48.9 61.7 69.6 39.5 ELF4 "ELFR, MEF" ENSG00000102034 "E74 like ETS transcription factor 4" Q99607 X 130064874-130110716 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Not detected" "Not detected" "Low region specificity" "Detected in many" "HPA058595, HPA060277" Enhanced Supported "Nucleoplasm,Nuclear bodies" "Nuclear bodies" Nucleoplasm "HPA058595: , HPA060277: " "unprognostic (1.33e-1)" "unprognostic (8.51e-2)" "unprognostic (3.83e-1)" "unprognostic (2.13e-2)" "unprognostic (1.14e-1)" "unprognostic (1.80e-1)" "unprognostic (4.43e-3)" "unprognostic (7.86e-3)" "unprognostic (3.50e-2)" "unprognostic (1.80e-1)" "unprognostic (1.29e-2)" "unprognostic (3.95e-1)" "prognostic unfavourable (6.49e-6)" "unprognostic (1.43e-1)" "unprognostic (5.46e-2)" "unprognostic (2.51e-1)" "prognostic favourable (1.42e-4)" 16.9 3.6 2.0 18.1 2.5 27.6 16.9 0.5 3.0 7.7 10.8 3.1 7.0 8.4 10.5 8.1 10.5 9.5 11.0 7.3 3.1 1.2 5.9 2.5 21.9 33.3 3.8 0.9 12.7 4.5 3.8 4.2 23.5 3.0 6.6 10.9 3.6 5.4 7.9 5.7 9.1 16.3 6.4 4.2 18.9 12.3 3.5 2.9 18.1 3.9 7.4 11.5 11.7 14.4 3.9 6.1 9.4 10.3 8.4 10.3 5.1 22.5 8.4 1.5 0.1 3.9 8.4 22.0 10.5 13.4 12.8 14.2 11.6 16.1 11.6 21.1 14.2 14.7 8.4 12.4 12.6 12.4 7.0 22.7 11.2 5.4 8.7 19.8 29.1 8.7 13.9 20.5 20.3 12.3 8.7 3.2 6.9 13.1 3.2 11.3 1.0 8.3 7.0 2.7 4.9 7.8 26.1 5.8 2.5 9.4 9.1 2.9 4.5 19.1 11.4 9.0 7.1 16.7 19.4 1.7 0.7 9.3 10.6 18.2 2.0 1.6 5.4 7.8 10.3 10.3 8.3 3.9 6.2 8.8 6.1 3.5 6.2 7.2 9.4 8.4 7.0 3.7 6.3 5.1 2.0 2.5 0.5 3.0 3.1 1.2 3.8 0.9 3.0 2.9 ELK4 SAP1 ENSG00000158711 "ELK4, ETS transcription factor" P28324 1 205597556-205631962 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 8.7" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA028863 Uncertain Supported Nucleoplasm Nucleoplasm "HPA028863: AB_10602492" "unprognostic (2.08e-1)" "unprognostic (2.71e-2)" "unprognostic (1.98e-1)" "unprognostic (1.59e-1)" "unprognostic (2.15e-1)" "prognostic favourable (4.65e-4)" "unprognostic (2.97e-1)" "unprognostic (1.48e-1)" "unprognostic (1.19e-1)" "unprognostic (3.53e-1)" "unprognostic (1.27e-2)" "unprognostic (2.64e-1)" "prognostic unfavourable (2.94e-6)" "unprognostic (2.21e-2)" "unprognostic (1.26e-1)" "unprognostic (1.08e-1)" "unprognostic (5.58e-3)" 14.1 7.1 10.0 14.7 12.7 12.0 13.8 16.2 10.4 10.1 8.9 10.4 8.6 7.3 11.3 9.2 11.7 9.5 11.4 10.8 10.6 5.0 15.2 15.6 13.8 19.1 10.0 6.9 13.1 12.4 13.6 16.8 9.5 9.5 32.6 8.7 12.2 12.4 8.2 14.7 17.6 13.5 10.5 8.2 18.3 9.4 8.4 11.0 24.4 10.8 8.3 19.6 15.1 13.2 2.2 1.5 8.7 1.1 1.2 3.1 0.6 8.2 7.4 2.9 7.6 7.0 9.1 7.5 5.5 5.8 4.4 5.2 3.2 8.3 17.4 5.2 6.9 10.3 6.2 6.8 7.7 19.8 4.4 7.5 12.1 6.7 9.6 14.1 30.1 7.9 8.4 7.0 14.3 18.4 6.9 14.7 6.1 11.1 11.6 5.3 4.9 4.5 8.6 18.2 14.2 5.9 18.0 3.4 4.1 14.3 7.9 9.4 7.3 4.7 13.3 8.9 10.5 7.9 10.5 11.0 10.0 11.8 7.8 5.8 10.4 8.7 0.8 1.2 1.6 1.1 2.1 1.4 1.8 2.1 1.1 2.2 2.2 3.1 0.4 1.2 0.6 1.5 1.8 0.6 10.0 12.7 16.2 10.4 10.6 5.0 10.0 6.9 9.5 11.0 ELL "C19orf17, ELL1, Men, PPP1R68" ENSG00000105656 "Elongation factor for RNA polymerase II" P55199 19 18442663-18522127 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA046076 Uncertain "HPA046076: " "unprognostic (9.49e-2)" "unprognostic (1.38e-1)" "unprognostic (3.26e-3)" "unprognostic (2.07e-1)" "unprognostic (1.64e-1)" "unprognostic (2.10e-1)" "unprognostic (8.26e-2)" "unprognostic (2.71e-1)" "unprognostic (2.34e-1)" "unprognostic (3.00e-2)" "unprognostic (6.28e-3)" "unprognostic (2.38e-2)" "unprognostic (1.57e-1)" "unprognostic (2.07e-1)" "unprognostic (5.12e-1)" "unprognostic (2.46e-1)" "unprognostic (1.06e-1)" 19.9 7.7 5.1 13.4 9.9 38.4 10.8 17.0 9.7 11.9 13.5 7.7 8.6 10.4 12.6 9.5 9.3 9.1 10.9 9.5 5.8 4.4 9.8 11.6 14.2 10.7 6.2 3.5 12.7 14.6 6.2 10.5 27.0 6.3 10.4 4.4 9.1 10.6 9.0 20.3 13.3 10.9 10.0 5.1 15.9 9.3 31.7 7.7 11.0 7.8 7.2 13.6 18.5 13.2 3.1 8.6 17.2 5.6 2.1 7.9 3.3 8.8 4.3 2.2 4.8 2.5 3.2 16.8 7.0 6.2 5.3 5.2 4.9 7.0 11.1 8.7 4.6 6.2 3.3 7.7 2.7 9.1 7.9 6.7 4.3 4.3 3.8 7.3 8.6 6.4 6.6 6.9 5.5 3.7 9.3 15.4 2.8 7.5 8.5 8.0 7.6 12.4 7.4 3.7 11.7 3.8 6.2 4.1 4.5 5.1 8.9 7.6 4.5 9.1 6.2 6.2 4.8 8.5 6.5 25.1 15.8 8.3 8.2 12.4 8.8 0.3 5.6 3.8 4.7 4.1 7.9 3.1 2.9 4.2 4.7 2.3 1.9 2.9 17.2 2.1 2.1 8.6 3.0 3.3 5.1 9.9 17.0 9.7 5.8 4.4 6.2 3.5 6.3 7.7 EML4 "C2orf2, ELP120, ROPP120" ENSG00000143924 "Echinoderm microtubule associated protein like 4" Q9HC35 2 42169350-42332548 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "Hep G2: 60.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA036687, HPA036688, HPA065337" Enhanced Supported "Intermediate filaments,Microtubules,Cytosol" 41000 Microtubules "Intermediate filaments, Cytosol" "HPA036687: AB_2675251, HPA036688: AB_10671968, HPA065337: AB_2685474" "unprognostic (1.70e-1)" "unprognostic (1.38e-1)" "unprognostic (8.17e-2)" "unprognostic (3.53e-3)" "unprognostic (1.79e-2)" "unprognostic (9.19e-2)" "unprognostic (8.61e-3)" "unprognostic (1.61e-2)" "unprognostic (2.96e-3)" "unprognostic (6.80e-2)" "unprognostic (7.44e-2)" "unprognostic (1.60e-2)" "unprognostic (1.86e-2)" "unprognostic (1.27e-1)" "unprognostic (1.05e-1)" "unprognostic (1.39e-1)" "unprognostic (2.13e-2)" 11.3 17.3 5.8 29.3 6.8 19.2 10.5 4.6 5.2 9.4 21.6 6.7 6.8 20.3 13.6 11.6 10.7 8.7 20.3 6.5 5.1 3.9 11.7 26.4 19.3 27.7 4.6 4.0 12.5 37.8 10.8 11.6 26.9 6.5 8.5 12.8 12.1 17.7 8.9 4.3 17.9 33.5 9.2 5.0 30.9 11.7 14.2 5.3 17.4 13.2 6.9 30.0 14.0 9.0 11.5 4.2 10.0 11.0 9.4 17.5 5.9 14.4 25.1 14.6 11.6 5.3 8.8 16.0 9.0 7.1 10.0 9.7 26.2 18.2 13.2 6.2 8.8 7.5 12.6 8.6 17.5 25.8 10.5 12.1 7.8 60.0 6.8 9.1 12.5 9.6 3.3 13.2 9.0 6.9 12.0 13.4 10.7 8.5 8.6 2.4 14.9 7.2 8.9 23.2 7.8 8.2 21.0 14.5 29.2 8.8 9.2 6.8 4.8 3.7 8.0 10.2 13.7 8.1 8.1 15.1 10.5 11.4 8.9 8.8 7.1 4.4 3.9 7.7 7.8 10.9 16.3 11.5 13.0 12.7 3.3 7.9 11.4 8.3 10.0 9.4 11.0 4.2 17.5 5.9 5.8 6.8 4.6 5.2 5.1 3.9 4.6 4.0 6.5 5.3 EP300 "KAT3B, p300" ENSG00000100393 "E1A binding protein p300" Q09472 22 41091786-41180079 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Biological rhythms, Cell cycle, Host-virus interaction, Transcription, Transcription regulation" "Acyltransferase, Transferase" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000146, HPA003128, HPA004112" Supported Enhanced Nucleoplasm Nucleoplasm "CAB000146: AB_2533138, HPA003128: AB_1078745, HPA004112: AB_1078746" "unprognostic (7.67e-2)" "unprognostic (5.56e-2)" "unprognostic (2.29e-1)" "unprognostic (2.52e-1)" "unprognostic (6.10e-3)" "unprognostic (1.66e-1)" "unprognostic (2.21e-2)" "unprognostic (2.13e-1)" "unprognostic (1.54e-1)" "unprognostic (8.97e-2)" "unprognostic (1.74e-2)" "unprognostic (8.54e-2)" "prognostic favourable (7.45e-5)" "unprognostic (7.97e-2)" "unprognostic (1.41e-1)" "unprognostic (1.01e-1)" "unprognostic (8.66e-2)" 16.8 14.8 19.1 13.9 15.5 45.3 14.5 33.0 20.6 14.8 16.8 15.6 18.9 11.1 18.1 11.6 16.8 15.7 16.5 10.7 16.6 8.3 11.5 12.2 14.1 12.9 16.9 12.7 20.2 15.7 26.4 14.5 27.7 13.8 13.2 12.2 12.3 15.3 17.9 19.5 18.2 17.4 13.8 12.7 15.9 14.7 20.6 18.6 29.3 16.9 10.9 14.1 18.7 22.5 4.3 4.4 9.8 3.9 5.7 3.9 2.3 15.5 11.2 19.0 11.8 12.1 13.0 17.0 7.5 10.9 11.3 10.8 14.2 5.7 16.2 6.6 14.8 12.5 27.4 10.3 12.5 15.8 18.2 12.2 12.8 11.1 13.7 28.8 13.8 12.7 10.8 16.3 13.6 12.5 12.8 22.3 8.9 5.7 8.3 9.0 13.7 7.8 17.1 8.9 10.1 10.7 20.7 6.1 6.4 26.6 13.6 13.0 9.6 16.8 16.1 11.3 13.7 8.0 10.6 15.3 7.2 25.3 8.3 8.9 10.7 5.0 3.2 3.0 3.7 3.9 3.2 4.3 3.6 3.9 4.4 2.9 3.1 2.6 9.8 5.7 2.1 3.0 2.6 2.3 19.1 15.5 33.0 20.6 16.6 8.3 16.9 12.7 13.8 18.6 EPS15 "AF-1P, MLLT5" ENSG00000085832 "Epidermal growth factor receptor pathway substrate 15" P42566 1 51354263-51519328 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Endocytosis, Host-virus interaction, Protein transport, Transport" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008451, CAB010164, HPA061431" Approved Enhanced Vesicles,Cytosol "Intracellular and membrane" 67000 "Vesicles, Cytosol" "CAB010164: AB_631445, HPA008451: AB_1848221, HPA061431: " "unprognostic (1.45e-2)" "prognostic unfavourable (6.44e-4)" "unprognostic (1.05e-2)" "unprognostic (7.72e-3)" "unprognostic (3.99e-1)" "unprognostic (1.42e-1)" "unprognostic (4.96e-3)" "unprognostic (9.26e-2)" "unprognostic (4.13e-2)" "unprognostic (5.80e-2)" "unprognostic (1.17e-1)" "unprognostic (1.41e-1)" "unprognostic (5.36e-2)" "unprognostic (8.73e-3)" "unprognostic (2.13e-1)" "unprognostic (1.21e-1)" "unprognostic (1.24e-1)" 39.0 26.9 35.5 25.3 27.8 13.2 19.3 22.2 41.0 25.7 16.7 35.7 16.2 11.4 21.8 21.3 19.6 14.1 19.3 18.9 40.7 26.0 21.0 19.1 24.4 30.7 36.2 11.2 22.4 10.9 17.0 14.6 22.8 20.3 22.5 15.5 25.7 24.3 16.4 30.9 18.1 19.3 18.2 36.8 33.8 15.2 32.4 33.1 25.0 20.3 23.4 32.1 25.3 17.0 16.1 10.8 14.9 12.2 10.7 18.7 8.0 14.7 4.4 9.6 9.0 22.2 22.2 23.9 10.3 16.4 8.5 12.6 6.0 8.2 30.2 10.7 16.2 14.1 12.4 9.9 12.9 34.1 7.8 26.9 7.6 7.2 20.9 15.2 24.8 18.0 9.2 14.8 20.2 15.8 16.6 13.8 12.9 7.2 12.2 8.3 13.1 7.2 10.0 14.5 6.6 11.2 18.4 6.6 9.2 12.3 21.9 17.9 8.9 10.8 21.8 7.9 8.5 15.8 8.6 16.5 16.7 20.4 11.7 17.3 6.9 14.9 10.1 11.6 10.1 10.7 15.3 16.1 12.2 15.6 10.8 10.0 7.3 10.5 7.8 10.7 12.2 7.1 18.7 8.0 35.5 27.8 22.2 41.0 40.7 26.0 36.2 11.2 20.3 33.1 ERC1 "CAST2, ELKS, KIAA1081, MGC12974, RAB6IP2" ENSG00000082805 "ELKS/RAB6-interacting/CAST family member 1" Q8IUD2 12 990509-1495933 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Protein transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019513, HPA019523, HPA024130" Approved Supported "Vesicles,Plasma membrane,Cytosol" Cytosol "Vesicles, Plasma membrane" "HPA019513: AB_1856012, HPA019523: AB_1856013, HPA024130: AB_1856014" "unprognostic (2.41e-1)" "unprognostic (4.00e-2)" "unprognostic (2.14e-1)" "unprognostic (5.70e-2)" "unprognostic (2.81e-1)" "unprognostic (1.32e-1)" "unprognostic (5.50e-2)" "unprognostic (8.49e-2)" "unprognostic (2.53e-1)" "unprognostic (3.26e-2)" "unprognostic (1.04e-1)" "unprognostic (6.79e-2)" "unprognostic (3.75e-3)" "unprognostic (4.19e-2)" "unprognostic (3.01e-1)" "unprognostic (7.37e-2)" "prognostic unfavourable (7.01e-4)" 12.6 11.4 10.3 12.5 14.7 7.4 15.1 41.7 10.4 11.2 11.9 8.5 9.2 4.3 17.1 11.0 13.7 9.8 9.9 14.7 10.0 11.2 11.2 8.0 8.8 5.4 9.0 6.4 12.5 8.6 24.3 19.4 13.2 10.7 11.4 7.5 10.1 9.3 14.4 9.2 9.9 6.4 22.1 8.5 7.3 8.6 11.0 9.9 9.8 15.3 7.2 8.6 15.7 15.3 8.6 2.9 2.1 3.8 1.1 3.5 0.5 2.9 7.3 3.9 2.6 10.4 8.8 5.4 9.2 7.4 6.3 5.8 6.4 3.6 4.5 1.3 11.9 5.0 8.3 7.1 8.8 9.5 4.2 11.1 7.3 3.2 7.9 5.7 2.6 7.1 6.2 11.1 20.8 8.1 3.3 9.0 4.7 3.2 1.8 1.2 6.2 3.5 3.6 14.8 1.4 6.2 5.3 2.3 4.6 14.4 3.3 5.2 3.4 2.4 15.0 10.9 11.1 8.0 8.6 2.4 4.5 6.7 7.1 3.4 4.8 1.4 2.8 2.1 1.6 1.0 2.2 8.6 2.4 2.4 2.4 5.6 3.5 2.6 2.1 1.1 3.8 2.9 2.2 0.5 10.3 14.7 41.7 10.4 10.0 11.2 9.0 6.4 10.7 9.9 ERG "erg-3, p55" ENSG00000157554 "ERG, ETS transcription factor" P11308 21 38380027-38661780 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in some" 5 "HUVEC TERT2: 42.7;MOLT-4: 14.0;REH: 45.3;TIME: 34.6" "Cancer enhanced" "Detected in all" "prostate cancer: 18.6" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 5 "myeloid DC: 1.7;NK-cell: 1.0" "Group enriched" "Detected in many" 5 "dendritic cells: 1.7;NK-cells: 1.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB018377, HPA046598" Approved Approved Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB018377: AB_675518, HPA046598: " "unprognostic (2.14e-1)" "prognostic unfavourable (6.18e-6)" "unprognostic (6.44e-3)" "unprognostic (8.64e-3)" "unprognostic (5.65e-2)" "unprognostic (1.91e-1)" "unprognostic (9.03e-4)" "unprognostic (4.30e-2)" "unprognostic (2.63e-2)" "unprognostic (1.29e-1)" "unprognostic (3.42e-2)" "unprognostic (2.89e-1)" "prognostic unfavourable (3.94e-4)" "unprognostic (4.31e-3)" "unprognostic (3.88e-2)" "unprognostic (2.64e-2)" "unprognostic (5.63e-3)" 39.1 4.2 5.7 6.5 8.5 6.6 20.5 3.6 7.0 17.9 5.2 2.3 5.6 3.3 16.9 9.0 6.2 9.2 11.6 10.1 6.2 3.6 10.8 6.0 19.9 7.4 8.0 1.8 7.7 4.8 2.3 3.9 23.2 8.0 8.1 3.6 7.8 4.2 5.6 13.5 5.3 6.2 11.8 4.7 32.5 5.0 4.8 5.0 2.4 10.8 9.1 3.6 9.6 15.8 0.0 1.7 0.0 0.2 1.0 0.0 0.4 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.0 0.0 0.0 7.0 0.0 0.0 0.3 0.0 42.7 0.0 0.0 0.0 0.3 14.0 0.0 0.1 0.0 45.3 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 34.6 0.2 0.7 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.4 5.7 8.5 3.6 7.0 6.2 3.6 8.0 1.8 8.0 5.0 ETV1 ER81 ENSG00000006468 "ETS variant 1" P50549 7 13891228-13991425 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 90.0;salivary gland: 45.8" "Cell line enhanced" "Detected in many" "AN3-CA: 22.2;SCLC-21H: 26.3;U-87 MG: 51.9;WM-115: 25.6" "Cancer enhanced" "Detected in all" "glioma: 22.5" "Region enriched" "Detected in all" 8 "cerebellum: 90.0" "Cell type enriched" "Detected in single" 5 "T-reg: 3.1" "Lineage enriched" "Detected in single" 5 "T-cells: 3.1" "Low region specificity" "Detected in all" "Region enhanced" "Detected in all" "cerebellum: 418.9" "HPA068389, HPA077249" Supported Approved Nucleoplasm Nucleoplasm "HPA068389: , HPA077249: " "unprognostic (2.45e-1)" "unprognostic (1.01e-1)" "unprognostic (6.98e-2)" "unprognostic (1.04e-1)" "unprognostic (1.49e-2)" "unprognostic (2.13e-2)" "unprognostic (1.64e-7)" "unprognostic (7.08e-3)" "unprognostic (7.21e-2)" "unprognostic (2.36e-1)" "unprognostic (2.01e-1)" "unprognostic (3.02e-1)" "unprognostic (1.51e-3)" "unprognostic (2.21e-2)" "unprognostic (2.05e-1)" "unprognostic (1.05e-1)" "unprognostic (1.20e-2)" 2.5 12.4 8.1 1.1 11.7 0.2 4.4 90.0 35.2 1.4 2.4 3.1 0.1 1.2 2.4 1.3 1.5 1.1 9.2 18.0 7.0 4.5 2.1 2.0 14.9 0.7 4.5 6.9 1.0 1.6 11.4 7.4 1.9 8.3 3.1 2.4 0.9 45.8 7.1 0.9 1.5 1.9 2.0 3.5 4.5 1.7 4.5 2.9 0.3 6.5 0.9 4.7 1.8 1.3 0.0 0.0 0.0 0.6 0.0 3.1 0.2 0.0 1.6 11.7 22.2 4.1 12.2 0.0 1.0 3.9 0.6 2.6 0.0 5.3 0.0 1.2 1.8 0.1 0.4 1.2 1.4 0.3 0.5 0.6 1.0 0.0 2.4 3.8 1.5 3.6 0.0 7.6 0.6 5.0 3.4 0.1 4.7 0.0 0.0 0.0 17.5 11.8 0.0 7.1 0.9 7.9 0.1 26.3 5.1 0.0 0.4 6.3 0.4 0.1 2.7 2.3 0.7 4.5 4.3 4.0 1.2 0.0 51.9 0.2 25.6 0.0 0.2 0.0 0.1 0.6 0.3 0.0 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.1 0.2 8.1 11.7 90.0 10.9 7.0 4.5 4.5 6.9 8.3 2.9 ETV4 "E1A-F, E1AF, PEA3" ENSG00000175832 "ETS variant 4" P43268 17 43527844-43579620 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 38.4" "Cell line enhanced" "Detected in many" "AN3-CA: 45.0;Hep G2: 42.2;SK-MEL-30: 48.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in single" "neutrophil: 1.3" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA005768 Approved Supported Nucleoli Nucleoli "HPA005768: AB_1848294" "unprognostic (2.32e-1)" "unprognostic (7.33e-2)" "unprognostic (2.14e-1)" "unprognostic (2.51e-1)" "unprognostic (1.97e-2)" "unprognostic (3.14e-3)" "prognostic unfavourable (2.48e-4)" "unprognostic (1.58e-2)" "unprognostic (5.34e-2)" "unprognostic (8.13e-2)" "unprognostic (7.05e-2)" "unprognostic (3.01e-1)" "unprognostic (7.79e-2)" "unprognostic (2.03e-1)" "unprognostic (7.08e-2)" "prognostic favourable (7.60e-4)" "unprognostic (1.69e-1)" 0.6 2.4 1.4 0.9 1.4 0.0 6.8 1.6 8.3 3.6 3.3 0.4 1.3 5.7 3.4 2.2 9.9 2.4 38.4 2.6 1.8 1.3 7.8 1.4 2.5 0.4 2.3 1.1 1.2 23.8 19.3 19.7 11.6 2.7 4.7 1.6 1.7 4.9 4.5 1.3 6.7 3.8 1.2 1.8 0.5 3.6 1.3 0.5 0.3 6.6 15.0 12.1 3.1 5.3 0.2 0.0 1.3 0.2 0.0 0.6 0.1 5.9 16.7 20.5 45.0 0.8 5.3 4.5 1.9 5.3 3.8 3.9 9.4 8.5 0.0 1.1 1.0 10.9 0.6 10.0 3.4 0.2 0.1 0.5 2.6 42.2 1.1 11.4 5.3 0.9 0.3 14.5 9.0 8.1 11.7 0.0 7.8 2.3 0.0 20.2 29.6 28.0 24.4 2.4 14.3 8.4 4.3 0.0 18.3 0.5 1.1 48.7 0.2 3.4 3.7 2.7 13.4 4.0 5.4 1.8 11.2 0.0 4.9 2.2 15.8 0.0 0.0 0.0 0.0 0.2 0.5 0.2 0.1 0.0 0.0 0.0 0.2 0.6 1.3 0.0 0.0 0.0 0.0 0.1 1.4 1.4 1.6 3.6 1.8 1.3 2.3 1.1 2.7 0.5 ETV5 ERM ENSG00000244405 "ETS variant 5" P41161 3 186046308-186110318 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "parathyroid gland: 55.3" "Cell line enhanced" "Detected in many" "SK-MEL-30: 55.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "intermediate monocyte: 3.1" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009590, HPA063065" Approved Supported Nucleoplasm Nucleoplasm "CAB009590: AB_2101008, HPA063065: " "unprognostic (3.85e-1)" "unprognostic (5.81e-2)" "unprognostic (1.54e-2)" "unprognostic (3.30e-1)" "unprognostic (9.00e-2)" "unprognostic (2.56e-3)" "prognostic unfavourable (7.85e-9)" "unprognostic (3.52e-3)" "unprognostic (2.97e-1)" "unprognostic (1.22e-2)" "unprognostic (4.18e-2)" "unprognostic (1.48e-1)" "unprognostic (1.57e-3)" "unprognostic (6.80e-2)" "unprognostic (1.57e-1)" "unprognostic (3.58e-2)" "unprognostic (3.84e-3)" 5.8 30.3 13.2 5.5 21.7 1.6 11.3 12.1 35.2 4.7 3.0 15.7 1.3 5.1 6.8 6.2 3.8 4.6 4.8 8.8 13.6 9.4 7.1 6.2 21.9 8.9 9.9 11.0 2.5 25.4 55.3 28.1 24.3 11.5 6.3 3.1 7.4 5.5 5.1 9.8 5.3 2.8 6.1 9.6 10.0 11.9 7.2 6.1 2.0 16.6 1.7 3.6 3.6 3.6 0.6 1.8 0.9 3.1 0.1 0.3 0.5 12.8 8.9 11.4 24.8 7.0 7.3 0.8 11.0 12.4 8.7 9.5 9.7 7.9 0.3 14.8 10.7 2.2 0.2 8.4 13.0 2.8 0.3 3.7 0.3 10.9 11.7 9.3 7.0 6.4 1.3 13.9 17.1 12.8 3.4 4.6 14.9 5.9 1.2 14.3 17.0 10.1 26.2 11.4 8.6 7.2 3.0 0.5 14.7 2.7 0.1 55.7 0.0 5.2 12.3 4.8 7.8 12.1 21.6 3.5 14.4 0.0 14.7 7.5 28.6 0.0 0.3 0.1 0.3 3.1 0.0 0.6 0.0 0.0 1.8 0.1 0.0 0.0 0.9 0.1 1.5 1.6 0.0 0.5 13.2 21.7 12.1 31.7 13.6 9.4 9.9 11.0 11.5 6.1 ETV6 TEL ENSG00000139083 "ETS variant 6" P41212 12 11649854-11895402 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HDLM-2: 38.9;NB-4: 20.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA000264 Enhanced Approved Nucleoli,Cytosol Nucleoli Cytosol "HPA000264: AB_1078763" "unprognostic (4.03e-3)" "unprognostic (3.08e-2)" "unprognostic (7.54e-3)" "unprognostic (2.60e-1)" "unprognostic (2.07e-1)" "unprognostic (1.35e-3)" "unprognostic (2.74e-2)" "unprognostic (4.02e-2)" "unprognostic (3.16e-1)" "unprognostic (9.46e-2)" "prognostic unfavourable (9.38e-5)" "unprognostic (1.15e-1)" "prognostic unfavourable (4.66e-8)" "unprognostic (1.33e-2)" "unprognostic (5.99e-2)" "unprognostic (8.92e-2)" "prognostic favourable (1.54e-5)" 17.2 8.9 5.1 20.0 7.6 32.8 20.4 1.6 9.1 10.5 14.5 6.0 9.8 7.2 10.8 14.2 11.3 8.9 15.3 6.7 5.6 3.8 9.2 9.6 16.0 13.4 6.0 3.1 10.5 10.4 8.4 8.7 7.7 7.4 14.9 11.0 8.0 41.9 12.4 6.9 23.9 14.6 25.0 9.4 17.8 9.7 4.7 5.7 30.6 10.0 10.0 19.9 19.0 15.8 2.9 6.2 11.4 7.1 2.4 2.2 1.3 2.5 3.5 3.2 5.5 2.4 2.3 3.8 1.9 3.2 2.5 3.0 0.2 12.2 2.1 1.9 3.2 3.3 1.4 5.8 3.0 38.9 0.7 13.7 1.9 1.3 3.0 14.4 15.0 4.5 3.6 2.4 5.1 7.5 1.0 7.3 2.2 1.6 8.1 20.7 5.1 0.9 2.3 3.0 5.6 5.7 16.2 0.6 3.2 3.8 3.7 3.5 1.2 9.1 8.5 5.6 4.8 1.8 4.0 3.2 2.4 1.2 3.6 0.1 6.4 5.6 5.7 6.6 1.5 6.6 2.0 2.9 2.2 1.4 4.1 2.3 1.3 0.8 11.4 2.4 7.1 6.2 1.4 1.3 5.1 7.6 1.6 9.1 5.6 3.8 6.0 3.1 7.4 5.7 EWSR1 EWS ENSG00000182944 "EWS RNA binding protein 1" Q01844 22 29268009-29300525 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" "Calmodulin-binding, Repressor, RNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004230, HPA051771, HPA062953" Enhanced Enhanced Nucleoplasm,Nucleoli Nucleoplasm Nucleoli "CAB004230: AB_675526, HPA051771: AB_2681602, HPA062953: AB_2684910" "unprognostic (1.96e-1)" "unprognostic (6.39e-3)" "unprognostic (1.32e-1)" "unprognostic (3.93e-2)" "unprognostic (3.59e-1)" "unprognostic (3.15e-2)" "prognostic unfavourable (1.27e-6)" "unprognostic (1.33e-1)" "unprognostic (1.09e-2)" "unprognostic (2.71e-2)" "unprognostic (7.04e-2)" "unprognostic (9.30e-2)" "prognostic unfavourable (1.21e-5)" "unprognostic (7.33e-3)" "unprognostic (1.79e-1)" "unprognostic (3.67e-2)" "unprognostic (1.50e-3)" 35.3 43.2 45.3 41.3 51.3 67.5 32.1 58.2 48.6 32.4 39.8 43.2 31.3 41.0 45.1 38.5 40.8 37.6 25.9 40.7 40.1 32.8 33.0 48.5 33.4 50.5 32.7 49.9 38.4 32.0 47.2 44.3 34.0 41.7 35.0 39.9 41.5 32.3 38.2 52.8 34.8 36.6 40.5 33.8 44.1 34.5 85.6 32.5 39.9 32.5 30.9 55.4 36.4 34.5 52.0 65.8 50.6 81.1 58.4 67.8 76.1 56.4 44.0 60.5 47.0 30.9 25.6 41.6 34.4 55.0 57.1 49.0 50.1 29.3 77.2 21.8 52.7 44.4 86.2 70.4 58.8 52.5 61.5 58.3 39.0 47.9 46.2 89.6 41.7 39.1 29.7 47.6 77.3 44.1 43.6 34.9 42.2 56.7 90.0 34.4 42.5 33.5 63.2 58.3 46.6 52.5 60.0 49.6 47.4 42.8 50.2 37.1 32.2 48.8 45.0 34.9 38.8 21.9 49.9 45.4 36.4 71.6 33.2 39.9 42.4 48.4 57.9 50.6 60.2 81.1 60.7 50.4 56.6 59.6 65.8 52.0 55.8 53.6 43.3 58.4 78.6 35.3 67.8 76.1 45.3 51.3 58.2 48.6 40.1 32.8 32.7 49.9 41.7 32.5 EZR VIL2 ENSG00000092820 Ezrin P15311 6 158765741-158819412 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cell shape" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004035, HPA021616, CAB047324, CAB075739" Enhanced Enhanced "Plasma membrane" 75000000 "Plasma membrane" "CAB004035: AB_2100309, CAB047324: , CAB075739: , HPA021616: AB_1848342" "unprognostic (4.79e-3)" "unprognostic (1.48e-1)" "unprognostic (1.97e-2)" "unprognostic (2.50e-1)" "unprognostic (1.07e-1)" "unprognostic (1.31e-3)" "unprognostic (1.76e-2)" "unprognostic (2.41e-1)" "unprognostic (1.32e-1)" "unprognostic (7.53e-2)" "prognostic unfavourable (1.70e-4)" "unprognostic (5.59e-2)" "prognostic favourable (9.56e-8)" "unprognostic (1.16e-1)" "unprognostic (1.32e-1)" "unprognostic (1.34e-2)" "unprognostic (9.00e-2)" 22.8 56.4 30.9 31.2 31.4 24.7 13.3 4.0 21.5 18.0 45.5 28.2 35.2 33.8 9.8 25.8 71.8 25.1 30.2 34.3 37.6 13.9 53.5 16.2 44.3 36.7 14.8 19.0 20.7 33.0 77.1 14.6 125.1 23.5 21.7 22.8 37.0 27.4 32.0 13.6 47.5 87.9 22.8 12.8 26.0 55.4 21.4 22.2 41.6 37.1 34.4 75.6 38.2 25.3 81.7 30.0 24.3 31.2 20.7 61.7 41.1 87.0 47.6 11.8 16.9 1.3 1.4 68.9 27.4 9.0 30.9 26.1 55.7 48.3 87.7 27.2 31.3 66.8 23.2 30.5 35.9 30.6 15.0 1.8 28.9 24.6 31.4 21.7 13.5 2.3 23.7 29.1 28.3 20.2 17.3 43.0 17.9 22.9 30.7 26.2 19.6 15.9 23.1 5.5 19.9 63.5 26.5 21.4 17.5 47.9 69.1 5.2 16.8 28.7 26.1 10.0 32.1 13.7 42.1 29.7 27.0 75.2 6.2 11.2 11.9 24.3 14.0 16.4 34.8 31.2 41.0 81.7 36.7 42.9 30.0 67.5 19.9 26.5 6.1 20.7 30.6 14.0 61.7 41.1 30.9 31.4 4.0 21.5 37.6 13.9 14.8 19.0 23.5 22.2 FCGR2B "CD32, CD32B, FCG2, FCGR2" ENSG00000072694 "Fc fragment of IgG receptor IIb" P31994 1 161663147-161678654 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins" "Host-virus interaction" "IgG-binding protein, Receptor" "Cancer-related genes, FDA approved drug targets, Proto-oncogene, Systemic lupus erythematosus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "blood: 53.3;placenta: 83.2" "Cell line enhanced" "Detected in some" "Daudi: 18.2;HMC-1: 23.0;NB-4: 5.1;RPMI-8226: 8.2" "Low cancer specificity" "Detected in many" "Cell type enhanced" "Detected in many" "basophil: 53.3;memory B-cell: 42.2" "Group enriched" "Detected in many" 18 "B-cells: 42.2;dendritic cells: 14.5;granulocytes: 53.3" "CAB007796, HPA014730" Enhanced "CAB007796: AB_562288, HPA014730: " "unprognostic (1.58e-1)" "unprognostic (5.14e-2)" "unprognostic (3.32e-3)" "unprognostic (3.12e-2)" "unprognostic (6.79e-3)" "unprognostic (4.05e-3)" "unprognostic (1.27e-1)" "unprognostic (4.65e-3)" "unprognostic (1.91e-1)" "unprognostic (4.72e-2)" "unprognostic (2.89e-2)" "unprognostic (3.49e-1)" "prognostic unfavourable (8.82e-4)" "unprognostic (3.51e-2)" "unprognostic (6.36e-2)" "unprognostic (4.31e-1)" "unprognostic (3.37e-1)" 11.3 2.4 0.0 2.0 0.2 0.0 4.1 0.0 0.0 1.9 3.4 0.2 0.9 0.2 2.1 2.1 2.3 3.7 0.0 0.2 2.0 9.5 5.6 2.5 0.5 0.8 0.6 0.0 0.3 83.2 0.3 2.0 3.3 0.2 0.5 2.0 4.6 3.1 4.7 6.7 1.5 0.1 1.7 5.6 3.3 1.2 42.2 14.5 53.3 1.9 0.1 0.3 2.4 0.0 0.1 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 18.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 23.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 5.1 0.1 0.0 0.0 0.0 8.2 0.0 0.0 0.1 0.1 0.0 0.0 1.6 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 2.2 0.0 53.3 1.8 5.4 0.3 1.9 0.1 42.2 0.1 0.2 14.5 34.3 0.0 0.3 11.2 0.1 1.7 0.0 0.0 2.4 FCRL4 "CD307d, FCRH4, IGFP2, IRTA1" ENSG00000163518 "Fc receptor like 4" Q96PJ5 1 157573749-157598080 "Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "intestine: 5.4;lymphoid tissue: 15.6" "Cell line enriched" "Detected in single" 102 "U-266/70: 10.1" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 12 "memory B-cell: 1.1" "Lineage enriched" "Detected in single" 12 "B-cells: 1.1" "Low region specificity" "Detected in many" HPA054030 Approved "HPA054030: " "unprognostic (6.06e-2)" "unprognostic (3.41e-3)" "unprognostic (2.57e-1)" "unprognostic (5.08e-2)" "unprognostic (4.69e-4)" "unprognostic (2.06e-2)" "unprognostic (6.38e-2)" "unprognostic (1.99e-1)" "unprognostic (2.14e-1)" "unprognostic (3.37e-1)" "unprognostic (6.77e-2)" 0.1 0.1 0.1 15.6 0.1 0.0 0.1 0.1 0.2 0.1 0.3 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 5.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.4 0.0 2.5 0.0 0.1 0.1 5.4 0.0 0.1 2.2 0.3 0.1 0.0 1.1 0.1 1.9 14.9 0.4 0.1 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.0 0.0 0.0 FEV Pet-1 ENSG00000163497 "FEV, ETS transcription factor" Q99581 2 218981087-218985657 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Neurogenesis, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 6.9;intestine: 7.0;pituitary gland: 5.4;stomach 1: 6.1" "Group enriched" "Detected in some" 6 "HMC-1: 18.7;SH-SY5Y: 23.9" "Group enriched" "Detected in some" 10 "pancreatic cancer: 3.0;prostate cancer: 9.9;stomach cancer: 2.4" "Region enhanced" "Detected in many" "pons and medulla: 6.9" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 13 "midbrain: 2.3;pons and medulla: 0.9" "Group enriched" "Detected in some" 34 "midbrain: 7.3;pons and medulla: 3.9" HPA067679 Supported Supported "Nuclear speckles" "Nuclear speckles" "HPA067679: " "unprognostic (4.58e-1)" "unprognostic (1.60e-1)" "unprognostic (7.21e-2)" "prognostic favourable (4.85e-4)" "unprognostic (2.87e-1)" "unprognostic (3.96e-1)" "unprognostic (1.52e-1)" "unprognostic (2.15e-1)" 0.1 4.1 0.0 1.2 3.5 0.0 0.0 0.0 2.6 0.0 2.0 0.7 0.0 7.0 0.1 0.0 0.0 0.1 0.0 0.0 1.1 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 4.2 0.0 5.4 0.0 6.9 4.0 3.2 0.0 0.0 0.0 0.0 0.0 5.4 0.0 0.1 0.0 6.1 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.8 0.0 0.0 0.0 0.0 18.7 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.7 23.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.0 2.6 1.1 0.2 0.2 0.0 6.9 1.0 FGFR1 "BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM" ENSG00000077782 "Fibroblast growth factor receptor 1" P11362 8 38411138-38468834 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Transcription, Transcription regulation" "Heparin-binding, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Craniosynostosis, Disease mutation, Dwarfism, FDA approved drug targets, Holoprosencephaly, Hypogonadotropic hypogonadism, Kallmann syndrome, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "AN3-CA: 109.2;BJ hTERT+: 49.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB033614, HPA056402" Approved 120000000 "CAB033614: AB_783377, HPA056402: " "unprognostic (9.53e-2)" "unprognostic (7.33e-2)" "unprognostic (2.44e-1)" "unprognostic (1.35e-2)" "unprognostic (4.23e-3)" "unprognostic (7.02e-2)" "unprognostic (6.59e-2)" "unprognostic (2.77e-1)" "unprognostic (1.81e-1)" "unprognostic (3.99e-2)" "unprognostic (7.97e-3)" "unprognostic (4.59e-2)" "unprognostic (7.69e-2)" "unprognostic (6.87e-3)" "unprognostic (5.60e-2)" "unprognostic (4.59e-3)" "unprognostic (1.05e-3)" 41.1 8.6 12.5 14.5 12.2 7.2 39.5 45.0 10.5 36.0 31.5 10.1 11.6 5.5 29.3 20.6 22.9 29.4 32.4 31.7 12.8 10.1 11.8 5.4 18.6 9.7 11.4 14.3 42.0 51.2 11.5 22.3 28.4 20.0 28.2 10.8 35.8 14.0 31.6 12.0 12.9 14.4 52.4 15.6 4.5 16.4 16.4 8.5 11.3 12.6 13.0 9.8 39.6 41.2 1.6 0.7 1.8 1.1 0.8 5.7 0.7 2.4 9.3 40.3 109.2 25.1 17.9 26.6 24.8 49.8 17.3 18.0 6.0 1.4 0.3 6.9 23.8 0.0 19.1 1.2 20.0 6.5 4.2 0.0 1.5 5.9 14.1 5.8 0.1 16.2 0.1 14.0 2.8 16.6 2.2 0.1 8.1 2.8 17.0 1.9 28.4 3.9 15.7 4.2 0.0 8.4 0.0 1.6 3.6 4.4 0.2 1.0 2.2 1.1 10.4 11.3 6.2 31.2 5.9 0.4 0.7 0.0 13.4 0.3 5.9 1.4 1.1 0.4 5.7 0.3 3.9 0.7 2.7 3.7 0.1 1.6 1.5 4.1 1.8 0.8 0.5 0.7 2.2 0.7 12.5 12.2 45.0 10.5 12.8 10.1 11.4 14.3 20.0 8.5 FGFR1OP FOP ENSG00000213066 "FGFR1 oncogene partner" O95684 6 166999182-167094789 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cilium biogenesis/degradation" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "testis: 50.3" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA071876 Supported Centrosome Centrosome "HPA071876: " "unprognostic (9.14e-2)" "unprognostic (2.24e-1)" "unprognostic (3.98e-2)" "unprognostic (2.39e-1)" "unprognostic (1.30e-1)" "unprognostic (1.69e-2)" "unprognostic (9.59e-2)" "unprognostic (1.00e-1)" "unprognostic (6.95e-2)" "unprognostic (8.83e-2)" "unprognostic (1.08e-3)" "unprognostic (4.06e-2)" "prognostic unfavourable (7.32e-4)" "unprognostic (1.29e-2)" "unprognostic (2.49e-1)" "unprognostic (3.15e-1)" "unprognostic (2.09e-3)" 6.2 12.2 11.2 12.9 12.5 9.8 10.2 11.9 13.0 10.1 9.5 6.9 11.8 10.8 13.6 14.1 8.8 19.1 7.9 6.4 10.8 9.1 12.2 24.9 6.7 9.4 6.4 11.5 11.8 10.2 8.2 17.2 6.6 9.4 7.4 12.1 8.9 8.1 11.6 5.8 7.9 13.0 7.4 7.4 9.4 7.8 50.3 8.0 14.5 12.5 6.2 11.8 7.0 8.2 6.8 10.0 24.1 4.1 3.5 6.8 3.0 12.0 6.7 17.0 11.6 10.0 7.5 20.7 15.6 10.5 12.8 12.4 24.9 10.3 14.4 8.9 9.5 11.4 14.9 11.0 24.1 9.0 12.9 9.9 12.1 27.0 5.4 17.6 10.5 4.1 8.2 26.2 12.3 8.8 32.3 12.4 16.3 11.1 14.1 25.8 14.5 5.2 16.3 11.6 11.9 13.3 6.5 12.7 12.8 12.7 13.7 5.4 11.2 21.8 5.7 12.8 21.3 15.2 19.5 10.6 14.5 14.6 14.4 16.5 15.6 0.2 4.1 13.5 3.3 3.6 4.9 6.8 3.9 3.1 6.5 5.0 2.3 3.7 24.1 3.5 3.6 10.0 6.8 3.0 11.2 12.5 11.9 13.0 10.8 9.1 6.4 11.5 9.4 8.0 FGFR3 "ACH, CD333, CEK2, JTK4" ENSG00000068078 "Fibroblast growth factor receptor 3" P22607 4 1793293-1808872 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" Apoptosis "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Craniosynostosis, Deafness, Disease mutation, Dwarfism, Ectodermal dysplasia, FDA approved drug targets, Lacrimo-auriculo-dento-digital syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "skin 1: 131.7" "Cell line enhanced" "Detected in many" "CACO-2: 19.1;HaCaT: 14.9;Hep G2: 32.1;NTERA-2: 15.6;RT4: 19.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004231, HPA067204" Enhanced Supported "Endoplasmic reticulum" "Intracellular and membrane" 670000 "Endoplasmic reticulum" "CAB004231: AB_627596, HPA067204: " "unprognostic (1.34e-1)" "unprognostic (5.29e-3)" "unprognostic (1.49e-1)" "prognostic unfavourable (3.77e-4)" "unprognostic (5.90e-2)" "unprognostic (1.24e-3)" "unprognostic (7.22e-2)" "unprognostic (2.54e-1)" "unprognostic (1.99e-1)" "unprognostic (2.17e-1)" "unprognostic (1.38e-1)" "unprognostic (2.88e-2)" "unprognostic (1.30e-1)" "unprognostic (9.11e-3)" "unprognostic (1.98e-1)" "unprognostic (4.74e-2)" "unprognostic (1.97e-1)" 1.5 1.5 24.7 1.7 30.3 1.6 4.2 10.2 22.0 4.1 4.9 15.8 3.4 9.9 1.8 2.7 26.9 2.0 5.0 2.0 21.6 11.7 9.6 7.4 4.5 1.3 17.6 21.5 1.1 23.0 1.2 3.0 5.6 15.1 3.7 3.8 1.7 3.8 9.0 1.7 131.7 7.4 1.3 9.0 2.1 4.9 8.1 10.6 0.1 1.3 8.5 7.3 8.5 10.1 0.1 0.6 0.1 0.1 0.2 0.3 0.0 0.0 1.5 9.0 2.6 0.0 0.1 9.2 1.0 0.1 0.4 0.2 19.1 0.4 0.0 7.6 0.3 14.9 2.6 0.1 0.1 0.1 9.6 5.9 1.5 32.1 0.0 0.0 0.1 0.0 5.0 0.1 0.0 0.0 6.4 0.0 0.0 9.5 0.3 0.2 15.6 0.0 0.5 0.5 0.1 1.3 19.1 2.6 0.7 0.8 1.6 0.0 8.9 1.1 0.4 0.0 0.9 0.2 0.6 0.0 0.0 0.0 0.1 0.7 0.5 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.2 0.0 0.6 0.1 0.0 24.7 30.3 10.2 22.0 21.6 11.7 17.6 21.5 15.1 10.6 FHIT "AP3Aase, FRA3B" ENSG00000189283 "Fragile histidine triad" P49789 3 59749310-61251459 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Apoptosis, Transcription, Transcription regulation" Hydrolase "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "RPMI-8226: 11.9;U-266/70: 24.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 5 "naive CD4 T-cell: 38.3" "Lineage enriched" "Detected in all" 14 "T-cells: 38.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002684, HPA018840, HPA018909" Enhanced Approved "Nucleoli fibrillar center,Plasma membrane" "Nucleoli fibrillar center, Plasma membrane" "CAB002684: , HPA018840: AB_1848538, HPA018909: AB_1848537" "unprognostic (2.36e-3)" "unprognostic (6.38e-2)" "unprognostic (1.59e-1)" "unprognostic (4.42e-2)" "unprognostic (1.10e-1)" "unprognostic (1.08e-2)" "unprognostic (1.18e-1)" "unprognostic (3.16e-2)" "unprognostic (2.77e-2)" "unprognostic (8.49e-2)" "unprognostic (2.36e-1)" "unprognostic (6.77e-2)" "prognostic favourable (1.36e-4)" "unprognostic (1.54e-1)" "unprognostic (5.96e-2)" "unprognostic (1.29e-2)" "unprognostic (1.80e-2)" 6.4 24.0 13.7 8.0 17.5 9.0 12.1 4.7 13.3 7.9 8.0 21.0 12.4 8.2 6.2 9.5 5.1 9.2 13.0 14.9 15.3 13.8 30.9 10.7 5.2 9.3 19.5 9.3 8.9 11.8 16.3 15.2 4.1 14.4 5.8 7.8 14.0 11.4 9.9 11.6 7.0 7.6 9.1 17.1 6.0 8.1 10.5 18.2 3.7 15.6 5.7 6.9 7.3 6.1 1.6 2.4 1.8 1.8 2.6 38.3 4.7 0.0 0.0 1.0 0.0 0.6 0.0 1.6 0.1 0.1 0.0 0.0 1.8 3.0 2.6 0.5 0.1 0.0 10.0 2.1 0.0 1.4 3.4 2.2 1.3 4.1 2.6 5.6 0.1 6.8 4.1 0.1 5.1 0.0 1.6 8.3 0.1 2.5 10.1 4.5 0.8 0.6 7.5 0.0 11.9 11.2 1.3 2.1 2.8 1.0 6.9 6.5 0.4 0.1 0.0 1.2 0.4 0.1 1.5 24.4 7.4 0.0 2.7 0.0 1.4 1.8 1.8 0.2 0.9 1.2 0.5 1.6 6.9 0.7 2.2 1.4 38.3 6.7 0.3 2.6 0.4 2.4 7.4 4.7 13.7 17.5 4.7 13.3 15.3 13.8 19.5 9.3 14.4 18.2 FIP1L1 "DKFZp586K0717, FIP1" ENSG00000145216 "Factor interacting with PAPOLA and CPSF1" Q6UN15 4 53377643-53460861 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "mRNA processing" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA037475, HPA058202" Supported Enhanced Nucleoplasm Nucleoplasm "HPA037475: AB_10696933, HPA058202: " "unprognostic (3.80e-1)" "unprognostic (5.46e-2)" "unprognostic (5.60e-3)" "unprognostic (1.40e-1)" "unprognostic (7.18e-2)" "unprognostic (4.71e-2)" "prognostic unfavourable (1.51e-4)" "unprognostic (1.87e-1)" "unprognostic (9.00e-3)" "unprognostic (1.14e-2)" "unprognostic (5.48e-2)" "unprognostic (1.42e-1)" "unprognostic (4.07e-1)" "unprognostic (1.10e-1)" "unprognostic (8.66e-3)" "unprognostic (3.10e-2)" "unprognostic (1.39e-1)" 25.7 24.4 20.2 27.6 25.8 35.8 24.0 23.0 25.1 24.5 18.0 19.4 16.1 16.0 27.4 17.7 23.4 22.4 16.2 19.7 17.1 16.6 19.7 19.0 20.3 24.5 20.1 26.0 32.2 16.9 26.6 26.6 28.2 20.9 21.7 21.0 16.2 21.5 18.0 33.9 24.5 20.0 23.5 19.4 24.5 20.4 40.2 22.4 42.4 22.7 17.8 29.2 26.6 22.6 26.5 32.7 36.5 24.0 33.7 32.4 21.3 17.9 11.8 21.7 13.0 16.4 16.8 27.7 22.7 28.7 18.6 14.4 17.2 16.7 33.0 17.7 24.3 11.3 23.5 16.9 24.1 11.4 12.8 26.0 9.8 15.9 26.1 38.6 22.3 19.1 15.4 23.5 24.1 13.6 29.9 15.4 14.6 13.2 34.8 17.8 14.2 11.7 31.2 9.8 14.5 15.1 16.2 16.9 18.3 15.9 18.4 26.1 10.4 14.3 14.4 19.1 16.6 17.7 27.2 19.4 11.2 41.6 16.5 24.2 33.9 25.8 16.9 36.5 25.7 17.8 29.2 26.5 25.8 25.1 22.6 24.2 28.9 25.4 20.7 33.7 24.0 32.7 32.4 21.3 20.2 25.8 23.0 25.1 17.1 16.6 20.1 26.0 20.9 22.4 FLI1 "EWSR2, SIC-1" ENSG00000151702 "Fli-1 proto-oncogene, ETS transcription factor" Q01543 11 128686535-128813267 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 40.2" "Cell line enhanced" "Detected in many" "HEL: 40.2;HUVEC TERT2: 22.3;REH: 18.8;TIME: 23.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA073099 Supported "Nucleoplasm,Nuclear bodies" "Nucleoplasm, Nuclear bodies" "HPA073099: " "unprognostic (1.38e-2)" "unprognostic (7.46e-2)" "unprognostic (6.16e-2)" "unprognostic (3.74e-2)" "unprognostic (6.22e-2)" "unprognostic (4.26e-3)" "unprognostic (1.33e-1)" "unprognostic (8.32e-3)" "unprognostic (2.97e-1)" "unprognostic (9.91e-2)" "unprognostic (1.60e-2)" "unprognostic (1.42e-1)" "prognostic unfavourable (4.60e-4)" "unprognostic (4.79e-2)" "unprognostic (2.07e-2)" "unprognostic (2.62e-1)" "unprognostic (4.79e-2)" 14.7 2.5 3.5 15.8 4.4 10.6 9.9 1.4 3.2 6.7 5.1 3.8 2.1 3.3 7.8 6.5 4.8 5.3 6.0 7.5 3.8 3.1 4.2 3.6 17.4 24.4 6.2 1.6 4.0 3.2 2.5 2.0 11.4 3.8 4.3 3.1 4.8 4.2 3.3 5.2 3.2 6.9 5.7 6.6 40.2 4.1 2.7 4.6 26.8 5.7 2.8 17.9 6.2 6.7 4.5 13.1 20.1 12.0 7.8 8.8 11.6 0.0 0.0 2.0 0.0 0.2 0.4 0.0 1.2 3.4 1.4 1.2 0.0 0.0 6.8 12.2 4.0 0.0 0.3 5.0 1.6 3.2 0.1 40.2 0.2 0.0 2.4 4.8 5.7 0.3 0.4 2.9 6.8 22.3 0.0 8.8 0.3 0.0 4.8 2.7 0.6 1.2 18.8 0.0 7.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 7.8 23.1 0.2 0.0 0.1 1.2 2.8 5.9 5.9 0.0 11.7 1.8 20.1 9.5 16.1 7.2 10.3 8.8 4.5 6.2 5.8 13.1 3.6 2.6 5.6 7.8 7.8 12.0 2.2 7.4 11.6 3.5 4.4 1.4 3.2 3.8 3.1 6.2 1.6 3.8 4.6 FOXO1 "FKH1, FKHR, FOXO1A" ENSG00000150907 "Forkhead box O1" Q12778 13 40469953-40666597 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Apoptosis, Autophagy, Differentiation, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 85.9" "Cell line enhanced" "Detected in many" "ASC diff: 18.9;Daudi: 20.0;HSkMC: 25.2;U-698: 25.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001252, CAB022326" Approved Approved Supported Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB022326: , HPA001252: AB_1078906" "unprognostic (4.72e-2)" "unprognostic (1.81e-1)" "unprognostic (8.54e-2)" "unprognostic (4.35e-1)" "unprognostic (2.42e-1)" "unprognostic (2.52e-1)" "prognostic favourable (3.74e-4)" "unprognostic (6.35e-2)" "unprognostic (1.60e-1)" "unprognostic (8.65e-3)" "unprognostic (1.71e-1)" "unprognostic (1.31e-1)" "prognostic favourable (1.33e-5)" "unprognostic (1.93e-1)" "unprognostic (5.44e-1)" "unprognostic (9.09e-2)" "unprognostic (9.63e-2)" 41.6 6.9 7.0 18.4 11.2 8.0 35.5 2.3 5.0 21.4 13.4 8.4 7.7 3.5 27.4 9.8 9.5 17.2 13.3 9.9 7.8 3.9 8.3 25.6 15.3 22.4 8.3 3.9 46.0 12.2 3.8 6.2 9.5 6.5 7.9 6.8 5.7 7.5 9.3 85.9 12.3 7.6 18.6 9.7 10.8 7.4 12.3 9.0 9.4 13.1 9.0 15.6 14.4 16.2 6.1 0.5 2.8 1.6 1.1 7.1 1.0 0.3 0.6 5.6 0.1 18.9 3.7 5.4 0.8 1.1 0.2 0.1 1.4 1.3 20.0 3.7 0.5 4.8 4.4 2.4 0.3 9.1 4.6 0.0 0.6 4.4 9.0 0.1 0.5 25.2 16.4 0.1 3.1 14.2 0.3 6.4 1.4 0.7 0.0 0.2 8.2 1.4 14.2 6.5 1.5 10.5 2.5 1.2 0.3 0.7 3.8 0.8 0.6 0.5 8.3 0.1 1.1 0.0 0.5 3.6 1.3 25.9 0.5 0.9 2.6 0.9 0.8 0.5 1.5 1.0 2.3 3.2 3.9 2.2 0.5 6.1 7.1 5.3 2.8 1.1 1.6 0.0 5.5 1.0 7.0 11.2 2.3 5.0 7.8 3.9 8.3 3.9 6.5 9.0 FOXO3 "AF6q21, FKHRL1, FOXO2, FOXO3A" ENSG00000118689 "Forkhead box O3" O43524 6 108559835-108684774 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Apoptosis, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Karpas-707: 39.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 15.7" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004074, HPA063104" Supported Enhanced Nucleoplasm Nucleoplasm "CAB004074: AB_2106672, HPA063104: " "unprognostic (3.42e-2)" "unprognostic (3.76e-2)" "unprognostic (4.28e-2)" "unprognostic (1.96e-2)" "unprognostic (6.68e-2)" "unprognostic (4.63e-2)" "unprognostic (4.08e-3)" "unprognostic (1.73e-1)" "unprognostic (3.81e-2)" "unprognostic (5.18e-2)" "unprognostic (1.98e-2)" "unprognostic (1.75e-1)" "unprognostic (2.54e-2)" "unprognostic (9.09e-2)" "unprognostic (1.13e-1)" "unprognostic (5.81e-2)" "unprognostic (5.68e-2)" 29.6 7.7 11.5 12.2 12.6 36.7 35.4 28.0 18.1 19.9 16.1 12.6 9.8 7.8 17.4 16.1 22.3 16.5 18.0 12.9 9.7 7.7 10.7 14.0 21.1 16.8 12.4 14.0 28.8 52.3 14.3 8.8 13.1 10.3 13.8 11.0 14.3 21.2 10.5 54.7 20.3 11.3 13.9 7.9 14.2 14.8 13.1 13.2 11.6 13.1 12.7 10.2 17.1 20.3 1.8 2.7 15.7 4.6 3.4 4.0 1.0 8.9 3.3 5.9 9.5 18.3 21.9 7.4 7.5 7.9 6.6 9.1 5.8 8.2 5.8 6.4 8.7 6.6 6.1 9.1 9.8 5.2 8.8 14.4 2.9 4.4 21.3 3.4 10.6 24.9 18.4 13.4 18.5 4.9 9.7 39.3 11.9 5.1 4.8 5.3 3.8 4.9 5.5 16.7 19.3 13.0 6.8 10.4 27.1 6.3 5.2 7.4 5.7 11.5 7.9 11.2 6.3 6.8 9.6 0.7 6.7 5.5 6.1 6.9 7.6 6.7 2.9 5.7 3.6 1.5 4.0 1.0 1.9 3.0 1.7 1.8 1.7 2.3 15.7 3.4 4.6 2.7 1.8 1.0 11.5 12.6 28.0 18.1 9.7 7.7 12.4 14.0 10.3 13.2 FOXO4 "AFX1, MLLT7" ENSG00000184481 "Forkhead box O4" P98177 X 71096197-71103535 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors" "Cell cycle, Differentiation, Myogenesis, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 98.6" "Cell line enriched" "Detected in many" 5 "BEWO: 60.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA039560, HPA040232" Enhanced Supported "Nuclear speckles,Cytosol" "Nuclear speckles" Cytosol "HPA039560: , HPA040232: " "unprognostic (4.64e-2)" "unprognostic (2.94e-2)" "unprognostic (2.19e-1)" "unprognostic (2.49e-1)" "unprognostic (4.79e-2)" "prognostic favourable (4.61e-4)" "unprognostic (1.09e-1)" "unprognostic (3.20e-2)" "unprognostic (1.58e-1)" "unprognostic (7.18e-2)" "unprognostic (2.13e-2)" "unprognostic (8.16e-2)" "prognostic favourable (3.46e-4)" "unprognostic (2.45e-2)" "unprognostic (2.07e-1)" "unprognostic (1.20e-1)" "unprognostic (1.75e-3)" 8.5 13.2 21.7 3.8 21.5 9.9 5.1 9.1 15.6 4.8 8.4 9.1 11.9 6.3 6.8 10.2 7.3 7.7 5.8 9.7 21.4 14.5 5.2 3.6 5.5 3.6 22.8 8.4 13.4 6.8 8.7 3.0 98.6 9.2 7.0 4.7 4.9 8.5 11.3 33.8 5.5 6.6 9.4 17.3 6.0 5.2 13.9 13.1 4.4 5.9 7.5 4.2 7.5 11.0 0.9 0.2 3.4 0.6 1.0 1.8 0.9 1.7 0.5 1.4 1.8 3.3 2.3 60.0 1.4 1.6 0.7 1.7 1.2 2.4 2.3 1.8 1.8 0.8 3.6 1.6 0.8 2.3 5.5 3.4 11.2 1.9 1.9 1.9 2.7 1.9 3.8 0.6 0.4 1.8 6.9 4.6 0.3 0.3 3.0 3.1 6.5 2.1 2.1 3.5 3.6 1.2 1.0 1.0 2.9 2.9 0.4 3.1 0.7 1.2 1.7 0.4 0.9 3.1 0.3 3.0 1.6 0.4 1.6 5.2 0.5 0.2 0.6 3.2 0.9 0.6 0.3 0.8 0.5 0.9 0.2 0.9 0.4 1.8 3.4 1.0 0.3 0.0 1.3 0.9 21.7 21.5 9.1 15.6 21.4 14.5 22.8 8.4 9.2 13.1 FOXP1 "12CC4, hFKH1B, HSPC215, QRF1" ENSG00000114861 "Forkhead box P1" Q9H334 3 70952817-71583993 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "hTEC/SVTERT24-B: 39.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "HPA003876, CAB011501" Supported Enhanced Nucleoplasm Nucleoplasm "CAB011501: AB_732428, HPA003876: AB_1078907" "unprognostic (2.31e-1)" "unprognostic (4.35e-3)" "unprognostic (2.09e-2)" "unprognostic (3.54e-2)" "unprognostic (2.69e-1)" "unprognostic (2.81e-3)" "unprognostic (1.68e-1)" "unprognostic (1.00e-1)" "unprognostic (1.23e-1)" "unprognostic (2.03e-1)" "unprognostic (4.38e-3)" "unprognostic (3.40e-1)" "unprognostic (6.14e-2)" "unprognostic (1.05e-1)" "unprognostic (8.65e-2)" "unprognostic (1.27e-1)" "unprognostic (6.05e-2)" 24.6 5.1 7.0 30.2 19.2 32.7 21.9 7.2 13.1 16.3 29.3 8.7 10.3 10.1 19.8 9.9 19.6 13.1 19.3 15.5 8.4 5.9 7.6 12.9 26.1 34.0 7.6 10.2 30.3 14.7 7.2 25.7 11.4 7.4 21.6 21.6 11.3 24.6 11.2 12.7 12.2 16.7 34.3 7.9 18.6 20.4 11.7 10.1 38.1 19.8 13.1 27.0 28.5 31.8 29.9 8.4 14.4 9.9 9.2 29.6 11.2 3.7 2.8 7.0 4.7 3.3 9.4 3.3 11.2 12.9 9.8 7.2 20.9 4.4 10.1 1.7 5.0 2.6 12.9 9.6 16.6 3.1 5.3 5.2 7.0 19.7 8.1 9.8 12.8 9.6 4.0 39.5 17.5 14.6 5.2 14.9 4.4 16.5 4.8 3.9 8.6 18.3 14.6 12.0 1.8 8.0 11.9 5.9 10.7 11.7 3.2 0.7 2.3 7.2 18.4 13.6 5.9 19.0 15.5 3.7 2.8 14.3 8.7 12.5 2.9 14.4 5.7 6.0 8.3 5.7 9.3 25.8 18.3 10.3 5.3 29.9 29.6 18.9 8.3 9.2 9.9 8.4 15.9 11.2 7.0 19.2 7.2 13.1 8.4 5.9 7.6 10.2 7.4 10.1 FSTL3 "FLRG, FSRP" ENSG00000070404 "Follistatin like 3" O95633 19 676365-683399 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins" "Osteogenesis, Transcription, Transcription regulation" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 6 "placenta: 201.0" "Cell line enhanced" "Detected in many" "BEWO: 35.5;hTCEpi: 39.2;SiHa: 72.5;U-2197: 37.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB024899, HPA045378" Approved Approved Nucleoplasm "Secreted in other tissues" 6800000 Nucleoplasm "CAB024899: , HPA045378: " "unprognostic (9.86e-3)" "unprognostic (1.32e-3)" "prognostic unfavourable (3.01e-4)" "prognostic unfavourable (3.03e-4)" "unprognostic (2.19e-3)" "unprognostic (1.51e-3)" "unprognostic (8.64e-3)" "prognostic unfavourable (4.61e-7)" "unprognostic (9.50e-2)" "prognostic unfavourable (1.65e-4)" "unprognostic (3.50e-2)" "unprognostic (5.91e-2)" "unprognostic (1.03e-3)" "unprognostic (7.22e-3)" "unprognostic (3.07e-1)" "unprognostic (3.75e-1)" "unprognostic (5.89e-3)" 19.9 29.1 4.0 10.7 6.2 5.6 24.7 1.3 4.2 13.1 14.9 3.8 8.1 3.8 12.8 15.6 12.7 14.1 13.1 27.0 5.0 2.0 13.7 5.1 26.9 8.7 7.3 4.5 16.8 11.7 1.4 5.3 201.0 6.0 14.3 3.1 12.0 4.5 11.0 4.1 6.2 6.5 20.6 10.4 3.9 9.1 34.5 4.9 0.7 7.2 5.5 1.4 16.7 18.3 0.9 2.2 0.1 4.4 0.6 2.6 2.0 1.9 15.6 1.1 0.8 4.9 12.6 35.5 26.5 3.9 6.6 2.4 5.7 3.0 0.8 10.7 17.8 13.7 0.8 22.6 2.2 1.6 1.8 0.7 21.8 4.6 21.2 1.3 2.6 15.7 39.2 7.3 30.7 1.1 1.6 1.1 10.0 6.8 0.5 0.8 1.3 5.4 1.4 0.7 1.7 9.2 0.3 0.7 1.2 72.5 1.4 0.8 1.3 0.7 15.9 6.7 23.1 37.4 9.7 1.8 0.8 0.4 1.0 4.2 3.0 0.0 4.4 0.0 1.0 4.4 0.2 0.3 1.4 1.1 2.2 0.9 2.6 1.6 0.1 0.6 3.2 0.9 0.2 2.0 4.0 6.2 1.3 4.2 5.0 2.0 7.3 4.5 6.0 4.9 FUS "ALS6, FUS1, hnRNP-P2, HNRNPP2, TLS" ENSG00000089280 "FUS RNA binding protein" P35637 16 31180110-31194871 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "DNA-binding, RNA-binding" "Amyotrophic lateral sclerosis, Cancer-related genes, Disease mutation, Neurodegeneration, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008784, CAB033036, CAB058691" Supported Enhanced Nucleoplasm 190000 Nucleoplasm "CAB033036: AB_2105208, CAB058691: , HPA008784: AB_1849181" "unprognostic (3.06e-2)" "unprognostic (2.53e-1)" "unprognostic (1.86e-2)" "unprognostic (8.68e-2)" "unprognostic (1.44e-1)" "unprognostic (8.03e-2)" "prognostic unfavourable (4.38e-4)" "unprognostic (2.15e-2)" "unprognostic (1.00e-1)" "unprognostic (5.22e-3)" "unprognostic (1.01e-1)" "unprognostic (1.01e-3)" "unprognostic (1.12e-3)" "unprognostic (1.87e-1)" "unprognostic (5.27e-1)" "unprognostic (1.66e-1)" "unprognostic (1.49e-2)" 44.0 24.2 35.0 47.1 43.3 41.7 29.9 64.1 59.0 39.7 32.4 48.6 22.6 28.0 54.5 44.7 29.6 48.6 35.9 32.0 32.7 34.6 30.3 24.4 27.7 51.3 31.1 39.0 66.7 28.8 41.7 24.8 44.1 39.2 29.1 30.2 39.3 27.6 30.5 43.6 24.3 28.7 46.5 33.7 36.2 27.7 40.7 30.7 66.3 29.1 40.1 49.6 30.3 31.4 16.4 22.3 24.2 29.0 14.2 24.8 9.4 47.8 41.5 54.7 35.5 13.5 11.5 58.2 64.4 23.4 29.5 22.5 56.0 32.2 73.7 46.0 32.5 20.9 54.5 41.7 28.2 43.8 35.4 62.3 31.4 56.4 22.5 66.2 42.9 23.2 11.5 42.5 28.9 28.1 66.0 25.1 36.6 58.6 48.1 58.6 83.3 45.6 79.0 72.8 42.2 32.9 35.1 35.7 64.0 42.3 29.9 31.9 36.0 73.7 34.8 47.2 47.4 31.1 68.1 23.4 44.7 103.8 26.4 45.1 57.0 5.6 17.5 24.2 24.8 29.0 24.0 12.8 17.4 21.8 19.3 16.4 20.3 21.1 14.9 14.2 25.1 22.3 13.9 9.4 35.0 43.3 64.1 59.0 32.7 34.6 31.1 39.0 39.2 30.7 GAS7 "KIAA0394, MGC1348" ENSG00000007237 "Growth arrest specific 7" O60861 17 9910609-10198551 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Differentiation, Neurogenesis" "Developmental protein" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 86.2" "Cell line enriched" "Detected in some" 9 "WM-115: 107.7" "Cancer enhanced" "Detected in all" "melanoma: 54.6" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "classical monocyte: 17.6" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004838, HPA064678" Enhanced Approved "Plasma membrane,Actin filaments,Focal adhesion sites" "Plasma membrane" "Actin filaments, Focal adhesion sites" "HPA004838: AB_2667263, HPA064678: " "unprognostic (1.68e-2)" "unprognostic (2.84e-3)" "unprognostic (1.80e-1)" "unprognostic (1.28e-3)" "unprognostic (1.15e-1)" "unprognostic (1.01e-2)" "unprognostic (7.32e-2)" "unprognostic (7.16e-2)" "unprognostic (2.88e-1)" "unprognostic (1.50e-2)" "unprognostic (2.48e-1)" "unprognostic (1.79e-1)" "unprognostic (1.94e-3)" "unprognostic (6.48e-2)" "unprognostic (8.78e-2)" "unprognostic (3.08e-2)" "prognostic unfavourable (6.89e-4)" 19.1 6.5 22.1 15.4 40.3 18.7 10.8 86.2 64.7 22.6 9.3 33.4 1.7 5.2 9.7 4.4 17.0 12.6 11.5 23.1 25.8 15.0 1.5 2.1 9.9 5.9 28.1 25.0 5.9 2.8 1.4 1.7 11.0 14.2 3.7 8.7 7.7 4.0 8.2 3.9 21.2 7.4 16.3 33.8 10.0 4.2 11.8 22.2 2.7 2.5 2.7 7.2 11.7 7.8 0.4 3.6 11.0 17.6 2.8 2.1 4.4 0.0 0.1 0.1 0.2 3.4 4.8 0.0 0.1 0.0 0.5 0.2 0.0 0.0 1.3 0.3 1.3 0.0 0.0 0.0 0.3 0.0 0.3 0.0 0.2 0.1 1.1 0.3 9.9 0.9 0.0 1.0 0.0 0.0 0.0 0.1 0.0 0.0 10.4 3.1 0.5 0.0 2.7 0.0 9.6 0.0 0.0 0.0 0.6 0.0 0.0 12.4 0.5 4.9 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.1 7.0 107.7 0.4 17.6 10.8 2.1 4.7 0.7 0.3 0.2 1.0 3.6 0.4 0.2 1.0 11.0 2.8 3.1 0.6 0.0 4.4 22.1 40.3 86.2 38.8 25.8 15.0 28.1 25.0 14.2 22.2 GOLGA5 "golgin-84, GOLIM5, ret-II, rfg5" ENSG00000066455 "Golgin A5" Q8TBA6 14 92794231-92839963 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000992, HPA063876" Enhanced Supported Supported "Golgi apparatus" "Golgi apparatus" "HPA000992: AB_1079009, HPA063876: AB_2685140" "unprognostic (2.06e-1)" "unprognostic (1.76e-1)" "unprognostic (1.57e-1)" "unprognostic (2.64e-1)" "unprognostic (1.73e-1)" "unprognostic (2.77e-2)" "unprognostic (1.68e-1)" "unprognostic (3.15e-1)" "unprognostic (1.78e-1)" "unprognostic (5.02e-2)" "unprognostic (1.15e-2)" "unprognostic (2.83e-2)" "unprognostic (7.67e-2)" "unprognostic (6.44e-2)" "unprognostic (1.76e-1)" "unprognostic (1.06e-2)" "unprognostic (2.49e-2)" 20.8 20.3 16.8 15.7 17.3 6.5 24.4 11.6 17.5 24.9 20.4 17.2 25.5 16.5 18.2 41.7 21.2 15.3 17.5 18.3 17.5 15.6 21.5 51.0 16.6 18.2 18.6 14.6 18.9 26.8 23.6 27.2 44.4 16.4 23.4 23.7 12.7 24.3 30.2 20.6 18.9 25.6 18.9 19.4 16.9 23.0 23.5 17.6 13.5 24.8 17.8 16.4 20.7 15.8 9.7 9.7 22.2 12.7 8.1 12.4 6.3 12.6 11.6 10.5 9.6 22.1 30.0 18.1 17.5 32.3 17.1 20.2 8.5 17.4 8.2 14.4 27.8 13.3 9.3 14.3 23.3 10.0 4.4 7.7 5.8 11.4 25.7 9.0 13.0 23.0 26.0 12.0 24.9 16.8 6.8 11.1 18.7 23.4 6.9 7.8 6.5 12.5 5.4 15.5 8.2 17.4 15.4 7.5 10.6 15.9 12.0 17.8 20.6 10.0 13.9 9.8 6.5 12.7 8.7 13.6 10.5 7.2 22.6 7.2 16.4 9.1 9.8 22.2 10.9 12.7 12.3 9.7 11.1 11.1 9.7 9.2 9.9 8.6 8.7 8.1 10.8 9.1 12.4 6.3 16.8 17.3 11.6 17.5 17.5 15.6 18.6 14.6 16.4 17.6 GOPC "CAL, dJ94G16.2, FIG, GOPC1, PIST" ENSG00000047932 "Golgi associated PDZ and coiled-coil motif containing" Q9HD26 6 117560269-117602542 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Protein transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "HPA019477, HPA024018" Approved Enhanced "Golgi apparatus" "Golgi apparatus" "HPA019477: AB_1849890, HPA024018: AB_1849891" "unprognostic (2.48e-2)" "unprognostic (1.63e-3)" "unprognostic (1.71e-1)" "unprognostic (5.56e-2)" "unprognostic (1.84e-2)" "unprognostic (3.17e-2)" "unprognostic (3.12e-2)" "unprognostic (9.21e-2)" "unprognostic (6.22e-2)" "unprognostic (6.77e-2)" "unprognostic (8.23e-2)" "unprognostic (9.46e-2)" "unprognostic (1.40e-2)" "unprognostic (2.67e-2)" "unprognostic (1.38e-1)" "unprognostic (9.55e-2)" "unprognostic (3.01e-2)" 18.4 15.6 17.2 21.1 22.2 6.5 21.5 30.0 27.8 26.9 19.3 17.0 25.7 12.7 25.3 20.1 15.1 20.3 17.3 22.8 18.9 17.8 15.6 19.2 14.1 19.0 18.6 21.8 28.3 16.9 32.6 34.2 21.2 21.2 18.0 21.8 10.7 17.5 24.6 17.6 19.5 17.3 20.7 18.7 18.5 15.5 17.6 18.3 32.1 25.3 13.2 17.4 18.7 26.4 9.9 11.0 9.8 5.5 10.6 11.9 4.9 5.8 6.3 8.3 11.0 18.1 21.5 13.1 24.3 17.9 13.3 13.8 9.6 6.6 17.6 10.6 13.6 13.2 15.9 11.7 18.8 8.8 8.9 16.1 16.5 15.5 19.0 21.4 10.8 25.5 32.7 9.8 28.9 11.3 15.0 7.2 26.8 5.3 8.9 16.7 7.1 6.8 13.7 16.0 12.7 10.1 5.4 11.8 9.2 24.4 8.5 6.5 6.1 20.9 13.4 0.9 12.2 12.3 26.0 13.0 11.6 15.0 16.6 18.2 10.2 9.8 5.0 3.8 8.4 4.5 11.9 9.7 9.1 8.9 6.6 9.9 10.7 10.8 3.7 10.6 5.5 11.0 8.9 4.9 17.2 22.2 30.0 27.8 18.9 17.8 18.6 21.8 21.2 18.3 GPHN KIAA1385 ENSG00000171723 Gephyrin Q9NQX3 14 66507407-67181803 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Molybdenum cofactor biosynthesis" "Multifunctional enzyme, Transferase" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003116, CAB004419, HPA024694" Enhanced Uncertain "Cytoplasmic bodies" "Cytoplasmic bodies" "CAB004419: AB_627670, HPA003116: AB_1078963, HPA024694: AB_1849616" "unprognostic (8.37e-2)" "unprognostic (2.53e-2)" "unprognostic (2.42e-1)" "unprognostic (1.20e-1)" "unprognostic (5.14e-2)" "unprognostic (4.89e-3)" "unprognostic (8.29e-2)" "unprognostic (1.41e-2)" "unprognostic (1.42e-1)" "unprognostic (2.23e-1)" "unprognostic (2.49e-2)" "unprognostic (8.54e-2)" "prognostic favourable (5.25e-12)" "unprognostic (9.81e-2)" "unprognostic (2.27e-1)" "unprognostic (7.50e-2)" "prognostic unfavourable (4.61e-5)" 13.0 12.4 26.1 10.9 31.1 5.2 17.1 40.9 31.2 11.0 18.2 9.3 15.6 11.1 12.3 20.8 8.6 7.5 8.2 11.9 26.4 22.9 34.5 49.0 14.1 7.3 18.3 11.5 7.2 22.9 17.4 24.5 5.8 13.9 11.1 13.2 7.4 10.8 21.3 23.4 10.7 10.8 11.6 16.4 5.6 13.5 7.8 16.2 3.1 12.2 10.0 6.8 7.4 15.1 3.1 3.0 0.5 2.5 2.3 6.2 1.5 22.3 4.4 7.8 8.6 9.3 7.9 5.0 6.4 3.1 6.5 6.6 1.3 10.1 0.0 1.1 3.1 7.9 7.8 12.4 8.6 6.8 8.5 6.6 6.3 13.6 4.8 3.7 9.9 6.7 7.3 1.8 7.2 7.6 4.5 8.5 3.6 11.9 6.6 14.0 3.3 10.2 0.0 15.1 6.5 10.5 4.4 13.9 5.4 4.3 19.0 7.0 10.2 6.4 2.8 6.6 14.6 6.4 6.5 11.3 4.8 0.1 5.2 0.5 6.3 0.0 1.3 0.5 3.9 2.5 6.2 2.4 4.9 2.9 1.9 3.1 3.5 3.3 0.0 2.3 1.9 3.0 5.3 1.5 26.1 31.1 40.9 27.0 26.4 22.9 18.3 11.5 13.9 16.2 HERPUD1 "HERP, KIAA0025, Mif1, SUP" ENSG00000051108 "Homocysteine inducible ER protein with ubiquitin like domain 1" Q15011 16 56932048-56944863 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Unfolded protein response" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HHSteC: 61.2;RPMI-8226: 76.8;U-266/70: 87.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB037041, CAB037104, HPA040754, HPA041219" Approved Uncertain "Plasma membrane,Cytosol" "Plasma membrane, Cytosol" "CAB037041: AB_1840910, CAB037104: AB_1840912, HPA040754: AB_10794068, HPA041219: AB_10794268" "unprognostic (1.92e-1)" "unprognostic (3.47e-1)" "unprognostic (8.64e-2)" "unprognostic (3.93e-3)" "unprognostic (3.39e-1)" "unprognostic (5.00e-3)" "unprognostic (1.17e-1)" "unprognostic (9.69e-3)" "unprognostic (3.33e-1)" "unprognostic (2.56e-1)" "unprognostic (2.84e-1)" "unprognostic (3.50e-1)" "prognostic favourable (1.41e-9)" "unprognostic (1.06e-1)" "unprognostic (3.93e-2)" "unprognostic (2.19e-2)" "unprognostic (2.27e-3)" 22.7 38.8 16.2 35.6 20.7 21.6 39.4 17.7 20.0 30.1 32.1 20.0 48.8 21.4 21.6 51.6 15.0 20.2 32.5 28.8 15.8 15.5 42.9 57.7 30.4 40.0 25.6 12.5 44.8 148.6 37.6 26.7 26.2 25.6 49.5 32.3 35.3 108.6 76.1 34.6 18.3 24.7 17.6 24.2 38.3 37.2 10.6 20.8 9.6 64.2 20.4 53.8 24.4 25.9 50.8 121.9 29.0 39.5 22.4 33.4 46.5 4.4 4.9 4.8 10.0 11.2 14.6 17.2 10.6 16.9 13.7 10.7 6.8 10.2 18.1 13.6 10.2 7.7 8.2 3.7 13.6 10.4 4.9 1.5 8.2 24.5 61.2 3.2 8.1 17.7 35.8 6.2 19.7 10.4 2.4 25.9 38.2 3.7 6.1 6.7 3.1 11.1 4.2 12.2 76.8 29.4 5.0 5.3 6.1 9.2 45.4 46.9 5.0 12.2 6.3 5.7 5.7 5.0 4.2 87.6 28.5 28.3 8.1 4.5 7.4 23.9 39.5 18.0 16.1 31.0 17.4 50.8 17.5 21.1 30.6 37.8 11.4 17.4 29.0 22.4 21.5 121.9 33.4 46.5 16.2 20.7 17.7 20.0 15.8 15.5 25.6 12.5 25.6 20.8 HEY1 "bHLHb31, CHF-2, CHF2, HERP2, HESR-1, HESR1, HRT-1" ENSG00000164683 "Hes related family bHLH transcription factor with YRPW motif 1" Q9Y5J3 8 79764010-79767863 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Notch signaling pathway, Transcription, Transcription regulation" "Developmental protein, DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 60.6" "Cell line enhanced" "Detected in many" "HEK 293: 48.4;PC-3: 11.0;SK-MEL-30: 33.1;WM-115: 11.3" "Cancer enhanced" "Detected in all" "glioma: 43.1" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 6 "neutrophil: 9.9" "Lineage enriched" "Detected in many" 6 "granulocytes: 9.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA055599, HPA063472" Enhanced Approved "Nucleoplasm,Nuclear membrane,Cytosol" "Nucleoplasm, Cytosol" "Nuclear membrane" "HPA055599: AB_2682858, HPA063472: " "unprognostic (1.15e-1)" "unprognostic (5.06e-2)" "unprognostic (5.13e-3)" "unprognostic (2.12e-1)" "unprognostic (1.86e-3)" "unprognostic (8.47e-2)" "unprognostic (4.21e-3)" "unprognostic (9.56e-2)" "unprognostic (1.72e-1)" "unprognostic (7.22e-2)" "unprognostic (1.25e-2)" "unprognostic (6.71e-3)" "unprognostic (5.92e-3)" "unprognostic (5.77e-2)" "unprognostic (8.53e-2)" "unprognostic (1.74e-2)" "unprognostic (1.00e-1)" 13.3 3.8 13.7 3.6 22.9 1.8 8.8 11.2 60.6 8.9 4.4 10.7 0.0 3.3 3.8 2.4 4.6 3.9 5.7 13.4 11.3 11.6 3.8 2.9 16.4 3.3 11.9 9.3 2.6 4.3 3.0 9.9 20.3 12.5 4.5 3.9 10.3 4.5 3.0 10.3 3.5 3.2 4.4 9.1 2.8 3.6 3.9 10.5 1.3 5.0 3.7 3.7 5.2 2.5 0.0 0.0 9.9 1.7 0.0 0.3 0.1 0.6 0.0 0.4 3.4 0.3 0.2 8.8 0.8 0.8 0.1 0.1 0.1 0.0 1.6 0.8 0.3 2.2 1.8 0.1 0.2 0.1 48.4 0.0 1.5 0.8 0.5 0.0 0.3 0.4 1.4 0.0 6.1 1.6 3.1 1.4 0.5 0.1 0.0 0.2 0.1 11.0 0.0 1.8 1.4 0.1 1.5 2.0 5.6 0.0 1.0 33.1 0.0 0.0 1.1 0.2 0.9 0.0 0.6 1.2 0.2 0.0 1.2 0.0 11.3 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 9.9 0.0 1.7 0.0 0.0 0.1 13.7 22.9 11.2 12.3 11.3 11.6 11.9 9.3 12.5 10.5 HIP1 ILWEQ ENSG00000127946 "Huntingtin interacting protein 1" O00291 7 75533300-75738962 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Apoptosis, Differentiation, Endocytosis, Transcription, Transcription regulation" "Actin-binding, Activator" "Cancer-related genes, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "A549: 27.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA013606, CAB015334, CAB016402, HPA017964" Enhanced Enhanced Vesicles Vesicles "CAB015334: AB_2117565, CAB016402: AB_627725, HPA013606: AB_1850717, HPA017964: AB_1850719" "unprognostic (8.23e-2)" "unprognostic (1.22e-1)" "unprognostic (2.20e-2)" "unprognostic (1.64e-1)" "unprognostic (1.04e-1)" "unprognostic (2.59e-1)" "unprognostic (2.73e-3)" "unprognostic (1.03e-2)" "unprognostic (1.11e-2)" "unprognostic (2.02e-2)" "unprognostic (2.70e-2)" "unprognostic (7.98e-2)" "unprognostic (1.73e-3)" "unprognostic (9.67e-2)" "unprognostic (1.75e-1)" "unprognostic (1.00e-2)" "unprognostic (1.09e-1)" 16.5 8.7 14.6 7.2 25.9 5.1 13.5 13.2 20.8 13.2 5.3 34.4 4.9 2.9 13.4 10.1 5.7 13.8 8.7 9.2 17.5 11.9 14.6 9.6 17.7 4.6 27.2 11.8 8.1 4.0 4.9 3.6 20.0 16.1 6.8 4.5 9.9 4.0 12.4 3.9 10.8 4.6 12.6 24.8 10.8 4.6 18.5 29.7 1.6 15.8 5.7 4.6 9.7 8.8 0.5 4.0 8.8 1.1 3.3 1.5 0.3 2.5 27.3 18.6 17.5 7.9 10.7 5.6 4.8 3.1 3.1 2.3 1.5 2.4 1.8 5.6 11.8 3.1 18.8 3.9 4.2 1.5 3.5 1.4 3.2 2.5 7.8 0.4 7.4 8.2 2.4 10.2 2.1 13.0 1.9 1.8 5.0 10.4 1.2 10.6 20.2 3.3 2.1 7.8 0.1 2.4 9.7 0.9 8.2 4.4 2.8 6.3 17.2 6.7 4.6 9.2 7.1 3.1 6.6 2.0 0.2 4.4 9.2 3.9 6.2 8.8 1.1 7.6 1.1 1.1 1.0 0.4 0.2 0.9 1.6 0.5 0.1 0.7 7.7 3.3 0.8 4.0 1.5 0.3 14.6 25.9 13.2 16.9 17.5 11.9 27.2 11.8 16.1 29.7 HIST1H4I "H4/m, H4FM" ENSG00000276180 "Histone cluster 1 H4 family member i" P62805 6 27138588-27139881 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "blood: 14.5" "Cell line enhanced" "Detected in many" "K-562: 29.3;SiHa: 17.6;U-2 OS: 30.2;U-266/84: 30.4" "Low cancer specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" HPA042201 Approved 30000000 "HPA042201: " "unprognostic (2.49e-2)" "prognostic favourable (9.70e-4)" "unprognostic (1.97e-2)" "unprognostic (2.51e-2)" "unprognostic (2.26e-1)" "unprognostic (2.25e-1)" "unprognostic (1.07e-1)" "unprognostic (2.16e-1)" "unprognostic (2.85e-1)" "unprognostic (1.29e-3)" "unprognostic (1.86e-3)" "unprognostic (1.95e-1)" "prognostic unfavourable (1.32e-5)" "unprognostic (6.28e-2)" "unprognostic (1.49e-1)" "unprognostic (1.80e-1)" "unprognostic (2.02e-2)" 0.1 2.5 2.4 1.7 0.0 0.1 0.0 0.8 2.7 1.1 0.0 1.7 0.0 1.3 0.5 0.0 1.9 0.8 2.6 0.8 2.7 0.0 1.5 2.0 0.0 1.6 0.0 0.0 0.2 2.9 0.0 2.3 3.2 1.8 2.6 0.0 1.9 6.0 5.5 14.5 4.6 2.4 3.4 3.1 1.6 3.4 1.9 1.2 1.3 0.1 2.1 3.3 0.1 0.1 0.1 3.2 2.4 0.5 9.4 0.0 2.6 0.3 0.1 0.0 2.2 5.0 1.1 5.5 0.1 0.2 0.9 6.1 0.4 0.1 0.0 0.1 0.1 29.3 9.0 0.0 5.0 1.4 2.2 0.7 2.1 1.3 1.1 8.2 0.1 0.9 6.3 2.3 17.6 8.1 1.9 15.5 0.7 1.1 2.3 30.2 2.8 0.3 9.1 30.4 5.7 1.3 6.6 2.3 9.2 2.6 14.1 1.5 2.0 1.3 4.6 1.3 1.4 2.5 6.0 1.6 1.7 14.5 2.4 4.6 5.5 3.4 3.1 HLA-A ENSG00000206503 "Major histocompatibility complex, class I, A" "P16188, P04439, P13746" 6 29941260-29945884 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Host-virus interaction, Immunity, Innate immunity" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "A-431: 154.8;fHDF/TERT166: 41.4;HBEC3-KT: 42.5;RPMI-8226: 40.3;U-266/70: 41.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" CAB078470 Supported "Golgi apparatus,Plasma membrane" "Plasma membrane" "Golgi apparatus" "CAB078470: AB_10985125" "unprognostic (1.56e-2)" "unprognostic (9.14e-2)" "unprognostic (1.34e-2)" "prognostic favourable (9.59e-4)" "unprognostic (3.49e-1)" "unprognostic (1.21e-1)" "unprognostic (1.12e-1)" "unprognostic (7.28e-2)" "unprognostic (3.42e-2)" "prognostic favourable (6.47e-4)" "unprognostic (2.96e-1)" "unprognostic (3.24e-1)" "unprognostic (1.84e-2)" "unprognostic (1.01e-1)" "unprognostic (2.32e-2)" "unprognostic (1.20e-2)" "unprognostic (1.54e-2)" 69.4 57.5 16.0 69.1 18.2 41.2 40.8 9.1 20.7 54.4 92.6 20.4 28.6 105.7 38.4 76.2 48.4 27.8 92.3 59.1 14.6 16.6 80.5 47.6 112.0 90.5 19.5 8.9 57.2 30.0 22.5 33.3 38.7 22.7 64.1 38.5 52.4 28.3 19.2 44.0 110.4 129.4 30.3 22.8 150.0 115.9 26.6 12.3 71.1 62.3 38.5 97.7 86.4 41.0 23.0 10.9 65.8 25.2 25.9 46.7 45.4 154.8 3.9 0.0 0.0 25.0 23.6 0.1 0.1 0.3 0.2 0.2 0.0 0.0 0.4 0.0 41.4 3.8 0.0 42.5 0.0 0.3 1.5 27.0 1.2 0.8 1.4 0.0 1.8 0.2 0.0 0.3 0.1 0.0 0.0 0.1 0.0 0.0 0.1 2.4 0.3 0.4 3.3 0.3 40.3 29.0 31.8 0.0 1.4 3.5 0.0 1.4 0.1 3.6 0.5 2.3 0.1 0.7 0.4 41.3 10.5 8.7 0.0 22.8 0.0 65.8 25.2 35.4 38.3 17.9 28.8 23.0 29.6 34.4 4.1 14.9 21.7 29.7 47.9 25.9 19.8 10.9 46.7 45.4 16.0 18.2 9.1 20.7 14.6 16.6 19.5 8.9 22.7 12.3 HLF MGC33822 ENSG00000108924 "HLF, PAR bZIP transcription factor" Q16534 17 55265012-55325065 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in all" "liver: 78.8" "Cell line enriched" "Detected in some" 6 "Hep G2: 58.6" "Cancer enhanced" "Detected in many" "liver cancer: 13.6" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 7 "memory CD4 T-cell: 2.4;T-reg: 2.1" "Lineage enriched" "Detected in single" 25 "T-cells: 2.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA068156, HPA071210" Enhanced Nucleoplasm Nucleoplasm "HPA068156: , HPA071210: " "unprognostic (1.24e-1)" "unprognostic (1.19e-3)" "unprognostic (1.27e-1)" "unprognostic (1.35e-1)" "unprognostic (3.30e-1)" "prognostic favourable (1.88e-4)" "unprognostic (5.30e-3)" "prognostic favourable (2.71e-7)" "unprognostic (1.42e-1)" "unprognostic (3.44e-2)" "unprognostic (1.24e-3)" "unprognostic (2.19e-1)" "prognostic favourable (3.55e-6)" "unprognostic (8.47e-2)" "unprognostic (1.64e-1)" "unprognostic (6.85e-2)" "unprognostic (1.60e-2)" 9.5 15.2 13.3 2.0 26.2 1.0 10.8 15.2 38.0 10.5 10.6 6.4 2.4 1.7 10.3 8.5 18.1 9.3 6.1 15.9 12.6 6.9 9.2 78.8 9.5 2.1 6.6 24.5 34.6 2.7 2.8 8.0 1.5 12.3 9.9 3.1 23.7 15.9 9.5 5.3 11.6 3.0 14.3 5.5 5.7 4.7 3.4 6.3 0.0 23.4 7.1 5.6 9.2 5.2 0.0 0.0 0.0 0.0 0.0 2.4 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.3 0.2 0.0 0.0 0.1 0.0 0.0 9.7 0.2 0.0 0.0 58.6 0.0 0.3 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.4 0.0 0.0 0.9 0.0 0.1 0.1 4.8 0.0 4.1 0.2 0.0 2.6 0.0 0.1 0.0 0.0 0.3 0.0 0.2 0.1 1.9 1.7 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.3 0.0 2.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 2.1 0.1 13.3 26.2 15.2 38.0 12.6 6.9 6.6 24.5 12.3 6.3 HMGA1 HMGIY ENSG00000137309 "High mobility group AT-hook 1" P17096 6 34236873-34246231 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 107.3" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "CAB032200, HPA065612, HPA068442" Enhanced Approved Nucleoplasm,Nucleoli 18000 Nucleoplasm Nucleoli "CAB032200: AB_2117771, HPA065612: , HPA068442: " "unprognostic (1.81e-1)" "unprognostic (1.25e-1)" "unprognostic (1.08e-1)" "prognostic unfavourable (7.13e-4)" "unprognostic (1.57e-1)" "unprognostic (1.20e-3)" "prognostic unfavourable (1.29e-6)" "prognostic unfavourable (3.36e-4)" "unprognostic (8.54e-2)" "unprognostic (1.84e-2)" "prognostic unfavourable (8.71e-4)" "unprognostic (1.55e-1)" "unprognostic (8.22e-2)" "unprognostic (4.52e-3)" "unprognostic (1.19e-1)" "unprognostic (4.37e-1)" "unprognostic (2.65e-2)" 15.8 3.5 14.8 35.7 13.5 55.4 13.0 13.8 19.0 26.1 22.0 5.9 7.7 42.3 8.6 7.2 79.4 15.1 17.8 13.0 11.7 12.6 14.6 6.9 16.0 46.1 10.7 8.7 3.9 13.0 4.1 5.1 31.8 12.5 8.7 21.2 9.9 22.0 6.9 33.7 38.3 36.0 3.8 8.4 31.6 24.2 32.6 7.2 107.3 12.5 39.6 72.7 13.0 29.6 26.6 33.4 12.8 10.1 7.3 22.4 11.0 120.4 47.7 24.5 17.1 11.4 84.6 107.0 48.7 55.7 37.8 21.1 31.2 84.5 56.8 24.6 19.9 25.9 28.8 86.9 30.1 12.4 19.3 17.4 16.1 41.7 24.2 62.2 20.1 36.2 9.7 68.4 35.8 114.1 70.1 2.9 52.6 12.2 53.9 76.6 119.2 80.9 80.2 0.5 62.7 25.6 11.1 42.8 18.1 5.1 24.7 45.0 9.9 66.8 98.9 19.7 62.2 28.6 45.6 23.4 36.2 73.4 41.7 26.0 98.3 6.2 10.1 12.8 10.2 10.1 13.3 26.6 18.7 16.0 30.7 16.4 22.4 17.7 2.6 7.3 9.4 33.4 21.0 11.0 14.8 13.5 13.8 19.0 11.7 12.6 10.7 8.7 12.5 7.2 HMGA2 "BABL, HMGIC, LIPO" ENSG00000149948 "High mobility group AT-hook 2" P52926 12 65824131-65966295 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Cell cycle, Cell division, DNA condensation, Growth regulation, Mitosis, Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "testis: 25.3" "Cell line enhanced" "Detected in many" "AF22: 66.0;NTERA-2: 38.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "CAB017809, HPA039076" Approved Supported Nucleoplasm,Nucleoli "Nucleoplasm, Nucleoli" "CAB017809: , HPA039076: " "unprognostic (2.39e-1)" "unprognostic (6.00e-2)" "unprognostic (2.08e-1)" "unprognostic (3.68e-3)" "unprognostic (5.21e-3)" "prognostic unfavourable (4.79e-4)" "unprognostic (4.05e-3)" "unprognostic (6.17e-3)" "unprognostic (6.71e-2)" "unprognostic (1.16e-1)" "unprognostic (1.54e-6)" "unprognostic (3.33e-2)" "unprognostic (4.55e-5)" "unprognostic (4.22e-2)" "unprognostic (2.53e-1)" "unprognostic (2.53e-2)" "prognostic unfavourable (2.86e-4)" 6.5 0.3 0.5 3.8 0.8 8.1 2.1 0.2 0.6 2.5 7.6 0.4 0.0 2.4 2.7 0.1 1.1 2.4 3.3 0.5 0.3 0.4 1.0 0.4 0.5 0.1 0.3 1.3 2.1 1.7 0.0 1.7 0.3 0.6 0.5 4.6 0.4 0.5 1.8 2.0 0.7 5.1 0.7 1.7 0.8 2.1 25.3 0.0 0.8 1.1 3.0 0.1 0.8 2.8 0.7 0.3 3.8 2.1 1.3 0.7 0.1 9.5 4.2 66.0 9.4 3.1 17.3 0.0 30.5 13.9 5.4 5.4 5.4 4.0 0.0 19.8 1.4 4.2 10.9 26.2 25.7 0.0 11.4 0.0 0.1 33.0 1.7 0.9 0.1 13.1 1.6 11.5 20.8 21.1 0.0 0.1 30.5 0.0 0.1 5.4 38.7 19.0 2.6 3.2 0.0 14.2 0.0 0.0 0.0 0.0 0.0 16.7 0.1 0.1 24.6 19.4 5.8 14.8 9.1 0.0 0.0 0.0 23.4 0.0 4.4 3.8 1.0 0.7 0.5 0.6 0.3 0.3 0.4 0.5 0.2 0.7 0.4 0.7 2.5 1.3 2.1 0.3 0.3 0.1 0.5 0.8 0.2 0.6 0.3 0.4 0.3 1.3 0.6 0.0 HNRNPA2B1 HNRPA2B1 ENSG00000122566 "Heterogeneous nuclear ribonucleoprotein A2/B1" P22626 7 26189927-26201529 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, mRNA processing, mRNA splicing, mRNA transport, Transport" "Ribonucleoprotein, RNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001666, HPA005812, CAB012403, HPA065537" Supported Enhanced Nucleoplasm "Intracellular and membrane" 11000000 Nucleoplasm "CAB012403: , HPA001666: AB_1850836, HPA005812: , HPA065537: " "unprognostic (1.19e-1)" "unprognostic (4.45e-1)" "unprognostic (2.33e-1)" "unprognostic (6.39e-2)" "unprognostic (5.64e-2)" "unprognostic (8.04e-3)" "prognostic unfavourable (1.03e-6)" "unprognostic (1.25e-2)" "unprognostic (9.12e-3)" "unprognostic (4.35e-3)" "unprognostic (1.31e-1)" "prognostic unfavourable (5.12e-4)" "prognostic unfavourable (8.01e-5)" "unprognostic (6.74e-2)" "unprognostic (3.36e-2)" "unprognostic (2.02e-1)" "unprognostic (1.56e-2)" 82.2 97.4 85.1 105.3 106.3 90.9 74.4 123.3 87.4 77.1 85.7 89.4 68.7 87.5 92.6 71.9 90.4 75.1 51.7 87.9 82.4 71.8 113.4 103.7 76.2 127.7 118.6 57.0 121.0 75.7 107.2 121.2 100.7 96.3 75.5 98.6 64.4 71.4 66.5 167.2 58.7 94.8 73.7 139.7 116.5 74.1 73.1 135.4 180.3 81.9 104.4 140.7 74.2 128.8 33.7 46.5 35.1 52.4 32.1 42.5 36.0 122.0 104.2 151.7 113.7 39.0 35.7 70.2 78.3 61.1 86.5 78.4 96.2 88.9 223.1 74.9 72.5 85.2 162.2 102.3 122.0 69.4 98.9 135.2 125.7 115.0 32.8 145.5 92.7 33.7 53.6 82.3 75.1 89.3 159.0 73.0 87.4 98.7 155.7 170.3 134.3 80.3 144.7 123.3 93.5 99.9 106.8 88.6 108.7 94.1 92.7 57.2 103.9 126.8 77.1 48.7 100.8 65.9 133.6 97.0 192.2 212.4 62.7 166.0 91.7 17.4 38.7 35.1 42.5 52.4 38.6 33.7 35.5 36.6 46.5 29.2 35.6 35.6 13.0 32.1 48.4 43.6 36.1 36.0 85.1 106.3 123.3 87.4 82.4 71.8 118.6 57.0 96.3 135.4 HOOK3 HK3 ENSG00000168172 "Hook microtubule tethering protein 3" Q86VS8 8 42896932-43030539 "Cancer-related genes, Predicted intracellular proteins" "Protein transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA024756 Approved Supported "Golgi apparatus,Centriolar satellite,Cytosol" "Centriolar satellite" "Golgi apparatus, Cytosol" "HPA024756: AB_1850913" "unprognostic (1.84e-2)" "unprognostic (1.61e-1)" "unprognostic (2.73e-1)" "unprognostic (8.61e-3)" "unprognostic (6.05e-2)" "unprognostic (1.77e-3)" "unprognostic (2.36e-1)" "unprognostic (2.23e-1)" "unprognostic (1.78e-1)" "unprognostic (3.97e-2)" "unprognostic (1.13e-1)" "unprognostic (4.13e-1)" "prognostic unfavourable (1.32e-4)" "unprognostic (1.63e-1)" "unprognostic (3.78e-1)" "unprognostic (2.55e-1)" "unprognostic (7.12e-2)" 15.5 9.3 11.3 10.1 15.1 13.1 16.3 16.0 19.2 13.5 11.3 10.3 14.1 10.2 13.7 12.0 14.8 11.7 20.0 9.5 11.2 11.3 9.9 10.7 14.6 10.3 14.7 11.7 13.4 13.9 13.4 14.4 12.0 13.1 17.7 10.9 6.8 17.1 15.2 24.1 11.0 11.9 19.3 17.5 11.6 12.8 14.5 14.3 7.4 37.5 8.9 10.1 19.2 17.6 1.8 3.8 10.2 3.2 2.0 2.0 1.8 7.3 7.3 17.8 9.6 13.2 11.7 6.8 9.3 7.8 7.8 7.3 9.6 8.6 9.1 9.6 12.4 4.1 14.7 6.3 12.7 6.2 4.2 17.2 6.0 6.6 7.4 1.8 10.2 9.5 4.6 10.5 9.1 11.2 9.4 10.7 9.4 1.8 13.9 3.4 6.4 2.2 8.2 18.6 2.3 5.8 10.9 4.5 7.2 10.6 4.5 4.9 8.2 6.2 20.0 11.7 9.2 14.1 5.9 10.6 11.5 12.0 9.9 6.6 17.3 10.2 3.2 3.1 2.0 3.2 0.8 1.6 1.9 1.5 3.8 1.8 1.1 1.5 3.8 2.0 3.1 2.4 1.4 1.8 11.3 15.1 16.0 13.1 11.2 11.3 14.7 11.7 13.1 14.3 HOXA11 "HOX1, HOX1I" ENSG00000005073 "Homeobox A11" P31270 7 27181510-27185223 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "cervix, uterine: 35.7;endometrium 1: 60.9;smooth muscle: 27.3" "Cell line enhanced" "Detected in many" "BJ hTERT+: 17.5;HEK 293: 24.6;THP-1: 17.6;U-937: 22.9" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA006770, HPA035623" Enhanced Supported Nucleoplasm Nucleoplasm "HPA006770: , HPA035623: AB_10601576" "unprognostic (5.95e-2)" "unprognostic (9.23e-2)" "unprognostic (3.07e-2)" "unprognostic (2.70e-2)" "unprognostic (6.29e-2)" "unprognostic (9.78e-2)" "unprognostic (2.82e-3)" "unprognostic (4.36e-2)" "unprognostic (1.61e-2)" "unprognostic (3.05e-2)" "unprognostic (2.08e-3)" "unprognostic (1.73e-2)" "prognostic unfavourable (2.57e-5)" "unprognostic (2.17e-2)" "unprognostic (6.90e-2)" "unprognostic (2.03e-2)" "unprognostic (2.56e-1)" 1.5 0.4 0.0 1.7 0.0 0.0 2.0 0.0 0.0 35.7 9.3 0.0 5.7 0.0 60.9 8.8 0.0 0.7 0.0 0.2 0.0 0.0 3.6 0.1 0.0 0.1 0.0 0.0 1.8 0.0 0.0 0.0 9.0 0.0 16.5 2.4 0.0 0.1 6.3 4.9 0.7 0.2 27.3 0.0 0.0 0.1 3.1 0.0 0.0 0.0 0.0 0.0 20.1 6.8 0.0 0.0 0.0 0.2 0.0 0.0 0.0 2.3 0.1 0.0 6.7 8.2 5.8 0.0 14.5 17.5 10.3 7.4 0.1 0.8 0.0 3.3 12.2 1.6 8.6 0.0 7.5 0.8 24.6 3.0 6.0 0.3 0.5 6.1 0.8 3.7 0.3 0.0 0.0 7.4 0.1 0.0 1.1 0.1 0.0 4.7 0.0 7.2 0.3 0.0 0.1 4.9 4.2 3.2 0.0 3.5 0.0 1.0 0.6 17.6 0.0 0.1 7.1 1.6 0.7 0.0 0.0 0.0 0.1 22.9 1.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 HOXA13 "HOX1, HOX1J" ENSG00000106031 "Homeobox A13" P31271 7 27193503-27200106 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "cervix, uterine: 48.5;prostate: 25.1" "Cell line enhanced" "Detected in many" "HAP1: 15.2;HEK 293: 21.1;PC-3: 10.5;RT4: 23.5;THP-1: 10.0;U-937: 11.2" "Cancer enhanced" "Detected in many" "prostate cancer: 10.9" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in single" HPA069061 Supported "Nucleoplasm,Intermediate filaments" Nucleoplasm "Intermediate filaments" "HPA069061: " "unprognostic (7.20e-2)" "unprognostic (1.89e-1)" "unprognostic (1.02e-1)" "unprognostic (8.04e-4)" "unprognostic (1.06e-3)" "unprognostic (2.24e-2)" "unprognostic (1.79e-1)" "unprognostic (1.40e-2)" "unprognostic (9.22e-3)" "unprognostic (7.30e-3)" "unprognostic (8.39e-3)" "unprognostic (1.54e-1)" "unprognostic (1.42e-11)" "unprognostic (2.58e-3)" "unprognostic (1.38e-1)" "unprognostic (1.72e-1)" "unprognostic (1.36e-2)" 0.6 0.2 0.1 0.0 0.1 0.0 0.1 0.1 0.1 48.5 6.9 0.0 7.1 0.0 5.5 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.1 16.5 0.0 25.1 8.6 0.0 0.1 17.9 1.2 0.4 0.1 15.7 0.1 0.1 0.1 0.2 0.0 0.0 0.1 0.0 0.0 12.1 12.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.9 0.0 1.4 0.1 0.0 0.0 7.4 8.2 2.9 1.9 1.5 0.1 0.0 0.9 3.5 0.0 15.2 0.0 2.5 0.0 21.1 1.0 4.0 0.1 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 4.8 0.0 10.5 1.5 0.3 0.0 0.0 23.5 0.4 0.0 1.8 0.0 0.1 0.0 10.0 0.0 0.2 2.7 0.1 0.1 0.0 0.0 0.0 0.0 11.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 HOXA9 "HOX1, HOX1G" ENSG00000078399 "Homeobox A9" P31269 7 27162435-27175180 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "kidney: 35.1" "Cell line enhanced" "Detected in some" "HEK 293: 42.7;PC-3: 14.9;RPTEC TERT1: 14.7;SCLC-21H: 39.7;U-937: 14.2" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in many" 4 "basophil: 5.4;myeloid DC: 6.0;NK-cell: 11.7" "Group enriched" "Detected in many" 5 "dendritic cells: 6.0;granulocytes: 5.4;NK-cells: 11.7" HPA061982 Uncertain Supported Nucleoplasm Nucleoplasm "HPA061982: " "unprognostic (4.72e-1)" "unprognostic (1.23e-2)" "unprognostic (2.86e-1)" "unprognostic (5.24e-3)" "unprognostic (2.36e-1)" "unprognostic (2.02e-1)" "unprognostic (8.35e-2)" "unprognostic (8.44e-3)" "unprognostic (5.50e-2)" "unprognostic (5.71e-2)" "unprognostic (9.87e-3)" "unprognostic (4.42e-2)" "unprognostic (2.80e-3)" "unprognostic (6.45e-2)" "unprognostic (7.58e-2)" "unprognostic (1.92e-2)" "unprognostic (1.35e-1)" 3.2 3.4 0.2 8.8 0.1 2.4 8.7 0.1 0.2 15.5 12.8 0.2 4.1 0.0 10.4 16.8 1.4 12.2 0.3 0.1 0.1 0.0 35.1 0.1 0.8 0.7 0.1 0.1 2.0 0.1 0.0 0.1 1.4 0.4 16.6 4.5 0.2 0.5 5.6 21.0 13.3 8.2 13.1 0.7 1.0 0.0 2.4 0.1 2.6 0.3 0.3 0.3 16.2 11.4 0.5 6.0 5.4 1.0 11.7 1.5 0.5 12.4 0.0 0.0 6.3 2.1 1.6 0.0 5.0 4.0 0.4 0.4 0.8 0.5 0.1 0.5 2.7 11.7 8.1 0.0 0.4 0.0 42.7 0.1 0.3 0.0 0.2 0.0 0.1 2.1 0.0 0.0 0.0 10.5 0.0 0.0 0.4 0.0 0.0 0.3 0.0 14.9 2.7 0.0 0.0 14.7 0.2 39.7 0.0 5.3 0.0 0.1 0.0 10.5 0.4 0.0 4.0 4.8 0.0 0.0 0.0 0.0 0.0 14.2 0.0 5.4 1.0 0.0 1.5 0.2 0.2 0.2 0.0 0.1 6.0 0.5 0.3 0.1 0.9 11.7 0.4 1.9 0.2 0.5 0.2 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.4 0.1 HOXC11 HOX3H ENSG00000123388 "Homeobox C11" O43248 12 53973126-53977643 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skeletal muscle: 7.0;skin 1: 9.2" "Cell line enhanced" "Detected in some" "AN3-CA: 23.0;BJ hTERT+: 11.6;HaCaT: 10.1;T-47d: 18.1" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA038291 Uncertain Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA038291: AB_10674552" "unprognostic (1.50e-3)" "unprognostic (1.93e-2)" "unprognostic (1.14e-2)" "unprognostic (1.51e-1)" "unprognostic (1.93e-3)" "unprognostic (1.17e-2)" "unprognostic (6.90e-3)" "unprognostic (1.32e-2)" "unprognostic (7.41e-3)" "unprognostic (4.46e-3)" "unprognostic (2.25e-1)" "unprognostic (3.26e-3)" "unprognostic (3.99e-2)" "unprognostic (1.06e-1)" "unprognostic (1.82e-1)" 4.8 0.0 0.1 0.1 0.1 0.0 1.2 0.1 0.1 2.5 0.1 0.1 0.1 0.8 2.0 1.0 0.1 0.7 0.1 0.1 0.1 0.0 2.0 0.1 0.1 0.7 0.1 0.1 0.5 0.1 0.0 0.1 0.6 0.3 0.5 0.0 0.1 0.1 2.0 7.0 9.2 2.7 0.4 0.1 0.1 0.0 1.6 0.1 0.5 0.1 0.1 0.1 1.2 3.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.9 0.7 0.0 23.0 2.2 3.3 0.0 3.3 11.6 4.9 3.6 0.2 0.9 0.0 0.2 3.1 10.1 4.4 0.0 2.2 0.6 0.1 0.1 7.5 0.0 0.0 0.1 0.1 0.6 0.9 0.0 0.3 0.0 0.9 0.0 3.1 1.4 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.4 0.8 0.0 0.1 2.1 5.2 2.0 18.1 0.0 0.0 0.0 4.0 0.3 0.2 0.0 0.0 0.0 0.0 0.3 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.3 0.1 HOXC13 "HOX3, HOX3G" ENSG00000123364 "Homeobox C13" P31276 12 53938765-53946544 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation, Ectodermal dysplasia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "breast: 4.4;skin 1: 13.5;tongue: 4.1" "Cell line enhanced" "Detected in many" "AN3-CA: 15.4;HaCaT: 32.4;SK-BR-3: 17.9;T-47d: 13.8" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA051634 Enhanced "HPA051634: AB_2616459" "unprognostic (5.16e-3)" "unprognostic (1.46e-1)" "unprognostic (1.29e-1)" "unprognostic (2.27e-3)" "unprognostic (2.78e-2)" "unprognostic (1.20e-1)" "unprognostic (2.20e-1)" "unprognostic (4.04e-2)" "unprognostic (1.53e-1)" "unprognostic (9.77e-2)" "unprognostic (9.74e-9)" "unprognostic (2.41e-1)" "unprognostic (1.41e-1)" "unprognostic (1.68e-1)" 2.6 0.0 0.0 0.0 0.0 0.0 4.4 0.0 0.3 0.4 0.5 0.0 0.0 0.0 0.6 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.9 0.0 0.0 2.5 0.0 0.6 13.5 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 4.1 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.4 5.1 0.0 15.4 0.2 0.0 9.2 0.9 2.1 1.4 0.8 1.3 0.2 0.0 0.2 0.0 32.4 3.9 1.0 0.8 0.0 3.1 0.0 4.2 0.0 0.0 0.0 3.3 0.0 7.6 0.0 3.0 0.0 5.5 0.0 5.6 9.5 0.0 0.0 0.1 1.3 0.0 0.2 0.0 0.0 2.9 0.0 0.0 5.1 17.9 2.3 13.8 0.0 0.0 0.0 6.7 0.1 2.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 HOXD11 "HOX4, HOX4F" ENSG00000128713 "Homeobox D11" P31277 2 176104216-176109754 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "No human protein/transcript evidence" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "endometrium 1: 15.8" "Cell line enhanced" "Detected in some" "HEK 293: 20.3;SCLC-21H: 6.2;U-251 MG: 4.6" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA055155 Supported Nucleoplasm Nucleoplasm "HPA055155: " "unprognostic (1.99e-1)" "unprognostic (1.48e-1)" "unprognostic (2.32e-2)" "unprognostic (9.05e-2)" "unprognostic (1.85e-3)" "unprognostic (2.48e-1)" "unprognostic (1.93e-2)" "unprognostic (2.13e-2)" "unprognostic (6.73e-2)" "unprognostic (5.00e-2)" "unprognostic (2.11e-8)" "unprognostic (2.09e-3)" "unprognostic (2.49e-2)" "unprognostic (2.27e-3)" 0.0 0.0 0.0 0.7 0.3 0.0 0.0 0.0 0.0 5.4 4.2 0.0 0.0 0.0 15.8 0.4 0.3 0.1 0.0 0.0 0.0 0.0 5.5 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 1.6 0.3 5.7 0.9 0.0 0.0 2.9 0.0 0.2 0.0 1.7 0.0 0.0 0.0 0.6 0.0 0.0 0.2 0.0 0.0 1.0 5.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.5 0.0 0.0 0.0 0.0 0.0 0.4 0.0 1.2 0.0 0.0 0.1 0.0 20.3 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 0.3 6.2 0.3 2.4 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 4.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 HOXD13 "HOX4I, SPD" ENSG00000128714 "Homeobox D13" P35453 2 176092891-176095938 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "cervix, uterine: 14.0;intestine: 13.1;prostate: 13.8;seminal vesicle: 19.0;vagina: 15.0" "Group enriched" "Detected in some" 4 "HAP1: 9.6;HEK 293: 27.6;HL-60: 30.7;NB-4: 18.3;SCLC-21H: 8.0" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA064064 Approved Nucleoplasm Nucleoplasm "HPA064064: " "unprognostic (2.04e-1)" "unprognostic (1.13e-1)" "prognostic unfavourable (6.95e-5)" "unprognostic (2.52e-3)" "unprognostic (7.25e-2)" "unprognostic (2.08e-2)" "unprognostic (4.62e-2)" "unprognostic (1.77e-1)" "unprognostic (4.66e-1)" "unprognostic (1.01e-2)" "unprognostic (2.82e-4)" "unprognostic (4.95e-2)" "unprognostic (3.70e-2)" "unprognostic (9.98e-3)" 0.4 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.2 14.0 13.1 0.1 0.1 0.0 0.3 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.0 0.1 0.1 0.1 13.8 8.8 0.1 0.1 19.0 0.6 0.0 0.1 3.7 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 3.8 15.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.6 0.0 1.1 2.5 0.0 0.0 0.0 0.0 0.0 0.0 9.6 0.0 1.5 0.0 27.6 4.2 0.0 0.0 0.0 30.7 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 18.3 0.9 1.5 0.0 0.1 0.0 0.0 0.2 8.0 1.9 1.9 0.0 4.4 0.0 0.0 0.0 1.0 0.0 0.4 2.5 0.0 0.0 0.0 1.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.1 HSP90AA1 "FLJ31884, Hsp89, Hsp90, HSP90N, HSPC1, HSPCA" ENSG00000080824 "Heat shock protein 90 alpha family class A member 1" P07900 14 102080738-102139699 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, Stress response" Chaperone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "vagina: 519.3" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB002058 Approved Supported Cytosol 94000000 Cytosol "CAB002058: " "prognostic unfavourable (5.59e-4)" "unprognostic (3.77e-2)" "unprognostic (1.78e-2)" "unprognostic (9.25e-2)" "unprognostic (2.53e-1)" "unprognostic (1.05e-3)" "prognostic unfavourable (3.09e-5)" "unprognostic (7.79e-3)" "unprognostic (5.71e-2)" "unprognostic (7.81e-3)" "unprognostic (3.68e-2)" "unprognostic (1.65e-2)" "prognostic favourable (1.18e-5)" "unprognostic (1.04e-1)" "unprognostic (2.54e-1)" "unprognostic (1.43e-1)" "unprognostic (1.12e-1)" 50.8 75.3 96.1 46.7 106.8 64.1 118.6 81.3 113.4 51.0 47.3 50.7 43.0 31.0 40.7 55.5 40.9 94.7 61.0 70.9 99.6 113.3 75.6 62.5 51.7 48.1 134.4 58.6 53.4 40.1 94.9 121.6 67.2 143.6 63.2 53.3 23.4 57.0 57.0 65.2 35.6 38.9 51.0 139.7 35.7 41.3 84.6 132.7 53.5 91.5 34.3 59.5 54.2 519.3 30.7 46.9 31.8 29.9 57.7 63.1 21.9 86.3 118.1 75.4 52.0 45.8 38.8 100.2 96.1 46.2 117.9 66.5 71.7 81.2 106.2 90.5 61.8 95.9 216.5 94.0 215.1 80.3 71.3 82.0 67.5 91.5 22.7 122.0 63.3 36.4 40.0 75.3 27.8 65.0 113.2 54.6 106.6 116.8 130.4 56.1 78.4 111.7 125.8 102.5 45.8 68.4 111.7 99.4 71.7 121.5 91.5 53.6 117.6 48.7 46.0 82.5 53.4 122.6 182.5 51.7 161.1 157.1 78.1 75.4 99.4 31.8 19.9 24.0 47.8 29.9 63.1 29.6 40.5 49.0 23.9 30.7 30.1 43.5 13.5 57.7 27.5 46.9 39.2 21.9 96.1 106.8 81.3 102.7 99.6 113.3 134.4 58.6 143.6 132.7 HSP90AB1 "HSPC2, HSPCB" ENSG00000096384 "Heat shock protein 90 alpha family class B member 1" P08238 6 44246166-44253888 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Stress response" Chaperone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005230, HPA055729, HPA072606, HPA074351" Enhanced Supported Cytosol "Intracellular and membrane" 62000000 Cytosol "CAB005230: AB_2121392, HPA055729: AB_2682899, HPA072606: AB_2732203, HPA074351: AB_2732252" "unprognostic (6.12e-3)" "unprognostic (2.96e-3)" "unprognostic (4.72e-2)" "unprognostic (9.24e-2)" "unprognostic (4.20e-1)" "unprognostic (1.15e-3)" "unprognostic (1.76e-3)" "unprognostic (2.74e-1)" "unprognostic (7.97e-2)" "prognostic favourable (4.03e-4)" "unprognostic (1.31e-1)" "unprognostic (1.60e-1)" "prognostic unfavourable (9.94e-4)" "unprognostic (3.02e-1)" "unprognostic (9.53e-2)" "unprognostic (2.63e-1)" "unprognostic (1.06e-1)" 79.9 116.1 88.0 65.9 105.0 74.6 107.8 92.1 118.2 92.3 60.4 61.7 80.9 40.6 113.3 107.6 71.6 138.4 63.8 115.0 89.0 110.5 72.0 70.7 76.2 73.8 109.7 94.4 238.4 113.9 151.6 95.3 83.6 133.7 93.5 76.4 52.7 64.8 100.3 197.1 67.9 49.0 102.1 93.9 57.5 77.3 45.9 100.2 58.3 133.8 89.8 102.5 86.2 223.4 75.9 50.5 7.2 45.7 55.7 82.5 74.9 138.6 89.0 79.1 97.1 54.3 56.9 82.8 62.7 61.5 116.1 81.8 133.0 42.5 177.7 68.0 65.2 80.9 192.3 93.3 143.7 58.8 77.8 138.3 50.4 173.8 39.3 138.0 95.8 52.5 63.2 91.2 78.8 111.1 184.5 66.3 78.9 140.0 114.9 83.3 92.2 68.2 110.9 80.8 97.5 78.5 84.4 115.8 70.8 48.7 70.6 87.9 91.8 69.1 69.6 69.3 116.0 56.6 143.1 76.8 120.4 321.0 75.3 101.5 78.9 7.2 30.2 6.8 49.3 45.7 82.5 75.9 55.2 56.4 50.5 63.2 75.2 71.3 3.7 55.7 43.3 31.4 42.6 74.9 88.0 105.0 92.1 118.2 89.0 110.5 109.7 94.4 133.7 100.2 IKZF1 "hIk-1, Hs.54452, IKAROS, LyF-1, PPP1R92, ZNFN1A1" ENSG00000185811 "IKAROS family zinc finger 1" Q13422 7 50304068-50405101 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors" "Cell cycle, Transcription, Transcription regulation" "Activator, Chromatin regulator, Developmental protein, DNA-binding, Repressor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 28.7;bone marrow: 55.2;lymphoid tissue: 86.7" "Cell line enhanced" "Detected in some" "Daudi: 26.6;HDLM-2: 45.2;HMC-1: 42.4;MOLT-4: 33.1;REH: 35.8;U-698: 68.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB009247, HPA035221, HPA035222" Enhanced "CAB009247: AB_2124699, HPA035221: AB_2674524, HPA035222: AB_2674525" "prognostic favourable (4.28e-4)" "prognostic favourable (2.02e-4)" "unprognostic (2.49e-3)" "unprognostic (2.41e-3)" "unprognostic (5.59e-1)" "prognostic favourable (8.63e-4)" "unprognostic (1.45e-2)" "unprognostic (1.37e-2)" "unprognostic (1.15e-2)" "unprognostic (2.43e-1)" "unprognostic (6.63e-2)" "unprognostic (2.95e-1)" "unprognostic (1.69e-3)" "unprognostic (1.71e-1)" "unprognostic (2.84e-2)" "unprognostic (6.77e-2)" "unprognostic (4.67e-2)" 3.5 1.5 2.9 25.5 3.8 55.2 2.3 0.7 1.8 1.6 3.6 2.8 0.8 2.4 1.6 2.1 2.2 2.4 2.9 1.6 3.4 1.8 2.5 2.3 8.3 44.4 5.9 1.1 1.1 1.3 0.2 1.2 1.2 3.4 2.2 2.5 1.5 5.2 0.7 0.9 1.9 14.5 1.4 5.1 31.0 3.7 1.1 4.1 86.7 2.4 1.2 26.3 4.5 2.9 24.0 12.6 12.8 23.6 12.8 28.7 12.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 26.6 0.0 0.0 0.0 0.0 0.0 0.0 45.2 0.0 9.1 0.0 0.0 0.0 16.1 42.4 0.0 0.0 0.0 0.0 0.0 11.7 3.1 0.0 0.0 33.1 16.0 0.4 0.0 35.8 0.0 7.5 0.0 0.0 0.3 0.3 0.1 0.2 0.1 0.0 22.2 0.0 0.0 0.3 0.0 0.0 14.5 7.4 68.0 0.1 17.5 0.1 10.2 7.7 12.8 20.4 23.6 17.0 24.0 21.2 19.9 8.2 21.3 28.7 20.7 11.2 12.8 22.3 12.6 17.1 12.7 2.9 3.8 0.7 1.8 3.4 1.8 5.9 1.1 3.4 4.1 IL2 "IL-2, TCGF" ENSG00000109471 "Interleukin 2" P60568 4 122451470-122456725 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins" "Adaptive immunity, Immunity" "Cytokine, Growth factor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 1.9;intestine: 2.4;lymphoid tissue: 1.9" "Cell line enriched" "Detected in single" 23 "MOLT-4: 2.3" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "memory CD4 T-cell: 1.9" "Lineage enriched" "Detected in single" 19 "T-cells: 1.9" "Not detected" "Not detected" "Low region specificity" "Detected in all" CAB010310 Uncertain "Secreted to blood" 20467 "CAB010310: AB_649346" "unprognostic (8.87e-5)" "unprognostic (6.13e-3)" "unprognostic (1.38e-3)" "unprognostic (9.79e-3)" "unprognostic (2.56e-2)" "unprognostic (7.32e-2)" "unprognostic (2.06e-5)" "unprognostic (5.21e-3)" "unprognostic (8.01e-2)" 0.6 0.0 0.0 0.6 0.0 0.4 0.5 0.0 0.0 0.9 0.3 0.5 0.1 0.0 0.8 0.6 0.5 0.0 0.0 0.0 0.2 0.3 0.7 1.1 0.0 0.1 0.0 0.0 0.0 0.0 0.4 1.9 0.1 0.0 0.0 0.4 2.4 0.0 0.2 0.8 0.3 0.0 0.4 1.9 0.8 0.4 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 IL21R CD360 ENSG00000103522 "Interleukin 21 receptor" Q9HBE5 16 27402162-27452042 "Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins" Receptor "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "blood: 17.9;lymphoid tissue: 47.8" "Cell line enhanced" "Detected in some" "Daudi: 10.1;HDLM-2: 42.9;Karpas-707: 19.9;RH-30: 15.1;RPMI-8226: 24.0;U-266/70: 10.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA042296 Uncertain Uncertain "Plasma membrane,Cytosol" "Plasma membrane, Cytosol" "HPA042296: AB_10806236" "unprognostic (2.91e-2)" "unprognostic (2.65e-3)" "unprognostic (6.64e-4)" "unprognostic (1.58e-3)" "unprognostic (2.14e-1)" "prognostic favourable (7.29e-4)" "unprognostic (8.33e-2)" "unprognostic (2.06e-1)" "unprognostic (8.50e-6)" "unprognostic (2.26e-2)" "unprognostic (1.13e-2)" "unprognostic (8.71e-2)" "unprognostic (2.34e-10)" "unprognostic (8.79e-2)" "unprognostic (4.42e-2)" "unprognostic (1.50e-1)" "unprognostic (9.58e-2)" 0.8 0.6 0.6 33.6 3.7 5.7 0.6 0.5 1.6 0.5 0.9 0.3 0.0 0.5 0.5 1.3 1.0 0.8 1.1 1.8 0.6 2.3 1.6 1.3 5.6 20.9 1.3 0.0 0.5 0.5 0.0 0.9 0.9 1.9 0.9 0.9 1.8 3.7 0.3 0.7 0.7 4.0 0.6 1.7 11.2 1.3 1.0 1.4 47.8 1.3 0.8 31.7 2.7 0.8 11.5 1.6 0.7 17.9 6.3 10.3 4.2 0.0 0.0 0.1 0.1 0.0 0.5 0.3 0.3 0.0 0.0 0.9 0.0 0.0 10.1 0.1 0.8 0.0 0.0 0.0 0.0 42.9 0.0 2.1 0.0 0.2 1.4 0.0 0.6 1.5 0.0 2.7 0.0 0.0 0.1 19.9 1.5 0.0 0.0 0.2 0.3 0.0 0.1 15.1 24.0 0.0 0.0 0.1 0.0 0.0 0.0 1.1 0.0 0.5 1.1 0.8 0.2 0.2 0.0 10.0 3.5 2.3 2.1 0.5 0.0 0.2 0.3 0.0 9.8 5.8 3.6 1.0 6.3 10.3 1.6 11.5 6.9 6.7 0.7 6.3 17.9 0.7 7.6 4.2 0.6 3.7 0.5 1.6 0.6 2.3 1.3 0.0 1.9 1.4 IRF4 "LSIRF, MUM1" ENSG00000137265 "Interferon regulatory factor 4" Q15306 6 391739-411447 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 48.7" "Cell line enhanced" "Detected in some" "HDLM-2: 49.1;Karpas-707: 45.6;RPMI-8226: 44.1;U-266/70: 41.3;U-266/84: 30.7;WM-115: 25.0" "Cancer enriched" "Detected in many" 9 "melanoma: 27.0" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "memory B-cell: 9.5;myeloid DC: 9.0;naive B-cell: 9.7;plasmacytoid DC: 10.4;T-reg: 4.8" "Group enriched" "Detected in many" 5 "B-cells: 9.7;dendritic cells: 10.4;T-cells: 4.8" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA002038, HPA002698, CAB013508" Enhanced Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB013508: , HPA002038: AB_1079148, HPA002698: AB_1851893" "prognostic favourable (6.44e-4)" "unprognostic (1.88e-3)" "unprognostic (1.00e-3)" "unprognostic (1.72e-4)" "unprognostic (2.74e-1)" "prognostic favourable (1.64e-6)" "unprognostic (4.72e-2)" "unprognostic (1.05e-1)" "unprognostic (1.89e-2)" "unprognostic (5.74e-4)" "unprognostic (8.51e-2)" "unprognostic (1.12e-1)" "unprognostic (9.18e-7)" "unprognostic (2.38e-1)" "unprognostic (6.24e-2)" "unprognostic (2.90e-1)" "unprognostic (3.65e-2)" 7.1 0.5 0.4 36.6 0.4 18.4 4.0 0.4 0.4 17.4 13.9 0.1 0.4 5.0 2.2 0.7 6.4 1.2 4.1 1.6 0.4 0.5 1.4 5.6 4.2 31.5 0.5 0.0 1.9 0.7 0.0 0.7 0.5 0.1 1.5 4.8 15.8 21.3 1.9 0.7 4.5 11.1 0.3 0.6 33.8 4.6 1.7 0.1 15.2 1.3 2.4 48.7 8.4 4.2 9.7 10.4 0.0 1.6 0.2 4.8 1.3 0.0 0.0 0.0 0.0 5.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 49.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 45.6 0.0 0.0 0.0 0.0 0.2 0.0 5.8 0.0 44.1 0.0 0.0 0.1 0.0 0.0 0.0 7.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 41.3 30.7 13.4 0.0 0.0 25.0 0.0 1.6 0.0 0.6 1.2 0.0 9.5 0.9 0.9 9.0 9.7 1.6 0.7 0.0 0.2 1.2 10.4 4.8 1.3 0.4 0.4 0.4 0.4 0.4 0.5 0.5 0.0 0.1 0.1 IRS4 "IRS-4, PY160" ENSG00000133124 "Insulin receptor substrate 4" O14654 X 108732482-108736409 "Cancer-related genes, Predicted intracellular proteins" Transducer "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "pituitary gland: 56.0" "Cell line enhanced" "Detected in some" "HEK 293: 13.6;NTERA-2: 1.7;RT4: 4.0;WM-115: 3.0" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in single" 7 "hypothalamus: 4.6" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "basal ganglia: 12.8;hypothalamus: 52.4" "Group enriched" "Detected in some" 6 "basal ganglia: 21.5;hypothalamus: 55.3" HPA017372 Uncertain "HPA017372: " "unprognostic (3.74e-3)" "unprognostic (3.27e-2)" "unprognostic (1.32e-2)" "unprognostic (2.52e-1)" "unprognostic (1.89e-1)" "unprognostic (2.12e-1)" "unprognostic (1.65e-1)" "unprognostic (1.05e-2)" "unprognostic (1.77e-1)" "unprognostic (9.28e-4)" "unprognostic (8.71e-2)" 0.0 0.0 0.2 0.0 0.3 0.0 0.1 0.0 0.6 1.9 0.0 0.1 0.3 0.1 2.6 0.3 0.3 0.5 0.0 0.0 0.3 4.6 0.0 0.0 0.1 0.0 0.5 0.1 9.5 0.0 0.0 56.0 0.1 0.6 0.2 0.0 2.7 0.0 0.5 0.0 0.6 0.0 1.0 0.2 0.1 0.5 0.1 0.5 5.1 3.3 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 13.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 4.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.0 0.3 0.3 4.6 0.5 0.1 0.6 0.5 ITK "EMT, LYK, PSCTK2" ENSG00000113263 "IL2 inducible T cell kinase" Q08881 5 157142933-157255191 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Adaptive immunity, Immunity" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 28.0;lymphoid tissue: 60.5" "Cell line enriched" "Detected in some" 5 "MOLT-4: 21.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Group enriched" "Detected in many" 28 "gdT-cell: 13.8;MAIT T-cell: 9.1;memory CD4 T-cell: 19.5;memory CD8 T-cell: 18.9;naive CD4 T-cell: 28.0;naive CD8 T-cell: 22.8;NK-cell: 9.2;T-reg: 23.1" "Group enriched" "Detected in many" 29 "NK-cells: 9.2;T-cells: 28.0" "Low region specificity" "Detected in some" "Low region specificity" "Detected in single" "unprognostic (2.08e-3)" "unprognostic (6.57e-4)" "unprognostic (5.06e-3)" "unprognostic (4.96e-5)" "unprognostic (1.52e-2)" "unprognostic (1.12e-4)" "unprognostic (8.45e-4)" "unprognostic (1.56e-2)" "unprognostic (1.87e-2)" "unprognostic (5.99e-3)" "unprognostic (1.76e-1)" "unprognostic (2.52e-1)" "unprognostic (4.52e-6)" "unprognostic (3.64e-1)" "unprognostic (4.42e-2)" "unprognostic (1.46e-1)" "unprognostic (3.26e-2)" 2.3 0.7 0.5 12.2 0.6 2.5 1.3 1.9 0.5 1.4 3.3 0.0 0.0 0.5 1.2 1.1 1.8 1.4 4.3 0.9 0.5 0.5 1.4 1.2 6.6 60.5 0.9 0.0 0.7 0.7 0.0 0.9 0.1 0.3 1.1 1.3 1.5 3.5 1.1 0.5 1.0 8.9 0.4 1.2 10.7 2.3 1.4 0.0 60.3 1.6 2.7 24.3 4.1 1.3 0.0 0.0 0.4 0.6 9.2 28.0 13.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.3 0.0 3.6 0.0 0.0 0.0 0.0 4.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 21.7 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 13.8 0.0 9.1 0.0 19.5 18.9 0.0 0.0 28.0 22.8 0.4 9.2 0.6 0.0 23.1 13.6 0.5 0.6 1.9 0.5 0.5 0.5 0.9 0.0 0.3 0.0 JAK2 JTK10 ENSG00000096968 "Janus kinase 2" O60674 9 4984390-5128183 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Adaptive immunity, Immunity, Innate immunity" "Chromatin regulator, Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in many" 5 "ASC diff: 18.9;HDLM-2: 26.7;HEL: 54.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 40.8" "Lineage enriched" "Detected in all" 4 "granulocytes: 40.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013089, HPA040820, HPA043870" Approved Supported "Nucleoplasm,Plasma membrane,Focal adhesion sites" Nucleoplasm "Plasma membrane, Focal adhesion sites" "CAB013089: AB_2533647, HPA040820: , HPA043870: " "unprognostic (2.24e-3)" "unprognostic (2.76e-2)" "unprognostic (1.50e-2)" "unprognostic (7.67e-2)" "unprognostic (5.50e-2)" "unprognostic (3.09e-2)" "unprognostic (1.48e-1)" "unprognostic (7.36e-2)" "unprognostic (1.09e-1)" "unprognostic (5.49e-3)" "unprognostic (1.58e-1)" "unprognostic (1.72e-2)" "unprognostic (3.85e-1)" "unprognostic (4.53e-2)" "unprognostic (3.43e-2)" "unprognostic (1.96e-1)" "unprognostic (7.37e-3)" 19.8 8.8 11.5 19.0 10.5 19.0 17.7 14.7 14.4 17.8 10.6 7.0 10.3 7.2 14.8 13.6 12.4 13.4 14.6 27.6 10.3 6.7 7.7 5.6 16.1 19.4 7.0 10.5 15.9 6.7 10.1 7.5 12.0 10.0 12.0 7.4 9.4 7.2 7.4 14.4 19.0 12.3 10.4 11.7 21.5 14.1 10.1 9.0 13.6 8.6 6.5 13.5 13.9 15.6 2.1 9.6 40.8 7.5 3.4 2.1 2.5 2.5 1.4 1.4 2.5 18.9 4.9 0.4 3.4 2.9 2.6 1.7 0.1 0.8 0.1 0.8 2.0 0.8 1.5 2.1 1.9 26.7 0.5 54.8 2.9 0.7 3.9 3.7 2.8 4.0 0.9 1.1 1.8 2.4 3.9 6.4 4.7 0.9 0.9 5.2 1.3 1.7 1.9 2.7 0.7 2.0 1.3 1.6 0.9 1.0 1.5 1.0 0.7 6.5 5.0 4.0 1.3 4.1 2.4 1.2 2.2 0.5 5.2 1.8 2.0 40.8 7.5 13.4 2.1 7.3 1.7 2.1 1.6 1.2 9.6 1.9 0.9 1.1 7.1 3.4 5.8 3.6 1.6 2.5 11.5 10.5 14.7 14.4 10.3 6.7 7.0 10.5 10.0 9.0 KAT6A "MOZ, MYST3, RUNXBP2, ZC2HC6A, ZNF220" ENSG00000083168 "Lysine acetyltransferase 6A" Q92794 8 41929479-42051990 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Acyltransferase, Chromatin regulator, Repressor, Transferase" "Cancer-related genes, Mental retardation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017023, HPA063266, HPA065052" Supported Approved "Nucleoli,Nuclear speckles,Cytosol" "Nuclear speckles" "Nucleoli, Cytosol" "CAB017023: , HPA063266: , HPA065052: " "unprognostic (3.51e-2)" "unprognostic (1.14e-1)" "unprognostic (2.04e-1)" "unprognostic (3.23e-2)" "unprognostic (2.28e-1)" "unprognostic (9.27e-3)" "unprognostic (3.61e-1)" "unprognostic (2.29e-1)" "unprognostic (2.95e-1)" "unprognostic (2.45e-2)" "unprognostic (1.50e-1)" "unprognostic (4.45e-2)" "unprognostic (4.20e-3)" "unprognostic (1.18e-1)" "unprognostic (2.24e-1)" "unprognostic (8.58e-2)" "unprognostic (2.95e-2)" 20.8 10.9 15.3 19.8 20.3 36.8 22.6 29.9 18.7 19.7 14.6 19.4 14.4 10.7 20.6 12.1 16.9 16.5 14.3 13.0 15.5 11.5 12.3 13.6 26.9 28.2 23.2 10.3 27.2 13.1 26.8 22.3 20.9 15.7 14.1 12.0 12.8 15.1 17.0 21.0 25.5 18.0 25.0 22.9 20.4 14.0 14.1 21.7 30.4 17.9 14.3 20.1 16.9 24.2 4.7 1.8 10.9 1.6 3.1 3.9 1.4 12.9 10.6 17.5 11.1 9.8 11.2 5.9 8.7 11.3 10.8 8.4 6.7 6.2 19.2 8.7 8.5 8.3 13.6 8.2 12.7 9.9 7.9 27.6 6.6 5.0 7.4 14.5 12.7 9.3 9.4 10.0 12.4 10.3 23.1 12.2 9.8 5.7 29.5 4.6 6.7 4.2 23.6 19.6 6.1 5.3 14.9 10.9 9.4 10.1 6.8 7.0 15.6 6.4 12.0 13.3 9.4 11.8 9.3 10.0 16.1 20.8 7.1 6.6 11.5 3.5 1.6 2.8 3.5 1.2 3.9 2.4 2.6 3.3 1.0 4.7 3.6 2.9 10.9 3.1 1.2 1.8 3.5 1.4 15.3 20.3 29.9 18.7 15.5 11.5 23.2 10.3 15.7 21.7 KAT6B "Morf, MOZ2, MYST4, qkf, querkopf, ZC2HC6B" ENSG00000156650 "Lysine acetyltransferase 6B" Q8WYB5 10 74825582-75032622 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Acyltransferase, Chromatin regulator, Repressor, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "PC-3: 22.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA006104 Supported Approved "Nucleoplasm,Nuclear bodies" "Nucleoplasm, Nuclear bodies" "HPA006104: AB_1079445" "unprognostic (4.17e-1)" "unprognostic (1.98e-1)" "unprognostic (1.82e-1)" "unprognostic (2.32e-2)" "unprognostic (7.83e-2)" "unprognostic (2.85e-2)" "unprognostic (3.56e-1)" "unprognostic (2.62e-1)" "unprognostic (2.54e-1)" "unprognostic (1.09e-1)" "unprognostic (9.47e-2)" "unprognostic (8.78e-2)" "prognostic favourable (4.82e-4)" "unprognostic (2.52e-1)" "unprognostic (3.70e-1)" "unprognostic (2.59e-2)" "unprognostic (3.15e-1)" 11.6 9.5 11.1 13.2 11.9 15.1 12.4 19.0 11.6 16.7 12.2 13.3 15.3 7.2 25.1 13.0 12.0 13.2 12.0 10.0 10.6 9.5 9.0 7.3 9.2 9.0 9.0 9.9 24.6 13.3 24.8 31.1 9.4 8.9 13.5 9.6 10.1 17.9 12.0 15.3 10.6 11.3 16.2 9.3 10.4 13.0 12.8 12.1 26.6 13.0 8.9 12.5 14.3 12.7 3.2 1.9 1.6 1.1 5.3 3.7 1.5 3.9 4.1 7.4 6.2 5.8 8.6 3.6 3.5 6.9 3.0 3.3 2.7 4.6 8.4 1.9 6.4 3.1 3.9 3.0 4.9 3.5 5.7 3.1 3.3 3.8 4.4 7.3 2.1 5.6 5.0 4.1 6.6 3.4 3.3 7.3 3.8 4.2 7.0 3.4 4.1 22.7 11.0 3.8 1.8 2.2 2.0 3.7 6.1 3.6 6.5 3.2 3.7 2.9 4.2 4.2 5.0 2.8 3.3 5.4 6.2 5.6 4.6 7.8 0.9 0.7 1.1 1.6 3.2 0.9 3.4 2.4 2.4 2.7 1.2 3.2 3.7 3.4 0.9 5.3 0.8 1.9 2.4 1.5 11.1 11.9 19.0 11.6 10.6 9.5 9.0 9.9 8.9 12.1 KDM5A "JARID1A, RBBP2" ENSG00000073614 "Lysine demethylase 5A" P29375 12 280129-389454 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, Chromatin regulator, Developmental protein, Dioxygenase, Oxidoreductase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA006201 Supported "Nuclear bodies,Cytosol" "Nuclear bodies" Cytosol "HPA006201: AB_1079160" "unprognostic (2.75e-1)" "unprognostic (1.68e-1)" "unprognostic (1.83e-1)" "unprognostic (1.12e-1)" "unprognostic (4.46e-2)" "unprognostic (1.60e-1)" "unprognostic (3.53e-3)" "unprognostic (1.81e-2)" "unprognostic (5.81e-2)" "unprognostic (3.19e-1)" "unprognostic (1.77e-3)" "unprognostic (6.11e-2)" "unprognostic (1.79e-2)" "unprognostic (1.10e-1)" "unprognostic (1.52e-1)" "unprognostic (2.60e-2)" "unprognostic (7.69e-2)" 13.6 14.4 10.6 13.7 13.0 41.6 13.1 21.8 13.2 11.8 10.3 14.8 11.3 7.8 14.2 8.1 13.6 11.2 10.0 10.1 11.5 5.7 9.0 10.7 13.1 14.9 15.1 9.1 15.2 11.5 16.8 13.8 12.4 11.3 10.6 10.9 10.6 12.9 8.6 9.7 20.3 13.0 10.4 10.1 15.5 10.6 21.2 14.8 28.8 11.4 7.1 16.1 13.1 18.8 17.2 16.8 33.7 14.1 18.6 18.1 10.1 7.6 13.7 10.1 7.8 9.1 8.7 11.2 6.8 9.0 10.2 11.1 8.1 9.3 12.8 2.1 11.3 7.2 10.5 7.7 12.3 20.1 8.7 15.6 14.4 4.8 7.4 20.3 12.3 9.4 7.3 12.5 16.8 10.3 9.3 18.0 8.6 5.1 14.5 5.8 15.7 4.3 13.6 26.4 6.0 4.9 17.6 3.9 11.4 13.3 6.0 7.2 6.5 12.8 14.1 6.7 9.7 7.5 11.3 6.4 7.0 29.4 8.7 8.9 9.9 30.2 11.3 22.2 17.7 13.1 18.1 14.1 13.8 14.2 11.8 17.2 15.1 12.9 33.7 18.6 14.1 16.8 10.5 10.1 10.6 13.0 21.8 13.2 11.5 5.7 15.1 9.1 11.3 14.8 KDSR "DHSR, FVT1, SDR35C1" ENSG00000119537 "3-ketodihydrosphingosine reductase" Q06136 18 63327726-63367510 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Lipid metabolism, Sphingolipid metabolism" Oxidoreductase "Cancer-related genes, Disease mutation, Palmoplantar keratoderma, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-266/70: 37.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003673, HPA044884" Approved "CAB003673: AB_425440, HPA044884: " "unprognostic (4.44e-2)" "unprognostic (8.57e-2)" "unprognostic (2.52e-2)" "unprognostic (4.56e-2)" "unprognostic (5.88e-3)" "unprognostic (7.50e-3)" "unprognostic (1.80e-2)" "unprognostic (2.66e-1)" "unprognostic (2.97e-1)" "unprognostic (1.97e-1)" "unprognostic (2.70e-2)" "unprognostic (6.81e-2)" "prognostic favourable (9.53e-6)" "unprognostic (3.32e-2)" "unprognostic (5.77e-2)" "unprognostic (2.22e-1)" "unprognostic (2.16e-3)" 21.1 19.4 19.0 11.1 22.4 6.4 29.7 12.5 17.2 18.2 17.3 23.9 14.2 10.0 19.4 30.0 17.8 14.3 17.7 15.8 19.7 16.9 21.3 52.6 15.3 11.5 32.1 14.6 29.1 14.3 19.6 10.5 24.9 19.5 18.0 11.0 15.9 16.1 17.4 12.4 28.8 13.1 18.9 39.0 9.1 11.8 10.4 23.3 8.8 21.2 12.3 9.9 19.9 22.8 4.0 5.6 0.9 5.6 9.8 19.5 3.7 5.9 2.6 2.8 3.1 22.0 16.5 5.4 19.5 12.0 4.3 5.8 1.1 4.0 6.0 8.4 7.6 26.1 3.5 11.0 5.3 11.2 5.8 4.6 3.5 1.3 16.9 8.4 3.2 15.7 20.9 6.9 19.8 4.2 3.7 8.6 11.4 2.4 9.3 3.9 3.3 9.8 6.3 8.1 8.5 11.9 3.8 3.5 6.8 9.4 4.6 8.4 2.5 4.8 10.0 18.4 4.4 6.1 8.5 37.6 17.1 3.4 13.8 5.2 5.4 0.0 3.7 0.3 4.8 5.6 19.5 4.0 10.2 7.6 5.6 3.6 7.3 4.6 0.9 9.8 2.6 2.8 12.9 3.7 19.0 22.4 12.5 15.9 19.7 16.9 32.1 14.6 19.5 23.3 KIF5B "KNS, KNS1" ENSG00000170759 "Kinesin family member 5B" P33176 10 32009010-32056431 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Motor protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009846, HPA037589, HPA037590" Approved Enhanced "Centriolar satellite,Cytosol" 260000 "Centriolar satellite, Cytosol" "CAB009846: AB_2280915, HPA037589: AB_2675563, HPA037590: AB_2675564" "unprognostic (4.94e-3)" "unprognostic (1.70e-1)" "unprognostic (1.06e-1)" "unprognostic (1.84e-1)" "unprognostic (4.00e-2)" "unprognostic (6.21e-2)" "unprognostic (1.06e-2)" "unprognostic (1.84e-1)" "unprognostic (2.70e-1)" "unprognostic (6.37e-3)" "unprognostic (2.03e-1)" "unprognostic (2.60e-1)" "unprognostic (1.81e-1)" "unprognostic (2.43e-2)" "unprognostic (2.39e-1)" "unprognostic (8.06e-2)" "unprognostic (1.76e-1)" 26.3 19.9 55.7 20.2 55.5 34.1 23.0 22.2 42.4 23.8 34.2 21.7 20.9 23.5 25.7 17.8 28.0 20.3 28.0 48.4 51.5 39.3 21.1 15.3 23.8 16.5 62.9 26.1 18.2 18.9 56.8 22.4 27.7 38.3 31.8 30.0 8.9 20.1 25.6 34.3 17.6 28.6 37.2 80.4 21.1 23.1 27.7 43.7 25.0 23.5 21.5 16.1 33.8 28.1 13.8 27.6 30.0 18.9 13.4 16.5 9.2 29.4 25.1 34.0 23.8 24.4 26.9 14.5 40.7 19.3 31.5 26.9 27.5 32.6 20.2 17.7 48.3 24.5 31.0 26.0 42.3 17.4 16.9 25.7 23.5 26.8 28.1 17.8 28.3 21.8 37.0 36.3 25.4 40.2 30.9 21.3 43.5 17.7 18.6 10.1 5.5 11.5 24.4 63.4 8.3 24.3 20.7 33.1 24.2 31.5 12.6 30.3 15.2 25.6 33.5 32.1 30.1 37.1 30.1 6.4 7.4 23.9 30.6 36.9 30.1 20.8 15.2 24.2 11.8 18.9 11.4 13.6 14.9 12.5 14.2 13.8 13.3 13.0 30.0 13.4 18.9 27.6 16.5 9.2 55.7 55.5 22.2 42.4 51.5 39.3 62.9 26.1 38.3 43.7 KLK2 ENSG00000167751 "Kallikrein related peptidase 2" P20151 19 50861568-50880567 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Hydrolase, Protease, Serine protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 29 "prostate: 163.5" "Cell line enhanced" "Detected in many" "NB-4: 9.9" "Cancer enriched" "Detected in some" 1666 "prostate cancer: 989.9" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" HPA000764 Supported "Secreted in male reproductive system" "HPA000764: AB_1079700" "unprognostic (3.05e-2)" "unprognostic (2.40e-1)" "unprognostic (1.69e-1)" "unprognostic (8.53e-2)" "unprognostic (1.15e-1)" "unprognostic (8.97e-2)" "unprognostic (3.22e-1)" "unprognostic (6.44e-2)" "unprognostic (8.06e-2)" "unprognostic (3.61e-1)" "unprognostic (2.11e-3)" "unprognostic (7.56e-2)" "unprognostic (8.10e-2)" "unprognostic (1.68e-1)" "unprognostic (2.04e-1)" 0.0 0.1 0.0 0.1 0.0 1.1 0.2 0.0 0.6 0.0 0.0 0.0 0.6 0.1 0.1 0.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 163.5 0.0 0.1 2.3 0.0 0.2 0.0 0.1 0.2 0.0 0.0 0.0 0.6 0.0 0.0 1.1 0.0 0.0 0.2 0.0 2.2 1.9 5.7 2.2 1.6 1.3 0.5 1.7 1.1 0.6 1.6 0.0 0.8 4.9 0.5 0.3 0.2 0.2 0.6 0.7 1.8 0.2 0.0 2.0 0.2 0.0 0.3 1.7 1.1 0.0 1.3 0.4 0.0 0.3 3.1 0.4 0.3 0.3 0.4 0.0 1.4 1.9 0.3 1.8 1.2 9.9 1.1 0.0 0.9 0.0 2.8 0.0 1.6 0.9 1.5 0.3 1.3 1.3 1.2 0.4 0.8 1.3 1.9 4.8 1.6 1.8 3.2 0.8 1.9 1.7 1.4 0.9 2.2 1.6 1.2 1.0 1.0 1.0 0.8 1.0 0.5 2.2 0.8 1.3 5.7 1.6 0.8 1.9 0.4 0.5 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 KMT2A "ALL-1, CXXC7, HRX, HTRX1, MLL, MLL1A, TRX1" ENSG00000118058 "Lysine methyltransferase 2A" Q03164 11 118436490-118526832 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors" "Apoptosis, Biological rhythms, Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Methyltransferase, Transferase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017794, CAB024270, HPA044910" Enhanced Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB017794: , CAB024270: , HPA044910: " "unprognostic (6.80e-2)" "unprognostic (8.93e-2)" "unprognostic (1.83e-1)" "unprognostic (4.56e-1)" "unprognostic (4.96e-2)" "unprognostic (1.72e-3)" "unprognostic (4.52e-3)" "unprognostic (6.07e-2)" "unprognostic (1.61e-1)" "unprognostic (8.46e-2)" "unprognostic (3.21e-1)" "unprognostic (1.16e-1)" "unprognostic (5.91e-3)" "unprognostic (7.90e-2)" "unprognostic (3.73e-1)" "unprognostic (1.67e-1)" "unprognostic (1.02e-1)" 14.4 11.3 17.7 17.0 19.2 28.6 16.8 43.8 21.2 17.3 14.6 19.8 18.1 8.5 21.8 17.1 10.6 15.7 14.1 10.2 17.3 13.4 13.1 9.3 15.3 19.6 16.6 18.7 35.6 16.8 28.9 21.8 10.2 15.4 15.6 12.4 14.4 14.2 19.2 11.1 16.8 14.2 15.2 12.1 15.7 12.3 7.9 23.4 16.6 16.6 7.8 19.4 18.8 24.6 6.7 3.5 8.3 2.0 6.5 5.3 0.8 11.9 5.5 14.9 11.2 9.1 10.9 4.4 5.4 7.8 5.7 6.6 11.1 8.7 14.7 11.1 7.9 10.4 15.8 5.9 11.3 16.2 6.1 28.8 5.1 6.0 5.1 17.2 5.6 5.2 6.1 12.4 16.7 8.8 18.7 12.6 7.1 9.3 11.4 10.1 9.0 8.2 8.7 14.3 4.9 8.4 9.0 12.3 8.0 13.5 4.4 2.8 7.6 5.8 13.0 9.8 8.8 7.1 9.6 3.7 2.8 9.9 3.7 12.7 5.8 8.3 2.0 4.6 5.3 1.3 4.3 6.2 4.8 4.6 0.8 6.7 4.9 4.8 1.3 6.5 1.4 3.5 3.9 0.8 17.7 19.2 43.8 21.2 17.3 13.4 16.6 18.7 15.4 23.4 KNL1 "AF15Q14, CASC5, CT29, D40, hKNL-1, hSpc105, KIAA1570, MCPH4, PPP1R55, Spc7" ENSG00000137812 "Kinetochore scaffold 1" Q8NG31 15 40594020-40664342 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Chromosome partition, Mitosis" "Cancer-related genes, Disease mutation, Mental retardation, Primary microcephaly" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "lymphoid tissue: 54.7;testis: 35.6" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "HPA026624, HPA049647" Enhanced Enhanced "Nucleoplasm,Nuclear bodies" Nucleoplasm "Nuclear bodies" "HPA026624: AB_10601696, HPA049647: " "unprognostic (5.35e-2)" "unprognostic (1.01e-1)" "unprognostic (5.59e-3)" "unprognostic (4.22e-2)" "unprognostic (1.59e-2)" "unprognostic (5.66e-2)" "unprognostic (1.41e-1)" "prognostic unfavourable (2.11e-4)" "unprognostic (2.06e-2)" "unprognostic (1.43e-1)" "unprognostic (3.20e-4)" "unprognostic (2.22e-2)" "unprognostic (1.93e-12)" "unprognostic (3.07e-2)" "unprognostic (3.08e-1)" "unprognostic (8.45e-2)" "unprognostic (7.36e-2)" 0.7 0.5 0.3 7.1 0.4 5.4 0.7 0.3 0.3 0.6 4.0 0.1 0.0 1.5 0.4 0.8 3.9 0.4 0.9 0.5 0.4 0.4 0.9 1.0 1.3 4.7 0.3 0.0 0.5 0.5 0.0 0.4 2.8 0.1 0.5 1.5 0.0 0.8 0.0 0.4 0.8 3.9 0.5 0.4 3.3 0.8 35.6 0.0 54.7 0.5 4.1 3.7 0.7 0.9 2.9 1.2 0.7 0.5 0.7 2.5 0.0 10.8 5.6 11.4 8.2 0.3 1.7 5.1 12.7 5.1 10.0 8.4 6.8 4.4 7.2 4.0 5.5 13.6 10.8 5.9 10.6 12.5 2.9 21.2 9.6 2.0 0.0 16.2 10.7 0.3 0.2 6.7 4.2 8.5 13.5 12.1 11.6 3.7 13.8 3.2 5.6 5.9 12.6 16.3 3.6 1.5 9.6 9.9 4.6 11.0 6.2 1.3 6.7 4.9 7.8 11.6 10.3 13.3 7.0 4.6 15.8 14.1 4.7 11.0 11.0 0.4 0.2 0.1 0.1 0.1 0.0 2.9 1.1 0.1 1.2 2.2 0.0 0.7 0.7 0.7 0.5 0.1 2.5 0.0 0.3 0.4 0.3 0.3 0.4 0.4 0.3 0.0 0.1 0.0 KTN1 "CG1, KIAA0004, KNT" ENSG00000126777 "Kinectin 1" Q86UP2 14 55559072-55701526 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003178, CAB015331, HPA017876" Enhanced Enhanced "Endoplasmic reticulum" "Endoplasmic reticulum" "CAB015331: , HPA003178: AB_1079218, HPA017876: AB_1852652" "unprognostic (7.00e-3)" "unprognostic (2.99e-2)" "unprognostic (8.60e-2)" "unprognostic (5.50e-2)" "unprognostic (2.49e-1)" "prognostic unfavourable (6.83e-5)" "prognostic unfavourable (3.76e-4)" "unprognostic (1.75e-1)" "unprognostic (1.21e-2)" "unprognostic (1.01e-1)" "unprognostic (9.08e-2)" "unprognostic (8.72e-2)" "prognostic favourable (1.01e-6)" "unprognostic (1.27e-1)" "unprognostic (2.75e-1)" "unprognostic (1.30e-1)" "unprognostic (1.04e-1)" 26.5 27.5 30.8 18.9 37.3 9.5 44.2 30.8 35.2 22.7 28.8 15.8 23.4 13.0 18.8 30.8 26.1 16.8 18.1 36.1 32.2 25.3 33.1 31.8 21.2 16.9 39.3 24.5 23.1 22.8 48.3 54.7 21.3 49.5 26.9 28.7 13.1 21.4 24.0 101.9 41.4 20.1 40.5 51.9 22.1 18.9 40.9 42.0 14.5 33.3 37.9 17.9 32.7 39.7 35.6 58.3 27.0 15.5 19.6 24.0 4.8 40.2 27.9 20.9 22.7 28.8 27.6 30.3 32.9 26.5 20.7 18.4 18.6 50.2 31.1 47.1 33.8 75.5 25.5 28.7 35.0 52.2 14.0 22.0 46.2 35.2 27.3 32.2 17.8 25.7 26.3 25.5 44.3 33.9 21.4 18.2 39.7 31.5 27.6 19.1 16.1 41.6 22.0 54.9 14.8 51.9 63.4 25.7 21.5 52.2 24.0 28.9 24.9 20.6 47.8 42.3 54.3 21.7 30.9 8.3 11.1 23.2 49.5 18.9 23.4 27.0 14.8 14.6 19.6 13.1 18.7 28.3 23.2 22.1 14.2 35.6 24.0 20.6 9.4 19.6 15.5 58.3 14.8 4.8 30.8 37.3 30.8 35.2 32.2 25.3 39.3 24.5 49.5 42.0 LASP1 "Lasp-1, MLN50" ENSG00000002834 "LIM and SH3 protein 1" Q14847 17 38869859-38921770 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Ion transport, Transport" Actin-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "intestine: 124.5" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA012072, CAB022049" Enhanced Supported "Plasma membrane,Focal adhesion sites,Cytosol" 26000000 "Plasma membrane, Cytosol" "Focal adhesion sites" "CAB022049: , HPA012072: AB_1852714" "unprognostic (1.23e-1)" "unprognostic (2.09e-2)" "unprognostic (1.77e-1)" "prognostic unfavourable (4.57e-4)" "unprognostic (1.47e-1)" "unprognostic (3.03e-2)" "prognostic unfavourable (2.41e-4)" "unprognostic (1.06e-3)" "unprognostic (2.24e-1)" "unprognostic (9.60e-2)" "unprognostic (9.87e-3)" "unprognostic (1.01e-1)" "unprognostic (9.65e-3)" "unprognostic (1.29e-3)" "unprognostic (3.95e-2)" "unprognostic (1.60e-3)" "unprognostic (4.53e-2)" 51.2 20.0 23.8 40.3 22.4 45.4 35.5 15.5 25.7 23.6 57.4 16.3 18.7 54.4 23.4 24.1 22.4 20.8 48.3 15.2 18.4 23.3 33.1 47.5 33.3 44.2 20.0 14.3 28.4 30.1 10.1 17.6 40.0 16.1 18.9 38.6 24.2 22.4 24.1 10.7 18.3 124.5 21.3 12.2 43.1 39.5 13.9 12.9 40.5 18.3 18.7 33.7 22.0 28.3 6.4 13.9 34.0 19.9 17.3 16.5 13.1 34.8 72.7 21.3 18.8 31.3 34.0 36.7 43.9 42.9 46.3 34.0 21.7 38.0 15.9 36.7 67.8 55.6 9.6 33.4 40.5 11.6 5.2 7.6 21.0 37.7 29.7 17.5 23.1 30.1 11.7 39.2 11.1 31.0 12.9 5.3 64.3 11.5 20.8 27.0 10.6 18.2 11.8 11.3 20.1 56.8 30.7 3.2 7.8 26.1 27.4 22.7 43.3 21.4 54.1 27.8 40.5 32.4 26.6 13.7 18.1 12.3 29.3 15.8 33.4 9.9 14.8 16.8 16.5 17.1 11.3 6.4 8.4 11.0 13.9 6.3 7.2 10.9 34.0 17.3 19.9 10.7 10.7 13.1 23.8 22.4 15.5 25.7 18.4 23.3 20.0 14.3 16.1 12.9 LCK ENSG00000182866 "LCK proto-oncogene, Src family tyrosine kinase" P06239 1 32251239-32286165 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Host-virus interaction" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 8 "blood: 112.2;lymphoid tissue: 153.0" "Group enriched" "Detected in some" 6 "MOLT-4: 98.9;U-698: 57.0" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in many" 14 "gdT-cell: 83.4;MAIT T-cell: 77.5;memory CD4 T-cell: 86.1;memory CD8 T-cell: 90.2;naive CD4 T-cell: 97.0;naive CD8 T-cell: 91.3;NK-cell: 42.8;T-reg: 112.2" "Group enriched" "Detected in many" 13 "NK-cells: 42.8;T-cells: 112.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA003494, CAB003816" Enhanced Approved "Golgi apparatus" "Golgi apparatus" "CAB003816: AB_562158, HPA003494: AB_1852751" "unprognostic (6.38e-3)" "unprognostic (5.45e-3)" "unprognostic (8.39e-2)" "prognostic favourable (2.96e-6)" "unprognostic (2.20e-2)" "prognostic favourable (2.91e-4)" "unprognostic (4.78e-3)" "unprognostic (1.33e-2)" "prognostic favourable (5.65e-5)" "unprognostic (3.07e-2)" "unprognostic (3.80e-2)" "unprognostic (2.83e-1)" "prognostic unfavourable (2.60e-5)" "unprognostic (8.15e-2)" "unprognostic (4.05e-2)" "unprognostic (7.39e-2)" "unprognostic (1.17e-2)" 2.6 0.7 0.4 28.2 0.5 3.8 1.3 0.3 0.5 1.7 3.9 0.5 0.9 2.2 1.1 4.5 2.3 1.6 3.8 1.0 0.4 0.4 3.0 2.3 6.6 34.9 0.9 0.5 1.2 0.8 0.0 0.8 0.7 0.6 2.2 1.9 1.3 8.4 1.3 0.9 1.0 16.5 0.7 1.0 28.9 3.5 0.7 0.5 153.0 2.9 1.5 27.1 5.8 2.1 6.1 0.5 2.5 0.3 42.8 112.2 109.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 12.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 98.9 0.0 1.1 0.0 3.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 57.0 0.0 0.0 0.0 0.6 0.3 0.4 83.4 0.3 77.5 4.0 86.1 90.2 0.3 6.1 97.0 91.3 2.5 42.8 0.3 0.5 112.2 109.3 0.4 0.5 0.3 0.5 0.4 0.4 0.9 0.5 0.6 0.5 LIFR CD118 ENSG00000113594 "LIF receptor alpha" P42702 5 38474963-38608354 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "AF22: 39.8;HHSteC: 17.0;SCLC-21H: 26.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004478, CAB010252" Approved "Nuclear speckles,Golgi apparatus" "Intracellular and membrane" 74000 "Nuclear speckles" "Golgi apparatus" "CAB010252: AB_2128043, HPA004478: " "unprognostic (6.00e-3)" "unprognostic (2.53e-1)" "unprognostic (1.05e-1)" "unprognostic (2.81e-3)" "unprognostic (8.80e-2)" "unprognostic (7.13e-2)" "unprognostic (1.11e-1)" "prognostic favourable (1.92e-4)" "unprognostic (1.78e-1)" "unprognostic (9.80e-2)" "unprognostic (2.73e-3)" "unprognostic (1.06e-1)" "prognostic favourable (1.40e-7)" "unprognostic (3.69e-2)" "unprognostic (1.15e-1)" "unprognostic (2.03e-2)" "unprognostic (1.65e-1)" 35.3 14.7 15.8 8.2 19.2 0.5 33.9 10.1 21.3 27.7 10.4 25.3 22.8 4.9 34.8 14.8 10.4 26.0 10.2 16.3 19.1 11.0 20.3 23.9 21.7 20.2 24.3 11.8 17.9 17.8 13.5 12.5 41.5 23.4 23.6 7.5 17.1 24.9 24.7 24.0 10.5 11.7 26.9 21.4 22.5 18.8 9.3 25.3 4.7 31.4 7.3 8.1 13.6 15.8 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.6 2.2 39.8 3.0 11.2 12.4 0.3 3.3 1.9 2.7 1.6 0.4 2.1 0.0 0.5 4.7 0.3 2.6 0.9 4.6 0.0 3.6 0.0 4.2 1.5 17.0 0.0 0.2 10.4 0.7 6.5 0.7 3.7 1.0 6.4 3.3 0.5 0.0 0.1 1.0 7.1 0.0 8.4 0.0 2.6 1.0 26.1 3.2 13.7 0.6 0.0 0.9 0.0 0.7 4.3 8.5 10.1 2.0 0.0 0.0 0.0 7.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.8 19.2 10.1 21.3 19.1 11.0 24.3 11.8 23.4 25.3 LMNA "CMD1A, HGPS, LGMD1B, LMN1, LMNL1, MADA, PRO1" ENSG00000160789 "Lamin A/C" P02545 1 156082573-156140089 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Cardiomyopathy, Charcot-Marie-Tooth disease, Congenital muscular dystrophy, Disease mutation, Emery-Dreifuss muscular dystrophy, Limb-girdle muscular dystrophy, Neurodegeneration, Neuropathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 6 "basophil: 10.4;memory CD4 T-cell: 8.9;myeloid DC: 34.8;T-reg: 35.4" "Group enriched" "Detected in all" 8 "dendritic cells: 34.8;granulocytes: 10.4;T-cells: 35.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004022, HPA006660, HPA012078" Supported Enhanced "Nucleoplasm,Nuclear bodies,Cytosol" 3200000 Nucleoplasm "Nuclear bodies, Cytosol" "CAB004022: AB_2136278, HPA006660: AB_1079231, HPA012078: " "unprognostic (2.22e-2)" "unprognostic (1.89e-1)" "unprognostic (1.04e-2)" "unprognostic (5.75e-2)" "unprognostic (7.43e-3)" "unprognostic (1.47e-1)" "unprognostic (5.23e-3)" "unprognostic (3.27e-2)" "unprognostic (8.33e-2)" "unprognostic (5.90e-2)" "unprognostic (5.10e-2)" "unprognostic (6.34e-2)" "unprognostic (1.41e-2)" "unprognostic (1.24e-1)" "unprognostic (2.89e-1)" "unprognostic (3.08e-2)" "unprognostic (1.44e-2)" 64.0 37.3 7.4 51.4 11.8 21.3 88.6 9.0 10.8 62.8 32.6 21.9 27.2 28.6 69.1 52.3 62.2 40.1 77.7 62.5 8.8 7.5 25.9 26.6 51.8 39.6 15.7 11.2 60.3 30.9 15.2 17.4 73.3 18.1 34.0 15.2 32.7 37.5 26.4 36.3 68.7 29.9 63.0 10.3 22.4 36.7 30.2 12.9 9.4 31.5 140.0 35.6 46.4 51.2 1.1 34.8 10.4 3.5 1.7 35.4 6.4 58.6 58.2 6.4 17.3 32.6 56.6 19.9 63.4 80.9 47.9 33.2 14.7 58.1 0.5 37.7 97.5 68.7 9.4 49.2 12.4 19.9 5.5 18.5 46.9 34.0 29.5 3.2 54.7 33.9 21.4 38.9 26.8 42.7 9.9 4.5 52.4 46.3 0.1 10.2 4.8 74.2 0.2 22.6 17.2 47.4 28.2 6.6 13.2 42.8 46.5 58.9 39.3 15.3 76.1 45.7 29.1 56.4 51.2 4.4 1.1 1.2 74.7 3.0 136.2 10.4 3.5 0.1 1.2 0.8 1.0 1.1 8.9 3.4 34.8 0.0 0.1 0.3 0.8 1.7 0.1 0.3 35.4 6.4 7.4 11.8 9.0 10.8 8.8 7.5 15.7 11.2 18.1 12.9 LMO1 "RBTN1, RHOM1, TTG1" ENSG00000166407 "LIM domain only 1" P25800 11 8224304-8268716 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "retina: 29.4;skeletal muscle: 29.1" "Cell line enhanced" "Detected in some" "HeLa: 21.2;SCLC-21H: 8.3;SH-SY5Y: 25.4;SiHa: 5.1" "Cancer enriched" "Detected in many" 6 "glioma: 6.4" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "unprognostic (3.74e-3)" "unprognostic (1.45e-1)" "unprognostic (4.75e-6)" "unprognostic (9.34e-2)" "unprognostic (2.37e-1)" "unprognostic (1.98e-1)" "unprognostic (7.06e-3)" "unprognostic (8.09e-2)" "unprognostic (2.24e-1)" "unprognostic (9.05e-2)" "unprognostic (4.36e-12)" "unprognostic (1.76e-2)" "unprognostic (8.88e-2)" "unprognostic (2.58e-2)" "unprognostic (3.13e-2)" 0.3 1.7 2.5 0.3 2.1 0.2 0.6 0.4 3.0 0.2 0.2 1.5 0.1 0.4 0.3 2.1 0.6 0.3 0.2 0.5 2.3 5.9 1.0 0.2 0.2 0.2 3.5 0.6 0.2 1.6 0.2 2.1 0.3 2.1 0.3 0.2 29.4 0.2 0.2 29.1 6.4 0.3 0.5 1.2 0.6 0.6 1.6 2.0 0.1 0.2 0.1 0.2 0.5 0.1 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.6 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.3 0.0 0.0 0.0 0.9 0.0 21.2 0.0 0.0 0.0 0.4 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.9 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 8.3 25.4 5.1 2.9 0.1 0.0 0.0 0.0 0.0 0.6 0.0 0.2 0.0 0.0 0.0 1.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 2.1 0.4 3.0 2.3 5.9 3.5 0.6 2.1 2.0 LMO2 "RBTN2, RBTNL1, RHOM2, TTG2" ENSG00000135363 "LIM domain only 2" P25791 11 33858576-33892289 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in some" "HEL: 22.8;HL-60: 22.7;K-562: 23.0;THP-1: 30.1;U-937: 10.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "basophil: 1.5;classical monocyte: 1.1;eosinophil: 3.0;intermediate monocyte: 3.1;myeloid DC: 4.3;neutrophil: 1.6;non-classical monocyte: 3.6" "Group enriched" "Detected in many" 7 "dendritic cells: 4.3;granulocytes: 3.0;monocytes: 3.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB016258, HPA029285, HPA070901, HPA070910" Approved Enhanced Nucleoplasm Nucleoplasm "CAB016258: AB_2136572, HPA029285: , HPA070901: , HPA070910: " "unprognostic (1.60e-1)" "unprognostic (1.47e-2)" "unprognostic (6.03e-2)" "unprognostic (1.71e-3)" "unprognostic (1.89e-1)" "unprognostic (1.14e-3)" "prognostic favourable (3.12e-4)" "unprognostic (1.73e-3)" "unprognostic (8.95e-2)" "unprognostic (5.76e-2)" "unprognostic (7.86e-3)" "unprognostic (3.69e-1)" "unprognostic (7.10e-2)" "unprognostic (9.65e-2)" "unprognostic (3.90e-1)" "unprognostic (1.45e-1)" "unprognostic (4.46e-2)" 18.2 6.1 13.8 13.6 15.6 28.8 14.5 5.2 18.4 9.4 5.5 10.3 6.4 6.2 9.7 9.9 6.9 8.6 9.1 6.4 15.8 12.2 12.9 5.5 15.9 22.2 14.2 7.2 5.1 3.9 4.2 8.3 8.5 11.9 8.3 2.7 14.6 4.5 4.0 25.0 4.2 5.5 6.6 13.9 22.0 4.4 3.6 11.1 1.0 10.7 8.1 13.3 11.1 14.8 0.5 4.3 3.0 3.6 0.0 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.1 0.0 0.0 0.9 0.5 5.6 0.0 0.0 0.0 0.1 0.0 0.0 0.1 22.8 0.0 0.0 0.1 22.7 7.9 0.0 0.0 0.0 0.0 4.4 23.0 0.0 0.0 0.1 2.1 9.7 0.4 0.0 6.4 0.3 0.0 0.0 0.3 1.9 0.0 0.1 0.2 0.0 0.0 30.1 0.3 0.0 0.1 0.7 0.0 0.0 0.1 0.2 2.1 10.6 0.1 1.5 1.1 3.0 0.0 3.1 0.1 0.5 0.0 0.0 4.3 0.0 0.0 0.0 1.6 0.0 3.6 0.3 0.0 0.5 13.8 15.6 5.2 9.5 15.8 12.2 14.2 7.2 11.9 11.1 LPP ENSG00000145012 "LIM domain containing preferred translocation partner in lipoma" Q93052 3 188153284-188890671 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell adhesion" Activator "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "smooth muscle: 127.8;urinary bladder: 105.1" "Cell line enhanced" "Detected in many" "Daudi: 28.8;EFO-21: 35.8;U-698: 59.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 18.0" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA011133, HPA017342" Enhanced Enhanced "Focal adhesion sites,Cytosol" 520000 "Focal adhesion sites, Cytosol" "HPA011133: AB_1853247, HPA017342: AB_1853249" "unprognostic (1.50e-1)" "unprognostic (4.97e-3)" "unprognostic (1.41e-1)" "unprognostic (2.18e-1)" "unprognostic (1.86e-1)" "unprognostic (4.05e-1)" "unprognostic (2.43e-3)" "unprognostic (7.97e-2)" "unprognostic (2.17e-1)" "unprognostic (5.56e-2)" "unprognostic (3.44e-3)" "unprognostic (2.10e-1)" "unprognostic (2.57e-3)" "unprognostic (2.25e-2)" "unprognostic (6.86e-2)" "unprognostic (2.82e-3)" "unprognostic (1.48e-1)" 19.6 4.2 2.7 29.5 2.8 3.1 12.5 3.0 2.7 42.2 29.9 2.1 19.6 5.0 68.6 14.9 59.7 10.0 37.9 9.3 2.6 2.8 10.9 5.3 11.4 6.0 2.8 1.6 26.1 4.4 4.7 3.2 5.2 3.0 37.7 12.8 8.5 7.0 28.4 11.6 5.9 17.2 127.8 3.2 9.5 12.1 30.7 1.5 5.1 5.4 4.2 7.8 105.1 38.3 5.9 4.9 18.0 4.5 4.3 5.0 1.4 7.5 7.0 5.1 3.4 11.1 11.4 5.5 4.9 6.3 3.6 2.4 12.6 3.6 28.8 35.8 11.2 3.2 1.5 3.3 9.1 3.1 1.7 1.4 5.4 3.3 4.7 0.6 1.7 8.1 4.7 8.1 7.0 6.1 0.0 0.6 6.3 2.4 1.4 0.6 2.0 2.3 1.8 3.8 0.1 4.0 8.0 0.3 0.0 10.6 3.5 6.0 2.7 2.4 13.1 8.4 6.5 6.0 12.2 0.0 1.1 59.7 4.2 1.3 7.6 0.8 4.5 1.9 5.0 4.2 3.2 2.9 4.3 3.6 2.4 5.9 2.3 2.9 18.0 4.3 4.0 4.9 1.6 1.4 2.7 2.8 3.0 2.7 2.6 2.8 2.8 1.6 3.0 1.5 LRIG3 "FLJ90440, KIAA3016" ENSG00000139263 "Leucine rich repeats and immunoglobulin like domains 3" Q6UXM1 12 58872149-58920522 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins" "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "hTCEpi: 27.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA010773 Approved Approved Cytosol Cytosol "HPA010773: AB_1853275" "unprognostic (1.79e-1)" "unprognostic (2.71e-1)" "unprognostic (1.01e-2)" "unprognostic (3.88e-2)" "unprognostic (2.53e-1)" "unprognostic (3.46e-2)" "unprognostic (1.83e-2)" "unprognostic (1.34e-3)" "unprognostic (1.21e-1)" "unprognostic (1.92e-1)" "unprognostic (3.04e-2)" "unprognostic (4.25e-2)" "unprognostic (2.74e-3)" "unprognostic (2.47e-2)" "unprognostic (1.10e-1)" "unprognostic (1.28e-2)" "unprognostic (1.46e-2)" 15.8 1.7 3.6 11.8 4.1 0.0 16.4 1.0 3.7 18.7 14.8 7.8 12.1 8.4 14.2 13.8 17.1 9.9 17.8 4.7 4.6 1.8 6.5 6.1 9.6 5.0 3.6 2.6 14.7 15.3 4.8 10.3 6.8 5.8 15.5 16.0 13.5 24.9 11.6 5.0 25.9 10.0 21.6 3.0 7.2 13.5 6.4 6.6 5.4 37.6 15.0 12.8 15.7 20.7 0.0 0.0 0.0 0.0 0.0 0.4 0.1 2.0 1.9 7.3 0.5 13.4 15.6 1.7 4.9 14.1 4.7 5.0 5.7 2.6 1.9 9.9 5.4 9.4 2.7 12.4 3.4 14.4 9.5 0.5 3.3 2.8 2.6 0.7 0.2 15.5 27.0 5.0 10.8 12.9 0.1 2.4 3.1 0.9 2.3 0.0 7.8 2.9 0.0 6.2 4.7 3.6 10.4 7.4 0.0 4.3 2.7 4.4 5.0 0.1 5.5 6.5 4.4 3.8 6.3 1.0 0.0 0.0 1.3 0.0 3.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 3.6 4.1 1.0 3.7 4.6 1.8 3.6 2.6 5.8 6.6 LYL1 bHLHa18 ENSG00000104903 "LYL1, basic helix-loop-helix family member" P12980 19 13099033-13103161 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 37.4;lymphoid tissue: 25.4" "Cell line enhanced" "Detected in some" "HEL: 32.3;HL-60: 22.6;HMC-1: 54.5;K-562: 25.3;NB-4: 33.1;REH: 24.3;THP-1: 21.9;U-937: 21.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "eosinophil: 8.8" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA075004 Approved "Golgi apparatus" "Golgi apparatus" "HPA075004: " "unprognostic (8.62e-2)" "unprognostic (1.58e-1)" "unprognostic (1.27e-2)" "unprognostic (3.29e-3)" "unprognostic (2.76e-1)" "unprognostic (3.64e-3)" "unprognostic (2.46e-1)" "unprognostic (1.05e-2)" "unprognostic (1.90e-2)" "unprognostic (5.87e-2)" "unprognostic (1.78e-3)" "unprognostic (1.36e-1)" "prognostic unfavourable (3.89e-4)" "unprognostic (1.18e-1)" "unprognostic (6.54e-2)" "unprognostic (1.33e-1)" "unprognostic (4.28e-1)" 6.3 3.0 3.4 19.9 5.8 37.4 8.0 1.1 3.8 4.0 3.7 5.5 1.3 3.0 5.3 3.9 5.9 3.8 3.5 4.9 4.5 2.9 3.9 2.0 8.1 24.0 7.1 1.6 3.2 1.6 0.8 1.7 8.0 5.1 6.2 1.4 4.4 6.4 2.4 3.5 2.0 8.8 3.3 6.0 25.4 4.2 11.9 4.1 3.6 3.5 1.4 18.9 3.3 7.0 4.6 1.4 8.8 3.6 0.0 0.5 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.1 0.0 6.3 2.2 0.0 0.0 0.1 0.0 0.0 3.7 0.0 32.3 0.0 0.3 0.3 22.6 54.5 0.1 0.0 0.0 0.0 8.3 25.3 1.1 0.0 0.0 0.1 33.1 0.0 0.8 24.3 0.0 2.7 0.0 0.0 0.0 2.4 0.7 0.0 1.5 0.0 21.9 13.3 0.0 0.0 0.9 0.0 0.0 0.0 5.1 0.0 21.8 0.0 2.5 2.3 8.8 0.1 2.9 0.2 2.8 0.3 0.2 1.4 4.6 0.2 0.2 3.6 0.0 3.6 0.4 0.5 0.6 3.4 5.8 1.1 3.7 4.5 2.9 7.1 1.6 5.1 4.1 MAF c-MAF ENSG00000178573 "MAF bZIP transcription factor" O75444 16 79585843-79600714 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Cataract, Disease mutation, Dwarfism, Mental retardation, Proto-oncogene, Tumor suppressor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in some" 12 "Karpas-707: 49.1;RPMI-8226: 80.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 4 "basophil: 20.7;MAIT T-cell: 6.3" "Group enriched" "Detected in many" 16 "granulocytes: 20.7;T-cells: 6.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB010296, HPA028289" Approved "CAB010296: AB_638562, HPA028289: AB_10602024" "unprognostic (6.76e-2)" "unprognostic (1.74e-2)" "unprognostic (6.45e-2)" "unprognostic (7.65e-2)" "unprognostic (7.89e-3)" "unprognostic (1.07e-2)" "unprognostic (1.63e-2)" "unprognostic (2.33e-1)" "unprognostic (8.76e-2)" "unprognostic (3.16e-2)" "unprognostic (9.46e-2)" "unprognostic (1.28e-1)" "prognostic unfavourable (3.74e-4)" "unprognostic (4.54e-2)" "unprognostic (7.83e-2)" "unprognostic (1.09e-2)" "unprognostic (4.56e-3)" 19.0 10.2 15.4 17.3 13.5 2.5 28.5 9.3 11.2 25.6 31.8 10.7 9.1 41.7 18.8 15.6 16.7 15.1 12.4 19.0 14.3 5.8 28.7 18.0 16.8 38.1 20.5 9.9 31.4 3.1 59.1 4.8 21.7 13.9 15.8 7.2 14.1 9.7 10.4 26.3 37.2 57.7 15.8 18.7 19.8 9.5 12.4 14.0 10.2 18.4 16.7 14.3 14.6 23.4 0.0 0.0 20.7 0.8 0.6 6.3 0.4 0.0 0.0 5.2 0.0 0.2 0.0 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.1 0.1 0.0 1.6 1.9 0.0 0.0 0.0 0.2 0.0 3.4 0.0 1.5 0.0 0.0 0.0 0.5 49.1 0.3 0.0 0.0 0.0 3.2 0.0 0.0 1.4 80.0 0.0 0.4 0.1 0.0 0.2 0.0 0.1 0.0 0.0 1.0 0.0 1.7 0.1 0.2 0.0 0.0 0.0 0.2 0.0 0.3 20.7 0.2 0.0 0.8 0.8 6.3 0.0 2.4 1.9 0.0 0.0 0.2 0.3 0.0 0.6 0.2 0.0 3.1 0.4 15.4 13.5 9.3 11.2 14.3 5.8 20.5 9.9 13.9 14.0 MAFB KRML ENSG00000204103 "MAF bZIP transcription factor B" Q9Y5Q3 20 40685848-40689240 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Proto-oncogene, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 87.6;parathyroid gland: 154.1" "Cell line enhanced" "Detected in some" "HSkMC: 15.8;hTCEpi: 33.3;SCLC-21H: 9.1;SiHa: 8.2;U-138 MG: 9.0;U-2197: 13.1;U-87 MG: 8.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 4 "intermediate monocyte: 27.4;non-classical monocyte: 36.7" "Lineage enriched" "Detected in many" 14 "monocytes: 36.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA005653 Approved Approved "Nucleoplasm,Nucleoli,Golgi apparatus,Cytosol" Nucleoplasm "Nucleoli, Golgi apparatus, Cytosol" "HPA005653: AB_1079293" "unprognostic (1.55e-1)" "unprognostic (1.17e-2)" "unprognostic (1.16e-3)" "prognostic unfavourable (5.64e-4)" "unprognostic (9.16e-2)" "unprognostic (3.92e-2)" "unprognostic (1.10e-1)" "unprognostic (2.10e-1)" "unprognostic (2.57e-2)" "unprognostic (6.09e-2)" "unprognostic (5.45e-3)" "unprognostic (9.92e-2)" "unprognostic (3.95e-2)" "unprognostic (1.05e-1)" "unprognostic (3.21e-3)" "unprognostic (3.49e-2)" "unprognostic (2.30e-2)" 38.3 7.9 3.2 13.0 4.0 17.0 19.5 1.0 9.7 10.6 6.9 3.0 1.2 3.3 5.6 8.9 16.8 7.0 9.2 12.4 3.6 2.3 10.9 14.0 21.9 28.9 4.7 3.4 7.0 6.1 154.1 2.3 9.4 5.0 7.6 3.3 5.6 10.4 2.7 11.0 41.6 7.6 5.5 7.7 87.6 4.7 7.5 3.8 6.9 18.2 20.5 11.4 8.2 10.9 0.0 2.5 0.7 36.7 0.0 0.0 2.5 0.0 0.0 0.0 1.4 0.8 0.1 0.2 0.2 0.0 0.1 0.0 0.2 0.1 0.0 1.0 0.2 2.0 0.0 0.0 0.0 0.0 0.7 0.0 0.6 0.1 0.5 0.0 0.1 15.8 33.3 0.1 1.1 0.2 0.0 0.0 0.0 0.5 0.1 3.8 1.4 0.0 0.0 0.0 0.0 0.3 0.2 9.1 0.7 8.2 0.8 2.0 0.8 0.1 0.2 9.0 0.1 13.1 0.0 0.0 0.0 0.0 8.7 0.3 0.0 0.1 7.3 0.0 0.0 27.4 0.0 0.0 0.0 0.0 2.5 0.0 0.0 0.0 0.7 0.0 36.7 0.0 0.0 2.5 3.2 4.0 1.0 9.7 3.6 2.3 4.7 3.4 5.0 3.8 MALT1 "MLT, PCASP1" ENSG00000172175 "MALT1 paracaspase" Q9UDY8 18 58671386-58754477 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Ubl conjugation pathway" "Hydrolase, Protease" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "RPTEC TERT1: 50.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB004494, HPA048432" Enhanced Approved "Nucleoli fibrillar center,Cytosol" "Nucleoli fibrillar center" Cytosol "CAB004494: AB_627909, HPA048432: " "unprognostic (3.25e-1)" "unprognostic (2.31e-1)" "unprognostic (3.64e-2)" "unprognostic (3.25e-2)" "unprognostic (1.65e-3)" "unprognostic (4.67e-2)" "unprognostic (6.46e-2)" "unprognostic (4.50e-2)" "unprognostic (3.33e-2)" "unprognostic (4.16e-3)" "unprognostic (3.74e-1)" "unprognostic (2.07e-1)" "unprognostic (2.53e-2)" "unprognostic (2.34e-1)" "unprognostic (2.97e-1)" "unprognostic (1.03e-1)" "unprognostic (6.00e-2)" 11.2 3.9 4.1 21.7 5.6 10.2 10.6 9.1 6.8 11.0 10.7 3.9 10.9 5.5 8.1 10.5 16.4 6.6 8.1 8.7 4.0 4.3 14.9 10.5 14.3 29.0 4.1 1.8 8.1 6.2 10.0 9.3 8.8 4.9 18.1 7.9 7.5 10.7 8.4 10.7 12.6 12.2 6.6 6.2 19.9 6.2 11.8 4.8 22.4 7.9 12.4 24.0 9.6 12.3 6.3 3.6 1.2 1.7 1.6 4.8 1.1 7.4 10.6 13.0 3.2 2.6 5.8 5.8 13.3 9.4 11.6 9.9 8.6 9.6 11.8 6.0 16.5 7.3 5.6 5.5 14.3 7.9 3.1 4.2 7.6 13.8 4.2 8.5 5.7 3.6 11.7 9.1 9.2 2.5 6.8 20.6 6.3 2.4 1.8 3.6 3.2 3.6 6.4 7.7 8.3 50.8 3.1 1.4 3.0 7.3 3.8 5.0 3.7 4.9 3.4 15.0 6.6 4.4 12.2 18.4 21.8 10.3 6.0 6.4 5.9 0.8 1.5 1.0 2.7 1.7 2.1 3.6 4.8 2.9 2.2 6.3 4.3 2.8 1.2 1.6 1.6 3.6 2.9 1.1 4.1 5.6 9.1 6.8 4.0 4.3 4.1 1.8 4.9 4.8 MAML2 "KIAA1819, MAM3" ENSG00000184384 "Mastermind like transcriptional coactivator 2" Q8IZL2 11 95976598-96343180 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Notch signaling pathway, Transcription, Transcription regulation" Activator "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HDLM-2: 27.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA035223 Approved Supported "Nucleoplasm,Nuclear bodies,Cytosol" "Nuclear bodies" "Nucleoplasm, Cytosol" "HPA035223: AB_10671101" "unprognostic (8.11e-2)" "unprognostic (2.51e-1)" "unprognostic (7.08e-2)" "unprognostic (9.07e-2)" "unprognostic (3.57e-3)" "unprognostic (3.32e-2)" "unprognostic (3.66e-2)" "unprognostic (2.33e-1)" "unprognostic (3.99e-2)" "unprognostic (8.05e-2)" "prognostic unfavourable (3.89e-4)" "unprognostic (9.11e-2)" "prognostic favourable (1.90e-4)" "unprognostic (9.76e-2)" "unprognostic (1.73e-2)" "unprognostic (1.99e-1)" "unprognostic (7.19e-2)" 26.3 5.5 10.2 16.1 8.1 4.2 19.7 27.8 13.4 15.8 9.2 10.4 8.4 4.3 11.2 8.5 9.3 11.7 10.8 8.9 10.5 6.9 13.8 3.5 15.0 10.9 6.9 3.4 11.7 8.2 13.3 15.2 18.8 9.3 12.3 8.9 10.8 16.6 12.3 4.4 14.2 8.9 10.2 14.4 16.8 6.5 4.3 10.6 21.2 11.8 4.8 13.6 16.0 15.3 2.1 1.2 4.7 1.1 4.2 6.4 2.0 5.5 1.1 9.6 2.5 10.0 11.6 2.1 6.4 9.6 4.2 4.4 0.6 11.8 1.2 15.2 14.8 5.1 1.9 6.2 5.9 27.4 0.7 0.7 2.0 2.1 5.8 0.0 0.0 16.9 0.6 7.5 4.5 2.4 3.1 1.7 7.5 0.4 0.1 1.5 1.0 1.8 1.9 1.8 6.4 6.3 7.8 0.1 0.8 2.4 1.0 2.7 0.9 0.2 10.4 7.5 1.8 2.5 4.0 1.2 0.2 1.8 3.6 1.1 13.7 0.1 1.1 0.0 1.5 0.6 2.6 1.9 3.2 4.1 1.2 2.1 6.4 4.3 4.7 4.2 0.7 0.9 1.2 2.0 10.2 8.1 27.8 7.0 10.5 6.9 6.9 3.4 9.3 10.6 MECOM "EVI1, KMT8E, MDS1, MDS1-EVI1, PRDM3" ENSG00000085276 "MDS1 and EVI1 complex locus" Q03112 3 169083499-169663618 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Apoptosis, Differentiation, Transcription, Transcription regulation" "Developmental protein, DNA-binding, Methyltransferase, Transferase" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HUVEC TERT2: 21.5;RPTEC TERT1: 27.6;RT4: 43.5;TIME: 20.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "NK-cell: 1.8" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA046537 Supported Supported "Nuclear speckles" "Nuclear speckles" "HPA046537: " "unprognostic (4.09e-2)" "unprognostic (1.96e-1)" "unprognostic (3.24e-3)" "unprognostic (7.29e-2)" "unprognostic (2.87e-2)" "unprognostic (2.53e-1)" "unprognostic (1.83e-2)" "unprognostic (4.77e-3)" "unprognostic (1.53e-2)" "unprognostic (3.27e-3)" "prognostic unfavourable (2.59e-4)" "unprognostic (1.87e-1)" "unprognostic (2.60e-3)" "unprognostic (6.54e-2)" "unprognostic (1.03e-1)" "unprognostic (2.81e-2)" "unprognostic (3.37e-3)" 25.9 0.7 3.3 5.7 5.6 0.3 9.1 3.4 5.3 13.5 13.9 1.6 22.1 11.2 15.4 5.7 10.4 14.3 8.1 8.2 3.3 2.9 32.2 2.6 30.0 1.5 4.6 1.4 6.2 27.8 1.1 5.3 10.0 4.7 9.3 17.5 4.2 5.9 25.3 16.0 2.3 5.9 5.6 5.8 6.4 39.4 2.7 3.5 0.2 4.7 3.3 3.5 18.1 18.5 0.3 0.0 0.6 1.5 1.8 1.0 0.0 9.6 0.1 0.2 0.0 1.3 1.0 0.1 1.3 1.5 0.5 0.8 3.8 9.9 0.0 15.2 0.2 5.1 4.0 5.9 1.1 0.5 6.3 6.1 1.6 0.1 0.1 0.0 1.9 2.1 0.8 0.3 4.5 21.5 4.6 0.7 3.8 1.0 0.0 0.0 0.2 2.5 3.6 4.9 0.2 27.6 43.5 0.3 1.1 0.4 2.5 0.1 2.9 0.0 20.4 3.8 2.5 1.0 6.4 0.5 0.1 0.3 1.9 0.0 0.5 0.3 0.0 0.6 0.4 0.2 1.0 0.1 0.1 0.0 0.0 0.3 0.2 0.0 0.3 1.8 1.5 0.0 0.1 0.0 3.3 5.6 3.4 5.3 3.3 2.9 4.6 1.4 4.7 3.5 MKL1 "BSAC, KIAA1438, MAL, MKL, MRTF-A" ENSG00000196588 "Megakaryoblastic leukemia (translocation) 1" Q969V6 22 40410281-40636702 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" Actin-binding "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "eosinophil: 50.9" "Group enriched" "Detected in all" 5 "dendritic cells: 26.4;granulocytes: 50.9;monocytes: 15.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA030782 Approved Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA030782: AB_10600930" "unprognostic (7.90e-3)" "unprognostic (4.51e-2)" "unprognostic (2.99e-1)" "unprognostic (1.29e-1)" "unprognostic (9.04e-2)" "unprognostic (9.37e-2)" "unprognostic (4.38e-3)" "unprognostic (1.02e-3)" "unprognostic (1.30e-1)" "unprognostic (1.35e-2)" "unprognostic (1.51e-1)" "unprognostic (3.74e-2)" "prognostic unfavourable (1.58e-7)" "unprognostic (9.05e-2)" "unprognostic (8.15e-2)" "unprognostic (1.30e-2)" "unprognostic (3.98e-1)" 18.1 11.1 15.4 25.4 19.1 69.2 15.8 16.2 26.1 17.6 14.2 13.5 10.1 11.3 27.6 12.9 12.3 17.5 13.2 16.3 14.2 11.1 11.3 8.9 17.4 25.6 11.8 16.6 16.9 14.5 10.2 10.5 18.9 12.6 14.2 9.4 13.3 16.9 15.7 14.3 18.0 13.6 15.7 11.0 23.9 14.3 25.4 10.8 28.2 17.3 9.0 25.5 15.5 14.6 4.9 26.4 50.9 15.0 3.8 5.6 7.5 10.7 14.6 6.3 7.5 8.0 6.1 12.4 10.5 6.8 9.7 9.4 6.8 3.3 11.5 4.3 11.0 14.2 5.3 12.9 6.3 12.7 9.3 19.0 16.3 10.1 7.9 22.0 37.5 6.6 15.6 9.4 6.5 7.1 5.3 5.2 4.6 10.5 8.6 24.7 5.0 5.1 14.0 7.1 5.8 7.7 8.1 3.5 3.8 17.2 8.7 6.3 5.8 24.9 11.6 6.6 17.7 8.7 9.0 7.0 6.2 16.5 5.4 11.1 12.7 12.0 15.0 50.9 4.4 11.6 4.1 3.2 4.0 3.4 17.8 4.9 5.6 4.7 14.5 3.8 15.0 26.4 5.2 7.5 15.4 19.1 16.2 26.1 14.2 11.1 11.8 16.6 12.6 10.8 MLF1 ENSG00000178053 "Myeloid leukemia factor 1" P58340 3 158571163-158607252 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cell cycle, Differentiation" "Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "heart muscle: 41.4;skeletal muscle: 53.6;testis: 101.1" "Cell line enhanced" "Detected in many" "A-431: 34.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "T-reg: 10.4" "Lineage enriched" "Detected in single" 12 "T-cells: 10.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA069479 Approved Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA069479: " "unprognostic (6.49e-2)" "unprognostic (1.98e-3)" "unprognostic (1.98e-1)" "prognostic unfavourable (2.15e-5)" "unprognostic (1.72e-2)" "unprognostic (2.65e-2)" "unprognostic (8.55e-2)" "unprognostic (4.11e-2)" "unprognostic (2.01e-1)" "unprognostic (2.07e-1)" "unprognostic (7.21e-2)" "unprognostic (1.07e-1)" "unprognostic (7.82e-2)" "prognostic unfavourable (5.54e-4)" "unprognostic (9.34e-3)" "unprognostic (2.47e-3)" "unprognostic (3.36e-2)" 3.5 2.6 6.0 1.8 11.9 0.9 5.3 3.4 7.1 3.1 2.7 6.5 0.5 0.8 4.9 5.6 3.5 18.3 4.9 41.4 6.3 6.3 5.7 1.2 5.2 1.0 4.9 6.3 6.2 3.1 5.2 10.4 1.0 20.1 2.0 1.7 2.8 2.2 1.6 53.6 1.8 1.3 4.5 4.7 1.2 1.9 101.1 5.7 0.0 5.3 18.9 1.4 4.2 1.5 0.6 0.3 0.4 0.3 0.8 10.4 2.3 34.1 4.5 11.5 0.0 6.1 7.2 3.4 3.5 3.4 13.0 11.8 0.0 19.5 0.0 13.5 6.1 6.6 0.1 6.0 17.3 0.0 7.5 2.0 3.3 0.3 4.2 0.0 2.6 4.4 8.8 6.2 3.4 3.0 2.5 0.0 8.5 5.0 0.0 0.1 2.7 10.0 0.0 6.4 0.4 9.9 2.4 14.9 8.8 16.1 5.7 16.9 16.4 3.4 1.1 12.1 12.4 14.3 13.7 6.1 3.8 0.0 8.7 0.0 8.7 0.0 0.0 0.0 3.6 0.0 1.6 0.6 8.3 8.7 0.3 0.3 2.1 4.4 0.4 0.8 0.3 0.2 10.4 2.3 6.0 11.9 3.4 7.1 6.3 6.3 4.9 6.3 20.1 5.7 MLLT1 "ENL, LTG19, YEATS1" ENSG00000130382 "MLLT1, super elongation complex subunit" Q03111 19 6210379-6279948 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" Activator "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA031166 Approved Supported Nucleoplasm Nucleoplasm "HPA031166: AB_10601874" "unprognostic (3.21e-1)" "unprognostic (2.75e-3)" "unprognostic (4.84e-2)" "unprognostic (3.36e-2)" "unprognostic (2.47e-1)" "prognostic favourable (6.03e-5)" "unprognostic (1.30e-3)" "unprognostic (1.44e-2)" "unprognostic (1.56e-1)" "unprognostic (1.98e-1)" "unprognostic (3.93e-3)" "unprognostic (4.76e-2)" "unprognostic (3.65e-3)" "unprognostic (1.14e-2)" "unprognostic (2.01e-1)" "unprognostic (1.66e-2)" "unprognostic (7.99e-3)" 20.1 13.7 21.8 17.1 23.4 8.8 12.9 32.7 28.6 17.7 16.8 16.8 17.7 13.4 22.1 15.5 13.1 25.5 19.3 18.2 16.9 14.3 10.7 12.8 16.7 10.9 13.0 18.5 29.8 22.4 26.2 10.7 45.2 14.6 17.2 6.8 18.7 21.7 18.8 23.5 18.8 13.1 15.0 10.6 13.9 15.1 10.7 13.7 10.8 18.9 12.1 10.2 20.6 23.6 1.5 5.2 4.9 3.5 1.9 2.5 1.6 24.4 12.0 14.9 17.5 11.7 10.1 17.3 15.2 9.9 12.8 13.2 19.8 8.3 17.8 19.9 19.9 15.3 11.8 14.9 7.7 14.9 18.4 22.1 32.6 14.9 22.5 14.3 20.3 16.3 13.1 12.2 10.0 14.5 21.3 20.8 8.4 13.5 24.4 13.7 18.1 25.4 21.0 11.1 14.2 6.9 15.2 25.9 23.5 15.7 17.4 18.8 15.7 17.0 15.1 18.0 14.0 27.8 20.9 25.6 19.8 14.0 20.8 24.7 25.5 0.2 1.9 0.4 1.8 3.0 2.5 1.5 1.3 1.7 1.4 1.4 1.1 1.5 4.9 1.9 3.5 5.2 0.5 1.6 21.8 23.4 32.7 28.6 16.9 14.3 13.0 18.5 14.6 13.7 MLLT10 AF10 ENSG00000078403 "MLLT10, histone lysine methyltransferase DOT1L cofactor" P55197 10 21524675-21743630 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "testis: 71.2" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA005747 Enhanced Supported Nucleoplasm Nucleoplasm "HPA005747: AB_1079393" "unprognostic (6.58e-2)" "unprognostic (1.57e-1)" "unprognostic (7.32e-2)" "unprognostic (1.47e-2)" "unprognostic (1.31e-2)" "prognostic favourable (8.75e-4)" "unprognostic (1.03e-3)" "unprognostic (9.56e-3)" "unprognostic (9.29e-2)" "unprognostic (1.78e-1)" "unprognostic (2.69e-2)" "unprognostic (7.85e-2)" "unprognostic (6.57e-2)" "unprognostic (1.26e-1)" "unprognostic (1.50e-1)" "unprognostic (1.07e-1)" "unprognostic (1.67e-1)" 16.3 12.1 11.7 18.4 14.3 21.9 12.8 25.4 13.6 19.0 17.0 12.0 13.6 8.5 26.3 12.8 14.7 14.5 13.7 15.8 10.2 8.5 12.3 13.5 12.3 11.6 10.5 9.9 21.4 12.3 16.6 23.2 20.3 11.8 12.6 11.3 14.6 13.2 16.3 13.4 18.7 12.1 18.7 11.2 10.6 11.4 71.2 14.3 14.6 18.1 9.7 15.2 18.5 19.6 5.5 6.9 12.0 6.8 5.3 7.2 2.8 14.3 12.2 18.9 13.1 12.0 15.1 20.7 9.1 5.8 11.4 11.2 13.0 15.4 17.2 5.1 10.1 13.5 20.8 12.2 11.5 11.9 12.0 26.6 10.6 18.7 14.8 0.6 17.2 11.2 14.6 9.5 11.0 15.1 28.4 13.4 9.0 11.1 20.7 12.5 7.7 3.9 18.0 10.1 14.4 11.0 6.8 6.6 18.4 12.1 14.5 20.4 6.8 18.5 13.6 7.2 12.6 14.3 9.0 11.7 13.4 19.2 8.3 10.3 5.5 10.6 6.8 12.0 5.3 4.6 5.2 5.0 6.2 5.7 5.6 5.5 7.2 6.7 5.8 5.3 5.2 6.9 4.6 2.8 11.7 14.3 25.4 13.6 10.2 8.5 10.5 9.9 11.8 14.3 MLLT11 AF1Q ENSG00000213190 "MLLT11, transcription factor 7 cofactor" Q13015 1 151057758-151068497 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 42.1" "Cell line enhanced" "Detected in many" "AF22: 38.4;EFO-21: 29.2;SH-SY5Y: 42.1;U-698: 35.8" "Cancer enhanced" "Detected in all" "glioma: 29.9" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA000540 Uncertain Supported Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "HPA000540: " "unprognostic (2.96e-2)" "unprognostic (1.98e-2)" "unprognostic (1.08e-2)" "prognostic unfavourable (4.26e-5)" "unprognostic (1.69e-1)" "unprognostic (1.96e-2)" "unprognostic (5.80e-2)" "unprognostic (1.17e-1)" "unprognostic (1.01e-2)" "unprognostic (2.49e-2)" "unprognostic (1.44e-1)" "unprognostic (1.01e-1)" "prognostic unfavourable (4.25e-12)" "unprognostic (5.66e-3)" "unprognostic (1.42e-1)" "unprognostic (1.29e-1)" "unprognostic (3.94e-3)" 1.9 7.5 13.6 3.4 9.1 1.1 1.2 16.3 42.1 1.9 2.1 5.1 1.2 0.8 3.7 1.2 1.3 0.8 11.1 11.8 11.3 16.4 1.2 1.2 5.3 2.3 10.3 1.2 4.2 1.3 8.4 1.8 1.2 3.2 1.3 1.1 1.2 1.5 1.2 2.6 1.0 2.0 4.2 5.8 2.1 0.9 1.2 1.2 2.0 1.2 1.2 2.6 3.2 1.2 2.4 1.0 6.5 1.0 4.2 9.2 2.8 1.2 5.2 38.4 6.0 0.6 1.0 0.6 2.4 2.6 2.3 4.2 0.5 2.5 1.9 29.2 1.8 1.5 9.2 2.2 1.3 11.2 2.5 5.0 3.8 0.1 1.2 0.3 0.8 1.7 0.3 12.7 0.5 16.9 5.3 0.9 7.4 0.4 17.6 3.3 16.7 0.8 16.8 5.1 0.1 4.3 1.1 23.1 42.1 0.2 0.4 1.2 1.4 0.6 11.8 5.0 5.5 1.8 4.3 0.9 0.8 35.8 12.4 0.3 9.3 1.6 0.6 1.6 5.9 0.7 2.7 2.4 3.9 6.0 0.8 2.1 5.3 9.2 6.5 4.2 1.0 1.0 3.6 2.8 13.6 9.1 16.3 21.0 11.3 16.4 10.3 1.2 3.2 1.2 MLLT3 "AF-9, AF9, YEATS3" ENSG00000171843 "MLLT3, super elongation complex subunit" P42568 9 20341665-20622543 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" Activator "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HEL: 72.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive CD4 T-cell: 14.4" "Group enriched" "Detected in many" 5 "NK-cells: 3.8;T-cells: 14.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001824 Approved Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA001824: AB_1079394" "unprognostic (3.31e-1)" "unprognostic (2.22e-1)" "unprognostic (1.23e-3)" "unprognostic (1.27e-2)" "unprognostic (1.99e-1)" "unprognostic (7.57e-2)" "unprognostic (3.83e-2)" "unprognostic (1.01e-3)" "unprognostic (2.12e-1)" "unprognostic (3.92e-3)" "unprognostic (1.05e-1)" "unprognostic (2.03e-2)" "prognostic favourable (1.84e-4)" "unprognostic (1.85e-1)" "unprognostic (4.81e-2)" "unprognostic (1.40e-2)" "unprognostic (1.68e-1)" 8.6 17.3 18.0 10.4 25.8 19.7 11.4 34.6 20.3 12.3 20.9 7.2 10.6 7.2 13.6 7.9 10.2 11.5 12.7 8.6 18.0 12.8 10.1 2.1 10.7 9.1 14.8 13.8 10.5 4.6 18.3 24.7 10.3 13.2 11.7 22.8 7.4 21.3 12.1 9.1 7.9 12.3 13.5 12.0 5.9 15.3 3.6 21.4 22.1 22.5 6.1 6.5 12.9 10.4 1.4 0.7 1.6 0.3 3.8 14.4 2.8 2.5 7.1 2.5 2.9 5.9 3.7 1.6 6.7 11.3 3.0 3.4 6.9 2.4 9.8 3.6 3.1 1.3 2.4 11.6 2.7 20.2 6.2 72.2 21.9 3.2 4.3 1.3 6.1 2.7 4.5 1.0 7.3 3.0 0.0 12.7 6.3 1.9 7.0 4.2 1.6 2.1 0.0 4.6 2.6 13.9 3.8 8.2 2.9 5.4 2.7 2.9 2.8 1.9 1.9 0.0 1.7 1.7 2.3 5.7 5.2 4.0 0.0 3.1 1.4 1.6 0.3 0.5 3.9 0.2 3.6 0.5 7.0 5.3 0.7 1.4 14.4 8.3 0.1 3.8 0.3 0.4 7.3 2.8 18.0 25.8 34.6 20.3 18.0 12.8 14.8 13.8 13.2 21.4 MLLT6 "AF17, FLJ23480" ENSG00000275023 "MLLT6, PHD finger containing" 17 38705542-38729803 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at transcript level" "Evidence at transcript level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA004021 Approved Approved Nucleoplasm Nucleoplasm "HPA004021: AB_1853995" "prognostic favourable (4.18e-4)" "unprognostic (1.50e-1)" "unprognostic (2.53e-1)" "unprognostic (1.44e-2)" "unprognostic (1.29e-1)" "prognostic favourable (3.98e-4)" "unprognostic (4.98e-2)" "unprognostic (1.79e-2)" "unprognostic (1.77e-1)" "unprognostic (7.12e-3)" "prognostic favourable (7.41e-4)" "unprognostic (1.78e-1)" "unprognostic (1.84e-2)" "unprognostic (9.12e-2)" "unprognostic (1.12e-1)" "unprognostic (2.05e-1)" "unprognostic (2.46e-3)" 6.5 7.6 10.0 10.3 10.6 7.3 6.3 14.1 16.9 6.2 6.8 7.2 11.1 7.2 9.2 8.6 5.5 10.3 9.2 7.5 9.7 5.8 1.2 8.5 11.8 8.5 9.6 13.0 9.0 12.8 10.1 4.8 7.2 7.3 5.7 10.0 10.3 12.5 22.3 8.5 8.9 8.2 8.1 11.7 6.7 4.1 9.2 6.3 7.2 4.8 10.1 5.5 11.5 1.4 0.9 2.0 0.8 2.8 6.0 1.7 5.7 6.4 6.5 14.2 7.2 6.5 3.4 3.6 6.6 4.4 5.3 2.3 11.3 16.4 5.2 4.2 15.0 4.2 7.4 3.9 17.5 11.4 6.0 10.7 10.5 3.5 9.2 8.2 6.6 7.6 3.9 8.8 7.2 10.0 13.9 3.8 4.8 18.0 8.9 0.8 3.3 10.6 8.9 15.1 5.1 13.3 14.6 16.1 3.8 12.4 10.6 12.3 6.8 9.5 5.2 7.7 7.2 6.5 23.6 7.7 11.0 7.6 8.5 5.5 1.7 0.8 0.4 6.0 0.5 4.6 1.4 3.2 4.2 0.4 1.4 3.1 4.1 2.0 2.8 0.3 0.9 1.7 1.7 MN1 "MGCR, MGCR1, MGCR1-PEN" ENSG00000169184 "MN1 proto-oncogene, transcriptional regulator" Q10571 22 27748277-27801498 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, Developmental protein" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 62.7" "Cell line enhanced" "Detected in some" "AF22: 22.0;HeLa: 8.9;RH-30: 8.9;TIME: 14.0;U-2 OS: 12.0;U-2197: 12.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 6 "non-classical monocyte: 1.7" "Lineage enriched" "Detected in single" 8 "monocytes: 1.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA003072 Approved Approved Nucleoplasm Nucleoplasm "HPA003072: AB_1079399" "unprognostic (5.64e-2)" "unprognostic (2.48e-2)" "unprognostic (1.09e-2)" "unprognostic (1.26e-1)" "unprognostic (2.88e-2)" "unprognostic (2.52e-2)" "unprognostic (7.01e-2)" "unprognostic (3.03e-2)" "unprognostic (4.17e-2)" "unprognostic (1.64e-1)" "unprognostic (4.00e-2)" "unprognostic (7.33e-2)" "unprognostic (5.13e-7)" "unprognostic (3.84e-2)" "unprognostic (2.00e-1)" "unprognostic (5.28e-3)" "unprognostic (2.21e-4)" 3.7 2.0 3.4 4.2 17.3 2.4 1.9 1.3 5.6 5.9 4.2 2.6 2.5 2.1 3.0 9.0 7.0 3.4 11.1 5.1 2.5 2.7 1.6 1.4 4.3 1.3 3.3 3.5 12.4 1.5 1.3 2.3 2.6 4.5 3.1 2.2 10.8 2.1 2.7 62.7 2.9 2.1 5.8 1.0 1.5 3.5 2.0 5.4 0.0 1.8 14.8 2.1 5.0 4.7 0.0 0.2 0.0 1.7 0.0 0.1 0.0 0.0 1.0 22.0 0.6 0.4 0.9 0.0 0.5 0.8 0.0 0.0 0.0 0.0 0.0 2.2 3.9 1.8 1.1 1.3 0.0 0.0 0.6 0.0 8.9 0.0 0.5 0.0 0.2 0.0 2.5 0.5 2.2 0.2 0.0 0.1 0.7 0.0 0.0 0.2 2.9 2.0 3.6 8.9 0.0 0.3 0.0 0.0 0.3 1.9 0.0 0.0 0.2 0.0 14.0 0.7 12.0 12.7 0.2 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.1 0.2 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.2 0.0 0.0 3.4 17.3 1.3 4.2 2.5 2.7 3.3 3.5 4.5 5.4 MSI2 ENSG00000153944 "Musashi RNA binding protein 2" Q96DH6 17 57255851-57684685 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "REH: 48.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB022300 Approved Supported Cytosol Cytosol "CAB022300: " "unprognostic (4.73e-2)" "unprognostic (2.28e-1)" "unprognostic (3.42e-2)" "unprognostic (1.26e-1)" "unprognostic (1.12e-1)" "unprognostic (1.08e-1)" "unprognostic (4.20e-2)" "unprognostic (2.20e-2)" "unprognostic (4.89e-2)" "unprognostic (2.96e-1)" "unprognostic (4.17e-2)" "unprognostic (1.18e-1)" "prognostic favourable (9.22e-8)" "prognostic favourable (2.00e-4)" "unprognostic (4.87e-2)" "unprognostic (1.57e-1)" "unprognostic (2.72e-3)" 3.4 34.7 20.0 22.4 21.5 8.4 8.8 18.0 25.3 9.7 14.4 7.7 14.2 5.0 6.7 36.3 4.6 11.1 23.5 28.5 13.9 16.9 18.0 3.6 6.9 9.6 21.0 6.4 22.8 6.1 41.4 23.1 10.7 19.7 10.5 7.4 14.6 9.8 48.5 25.6 3.6 5.4 4.6 14.8 8.7 7.7 7.5 9.5 23.7 12.4 8.4 8.6 11.6 5.0 1.9 3.0 4.8 1.5 1.9 4.1 0.5 3.4 5.8 20.1 7.7 2.3 2.2 15.8 3.8 4.4 5.0 3.0 6.9 5.8 15.8 13.5 2.3 3.4 12.8 5.1 9.3 22.0 8.9 6.9 12.9 15.8 5.0 7.6 7.0 2.8 6.7 0.6 8.2 5.1 15.0 11.9 17.5 7.9 34.2 2.1 7.2 9.4 48.0 30.1 12.5 12.2 22.2 22.3 41.5 6.2 5.9 17.7 10.6 5.9 6.5 3.2 8.3 2.8 6.5 16.5 14.0 19.2 8.4 4.6 19.3 4.4 0.4 4.8 2.0 0.3 1.5 1.9 1.9 1.8 0.6 1.1 1.8 1.7 0.4 1.9 1.5 3.0 4.1 0.5 20.0 21.5 18.0 25.3 13.9 16.9 21.0 6.4 19.7 9.5 MSN ENSG00000147065 Moesin P26038 X 65588377-65741931 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000263, CAB010898, HPA011135, HPA011227, CAB047336, CAB047337, CAB047338" Enhanced Enhanced "Plasma membrane" 340000000 "Plasma membrane" "CAB010898: AB_260635, CAB047336: , CAB047337: , CAB047338: , HPA000263: AB_1856043, HPA011135: AB_1854053, HPA011227: AB_1854054" "unprognostic (1.03e-1)" "unprognostic (7.89e-2)" "unprognostic (7.64e-2)" "unprognostic (5.38e-2)" "unprognostic (4.08e-3)" "unprognostic (3.51e-2)" "unprognostic (1.11e-2)" "unprognostic (1.44e-2)" "unprognostic (3.35e-2)" "unprognostic (1.70e-2)" "unprognostic (9.04e-3)" "unprognostic (1.32e-1)" "prognostic unfavourable (1.60e-5)" "unprognostic (5.68e-3)" "unprognostic (7.75e-2)" "unprognostic (7.21e-2)" "unprognostic (6.81e-2)" 36.3 17.6 10.2 40.7 14.4 38.5 98.2 8.6 18.6 25.1 21.3 19.2 7.6 6.5 33.4 14.2 15.7 21.8 20.2 53.8 11.5 10.4 25.6 29.5 102.8 85.0 17.5 5.4 28.8 19.4 5.7 10.2 24.2 30.0 23.1 13.0 16.6 16.3 21.9 13.6 19.5 18.3 41.4 21.8 31.6 17.3 9.0 12.9 18.7 26.2 17.6 38.1 22.7 28.9 16.0 36.4 54.1 69.0 28.0 37.1 81.8 27.8 21.4 21.0 17.3 25.2 33.3 0.1 70.7 45.8 39.2 30.4 0.0 4.9 23.4 63.2 62.5 19.2 22.1 50.4 51.2 43.3 6.1 64.9 37.1 0.0 23.8 78.8 105.1 24.9 10.9 72.1 63.8 86.5 31.4 73.0 62.0 0.0 46.5 59.1 26.0 40.7 24.4 37.7 17.8 41.9 0.0 0.1 0.0 56.8 0.4 22.5 0.2 42.9 137.0 44.7 28.4 60.1 46.8 26.5 40.1 25.4 32.7 100.1 49.7 30.8 44.4 30.0 37.1 58.9 27.9 16.0 20.4 29.1 36.4 13.9 14.0 21.3 54.1 28.0 69.0 5.2 15.5 81.8 10.2 14.4 8.6 18.6 11.5 10.4 17.5 5.4 30.0 12.9 MTCP1 "P13MTCP1, p8MTCP1" ENSG00000214827 "Mature T cell proliferation 1" P56278 X 155061622-155147937 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HeLa: 14.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA032040 Approved "Nucleoplasm,Plasma membrane" Nucleoplasm "Plasma membrane" "HPA032040: " "unprognostic (2.42e-2)" "unprognostic (2.07e-2)" "unprognostic (1.14e-1)" "unprognostic (6.29e-3)" "unprognostic (8.30e-2)" "unprognostic (4.10e-1)" "unprognostic (2.40e-5)" "unprognostic (9.30e-2)" "unprognostic (1.17e-1)" "unprognostic (4.94e-2)" "unprognostic (5.72e-2)" "unprognostic (1.15e-2)" "prognostic unfavourable (4.52e-8)" "unprognostic (1.55e-3)" "unprognostic (1.06e-2)" "unprognostic (1.39e-2)" "unprognostic (1.75e-2)" 6.4 7.1 4.1 5.3 5.3 7.2 15.8 4.4 4.8 6.0 6.2 3.4 7.7 5.7 6.0 8.2 7.0 6.1 4.4 30.1 4.7 2.9 6.7 12.8 8.5 15.5 4.5 2.7 9.1 20.7 3.9 6.5 3.5 6.4 5.8 6.1 3.9 7.3 7.0 11.4 12.0 6.7 8.7 7.2 6.7 6.2 16.1 3.8 2.5 8.2 5.4 7.2 6.9 4.0 0.2 0.0 0.8 0.7 0.5 2.0 0.1 1.4 4.9 2.4 3.8 1.6 1.3 2.6 3.0 1.5 1.9 4.7 4.2 7.4 2.6 3.0 0.6 4.7 3.1 3.5 2.3 1.8 3.1 1.2 14.0 2.3 1.3 2.8 3.2 2.4 1.6 3.1 3.0 1.7 1.1 4.8 1.3 2.0 3.7 6.0 1.1 0.8 3.9 2.5 6.0 2.4 2.0 1.2 1.8 2.1 1.2 2.1 2.1 1.3 1.8 2.2 3.8 2.1 2.2 10.5 4.5 5.1 4.2 3.4 3.1 0.0 0.6 0.8 1.1 0.0 2.0 0.2 1.2 0.4 0.0 0.1 0.2 1.4 0.0 0.5 0.7 0.0 0.0 0.1 4.1 5.3 4.4 4.8 4.7 2.9 4.5 2.7 6.4 3.8 MUC1 "ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM" ENSG00000185499 "Mucin 1, cell surface associated" P15941 1 155185824-155192916 "Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 168.1;kidney: 158.5;lung: 143.5" "Group enriched" "Detected in many" 7 "CAPAN-2: 139.8;RPTEC TERT1: 107.3;T-47d: 47.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in some" "Cell type enhanced" "Detected in some" "T-reg: 4.0" "Group enriched" "Detected in many" 10 "granulocytes: 1.3;T-cells: 4.0" "CAB000036, CAB001986, HPA004179, HPA007235, HPA008855" Enhanced Supported "Plasma membrane" "Secreted in other tissues" 4900000 "Plasma membrane" "CAB000036: AB_2148557, CAB001986: , HPA004179: AB_1846282, HPA007235: AB_1846281, HPA008855: AB_1846283" "unprognostic (4.74e-2)" "unprognostic (2.84e-2)" "unprognostic (2.19e-1)" "unprognostic (8.01e-2)" "unprognostic (1.32e-2)" "unprognostic (1.70e-1)" "unprognostic (2.61e-3)" "unprognostic (6.34e-2)" "unprognostic (1.43e-1)" "unprognostic (3.23e-1)" "prognostic unfavourable (4.60e-4)" "unprognostic (4.75e-1)" "unprognostic (2.05e-2)" "unprognostic (1.13e-1)" "unprognostic (8.12e-2)" "unprognostic (1.42e-1)" "unprognostic (1.21e-1)" 1.5 0.7 0.8 12.6 1.2 0.9 12.6 0.4 0.7 31.6 15.9 1.2 2.4 2.9 10.5 9.8 51.8 18.7 168.1 0.8 0.5 0.3 158.5 2.0 143.5 0.3 0.5 0.3 14.9 74.2 0.0 4.7 15.5 2.1 6.1 16.1 0.8 17.0 5.9 0.8 1.8 3.6 2.8 0.7 0.6 105.0 4.3 0.5 0.7 15.7 10.5 47.8 12.3 5.2 0.0 0.2 1.3 0.1 0.0 4.0 0.2 1.8 0.9 0.6 0.5 0.4 0.5 0.2 0.6 1.5 0.7 1.9 0.0 139.8 0.0 10.2 1.1 2.8 0.1 0.0 0.2 1.2 0.1 0.2 11.8 0.0 0.3 0.0 4.4 1.2 0.2 0.3 0.2 0.2 1.0 1.9 0.5 14.2 0.1 0.1 0.4 0.2 0.2 0.0 3.4 107.3 0.1 0.6 0.2 3.4 5.9 0.1 47.1 0.6 0.2 0.4 0.8 1.3 0.1 2.2 1.1 0.0 0.7 0.1 0.1 1.3 0.1 0.0 0.0 0.0 0.8 0.0 2.3 0.4 0.2 0.0 0.3 0.7 0.0 0.0 0.0 0.0 4.0 0.2 0.8 1.2 0.4 0.7 0.5 0.3 0.5 0.3 2.1 0.5 MYB c-myb ENSG00000118513 "MYB proto-oncogene, transcription factor" P10242 6 135181315-135219173 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "lymphoid tissue: 104.9" "Cell line enhanced" "Detected in many" "HL-60: 38.9;MOLT-4: 70.8;NB-4: 36.9;REH: 43.7;THP-1: 61.8;U-937: 33.7" "Cancer enhanced" "Detected in many" "breast cancer: 17.7" "Region enhanced" "Detected in some" "basal ganglia: 4.7" "Group enriched" "Detected in some" 4 "basophil: 5.6;eosinophil: 10.0" "Lineage enriched" "Detected in many" 6 "granulocytes: 10.0" "Low region specificity" "Detected in some" "Low region specificity" "Detected in some" "CAB017704, HPA071605" Approved Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB017704: , HPA071605: " "unprognostic (1.69e-1)" "unprognostic (5.82e-2)" "unprognostic (1.82e-3)" "unprognostic (1.37e-2)" "unprognostic (4.06e-1)" "unprognostic (8.35e-3)" "unprognostic (1.13e-3)" "unprognostic (2.48e-2)" "unprognostic (6.44e-2)" "unprognostic (1.00e-1)" "unprognostic (3.71e-2)" "prognostic favourable (9.65e-4)" "unprognostic (2.41e-11)" "prognostic favourable (9.87e-4)" "unprognostic (8.35e-2)" "unprognostic (3.04e-2)" "unprognostic (9.40e-2)" 0.5 0.7 1.3 9.1 4.7 18.9 13.2 0.3 0.6 1.4 15.4 0.5 0.3 6.5 0.9 1.0 3.7 5.0 1.7 0.6 0.7 0.7 0.4 0.5 1.8 3.3 0.3 0.5 1.0 0.3 0.4 0.3 0.6 0.5 1.6 16.7 0.5 0.8 1.5 1.0 3.5 5.9 0.7 0.4 1.4 0.9 2.0 0.6 104.9 0.4 2.0 4.7 0.7 1.5 0.1 1.7 10.0 0.8 0.0 0.5 0.1 0.3 0.0 0.3 0.5 0.0 0.0 0.0 0.1 0.0 0.2 0.1 0.0 0.2 1.8 0.0 0.0 0.1 1.0 0.0 0.1 3.1 0.4 24.8 0.1 0.0 0.0 38.9 19.6 0.0 0.0 0.1 0.0 0.0 20.1 3.7 0.2 2.0 70.8 36.9 0.2 0.3 43.7 1.0 6.0 0.0 0.2 1.9 1.2 0.0 1.9 0.0 1.4 61.8 0.0 0.0 0.3 1.4 0.4 4.7 1.2 12.0 0.0 33.7 0.4 5.6 0.8 10.0 0.0 0.1 0.2 0.0 0.0 0.0 0.2 0.1 0.1 0.2 0.0 0.0 0.0 1.7 0.5 0.1 1.3 4.7 0.3 0.6 0.7 0.7 0.3 0.5 0.5 0.6 MYC "bHLHe39, c-Myc, MYCC" ENSG00000136997 "MYC proto-oncogene, bHLH transcription factor" P01106 8 127735434-127741434 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "RPMI-8226: 129.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB000084, CAB010307, HPA055893, HPA066556" Approved Enhanced Nucleoplasm Nucleoplasm "CAB000084: , CAB010307: AB_631274, HPA055893: , HPA066556: " "unprognostic (1.45e-2)" "unprognostic (4.00e-3)" "unprognostic (3.94e-3)" "unprognostic (2.41e-3)" "unprognostic (8.14e-2)" "unprognostic (3.36e-3)" "unprognostic (5.80e-2)" "unprognostic (4.94e-3)" "unprognostic (1.59e-1)" "prognostic unfavourable (7.52e-4)" "unprognostic (5.19e-3)" "unprognostic (9.86e-3)" "prognostic unfavourable (5.49e-8)" "unprognostic (7.85e-2)" "unprognostic (4.66e-2)" "unprognostic (2.48e-1)" "prognostic unfavourable (4.96e-5)" 67.4 20.8 3.2 46.6 7.1 16.3 36.0 1.2 5.0 23.9 23.3 3.8 11.8 11.1 23.8 14.4 47.6 59.5 32.4 23.7 5.8 2.2 11.2 36.6 16.0 40.5 5.8 1.2 38.7 64.6 2.1 7.4 14.9 9.8 20.6 11.3 6.1 14.4 21.8 69.6 78.5 17.2 21.3 12.0 38.3 24.7 16.3 3.8 40.2 9.0 48.4 27.1 28.9 37.3 25.5 8.8 1.0 10.3 20.9 55.2 22.0 7.1 13.8 1.2 12.3 20.0 23.7 3.6 8.6 3.7 10.7 9.0 18.8 18.7 72.9 12.0 5.1 15.5 63.9 27.8 7.1 17.2 22.3 43.9 23.4 24.5 18.4 30.7 7.0 16.5 61.5 7.2 57.0 12.3 64.8 38.6 5.3 20.5 50.1 66.8 3.4 27.6 27.9 5.2 129.7 9.0 7.4 84.9 8.0 4.0 33.5 22.2 13.6 20.2 14.9 8.1 9.6 6.2 10.7 0.7 1.2 35.2 7.1 34.3 4.0 0.7 10.3 0.1 8.6 9.1 43.4 25.5 31.1 18.6 8.8 20.6 55.2 34.8 1.0 20.9 6.1 0.3 24.8 22.0 3.2 7.1 1.2 3.6 5.8 2.2 5.8 1.2 9.8 3.8 MYH11 "SMHC, SMMHC" ENSG00000133392 "Myosin heavy chain 11" P35749 16 15703172-15857033 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Actin-binding, Calmodulin-binding, Motor protein, Muscle protein, Myosin" "Aortic aneurysm, Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "smooth muscle: 507.4;urinary bladder: 394.5" "Cell line enhanced" "Detected in some" "BEWO: 3.5;NB-4: 3.8;U-698: 9.7" "Cancer enhanced" "Detected in many" "prostate cancer: 173.2" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Region enhanced" "Detected in many" "midbrain: 54.5" "CAB002302, HPA014539, HPA015310" Enhanced Supported "Plasma membrane,Cytosol" 130000000 "Plasma membrane, Cytosol" "CAB002302: AB_563902, HPA014539: AB_1854260, HPA015310: AB_1854261" "unprognostic (7.99e-2)" "unprognostic (3.07e-2)" "unprognostic (4.18e-2)" "unprognostic (9.21e-3)" "unprognostic (6.70e-2)" "unprognostic (2.75e-2)" "prognostic favourable (1.10e-5)" "unprognostic (1.41e-2)" "unprognostic (1.87e-1)" "unprognostic (3.44e-2)" "unprognostic (1.28e-1)" "unprognostic (1.14e-1)" "unprognostic (1.19e-3)" "unprognostic (4.06e-2)" "unprognostic (9.53e-2)" "unprognostic (5.00e-2)" "unprognostic (5.45e-3)" 13.2 3.0 0.6 31.5 1.2 0.0 5.9 0.5 1.7 90.3 227.5 1.3 100.0 11.6 102.0 38.4 233.0 43.8 94.3 6.2 0.6 0.7 4.7 0.7 8.5 1.5 1.4 2.6 45.5 1.3 0.0 1.0 5.3 3.6 164.7 22.2 37.0 8.8 127.2 6.4 5.0 50.6 507.4 1.4 3.7 77.7 22.3 0.2 0.1 3.7 6.2 3.0 394.5 57.5 1.5 0.9 6.0 0.9 1.1 1.5 0.4 0.1 0.4 0.2 0.1 0.0 0.0 3.5 0.1 0.0 0.0 0.0 0.0 0.3 0.1 0.2 0.0 0.6 0.0 0.0 0.0 0.4 0.4 0.2 0.1 0.0 0.0 0.1 1.0 0.0 0.0 0.0 0.0 0.0 0.1 1.5 0.0 0.3 0.3 3.8 0.4 0.1 0.4 0.1 1.9 0.0 0.2 0.7 1.4 0.2 0.5 1.2 0.4 0.0 0.3 0.1 0.3 2.0 0.1 0.4 0.4 9.7 0.4 0.4 0.4 3.1 0.9 2.7 1.2 0.6 1.2 1.5 1.5 1.4 0.5 1.2 1.4 1.4 6.0 1.1 0.6 0.9 1.4 0.4 0.6 1.2 0.5 1.7 0.6 0.7 1.4 2.6 3.6 0.2 MYH9 "DFNA17, EPSTS, FTNS, MHA, NMHC-II-A, NMMHCA" ENSG00000100345 "Myosin heavy chain 9" P35579 22 36281277-36388067 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell adhesion, Cell shape" "Actin-binding, Calmodulin-binding, Motor protein, Myosin" "Alport syndrome, Cancer-related genes, Cataract, Deafness, Disease mutation, Non-syndromic deafness" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001644, CAB015386, HPA064783" Enhanced Supported "Plasma membrane,Actin filaments,Cytosol" 3100000000 "Plasma membrane, Actin filaments" Cytosol "CAB015386: AB_784698, HPA001644: AB_1079439, HPA064783: AB_2732721" "unprognostic (1.38e-1)" "unprognostic (9.12e-2)" "unprognostic (4.21e-2)" "unprognostic (6.34e-2)" "unprognostic (1.49e-1)" "unprognostic (3.90e-2)" "unprognostic (9.56e-2)" "unprognostic (8.28e-2)" "unprognostic (5.50e-2)" "unprognostic (6.38e-2)" "unprognostic (1.93e-2)" "unprognostic (1.61e-1)" "unprognostic (7.98e-2)" "unprognostic (9.48e-2)" "unprognostic (1.64e-1)" "unprognostic (1.62e-1)" "unprognostic (2.59e-2)" 115.5 26.1 11.9 43.7 12.9 55.6 59.0 9.3 16.8 67.1 44.6 18.0 26.4 26.9 120.8 39.7 48.3 45.6 66.9 39.2 11.0 8.1 45.0 42.8 74.4 57.7 15.1 9.2 56.4 43.9 19.0 15.4 65.7 17.9 47.6 23.6 32.4 66.2 27.2 36.9 40.3 49.8 46.7 13.5 91.5 37.1 25.8 11.9 76.0 42.5 38.4 65.0 56.0 53.7 6.9 8.2 28.5 11.5 4.2 16.6 19.3 60.6 28.2 9.0 7.6 16.8 21.1 45.7 40.7 52.7 58.2 43.7 30.4 17.5 15.7 24.2 68.1 42.1 13.1 79.7 60.0 35.4 12.4 30.3 30.3 25.9 51.5 34.4 48.6 24.9 24.6 78.6 66.8 47.9 6.6 21.3 46.5 16.1 12.2 20.3 5.3 17.4 23.3 27.9 14.6 32.9 59.1 13.5 5.5 57.2 22.5 26.2 16.8 17.8 137.0 129.1 39.2 24.7 73.5 14.1 11.1 13.3 48.9 17.4 37.4 26.8 10.4 28.5 16.6 9.6 14.7 6.9 12.0 13.2 8.2 6.4 9.6 10.1 19.7 4.2 11.5 3.8 12.6 19.3 11.9 12.9 9.3 16.8 11.0 8.1 15.1 9.2 17.9 11.9 MYO5A "GS1, MYH12, MYO5, MYR12" ENSG00000197535 "Myosin VA" Q9Y4I1 15 52307283-52529050 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Protein transport, Transport" "Actin-binding, Calmodulin-binding, Motor protein, Myosin" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 34.5;parathyroid gland: 47.6" "Cell line enhanced" "Detected in many" "Karpas-707: 58.9;RPMI-8226: 39.9" "Cancer enhanced" "Detected in all" "melanoma: 25.2" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001356 Enhanced Approved "Focal adhesion sites,Centriolar satellite" "Focal adhesion sites, Centriolar satellite" "HPA001356: AB_1079441" "unprognostic (1.54e-1)" "unprognostic (1.78e-1)" "unprognostic (6.95e-2)" "unprognostic (2.29e-2)" "unprognostic (1.97e-2)" "unprognostic (3.91e-2)" "unprognostic (2.30e-2)" "unprognostic (6.65e-2)" "unprognostic (7.89e-2)" "unprognostic (4.74e-2)" "unprognostic (9.36e-3)" "unprognostic (1.71e-1)" "unprognostic (5.63e-3)" "unprognostic (3.79e-3)" "unprognostic (1.24e-1)" "unprognostic (7.16e-2)" "prognostic unfavourable (4.22e-4)" 8.4 7.1 16.6 9.5 27.5 15.7 5.5 27.4 34.5 6.2 4.4 7.8 0.4 3.3 4.2 3.2 5.0 3.6 7.3 4.6 15.9 15.4 4.6 2.7 7.3 11.2 15.6 17.6 5.4 4.3 47.6 10.5 5.2 29.3 4.5 5.2 9.9 4.0 3.4 4.1 10.4 3.9 7.7 10.1 7.3 4.1 4.6 7.1 3.1 6.8 2.7 10.3 7.3 4.2 2.3 5.2 6.3 4.4 0.7 4.5 1.9 5.4 9.6 5.1 6.1 5.2 6.4 5.5 9.9 9.0 5.3 4.2 0.9 2.2 5.2 2.6 11.8 4.5 11.7 10.2 6.6 29.4 2.7 4.8 2.5 1.1 2.7 2.5 4.7 4.2 6.4 7.8 15.5 30.8 0.1 58.9 10.2 9.6 2.2 0.3 2.3 7.7 4.1 8.2 39.9 4.4 3.9 3.8 2.2 9.2 7.6 18.0 4.0 2.8 14.7 10.7 4.6 5.0 9.6 6.1 13.5 6.3 11.7 7.3 15.4 0.9 4.4 5.4 2.9 3.6 4.5 2.3 2.9 1.9 5.2 1.6 0.5 1.0 6.3 0.7 2.6 3.1 4.1 1.9 16.6 27.5 27.4 34.5 15.9 15.4 15.6 17.6 29.3 7.1 NAB2 MADER ENSG00000166886 "NGFI-A binding protein 2" Q15742 12 57088894-57095476 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" Repressor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004510, HPA027464" Approved Approved Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB004510: AB_627982, HPA027464: AB_10601138" "prognostic favourable (7.41e-4)" "unprognostic (4.04e-2)" "unprognostic (2.20e-3)" "unprognostic (2.43e-2)" "unprognostic (4.74e-2)" "unprognostic (2.10e-1)" "unprognostic (1.88e-3)" "unprognostic (1.80e-1)" "unprognostic (5.85e-2)" "unprognostic (1.19e-1)" "unprognostic (2.13e-1)" "unprognostic (6.98e-2)" "prognostic unfavourable (9.38e-6)" "unprognostic (1.95e-1)" "unprognostic (9.76e-2)" "unprognostic (5.67e-3)" "unprognostic (6.19e-3)" 9.5 12.6 11.7 9.9 14.2 4.8 7.9 33.3 20.4 18.7 13.7 5.3 9.6 8.2 22.8 18.9 10.5 15.6 14.5 9.6 8.6 6.8 8.4 18.7 12.8 9.1 4.4 14.6 29.2 8.5 14.5 17.0 13.4 6.8 15.0 4.4 8.5 5.6 14.5 7.1 18.6 7.1 14.5 4.1 8.0 8.2 11.8 7.0 12.4 9.8 7.7 8.6 14.5 26.5 4.2 1.2 0.9 5.4 0.9 2.5 1.2 5.5 3.5 18.7 17.1 16.8 22.0 2.0 16.6 15.0 10.5 8.8 5.7 3.2 3.5 6.8 16.3 10.0 6.4 12.2 5.6 1.4 1.7 4.1 2.7 5.8 12.8 3.3 10.0 24.5 13.5 12.5 4.3 2.8 9.4 3.6 12.2 25.7 5.0 16.1 3.8 6.2 3.7 24.6 1.8 4.5 2.1 2.1 4.9 8.0 4.7 34.9 10.5 7.3 3.1 15.5 13.0 11.0 4.8 8.6 2.1 1.8 15.1 2.2 9.3 0.0 2.3 0.3 1.2 5.3 1.4 2.1 2.0 1.5 1.2 4.2 2.5 2.5 0.9 0.9 5.4 0.0 1.9 1.2 11.7 14.2 33.3 20.4 8.6 6.8 4.4 14.6 6.8 7.0 NCOA1 "bHLHe74, F-SRC-1, KAT13A, NCoA-1, RIP160, SRC1" ENSG00000084676 "Nuclear receptor coactivator 1" Q15788 2 24491914-24770702 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Acyltransferase, Transferase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "RH-30: 40.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB019402, HPA070213, HPA070520" Supported Enhanced "Nucleoplasm,Plasma membrane,Cytosol" Nucleoplasm "Plasma membrane, Cytosol" "CAB019402: AB_2196189, HPA070213: , HPA070520: " "unprognostic (2.73e-1)" "unprognostic (5.82e-2)" "unprognostic (2.46e-2)" "unprognostic (9.89e-3)" "unprognostic (7.60e-2)" "unprognostic (2.36e-2)" "unprognostic (7.06e-3)" "unprognostic (1.45e-1)" "unprognostic (1.43e-1)" "unprognostic (1.72e-1)" "unprognostic (2.93e-3)" "unprognostic (1.16e-1)" "unprognostic (2.10e-2)" "unprognostic (7.15e-2)" "unprognostic (3.08e-1)" "unprognostic (1.29e-1)" "unprognostic (2.92e-2)" 9.8 10.0 15.3 7.3 18.0 8.9 10.5 15.9 17.1 13.7 8.9 13.5 4.9 12.5 13.0 11.5 10.8 10.0 8.3 8.8 20.8 12.2 11.9 8.8 9.4 8.2 10.8 9.9 17.2 10.3 23.9 16.0 10.1 14.2 9.6 10.1 19.9 10.6 13.0 42.5 9.3 10.9 11.6 9.7 9.6 7.6 11.4 10.7 8.5 7.0 12.2 9.3 9.7 10.8 2.5 5.5 14.2 3.5 3.4 4.1 1.8 6.6 4.9 8.7 4.5 9.6 8.8 13.3 3.5 7.1 4.5 4.0 4.6 2.8 4.8 1.5 6.4 1.6 5.2 3.0 4.9 22.8 7.5 17.2 2.0 1.9 6.0 7.9 14.4 14.0 4.6 4.3 3.5 4.5 10.4 8.0 6.8 4.4 7.0 2.8 4.1 3.3 5.5 40.1 2.4 4.9 9.0 8.0 6.3 8.2 5.0 3.6 6.0 4.0 4.9 7.5 5.9 5.1 3.5 9.3 8.0 8.4 4.3 5.0 3.7 11.0 3.5 6.9 3.8 2.7 4.1 1.8 3.4 4.1 2.6 2.5 3.3 4.0 14.2 3.4 2.8 5.5 3.7 1.8 15.3 18.0 15.9 17.1 20.8 12.2 10.8 9.9 14.2 10.7 NCOA2 "bHLHe75, GRIP1, KAT13C, NCoA-2, TIF2" ENSG00000140396 "Nuclear receptor coactivator 2" Q15596 8 70109762-70403805 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" Activator "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA060243 Supported "Nucleoplasm,Nuclear bodies" "Nucleoplasm, Nuclear bodies" "HPA060243: " "unprognostic (9.79e-3)" "unprognostic (1.40e-1)" "unprognostic (2.72e-1)" "unprognostic (4.94e-3)" "unprognostic (1.91e-2)" "unprognostic (2.18e-3)" "unprognostic (1.30e-1)" "unprognostic (6.77e-2)" "unprognostic (2.06e-1)" "unprognostic (7.00e-2)" "unprognostic (2.20e-2)" "unprognostic (2.63e-2)" "prognostic favourable (5.08e-4)" "unprognostic (2.52e-1)" "unprognostic (3.35e-1)" "unprognostic (1.07e-1)" "unprognostic (1.76e-1)" 13.6 13.2 16.9 13.1 14.0 22.5 14.9 19.2 14.0 13.9 17.3 10.1 49.7 12.4 16.6 33.6 20.0 12.5 12.6 15.8 13.9 13.0 16.4 25.5 15.5 16.9 10.8 11.4 18.5 9.7 23.4 17.1 16.2 10.0 14.8 11.8 15.3 14.8 21.7 13.2 14.9 28.8 19.2 9.6 14.5 11.7 15.5 12.9 15.3 13.4 10.3 13.8 18.9 17.2 3.8 2.5 9.4 7.8 2.1 3.8 1.6 8.6 10.8 11.9 6.7 10.8 11.2 12.2 5.0 5.0 3.8 3.7 5.5 10.0 10.2 2.0 9.1 5.1 14.6 6.9 4.3 24.2 11.6 17.9 5.5 8.7 5.7 3.6 4.8 9.7 7.7 5.2 7.5 2.6 5.6 15.7 4.4 8.6 8.9 3.6 6.2 5.1 8.8 5.0 6.4 6.1 14.4 9.1 6.7 8.6 4.6 7.1 10.9 6.6 3.4 5.6 7.1 7.0 2.6 20.7 10.5 10.0 5.7 4.8 8.1 4.5 2.5 3.5 3.8 3.9 2.8 2.2 2.3 3.3 2.5 3.8 2.8 2.7 9.4 2.1 7.8 1.1 3.2 1.6 16.9 14.0 19.2 13.5 13.9 13.0 10.8 11.4 10.0 12.9 NCOA4 "ARA70, DKFZp762E1112, ELE1, PTC3, RFG" ENSG00000266412 "Nuclear receptor coactivator 4" Q13772 10 46005088-46030714 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" Activator "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 100.1" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Group enriched" "Detected in all" 4 "dendritic cells: 30.2;granulocytes: 100.1;monocytes: 40.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA051260, HPA065208" Uncertain Approved "Nucleoli,Golgi apparatus,Cytosol" Nucleoli "Golgi apparatus, Cytosol" "HPA051260: , HPA065208: " "unprognostic (4.23e-2)" "unprognostic (1.50e-1)" "unprognostic (2.44e-2)" "unprognostic (1.82e-1)" "prognostic favourable (3.26e-4)" "unprognostic (1.34e-1)" "unprognostic (1.80e-1)" "unprognostic (9.34e-2)" "unprognostic (4.67e-2)" "unprognostic (5.22e-2)" "unprognostic (9.16e-2)" "unprognostic (2.04e-2)" "prognostic favourable (8.04e-6)" "unprognostic (1.35e-1)" "unprognostic (4.71e-3)" "unprognostic (1.14e-1)" "unprognostic (2.78e-1)" 18.5 6.9 5.5 9.5 10.0 17.4 10.0 5.5 11.3 10.8 22.5 13.6 5.9 27.0 9.9 9.4 17.0 6.3 9.0 16.6 5.7 20.8 40.9 11.6 11.6 8.7 7.1 11.0 9.1 9.3 9.6 28.4 13.5 14.7 12.4 9.9 12.6 8.5 15.5 6.8 36.4 11.2 9.7 23.8 8.9 6.4 8.1 26.8 13.2 13.9 16.3 13.0 6.4 7.3 30.2 100.1 40.4 13.4 10.9 53.9 31.3 13.3 15.6 16.0 41.4 37.6 39.1 28.8 46.7 28.5 27.9 20.4 23.2 35.4 34.7 47.1 32.0 16.3 31.7 31.7 25.0 16.8 23.9 18.3 58.5 29.1 60.8 53.4 36.5 31.8 24.2 40.7 41.8 26.0 21.4 38.7 14.0 29.5 22.8 9.4 7.8 17.5 22.7 21.2 34.1 26.7 15.7 10.6 29.1 33.3 28.8 24.0 29.9 38.5 17.6 21.2 18.6 19.4 15.9 17.0 35.2 22.0 51.2 9.3 69.1 40.4 70.7 10.0 26.8 10.9 7.3 9.4 9.5 30.2 6.6 10.2 8.6 100.1 13.4 30.4 9.3 10.8 53.9 NDRG1 "CAP43, DRG1, NDR1, RTP, TDD5" ENSG00000104419 "N-myc downstream regulated 1" Q92597 8 133237171-133302022 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Charcot-Marie-Tooth disease, Neurodegeneration, Neuropathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "hTCEpi: 69.0;hTERT-HME1: 139.1;U-87 MG: 93.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA006881 Approved Supported Microtubules,Cytosol Cytosol Microtubules "HPA006881: AB_1078392" "unprognostic (6.96e-3)" "unprognostic (3.31e-3)" "unprognostic (8.53e-2)" "unprognostic (1.41e-3)" "unprognostic (1.54e-3)" "unprognostic (2.60e-2)" "prognostic unfavourable (1.47e-4)" "unprognostic (3.04e-3)" "unprognostic (5.33e-2)" "unprognostic (4.29e-2)" "unprognostic (9.09e-2)" "unprognostic (2.46e-1)" "prognostic unfavourable (4.13e-4)" "unprognostic (7.27e-2)" "unprognostic (1.91e-1)" "unprognostic (2.47e-3)" "unprognostic (4.28e-2)" 43.9 23.6 42.0 17.0 80.9 18.0 29.8 6.4 36.2 33.1 47.7 73.2 24.2 74.2 20.9 20.6 83.0 24.7 26.8 22.2 48.7 32.9 62.6 12.1 31.0 11.4 96.3 19.8 37.5 16.7 17.8 18.6 32.5 50.0 115.0 22.4 16.2 29.0 26.4 13.2 56.9 78.2 19.2 102.0 11.5 45.7 15.0 74.3 10.3 21.4 40.0 34.9 58.7 64.9 1.9 12.2 8.9 4.1 1.3 9.3 2.9 21.5 2.7 0.1 0.1 13.7 9.6 2.9 1.5 11.8 1.1 6.1 1.3 3.0 0.1 15.5 6.4 7.0 0.2 34.0 2.4 1.3 25.5 0.2 5.5 1.6 5.2 0.7 0.5 8.9 69.0 5.8 139.1 5.1 0.2 15.1 1.9 1.2 2.0 2.1 0.3 17.9 0.2 2.4 10.0 3.5 3.2 1.6 1.6 3.3 35.7 8.6 0.1 2.3 6.6 9.7 5.0 4.2 1.2 11.3 29.6 0.1 93.6 8.1 19.0 8.9 4.1 0.0 6.3 3.7 9.3 1.7 5.9 7.5 6.1 1.9 4.6 3.1 4.2 1.3 4.0 12.2 8.0 2.9 42.0 80.9 6.4 36.2 48.7 32.9 96.3 19.8 50.0 74.3 NFATC2 "NF-ATP, NFAT1, NFATp" ENSG00000101096 "Nuclear factor of activated T cells 2" Q13469 20 51386957-51562831 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 44.6" "Cell line enhanced" "Detected in many" "HDLM-2: 14.2;HMC-1: 16.3;WM-115: 24.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA008789, CAB018567, HPA024369" Enhanced Supported Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB018567: AB_628012, HPA008789: AB_1079474, HPA024369: AB_1854413" "unprognostic (2.69e-3)" "unprognostic (2.92e-2)" "unprognostic (2.31e-1)" "unprognostic (1.58e-2)" "unprognostic (1.15e-1)" "unprognostic (1.26e-2)" "unprognostic (3.94e-2)" "unprognostic (4.05e-2)" "unprognostic (9.26e-2)" "unprognostic (3.74e-3)" "unprognostic (2.17e-2)" "unprognostic (4.86e-2)" "prognostic unfavourable (1.57e-4)" "unprognostic (9.25e-2)" "unprognostic (1.02e-1)" "unprognostic (1.05e-2)" "unprognostic (6.59e-2)" 8.6 2.4 4.1 44.6 8.2 4.4 9.8 1.1 5.1 8.4 7.8 6.8 3.9 8.4 7.0 7.6 4.0 5.6 19.4 8.5 4.1 3.3 3.4 6.7 6.1 25.2 8.4 0.7 5.0 8.7 3.9 3.7 8.1 10.4 5.4 4.1 6.2 7.9 7.2 5.4 7.0 11.7 5.9 6.5 16.0 11.0 4.5 6.5 8.6 7.0 13.2 18.7 4.5 4.9 1.6 1.7 3.8 0.7 7.6 7.7 1.6 1.5 1.7 0.0 2.1 0.0 0.0 4.5 0.2 1.1 0.7 0.3 8.2 1.5 10.9 1.3 0.5 0.0 0.5 0.0 0.6 14.2 0.2 4.6 1.2 2.1 0.0 1.3 16.3 0.0 0.0 0.6 0.0 5.0 4.5 7.3 0.0 1.8 1.9 7.7 0.1 3.9 0.8 0.0 4.8 0.2 0.0 0.1 0.0 5.1 1.2 11.9 2.0 3.1 0.5 1.0 1.9 2.5 0.1 6.2 4.0 11.2 1.0 5.1 24.5 0.3 0.0 3.8 7.7 0.7 3.2 1.6 4.3 6.1 1.7 1.6 2.4 4.4 0.2 7.6 0.2 0.6 2.3 1.6 4.1 8.2 1.1 5.1 4.1 3.3 8.4 0.7 10.4 6.5 NFIB "NFI-RED, NFIB2, NFIB3" ENSG00000147862 "Nuclear factor I B" O00712 9 14081843-14398983 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "DNA replication, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "AN3-CA: 53.9;HBEC3-KT: 21.8;HUVEC TERT2: 21.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 2.4" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA003956 Supported Supported "Nucleoplasm,Nucleoli fibrillar center" "Nucleoplasm, Nucleoli fibrillar center" "HPA003956: AB_1854424" "unprognostic (1.93e-1)" "unprognostic (3.18e-2)" "unprognostic (4.00e-1)" "unprognostic (2.16e-3)" "unprognostic (1.12e-1)" "unprognostic (2.55e-2)" "unprognostic (1.32e-1)" "unprognostic (4.72e-3)" "unprognostic (7.46e-2)" "unprognostic (9.35e-2)" "unprognostic (3.68e-1)" "unprognostic (1.12e-1)" "prognostic favourable (3.53e-4)" "unprognostic (4.69e-1)" "unprognostic (2.39e-1)" "unprognostic (1.87e-2)" "unprognostic (1.62e-1)" 29.3 9.5 22.6 9.2 12.9 1.0 39.7 30.0 22.9 14.8 17.0 13.6 34.1 11.3 16.8 22.3 11.5 17.0 18.0 24.1 22.0 9.3 18.8 22.3 16.3 9.8 10.8 15.5 18.7 17.5 8.2 6.0 14.7 13.7 21.3 10.4 9.2 40.0 41.3 20.8 23.6 16.8 24.2 14.9 10.4 14.2 7.6 15.6 2.7 18.8 13.9 7.7 27.4 23.4 0.3 0.3 2.4 0.4 0.5 1.0 1.3 6.3 4.5 2.8 53.9 13.6 7.9 0.1 0.1 0.0 1.3 4.7 0.0 2.6 0.1 4.2 0.4 1.4 2.6 21.8 2.3 0.9 2.6 19.4 10.1 0.6 4.5 0.5 0.1 6.8 3.0 4.9 18.1 21.8 0.6 0.1 1.8 2.9 0.0 0.1 1.0 5.3 0.0 2.5 0.0 4.0 2.3 4.5 16.8 4.6 5.7 1.8 11.5 0.0 21.2 4.2 6.3 3.2 4.0 0.5 0.4 1.5 3.7 0.0 5.3 1.3 0.1 0.2 0.3 0.2 1.0 0.2 0.2 0.2 0.1 0.3 0.2 0.1 2.4 0.5 0.4 0.3 0.5 1.3 22.6 12.9 30.0 18.8 22.0 9.3 10.8 15.5 13.7 15.6 NFKB2 "LYT-10, NF-kB2, p105, p49/p100, p52" ENSG00000077150 "Nuclear factor kappa B subunit 2" Q00653 10 102394110-102402529 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HDLM-2: 49.5;Karpas-707: 54.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008422, CAB022098, HPA023900" Enhanced Approved Nucleoplasm,Cytosol Cytosol Nucleoplasm "CAB022098: , HPA008422: AB_1854434, HPA023900: AB_1854435" "unprognostic (1.10e-2)" "unprognostic (1.43e-1)" "prognostic unfavourable (3.86e-4)" "unprognostic (1.53e-2)" "unprognostic (8.08e-3)" "unprognostic (2.15e-1)" "unprognostic (2.38e-3)" "unprognostic (3.98e-2)" "prognostic favourable (8.45e-5)" "unprognostic (4.04e-1)" "unprognostic (8.34e-2)" "unprognostic (4.14e-2)" "prognostic unfavourable (6.69e-12)" "unprognostic (2.37e-3)" "unprognostic (1.63e-1)" "unprognostic (4.90e-2)" "unprognostic (1.56e-1)" 14.9 10.8 5.6 43.6 7.1 40.6 18.7 2.0 4.9 12.5 20.1 4.2 9.4 11.3 18.8 11.0 12.9 10.8 20.4 10.9 4.6 2.5 15.5 14.5 20.6 34.2 6.6 2.5 15.1 17.4 5.2 6.3 12.8 7.9 19.6 5.2 7.3 16.7 15.1 13.6 10.4 14.1 24.0 7.7 28.0 13.1 6.6 5.8 19.5 11.5 14.8 39.2 21.9 24.4 5.2 1.4 7.5 3.4 1.3 2.0 0.9 21.0 13.1 2.6 10.5 3.3 5.0 6.2 6.0 19.2 6.1 8.9 7.8 17.3 9.7 15.0 3.6 12.8 6.0 8.2 2.4 49.5 3.5 2.4 3.2 4.5 9.2 1.6 14.1 6.9 4.0 10.2 10.1 2.1 2.3 54.1 2.3 7.2 2.4 6.6 3.3 4.7 5.3 7.3 7.7 10.3 6.2 0.5 2.9 4.9 11.9 8.4 9.2 4.7 6.3 6.3 9.3 8.9 15.9 35.8 33.1 10.2 10.3 4.2 3.3 0.3 2.4 0.1 1.4 1.5 1.4 5.2 1.7 1.5 1.4 4.5 1.8 1.5 7.5 1.3 3.4 0.9 2.0 0.9 5.6 7.1 2.0 4.9 4.6 2.5 6.6 2.5 7.9 5.8 NIN ENSG00000100503 Ninein Q8N4C6 14 50719763-50831121 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Disease mutation, Dwarfism, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA005939, HPA070691" Approved Enhanced Nucleoplasm,Nucleoli,Centrosome Centrosome "Nucleoplasm, Nucleoli" "HPA005939: , HPA070691: " "unprognostic (1.98e-1)" "unprognostic (1.06e-1)" "unprognostic (3.54e-2)" "unprognostic (3.96e-1)" "unprognostic (1.52e-1)" "unprognostic (1.43e-2)" "unprognostic (3.41e-2)" "unprognostic (3.31e-1)" "unprognostic (5.81e-3)" "unprognostic (1.78e-2)" "unprognostic (2.07e-1)" "unprognostic (4.06e-1)" "unprognostic (2.46e-2)" "unprognostic (2.67e-1)" "unprognostic (1.28e-1)" "unprognostic (2.58e-2)" "unprognostic (7.66e-3)" 13.0 6.1 15.1 24.9 10.3 34.8 9.7 12.6 14.0 8.0 9.2 7.6 4.5 5.0 11.8 6.1 11.8 8.2 7.6 16.4 11.7 4.9 6.7 5.2 10.7 30.2 7.6 10.0 11.0 5.4 9.1 12.3 20.2 7.1 6.5 7.7 6.2 8.2 5.1 16.9 10.9 8.3 12.0 7.1 18.2 9.3 4.6 9.0 16.4 7.8 5.1 25.8 11.7 10.3 6.8 6.3 18.4 2.3 1.5 6.0 1.3 12.2 8.7 18.1 15.4 7.0 11.2 7.6 10.5 9.1 8.9 7.5 5.6 6.5 28.8 7.2 14.1 12.9 14.5 6.6 18.7 13.9 4.5 10.6 5.3 5.3 4.1 18.4 30.6 7.7 5.3 15.5 6.4 14.1 2.6 11.8 13.4 13.4 13.9 7.4 2.5 9.6 15.8 33.5 2.0 8.0 13.9 8.4 9.5 13.2 4.0 11.3 7.5 16.4 20.5 22.6 31.4 8.6 11.6 9.5 4.8 19.9 5.9 15.0 12.2 12.6 2.3 18.4 3.3 1.7 3.5 6.8 2.2 6.0 1.5 5.5 4.4 3.8 8.3 1.5 1.5 6.3 1.9 1.3 15.1 10.3 12.6 14.0 11.7 4.9 7.6 10.0 7.1 9.0 NONO "NMT55, NRB54, P54, P54NRB, PPP1R114" ENSG00000147140 "Non-POU domain containing octamer binding" Q15233 X 71283192-71301168 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Biological rhythms, DNA damage, DNA recombination, DNA repair, Immunity, Innate immunity, mRNA processing, mRNA splicing, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor, RNA-binding" "Cancer-related genes, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB022069, HPA054094, HPA054559" Enhanced Enhanced "Nucleoplasm,Nucleoli fibrillar center,Nuclear speckles" 150000 Nucleoplasm "Nucleoli fibrillar center, Nuclear speckles" "CAB022069: , HPA054094: AB_2682376, HPA054559: AB_2682522" "unprognostic (2.39e-3)" "unprognostic (2.22e-2)" "unprognostic (2.64e-1)" "prognostic unfavourable (9.29e-4)" "unprognostic (8.87e-2)" "unprognostic (5.54e-2)" "unprognostic (1.02e-3)" "unprognostic (9.34e-2)" "unprognostic (2.32e-2)" "unprognostic (1.41e-2)" "unprognostic (3.12e-1)" "unprognostic (2.07e-1)" "unprognostic (7.29e-3)" "unprognostic (6.79e-2)" "unprognostic (5.73e-3)" "unprognostic (2.76e-2)" "unprognostic (3.04e-2)" 37.2 55.9 30.2 37.7 30.8 51.2 37.2 54.8 38.6 45.4 33.4 36.0 38.4 29.9 52.4 40.5 41.0 40.5 37.2 30.5 27.5 29.0 40.1 43.3 37.3 45.7 28.8 31.7 69.2 61.0 39.4 48.2 42.4 27.5 40.8 37.5 42.5 39.8 41.4 37.2 38.4 35.2 40.5 38.3 45.9 40.3 34.4 29.0 98.4 51.0 39.1 57.4 43.6 36.8 44.1 47.3 35.3 51.8 45.4 51.8 58.9 58.5 64.8 89.7 49.2 36.6 37.8 49.1 48.0 44.7 65.0 57.4 51.4 43.5 66.6 53.5 44.2 43.8 133.8 41.7 71.6 50.7 89.4 54.6 68.0 51.1 31.0 76.6 48.0 40.0 29.8 65.7 44.1 53.3 69.6 69.9 59.9 52.0 99.0 69.8 111.6 52.6 89.1 94.0 57.1 49.8 51.8 62.3 77.3 62.2 40.6 55.1 38.2 49.6 48.9 42.1 63.2 58.8 55.5 40.3 76.3 75.8 31.4 89.1 60.1 35.3 44.8 34.9 45.8 47.6 51.8 43.7 46.6 44.9 47.3 44.1 50.8 50.2 20.8 45.4 51.8 41.2 50.1 58.9 30.2 30.8 54.8 38.6 27.5 29.0 28.8 31.7 27.5 29.0 NOTCH1 TAN1 ENSG00000148400 "Notch 1" P46531 9 136494433-136545786 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters" "Angiogenesis, Differentiation, Notch signaling pathway, Transcription, Transcription regulation" "Activator, Developmental protein, Receptor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HaCaT: 24.5;HMC-1: 21.3;hTCEpi: 23.6;MOLT-4: 37.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 8.8" "Group enriched" "Detected in many" 4 "granulocytes: 8.8;NK-cells: 2.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008112, CAB022466, HPA067168" Supported Approved Nucleoplasm 8100000 Nucleoplasm "CAB008112: AB_2153490, CAB022466: , HPA067168: " "unprognostic (1.77e-1)" "unprognostic (2.65e-2)" "unprognostic (2.16e-1)" "unprognostic (8.38e-3)" "unprognostic (3.04e-1)" "unprognostic (1.13e-1)" "unprognostic (7.56e-2)" "unprognostic (1.02e-1)" "unprognostic (5.74e-3)" "unprognostic (5.50e-3)" "unprognostic (8.78e-2)" "unprognostic (8.50e-2)" "prognostic unfavourable (5.45e-4)" "unprognostic (2.14e-2)" "unprognostic (1.92e-1)" "unprognostic (5.65e-2)" "unprognostic (8.84e-2)" 20.0 4.0 10.0 14.5 10.4 14.6 12.8 3.8 18.8 12.8 14.2 19.9 8.2 9.8 11.2 5.1 13.3 9.6 13.1 9.6 10.7 5.8 9.4 7.2 17.4 13.7 11.6 7.5 9.2 17.8 3.7 5.6 8.5 9.3 12.1 5.7 10.4 14.2 11.8 8.2 32.3 10.8 7.7 6.6 20.7 8.6 4.1 9.9 34.8 9.4 10.2 10.9 12.3 22.2 0.6 1.1 8.8 1.0 2.7 1.3 0.9 4.4 7.3 6.1 3.0 0.2 0.5 7.6 2.2 0.6 1.3 0.4 1.0 0.5 5.9 4.6 1.7 24.5 2.0 10.0 0.2 13.5 1.1 3.3 3.0 0.4 3.4 3.5 21.3 0.3 23.6 1.7 3.7 7.8 1.4 1.1 0.8 7.9 37.4 5.7 5.1 3.4 7.7 4.9 11.0 0.9 3.7 0.0 0.4 3.2 3.4 1.4 2.1 5.6 11.5 3.2 4.7 3.1 2.4 1.2 1.0 2.4 2.2 2.5 16.5 0.7 1.0 2.8 1.3 0.4 0.8 0.4 0.6 1.0 0.6 0.6 0.4 1.1 8.8 2.7 0.4 1.1 0.4 0.9 10.0 10.4 3.8 11.7 10.7 5.8 11.6 7.5 9.3 9.9 NPM1 "B23, NPM" ENSG00000181163 "Nucleophosmin 1" P06748 5 171387116-171411137 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Host-virus interaction" "Chaperone, RNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA011384, CAB012983" Supported Enhanced Nucleoplasm,Nucleoli 810000 Nucleoli Nucleoplasm "CAB012983: AB_2533084, HPA011384: AB_1854692" "unprognostic (1.84e-3)" "unprognostic (2.59e-1)" "unprognostic (2.23e-2)" "unprognostic (3.30e-2)" "unprognostic (2.65e-1)" "prognostic unfavourable (7.48e-4)" "prognostic unfavourable (4.82e-6)" "unprognostic (1.86e-2)" "unprognostic (5.25e-3)" "unprognostic (1.39e-1)" "unprognostic (2.26e-3)" "unprognostic (1.27e-1)" "prognostic unfavourable (2.89e-6)" "unprognostic (2.19e-1)" "unprognostic (1.17e-1)" "unprognostic (1.52e-1)" "unprognostic (1.24e-2)" 56.8 44.7 29.9 61.1 33.6 76.0 67.0 37.7 34.6 113.5 57.8 24.8 39.3 36.7 78.2 50.5 81.6 65.0 44.0 48.5 28.8 31.6 64.9 78.8 59.5 128.1 36.1 27.9 177.4 102.0 27.1 57.9 65.2 36.1 87.2 49.3 29.5 47.3 48.2 67.9 42.7 52.8 92.4 43.2 85.9 54.0 56.7 31.3 111.3 112.6 66.5 82.1 116.8 65.7 85.3 54.1 12.3 29.1 59.0 126.6 91.4 118.4 80.2 97.5 138.1 59.6 108.9 145.4 107.8 98.5 146.1 131.6 191.5 83.7 317.2 85.7 62.3 69.5 135.3 245.1 190.4 98.7 107.3 111.9 78.7 141.0 88.4 225.3 92.8 96.0 86.4 99.1 195.6 109.0 136.0 73.0 106.0 147.1 147.0 160.3 122.0 98.6 132.0 107.6 162.6 124.6 83.6 76.9 61.8 64.4 105.4 195.1 129.3 100.0 68.0 48.9 107.8 56.2 181.5 58.5 106.3 190.8 73.9 183.5 97.4 12.3 26.9 8.4 45.7 29.1 84.6 85.3 85.1 66.2 54.1 62.8 126.6 99.0 4.0 59.0 23.1 48.7 73.2 91.4 29.9 33.6 37.7 34.6 28.8 31.6 36.1 27.9 36.1 31.3 NR4A3 "CHN, CSMF, MINOR, NOR1" ENSG00000119508 "Nuclear receptor subfamily 4 group A member 3" Q92570 9 99821855-99866891 "Cancer-related genes, Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "seminal vesicle: 80.6" "Group enriched" "Detected in some" 5 "BJ hTERT+: 21.0;HeLa: 7.3;SK-MEL-30: 14.5;U-266/70: 8.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "eosinophil: 1.3;NK-cell: 1.3" "Group enriched" "Detected in many" 6 "granulocytes: 1.3;NK-cells: 1.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA043360 Uncertain "HPA043360: AB_10961186" "prognostic favourable (5.97e-4)" "unprognostic (6.92e-3)" "unprognostic (5.34e-2)" "unprognostic (2.78e-3)" "unprognostic (1.40e-1)" "unprognostic (9.46e-2)" "unprognostic (2.89e-2)" "unprognostic (3.30e-2)" "unprognostic (2.65e-3)" "unprognostic (1.40e-2)" "unprognostic (2.28e-1)" "unprognostic (3.30e-1)" "unprognostic (2.25e-1)" "unprognostic (1.29e-3)" "unprognostic (6.11e-2)" "unprognostic (2.80e-2)" "unprognostic (1.69e-1)" 19.9 46.5 3.5 10.2 4.5 22.1 5.9 1.6 5.0 9.7 4.8 9.5 6.3 0.8 10.7 6.1 3.1 15.7 16.6 37.3 4.1 2.5 3.8 7.1 12.4 1.2 1.6 3.1 37.2 4.0 4.0 12.2 4.7 5.0 12.0 3.2 7.0 1.6 80.6 28.5 1.5 4.2 23.0 5.1 2.6 9.0 1.3 3.4 7.6 4.2 15.5 1.9 23.5 7.5 0.0 0.2 1.3 0.0 1.3 0.0 0.0 0.1 0.1 0.6 0.1 1.2 0.4 1.0 1.3 21.0 0.2 0.2 0.2 0.1 0.1 0.3 0.5 0.1 0.4 0.0 0.1 1.8 0.3 0.1 7.3 0.0 0.1 0.1 2.0 0.3 0.0 0.5 0.1 0.0 0.0 0.5 0.1 0.6 0.0 0.2 0.0 0.6 0.0 0.9 0.0 0.0 0.1 0.4 0.4 2.3 1.7 14.5 0.0 0.0 0.1 1.4 0.4 1.7 0.1 8.6 0.1 0.0 0.9 0.0 0.8 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.8 1.3 0.0 0.0 0.0 0.0 3.5 4.5 1.6 5.0 4.1 2.5 1.6 3.1 5.0 3.4 NRG1 "GGF, HGL, HRG, NDF, NRG1-IT2" ENSG00000157168 "Neuregulin 1" Q02297 8 31639386-32767959 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Growth factor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 28.3" "Cell line enhanced" "Detected in many" "A549: 38.9;BJ: 26.6;fHDF/TERT166: 29.8;HBF TERT88: 26.2;hTEC/SVTERT24-B: 27.9;hTERT-HME1: 29.3" "Cancer enhanced" "Detected in many" "head and neck cancer: 4.4" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 5 "classical monocyte: 22.8" "Lineage enriched" "Detected in many" 5 "monocytes: 22.8" "Low region specificity" "Detected in all" HPA010964 Uncertain Approved Nucleoplasm "Secreted to blood" Nucleoplasm "HPA010964: AB_1854641" "unprognostic (5.76e-3)" "unprognostic (8.60e-2)" "unprognostic (1.96e-4)" "unprognostic (2.67e-1)" "unprognostic (1.94e-4)" "unprognostic (4.99e-2)" "unprognostic (6.69e-2)" "unprognostic (7.72e-2)" "unprognostic (2.98e-1)" "unprognostic (5.65e-2)" "unprognostic (7.99e-2)" "unprognostic (8.49e-2)" "unprognostic (4.47e-2)" "unprognostic (1.31e-1)" "unprognostic (2.88e-1)" "unprognostic (5.40e-2)" "unprognostic (7.83e-2)" 0.7 2.1 4.6 5.0 3.3 1.2 8.8 14.8 8.1 10.6 4.2 0.3 2.1 3.5 2.5 1.1 3.7 2.0 4.8 2.2 4.7 15.4 11.5 23.6 5.7 0.6 6.2 3.5 2.9 0.9 0.8 23.9 0.2 28.3 3.2 5.4 3.6 2.5 1.6 0.2 4.3 5.7 1.1 2.5 1.7 3.1 6.4 0.8 0.2 13.8 7.2 2.2 7.2 3.5 0.0 4.9 0.8 22.8 0.0 0.0 4.6 0.1 38.9 0.7 0.0 0.3 0.8 0.0 26.6 18.9 22.1 16.9 0.0 0.8 0.0 4.9 29.8 21.0 0.2 10.6 26.2 0.0 0.2 0.5 0.5 0.5 0.1 0.0 0.0 0.3 1.1 27.9 29.3 12.7 0.0 0.1 7.9 0.0 0.0 0.0 0.9 0.0 0.0 0.2 0.0 16.3 1.1 1.1 1.3 2.0 0.0 0.0 0.0 0.0 9.2 15.4 4.7 24.5 14.8 0.0 0.0 0.2 7.9 0.0 1.8 0.0 22.8 0.2 0.0 2.1 0.0 0.0 0.0 0.0 4.9 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 4.6 4.6 3.3 14.8 8.1 4.7 15.4 6.2 3.5 28.3 0.8 NSD1 "ARA267, FLJ22263, KMT3B, STO" ENSG00000165671 "Nuclear receptor binding SET domain protein 1" Q96L73 5 177133025-177300215 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, Chromatin regulator, Methyltransferase, Repressor, Transferase" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA048431, HPA070333, HPA073705" Supported Supported "Nucleoplasm,Plasma membrane" "Nucleoplasm, Plasma membrane" "HPA048431: , HPA070333: , HPA073705: " "unprognostic (3.48e-2)" "unprognostic (7.46e-2)" "unprognostic (7.14e-3)" "unprognostic (2.64e-3)" "unprognostic (1.38e-1)" "unprognostic (9.67e-2)" "unprognostic (2.29e-2)" "unprognostic (7.08e-2)" "unprognostic (1.68e-3)" "unprognostic (8.04e-2)" "unprognostic (1.48e-1)" "unprognostic (2.09e-1)" "unprognostic (7.77e-3)" "unprognostic (3.53e-2)" "unprognostic (1.01e-1)" "unprognostic (7.51e-2)" "unprognostic (7.32e-2)" 11.8 13.2 11.9 25.4 15.7 23.9 14.0 28.9 16.7 15.6 14.2 18.5 17.0 10.6 19.0 13.9 17.8 13.6 15.8 11.7 12.8 11.5 14.4 10.5 12.3 19.4 12.9 11.7 16.6 27.1 24.6 19.3 16.0 13.4 14.2 14.3 13.8 13.5 18.7 20.6 16.1 14.5 15.6 13.2 16.1 13.1 28.1 16.1 27.3 20.1 10.6 22.7 13.4 20.2 10.2 8.9 18.7 10.8 10.9 7.8 2.9 9.7 12.6 13.1 11.3 6.4 8.3 0.4 8.8 8.9 12.4 11.6 2.8 8.2 20.1 10.0 12.1 8.4 20.8 19.6 15.1 34.0 12.6 8.9 14.2 0.1 10.7 19.2 10.6 7.8 11.9 14.7 13.8 18.0 12.1 7.1 12.5 20.4 13.3 6.2 14.2 11.1 14.8 1.7 6.2 8.0 11.8 15.9 11.0 22.9 10.0 6.9 10.0 16.0 13.3 8.7 12.6 5.5 10.9 8.3 7.2 14.4 5.0 9.4 9.3 10.7 9.1 9.4 7.5 6.1 6.3 8.5 6.3 5.0 6.7 10.2 7.8 6.3 18.7 10.9 10.8 8.9 5.7 2.9 11.9 15.7 28.9 16.7 12.8 11.5 12.9 11.7 13.4 16.1 NSD2 "KMT3G, MMSET, WHSC1" ENSG00000109685 "Nuclear receptor binding SET domain protein 2" O96028 4 1871424-1982207 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Methyltransferase, Transferase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA015801, CAB068246, CAB068247" Enhanced Supported Nucleoplasm Nucleoplasm "CAB068246: , CAB068247: , HPA015801: AB_1858830" "unprognostic (3.70e-1)" "unprognostic (9.80e-2)" "unprognostic (3.33e-2)" "unprognostic (1.77e-1)" "unprognostic (4.01e-1)" "unprognostic (1.31e-2)" "prognostic unfavourable (2.61e-4)" "unprognostic (3.24e-2)" "unprognostic (6.22e-2)" "unprognostic (7.66e-2)" "unprognostic (2.09e-1)" "unprognostic (9.25e-3)" "prognostic unfavourable (7.19e-4)" "unprognostic (3.89e-2)" "unprognostic (2.95e-1)" "unprognostic (1.31e-1)" "unprognostic (6.15e-2)" 8.7 7.6 17.6 11.5 16.2 35.1 8.5 20.6 18.2 7.0 14.8 12.4 6.3 14.0 9.5 7.4 12.7 6.8 6.9 11.9 15.1 10.9 8.4 7.5 11.1 18.8 14.7 16.1 7.0 11.7 10.7 11.8 9.8 14.6 8.7 17.7 9.4 10.2 7.4 11.8 12.1 14.6 10.5 15.3 13.5 11.0 26.3 13.4 46.7 13.8 5.5 17.7 8.6 9.4 4.9 3.9 4.1 1.8 2.7 4.3 0.6 27.4 13.9 41.9 18.3 4.5 6.7 12.2 22.2 19.7 27.2 30.5 12.2 32.6 29.6 7.6 18.3 12.0 27.0 18.3 46.8 14.2 11.1 35.2 19.2 7.2 5.7 21.5 18.5 2.6 4.6 23.9 23.0 21.4 19.0 31.1 22.3 10.8 57.5 22.6 17.6 16.0 32.9 27.3 10.2 11.2 13.0 26.0 20.8 18.2 6.8 8.3 16.1 14.5 16.5 27.2 20.3 17.2 44.6 14.6 15.4 26.8 16.3 21.4 25.2 2.1 1.7 1.7 2.9 1.8 3.2 1.8 3.2 3.2 1.5 4.9 2.8 2.3 4.1 2.7 1.4 3.9 4.3 0.6 17.6 16.2 20.6 18.2 15.1 10.9 14.7 16.1 14.6 13.4 NSD3 "FLJ20353, KMT3F, WHISTLE, WHSC1L1" ENSG00000147548 "Nuclear receptor binding SET domain protein 3" Q9BZ95 8 38269697-38382272 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Methyltransferase, Transferase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA005659, CAB013721, HPA018893" Uncertain Approved Nucleoplasm,Mitochondria Mitochondria Nucleoplasm "CAB013721: , HPA005659: AB_1080596, HPA018893: AB_1858833" "unprognostic (6.21e-2)" "unprognostic (3.73e-2)" "unprognostic (2.18e-2)" "unprognostic (4.12e-1)" "unprognostic (2.25e-1)" "unprognostic (1.53e-2)" "unprognostic (4.35e-2)" "unprognostic (1.97e-2)" "unprognostic (2.49e-1)" "unprognostic (5.72e-2)" "prognostic unfavourable (7.48e-4)" "unprognostic (5.06e-2)" "unprognostic (5.60e-3)" "unprognostic (6.69e-2)" "unprognostic (4.04e-1)" "unprognostic (1.05e-2)" "unprognostic (1.60e-2)" 19.2 11.3 31.1 15.8 31.4 36.3 20.1 51.5 37.7 18.5 15.5 16.7 14.0 16.2 16.0 12.5 17.0 16.8 17.0 12.7 24.4 16.6 14.2 11.2 17.9 22.3 25.0 26.8 26.5 16.3 21.0 24.2 22.5 21.9 16.4 18.7 12.3 18.3 17.9 12.3 16.2 17.7 16.0 15.3 17.2 19.7 9.3 25.6 16.7 19.2 6.9 20.4 19.6 23.3 26.7 5.6 26.2 5.1 8.6 18.0 2.9 23.9 13.8 23.7 16.0 16.6 19.2 17.6 20.1 22.3 17.4 20.3 7.3 13.3 28.6 18.5 13.7 14.4 18.7 16.1 24.9 11.3 11.0 36.4 11.1 8.6 17.1 16.0 13.2 10.3 16.4 15.7 32.1 20.0 25.8 19.0 16.5 8.6 46.7 13.6 16.1 6.5 21.4 25.9 9.0 12.4 18.6 13.4 18.1 16.3 14.3 14.0 18.1 12.2 19.0 18.2 18.9 27.0 11.8 17.0 20.2 27.6 15.3 16.2 13.1 13.9 5.1 9.1 8.0 2.4 5.3 16.5 12.0 7.1 4.1 26.7 15.0 6.3 26.2 8.6 1.5 5.6 18.0 2.9 31.1 31.4 51.5 37.7 24.4 16.6 25.0 26.8 21.9 25.6 NTRK1 "MTC, TRK, TRKA" ENSG00000198400 "Neurotrophic receptor tyrosine kinase 1" P04629 1 156815640-156881850 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins" "Differentiation, Neurogenesis" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 8 "adrenal gland: 15.8;blood: 32.3;brain: 28.3" "Cell line enriched" "Detected in some" 4 "HMC-1: 41.1" "Cancer enhanced" "Detected in some" "glioma: 1.3" "Region enriched" "Detected in many" 5 "pons and medulla: 28.3" "Cell type enriched" "Detected in single" 127 "basophil: 32.3" "Lineage enriched" "Detected in single" 323 "granulocytes: 32.3" "Region enhanced" "Detected in some" "basal ganglia: 8.2" "Low region specificity" "Detected in all" "CAB004606, HPA035799, HPA076570" Approved Approved Vesicles,Cytosol 140000 "Vesicles, Cytosol" "CAB004606: AB_628397, HPA035799: , HPA076570: " "unprognostic (5.89e-3)" "unprognostic (7.56e-2)" "unprognostic (2.74e-2)" "unprognostic (5.99e-3)" "unprognostic (7.26e-2)" "unprognostic (1.43e-3)" "unprognostic (1.56e-1)" "unprognostic (7.42e-3)" "unprognostic (7.63e-2)" "unprognostic (1.35e-1)" "unprognostic (6.73e-2)" "unprognostic (2.29e-2)" "unprognostic (3.18e-11)" "unprognostic (2.18e-3)" "unprognostic (3.79e-2)" "unprognostic (1.07e-1)" "unprognostic (4.89e-1)" 1.0 15.8 0.5 0.8 6.0 0.9 0.4 0.0 0.7 0.9 1.1 0.1 0.0 0.8 1.6 2.0 0.7 0.6 2.1 1.5 0.0 1.2 2.9 0.2 1.9 0.3 2.1 0.6 0.3 0.3 0.3 1.1 0.5 28.3 2.2 0.2 3.1 1.2 0.5 0.7 0.2 0.4 1.1 1.2 0.2 1.0 2.4 1.5 0.4 0.3 0.0 0.4 0.7 0.8 0.0 0.0 32.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 5.6 0.0 6.6 0.0 0.0 0.0 0.0 41.1 0.0 0.0 0.0 0.0 0.0 2.1 0.7 0.0 0.0 0.0 1.1 0.0 0.6 1.2 0.0 0.1 0.0 0.0 0.7 9.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.6 0.0 0.0 1.6 0.2 0.0 0.0 0.0 0.0 32.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 6.0 0.0 0.6 0.0 1.2 2.1 0.6 28.3 1.5 NTRK3 TRKC ENSG00000140538 "Neurotrophic receptor tyrosine kinase 3" Q16288 15 87859751-88256768 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Differentiation, Neurogenesis" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 41.8" "Cell line enriched" "Detected in some" 8 "U-138 MG: 47.4" "Cancer enhanced" "Detected in some" "glioma: 2.5" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009233, HPA027484, HPA048065" Approved Supported "Nuclear membrane,Nucleoli" 11000000 Nucleoli "Nuclear membrane" "CAB009233: AB_632555, HPA027484: , HPA048065: " "unprognostic (1.27e-3)" "unprognostic (1.24e-2)" "unprognostic (1.98e-2)" "unprognostic (2.04e-2)" "unprognostic (1.65e-1)" "unprognostic (3.34e-1)" "unprognostic (3.18e-2)" "unprognostic (2.23e-2)" "unprognostic (2.34e-1)" "unprognostic (3.91e-1)" "unprognostic (2.88e-1)" "unprognostic (1.09e-1)" "unprognostic (5.78e-3)" "unprognostic (6.45e-3)" "unprognostic (1.06e-2)" "unprognostic (1.26e-2)" "unprognostic (2.49e-3)" 20.8 7.4 22.0 2.5 28.1 1.5 6.2 30.4 41.8 7.0 4.0 8.4 1.3 2.0 12.4 6.7 3.4 9.5 3.9 5.5 22.0 11.1 5.1 2.0 5.7 3.1 11.2 18.7 5.1 2.9 1.6 7.9 2.8 14.7 6.8 4.7 8.0 11.5 8.7 1.9 2.9 2.5 7.7 13.7 4.1 3.0 13.8 13.7 0.0 2.5 0.7 4.3 7.1 4.8 0.7 0.4 1.3 0.5 0.5 0.8 0.0 0.0 5.9 1.2 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.5 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.1 0.0 0.0 1.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 47.4 0.9 0.0 0.5 0.0 0.0 0.0 1.4 0.0 0.1 1.2 0.5 0.4 0.3 0.1 0.2 0.4 0.3 0.3 0.1 0.7 0.4 0.4 1.3 0.5 0.1 0.4 0.8 0.0 22.0 28.1 30.4 28.9 22.0 11.1 11.2 18.7 14.7 13.7 NUMA1 ENSG00000137497 "Nuclear mitotic apparatus protein 1" Q14980 11 72002864-72080693 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Chromosome partition, Mitosis" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019841, HPA019859, HPA029912" Enhanced Enhanced Nucleoplasm Nucleoplasm "HPA019841: AB_1854708, HPA019859: AB_1854709, HPA029912: AB_10602811" "unprognostic (1.60e-2)" "unprognostic (3.31e-1)" "unprognostic (2.06e-2)" "unprognostic (2.84e-1)" "unprognostic (1.14e-1)" "unprognostic (6.47e-2)" "unprognostic (5.75e-2)" "unprognostic (8.74e-3)" "unprognostic (5.91e-2)" "unprognostic (9.45e-2)" "unprognostic (1.60e-2)" "unprognostic (2.51e-2)" "prognostic favourable (7.92e-4)" "unprognostic (1.28e-1)" "unprognostic (1.37e-1)" "unprognostic (1.49e-1)" "unprognostic (1.39e-1)" 29.7 33.5 23.6 20.6 28.1 26.8 33.1 38.4 31.8 51.9 37.7 55.6 40.1 25.5 58.3 30.9 34.1 37.8 31.2 21.2 21.6 19.4 23.0 13.1 28.3 23.3 37.6 24.8 51.4 30.0 70.7 29.5 26.0 28.3 50.3 24.2 41.2 35.3 40.1 43.7 41.9 30.2 45.3 29.5 23.0 31.2 25.9 39.5 39.4 32.6 22.5 31.8 50.5 37.2 10.3 12.9 4.9 5.7 7.0 9.7 6.6 18.5 23.6 29.6 19.9 26.3 27.5 15.1 25.1 29.1 26.2 22.9 24.5 34.4 25.3 22.0 30.7 39.9 27.0 25.4 24.0 26.0 12.7 31.0 37.1 18.6 21.2 23.4 22.6 29.0 16.8 25.6 25.9 22.1 18.2 30.6 17.8 35.8 30.2 13.1 18.4 17.0 37.1 51.6 19.5 19.6 29.1 35.8 50.8 40.0 37.1 37.3 49.9 13.7 30.4 27.8 21.7 39.2 16.6 19.8 19.6 35.6 18.6 11.1 15.8 4.9 5.6 2.5 9.7 3.5 7.4 5.2 6.0 7.5 4.9 10.3 7.5 5.2 4.6 7.0 5.7 12.9 7.2 6.6 23.6 28.1 38.4 31.8 21.6 19.4 37.6 24.8 28.3 39.5 NUP214 "CAIN, CAN, D9S46E, N214" ENSG00000126883 "Nucleoporin 214" P35658 9 131125561-131234670 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters" "Host-virus interaction, mRNA transport, Protein transport, Translocation, Transport" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 131.5" "Cell line enhanced" "Detected in all" "K-562: 71.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "classical monocyte: 43.7;neutrophil: 131.5" "Group enriched" "Detected in many" 5 "granulocytes: 131.5;monocytes: 43.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA048789 Approved "Nucleoplasm,Vesicles,Focal adhesion sites" 100000 Nucleoplasm "Vesicles, Focal adhesion sites" "HPA048789: " "unprognostic (1.30e-1)" "unprognostic (9.51e-3)" "unprognostic (9.92e-3)" "unprognostic (1.15e-1)" "unprognostic (7.42e-2)" "unprognostic (8.31e-2)" "unprognostic (1.07e-3)" "unprognostic (2.10e-2)" "unprognostic (3.35e-1)" "unprognostic (4.95e-1)" "unprognostic (6.60e-3)" "unprognostic (1.08e-1)" "prognostic favourable (2.39e-5)" "unprognostic (5.49e-2)" "unprognostic (6.84e-2)" "unprognostic (1.82e-1)" "unprognostic (1.53e-1)" 16.9 10.3 11.5 13.8 13.9 29.4 12.9 13.0 14.4 10.2 11.4 19.8 10.4 9.0 15.0 13.7 16.1 12.1 10.2 9.7 9.5 8.1 19.0 15.1 11.7 13.3 13.2 8.8 14.2 17.0 16.7 16.9 13.0 11.3 11.1 10.8 15.3 13.0 11.1 15.5 17.5 11.7 11.1 14.3 35.8 12.3 63.7 13.3 27.4 11.8 7.6 16.8 10.7 11.2 1.2 16.8 131.5 43.7 1.2 0.8 17.9 6.7 9.6 8.2 4.9 6.6 6.4 8.6 6.0 6.2 7.8 6.3 7.8 4.9 10.9 4.8 8.2 15.4 11.0 7.8 7.6 7.9 5.4 6.8 13.7 15.2 5.8 10.6 7.3 7.0 7.2 10.0 8.1 8.0 71.4 6.3 8.0 12.5 13.9 16.0 8.9 8.5 4.8 10.3 10.9 9.0 6.2 7.0 7.2 10.0 9.2 5.2 12.1 26.4 6.8 13.8 7.8 9.0 9.6 5.5 10.7 10.5 6.7 6.4 8.3 3.5 43.7 17.3 0.7 18.4 0.8 1.2 0.7 0.6 16.8 1.1 0.7 0.7 131.5 1.2 15.0 1.5 0.4 17.9 11.5 13.9 13.0 14.4 9.5 8.1 13.2 8.8 11.3 13.3 NUP98 NUP96 ENSG00000110713 "Nucleoporin 98" P52948 11 3671083-3797792 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, mRNA transport, Protein transport, Translocation, Transport" "Hydrolase, Protease, Serine protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA074810 Supported Nucleoplasm,Vesicles Nucleoplasm Vesicles "HPA074810: " "unprognostic (1.11e-1)" "unprognostic (1.49e-1)" "unprognostic (7.41e-2)" "unprognostic (2.13e-1)" "unprognostic (7.71e-3)" "unprognostic (3.40e-1)" "unprognostic (4.08e-3)" "unprognostic (6.47e-2)" "unprognostic (1.04e-2)" "unprognostic (1.83e-2)" "unprognostic (7.76e-3)" "unprognostic (1.02e-1)" "unprognostic (1.23e-1)" "unprognostic (5.09e-1)" "unprognostic (1.91e-1)" "unprognostic (2.46e-1)" "unprognostic (1.21e-1)" 20.2 13.5 8.7 23.5 11.7 40.8 23.5 14.2 13.2 18.0 15.3 14.6 17.8 11.2 19.2 17.5 18.6 17.3 17.1 18.2 7.8 8.0 12.8 20.1 20.7 17.4 11.4 8.7 25.5 19.0 25.7 23.6 20.7 12.7 18.6 15.2 17.8 17.4 25.0 35.2 18.5 15.7 20.8 10.4 18.3 16.0 57.0 10.6 27.5 20.9 15.0 26.6 22.6 19.3 8.9 9.9 24.9 10.0 6.1 13.2 8.7 29.8 23.4 19.3 21.3 21.4 17.6 17.0 21.3 24.9 29.3 26.4 25.7 37.1 29.2 10.1 25.5 32.2 33.9 21.0 40.0 20.7 24.5 31.3 19.2 17.6 18.0 39.9 26.4 20.0 14.5 16.1 29.4 22.7 38.9 23.5 31.1 12.2 40.1 13.0 24.4 18.0 24.5 23.5 14.0 16.7 23.6 17.8 11.9 30.9 25.1 14.2 15.4 15.7 16.6 23.5 20.4 25.6 19.4 14.2 24.2 31.0 15.9 17.2 24.7 19.1 7.9 15.5 11.0 10.0 11.0 8.9 10.7 9.7 9.9 7.8 12.2 10.5 24.9 6.1 6.3 2.7 13.2 8.7 8.7 11.7 14.2 13.2 7.8 8.0 11.4 8.7 12.7 10.6 NUTM1 "C15orf55, DKFZp434O192, FAM22H, NUT" ENSG00000184507 "NUT midline carcinoma family member 1" Q86Y26 15 34343315-34357737 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 127 "testis: 48.9" "Cell line enhanced" "Detected in some" "BEWO: 1.0;NTERA-2: 2.2" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA040421 Enhanced "HPA040421: AB_10793965" "unprognostic (4.14e-2)" "unprognostic (3.61e-1)" "unprognostic (2.11e-1)" "unprognostic (7.38e-2)" "unprognostic (1.99e-1)" "unprognostic (8.37e-2)" "unprognostic (8.66e-2)" "unprognostic (2.76e-1)" "unprognostic (1.34e-1)" "unprognostic (5.55e-2)" "unprognostic (1.34e-2)" "unprognostic (5.97e-3)" "unprognostic (1.61e-1)" "unprognostic (2.77e-1)" "unprognostic (4.27e-2)" "unprognostic (4.79e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.0 0.0 0.0 0.1 48.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.3 0.2 0.0 0.1 0.4 0.4 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.6 0.1 0.1 0.1 0.0 0.5 0.3 0.0 0.0 0.4 0.5 0.1 0.2 0.1 0.0 0.1 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.3 0.1 2.2 0.3 0.2 0.2 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.2 0.6 0.2 0.0 0.7 0.2 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 NUTM2A FAM22A ENSG00000184923 "NUT family member 2A" Q8IVF1 10 87225448-87236908 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in some" "HMC-1: 14.2" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "eosinophil: 1.3" "Low lineage specificity" "Detected in single" HPA064635 Approved "Nuclear bodies" "Nuclear bodies" "HPA064635: " "unprognostic (1.75e-2)" "unprognostic (1.33e-2)" "unprognostic (1.03e-1)" "unprognostic (8.29e-2)" "unprognostic (5.67e-2)" "unprognostic (8.08e-2)" "unprognostic (1.75e-2)" "unprognostic (6.84e-2)" "unprognostic (2.46e-3)" "unprognostic (1.75e-2)" "unprognostic (7.24e-2)" "unprognostic (1.40e-1)" "unprognostic (4.24e-3)" "unprognostic (1.35e-1)" "unprognostic (1.11e-1)" "unprognostic (1.96e-2)" "unprognostic (2.65e-1)" 3.5 1.8 2.8 0.4 2.5 1.7 1.1 1.5 2.9 1.1 1.8 1.3 1.7 2.1 0.9 1.9 0.8 3.0 3.4 2.2 1.5 1.3 1.6 0.9 2.9 3.0 2.4 2.9 2.0 1.3 2.5 1.0 5.9 0.8 2.3 4.4 2.0 0.7 3.6 1.7 1.8 2.4 2.6 0.2 1.4 1.2 0.4 0.0 1.3 0.2 0.0 0.2 0.2 1.4 0.2 0.7 0.0 1.8 0.9 0.9 0.6 1.8 0.8 0.5 0.2 0.7 1.4 0.1 0.0 1.4 0.0 0.9 0.1 0.3 1.5 1.7 0.4 0.2 0.7 0.6 14.2 0.5 4.1 0.9 1.1 0.0 1.8 0.4 0.2 0.7 1.1 2.4 3.2 0.5 1.7 0.2 0.0 0.5 0.1 1.8 2.7 0.7 0.6 0.6 0.3 0.9 1.4 0.0 0.2 0.8 0.1 0.0 0.1 0.7 0.8 1.4 0.0 0.0 0.2 1.3 0.1 0.2 0.0 0.4 0.0 0.1 0.0 0.0 0.1 0.2 0.4 0.0 0.2 0.0 0.0 0.2 NUTM2B "bA119F19.1, FAM22B" ENSG00000188199 "NUT family member 2B" A6NNL0 10 79703227-79714681 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "No human protein/transcript evidence" "No human protein/transcript evidence" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HMC-1: 6.2" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "eosinophil: 1.0" "Low lineage specificity" "Detected in single" HPA064635 Approved "Nuclear bodies" "Nuclear bodies" "HPA064635: " "unprognostic (9.51e-2)" "unprognostic (6.09e-2)" "unprognostic (1.21e-2)" "unprognostic (1.10e-1)" "unprognostic (3.63e-1)" "unprognostic (6.60e-2)" "unprognostic (2.47e-2)" "unprognostic (7.66e-2)" "unprognostic (1.33e-2)" "unprognostic (1.95e-1)" "unprognostic (7.79e-3)" "unprognostic (1.15e-1)" "unprognostic (9.70e-2)" "unprognostic (9.97e-2)" "unprognostic (5.72e-2)" "unprognostic (5.37e-2)" "unprognostic (2.32e-2)" 0.9 1.8 2.8 1.6 2.6 3.6 0.6 2.2 3.0 1.1 1.0 0.6 0.9 1.6 0.4 2.3 0.3 2.1 2.8 1.9 1.6 1.1 1.9 1.6 1.7 2.0 2.1 2.2 2.7 0.7 1.6 0.4 3.0 0.7 2.3 2.2 1.2 0.2 1.9 2.0 0.9 4.6 1.1 1.6 0.4 0.7 0.5 0.4 1.0 0.8 0.1 0.1 0.1 1.4 1.4 2.9 2.3 1.0 0.9 1.5 0.6 1.1 0.9 0.9 0.2 3.3 3.3 0.5 0.5 1.4 0.2 1.5 0.5 2.0 1.2 2.3 0.5 0.8 1.3 1.8 6.2 2.0 1.0 0.4 0.7 0.0 3.4 1.8 0.6 2.8 0.4 4.8 3.4 1.8 0.7 0.5 0.4 1.2 0.4 1.7 4.0 2.1 2.6 3.7 0.6 3.1 1.7 0.3 0.6 0.5 1.0 0.7 0.2 0.8 0.0 0.3 0.0 0.0 0.0 1.0 0.1 0.1 0.0 0.2 0.0 0.0 0.0 0.5 0.1 0.0 0.4 0.1 0.8 0.4 0.0 0.1 OLIG2 "BHLHB1, bHLHe19, OLIGO2, PRKCBP2, RACK17" ENSG00000205927 "Oligodendrocyte transcription factor 2" Q13516 21 33025845-33029196 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "brain: 66.2" "Cell line enhanced" "Detected in some" "HMC-1: 29.3;NB-4: 21.2;THP-1: 18.4;WM-115: 6.0" "Cancer enriched" "Detected in some" 52 "glioma: 46.9" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 8 "eosinophil: 15.4" "Lineage enriched" "Detected in single" 154 "granulocytes: 15.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003254, CAB019381" Enhanced Uncertain "Nucleoplasm,Plasma membrane" Nucleoplasm "Plasma membrane" "CAB019381: , HPA003254: AB_1854795" "unprognostic (5.14e-1)" "unprognostic (4.56e-1)" "unprognostic (1.44e-2)" "unprognostic (8.27e-2)" "unprognostic (3.24e-2)" "unprognostic (4.34e-2)" "unprognostic (4.81e-2)" "unprognostic (5.41e-2)" "unprognostic (1.39e-1)" "unprognostic (5.78e-5)" "unprognostic (2.76e-1)" 1.3 1.3 24.1 1.4 19.1 1.4 1.3 4.2 66.2 1.3 1.3 41.4 0.0 1.7 1.3 1.3 1.3 1.3 1.3 1.3 23.6 15.6 1.3 1.3 1.3 1.3 20.9 15.5 1.3 1.3 1.3 0.0 1.3 17.1 1.3 1.3 0.0 1.3 1.3 1.3 1.3 1.5 1.3 16.8 1.3 1.4 1.3 16.6 0.0 1.3 0.0 1.3 1.4 0.0 0.0 0.0 15.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 0.0 0.0 0.0 0.6 4.2 0.0 0.0 0.0 0.8 29.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 21.2 1.9 0.0 0.0 1.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 18.4 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.7 0.0 6.0 1.8 0.0 15.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 24.1 19.1 4.2 27.6 23.6 15.6 20.9 15.5 17.1 16.6 P2RY8 P2Y8 ENSG00000182162 "P2Y receptor family member 8" Q86VZ1 X 1462572-1537107 "Cancer-related genes, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 26.7;lymphoid tissue: 19.0" "Cell line enhanced" "Detected in some" "Daudi: 33.2;RPMI-8226: 20.4;THP-1: 20.4;U-266/70: 27.9;U-698: 54.3;U-937: 16.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" HPA003631 Enhanced "HPA003631: AB_1079543" "unprognostic (4.32e-2)" "unprognostic (3.22e-5)" "unprognostic (6.31e-2)" "unprognostic (2.51e-2)" "unprognostic (1.17e-1)" "prognostic favourable (7.80e-5)" "prognostic favourable (1.73e-4)" "unprognostic (5.27e-3)" "unprognostic (5.76e-3)" "unprognostic (5.52e-3)" "prognostic favourable (6.54e-4)" "unprognostic (4.29e-2)" "unprognostic (8.45e-3)" "unprognostic (2.90e-1)" "unprognostic (4.00e-2)" "unprognostic (3.55e-1)" "unprognostic (2.80e-1)" 2.9 4.8 0.5 8.9 2.2 13.9 8.2 0.9 1.8 4.7 1.6 0.5 0.5 1.3 7.1 0.5 0.8 0.8 1.6 11.8 0.9 0.2 13.5 0.8 2.1 19.0 3.6 1.7 5.8 1.1 1.0 6.9 3.4 2.7 1.6 1.3 0.5 1.6 0.5 1.1 0.4 7.8 0.5 3.9 16.6 2.0 0.5 2.0 0.5 8.1 0.5 16.7 2.7 2.8 18.5 5.8 17.8 7.3 15.6 26.7 18.3 0.1 0.1 0.1 0.4 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.2 33.2 0.1 0.0 0.1 0.0 0.0 0.0 1.2 0.1 0.3 0.3 1.6 0.0 14.5 3.5 0.0 0.0 0.0 0.0 0.0 0.3 14.0 0.0 0.0 16.4 16.4 0.2 0.3 14.8 0.1 20.4 0.0 0.2 0.0 0.2 0.1 0.3 0.1 0.1 20.4 0.0 0.3 0.3 0.1 0.0 27.9 5.2 54.3 0.0 16.9 0.0 17.8 7.3 12.4 26.7 5.5 24.6 15.4 20.2 25.1 5.8 18.5 16.1 16.5 4.7 15.6 2.2 1.5 15.9 18.3 0.5 2.2 0.9 1.8 0.9 0.2 3.6 1.7 2.7 2.0 PAFAH1B2 ENSG00000168092 "Platelet activating factor acetylhydrolase 1b catalytic subunit 2" P68402 11 117144267-117176894 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Lipid degradation, Lipid metabolism" Hydrolase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA051836 Approved Supported "Nucleoli,Plasma membrane,Cytosol" 1600000 Cytosol "Nucleoli, Plasma membrane" "HPA051836: " "unprognostic (1.08e-2)" "unprognostic (3.14e-2)" "unprognostic (2.07e-2)" "unprognostic (3.88e-2)" "unprognostic (9.94e-2)" "unprognostic (1.21e-3)" "prognostic unfavourable (9.44e-4)" "prognostic unfavourable (3.07e-4)" "unprognostic (1.01e-1)" "prognostic favourable (4.25e-4)" "prognostic unfavourable (7.79e-5)" "unprognostic (8.18e-2)" "unprognostic (1.11e-2)" "unprognostic (9.97e-2)" "unprognostic (3.25e-1)" "unprognostic (2.46e-1)" "unprognostic (1.34e-1)" 21.5 34.1 30.6 19.2 29.7 33.5 32.3 43.5 41.3 21.6 20.2 33.3 12.7 21.1 23.4 22.8 23.3 20.8 19.3 26.2 31.9 36.8 24.6 22.5 20.5 17.7 39.3 31.6 23.6 23.0 23.1 24.2 26.9 39.6 22.2 19.6 17.3 19.3 17.4 14.1 20.8 18.0 19.9 51.6 18.3 21.4 29.9 26.3 15.1 30.9 10.8 20.4 25.9 20.3 26.8 21.6 36.8 35.7 18.9 31.4 26.9 14.8 17.0 19.7 28.3 22.0 15.4 15.3 25.0 21.9 13.9 12.7 31.0 32.8 16.1 35.9 29.9 23.9 28.5 32.3 18.4 14.3 11.0 41.3 15.6 19.9 19.7 14.2 15.8 17.0 25.6 27.8 35.1 22.8 21.9 12.3 21.3 9.5 13.7 21.0 18.0 13.4 15.4 22.3 17.6 21.3 23.3 21.9 29.1 28.8 21.8 9.5 24.3 12.3 36.4 25.5 16.9 12.4 17.7 3.9 5.9 21.6 10.3 27.4 21.4 32.1 30.8 26.7 24.2 33.3 28.2 26.8 28.0 25.3 21.6 25.4 29.3 31.4 36.8 18.9 35.7 15.8 19.5 26.9 30.6 29.7 43.5 37.8 31.9 36.8 39.3 31.6 39.6 26.3 PATZ1 "dJ400N23, MAZR, PATZ, RIAZ, ZBTB19, ZNF278, ZSG" ENSG00000100105 "POZ/BTB and AT hook containing zinc finger 1" Q9HBE1 22 31325804-31346232 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA047893, HPA048315" Approved Supported Nucleoplasm Nucleoplasm "HPA047893: , HPA048315: " "unprognostic (3.25e-1)" "unprognostic (8.72e-2)" "unprognostic (1.77e-1)" "unprognostic (2.88e-3)" "prognostic favourable (1.06e-4)" "unprognostic (1.77e-1)" "unprognostic (8.34e-3)" "prognostic favourable (8.71e-5)" "unprognostic (1.14e-1)" "unprognostic (1.41e-2)" "unprognostic (1.99e-3)" "unprognostic (1.76e-1)" "prognostic favourable (8.54e-8)" "unprognostic (9.22e-2)" "unprognostic (2.15e-1)" "unprognostic (1.51e-1)" "prognostic favourable (7.79e-6)" 9.6 11.2 13.0 12.7 12.9 12.9 12.1 16.8 16.0 14.2 13.0 21.7 21.8 9.4 19.6 14.4 7.3 22.2 14.1 10.4 14.0 11.8 11.4 11.0 17.4 30.3 15.3 13.4 27.7 16.6 25.4 11.0 8.9 13.6 14.0 6.8 17.5 17.5 17.8 9.1 7.5 11.9 15.6 12.5 14.3 10.5 13.0 15.5 38.5 18.9 8.2 13.8 17.4 14.2 4.7 7.1 4.8 1.8 3.5 5.7 2.0 8.3 10.5 21.5 12.6 5.7 5.3 11.3 2.5 6.5 10.4 9.6 7.3 8.1 17.8 9.3 4.7 6.5 14.5 7.8 5.4 10.4 13.3 7.5 7.3 14.9 9.3 25.1 10.1 8.2 9.4 6.6 7.4 8.2 3.1 7.2 6.6 25.4 16.0 17.3 14.4 12.4 27.2 9.1 5.9 7.0 17.7 28.1 22.5 6.4 7.8 14.0 15.5 16.1 5.8 7.0 13.3 4.3 8.6 9.3 6.1 16.2 2.9 3.3 11.9 0.0 1.8 4.8 3.4 1.1 3.5 4.7 2.6 4.4 2.5 3.8 5.7 4.1 0.8 3.5 0.6 7.1 3.7 2.0 13.0 12.9 16.8 16.0 14.0 11.8 15.3 13.4 13.6 15.5 PAX3 "HUP2, WS1" ENSG00000135903 "Paired box 3" P23760 2 222199888-222298996 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Myogenesis, Neurogenesis, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Deafness, Disease mutation, Proto-oncogene, Waardenburg syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 19.1;retina: 39.6" "Cell line enhanced" "Detected in some" "BJ hTERT+ SV40 Large T+: 7.5;BJ hTERT+ SV40 Large T+ RasG12V: 8.9;HBF TERT88: 6.6;RH-30: 12.9;SK-MEL-30: 22.7" "Cancer enriched" "Detected in some" 24 "melanoma: 20.3" "Group enriched" "Detected in some" 6 "cerebellum: 19.1;pons and medulla: 7.8" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 7 "cerebellum: 3.9;midbrain: 1.6;pons and medulla: 1.4" "Group enriched" "Detected in many" 5 "cerebellum: 10.0;midbrain: 11.7;pons and medulla: 3.5" "HPA063659, HPA069000" Uncertain Enhanced Nucleoplasm Nucleoplasm "HPA063659: , HPA069000: " "unprognostic (2.57e-2)" "unprognostic (1.48e-2)" "unprognostic (1.27e-2)" "unprognostic (1.65e-1)" "unprognostic (2.61e-2)" "unprognostic (3.70e-1)" "unprognostic (6.18e-2)" "unprognostic (1.41e-1)" "unprognostic (2.26e-1)" "unprognostic (9.70e-2)" 0.8 0.1 0.0 0.1 0.8 0.1 2.9 19.1 0.2 0.3 0.1 0.1 0.3 0.1 0.2 0.1 0.1 0.1 0.1 0.3 0.0 0.2 0.1 0.1 0.1 0.2 2.2 0.0 0.1 0.2 0.1 0.0 0.1 7.8 0.4 0.1 39.6 7.9 0.2 8.6 7.9 0.1 0.1 4.2 0.1 0.2 2.9 0.8 0.0 0.1 3.9 0.5 0.1 0.2 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 3.9 0.0 0.0 0.0 0.0 5.1 5.1 7.5 8.9 0.0 0.5 0.0 0.0 3.4 0.0 0.0 0.0 6.6 0.0 5.8 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.1 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 5.3 0.1 0.0 0.0 12.9 0.0 0.0 0.0 1.3 0.0 0.0 0.0 22.7 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 2.8 0.0 6.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.8 19.1 0.1 0.0 0.2 2.2 0.0 7.8 0.8 PAX5 BSAP ENSG00000196092 "Paired box 5" Q02548 9 36833275-37034185 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Neurogenesis, Spermatogenesis, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 21.6;lymphoid tissue: 33.4" "Group enriched" "Detected in some" 8 "Daudi: 21.0;REH: 61.0;U-698: 27.6" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in single" 5 "midbrain: 1.6" "Group enriched" "Detected in some" 209 "memory B-cell: 20.1;naive B-cell: 21.6" "Lineage enriched" "Detected in single" 216 "B-cells: 21.6" "Region enriched" "Detected in single" 11 "midbrain: 4.7" "Group enriched" "Detected in some" 6 "hippocampal formation: 3.8;midbrain: 10.8;pons and medulla: 3.2" "CAB026269, CAB026869, HPA056394, HPA068498" Enhanced Supported Approved Nucleoplasm,Vesicles,Cytosol Nucleoplasm "Vesicles, Cytosol" "CAB026269: , CAB026869: , HPA056394: , HPA068498: " "unprognostic (4.69e-4)" "unprognostic (3.83e-1)" "unprognostic (9.13e-2)" "unprognostic (1.42e-1)" "unprognostic (2.65e-2)" "unprognostic (1.15e-1)" "unprognostic (2.09e-2)" "unprognostic (2.95e-2)" "unprognostic (2.48e-1)" "unprognostic (2.00e-2)" "unprognostic (1.03e-1)" "unprognostic (2.46e-2)" "unprognostic (1.11e-3)" "unprognostic (3.15e-1)" "unprognostic (8.96e-2)" "unprognostic (6.03e-2)" "unprognostic (1.01e-1)" 0.4 0.2 0.2 33.4 0.2 5.5 0.2 0.2 0.2 0.2 0.7 0.1 0.0 0.0 0.2 0.0 0.7 0.2 0.4 0.2 0.2 0.3 0.5 0.3 0.3 23.2 1.6 0.0 0.2 0.2 0.0 0.5 0.1 0.2 0.3 0.3 0.4 2.5 0.0 0.6 0.2 8.7 0.0 0.3 16.5 0.7 0.9 0.0 2.3 0.4 0.2 30.1 1.3 0.2 21.6 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 21.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.0 0.0 0.6 0.1 61.0 0.1 0.1 0.0 0.0 4.3 1.0 0.0 0.2 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 27.6 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 20.1 0.0 0.0 0.0 21.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.2 0.2 0.2 0.2 0.3 1.6 0.0 0.2 0.0 PAX7 Hup1 ENSG00000009709 "Paired box 7" P23759 1 18631006-18748866 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Myogenesis, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "skeletal muscle: 12.9;tongue: 12.0" "Group enriched" "Detected in some" 7 "A549: 3.4;CAPAN-2: 3.7;U-2 OS: 8.0" "Group enriched" "Detected in some" 6 "breast cancer: 0.5;cervical cancer: 1.5;lung cancer: 1.2" "Low region specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in single" 17 "midbrain: 5.5" "Low region specificity" "Detected in some" "unprognostic (8.41e-4)" "unprognostic (2.07e-1)" "unprognostic (5.35e-2)" "unprognostic (3.96e-2)" "unprognostic (4.21e-1)" "unprognostic (1.96e-1)" "unprognostic (1.34e-1)" 0.4 0.1 0.6 0.0 0.6 0.0 0.0 0.0 3.4 0.1 0.0 0.0 0.0 0.1 0.0 2.3 0.5 0.1 0.0 0.0 0.8 0.8 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 2.4 0.0 3.4 0.3 0.0 0.0 0.1 0.1 12.9 0.0 0.1 0.0 1.0 0.0 0.0 0.3 0.0 0.0 0.0 12.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 3.7 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.6 0.0 3.4 0.8 0.8 2.4 0.0 3.4 0.0 PAX8 ENSG00000125618 "Paired box 8" Q06710 2 113215997-113278950 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Congenital hypothyroidism, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "kidney: 69.3;thyroid gland: 120.5" "Group enriched" "Detected in some" 10 "EFO-21: 26.7;RPTEC TERT1: 63.0" "Group enriched" "Detected in many" 12 "endometrial cancer: 60.6;ovarian cancer: 63.5;renal cancer: 33.2;thyroid cancer: 122.2" "Low region specificity" "Detected in some" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Region enriched" "Detected in some" 4 "pons and medulla: 5.8" "HPA030062, CAB055097, CAB061888, HPA064554" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB055097: AB_2236705, CAB061888: AB_10895719, HPA030062: AB_10603982, HPA064554: " "unprognostic (2.63e-3)" "unprognostic (3.80e-1)" "unprognostic (1.17e-1)" "prognostic unfavourable (1.75e-5)" "unprognostic (7.24e-2)" "unprognostic (5.16e-5)" "unprognostic (1.56e-2)" "unprognostic (3.29e-2)" "unprognostic (1.03e-1)" "unprognostic (2.16e-1)" "unprognostic (4.13e-2)" "unprognostic (4.00e-2)" "unprognostic (3.37e-2)" "unprognostic (3.27e-1)" "unprognostic (2.37e-1)" "unprognostic (8.93e-3)" "unprognostic (1.02e-1)" 0.9 1.4 1.1 0.5 0.4 0.0 0.6 0.2 0.8 3.8 0.4 0.2 11.7 0.1 2.2 15.2 0.6 9.6 0.8 0.6 0.5 0.5 69.3 0.4 0.5 0.7 0.4 0.3 3.8 0.6 0.1 0.7 0.8 1.5 1.1 0.1 0.5 0.5 10.0 0.3 0.5 0.6 0.4 0.8 0.3 0.4 1.9 0.2 0.4 120.5 0.0 0.2 0.8 1.9 4.4 2.8 1.5 3.4 1.9 2.5 1.1 2.9 0.2 0.1 0.0 0.1 0.0 1.0 0.8 2.6 0.2 0.4 1.8 0.5 0.5 26.7 0.2 0.0 0.5 0.8 0.2 1.2 0.0 0.4 0.2 1.0 0.3 0.0 0.0 0.7 0.1 0.2 0.6 0.0 0.4 2.0 0.8 0.6 0.3 1.2 0.1 1.8 0.0 0.2 0.6 63.0 4.6 0.5 0.0 3.3 0.0 1.8 0.0 1.1 0.9 4.6 0.1 0.8 2.3 0.4 1.3 0.1 4.0 0.6 0.0 1.5 3.4 0.0 0.6 1.8 1.5 4.4 1.5 1.1 2.8 1.9 2.5 1.5 0.5 1.9 1.3 1.1 0.8 1.1 1.1 0.4 0.2 0.8 0.5 0.5 0.4 0.3 1.5 0.2 PBX1 ENSG00000185630 "PBX homeobox 1" P40424 1 164555584-164899296 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Sexual differentiation, Steroidogenesis, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HEL: 30.5;NTERA-2: 29.9;SK-BR-3: 61.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "basophil: 2.9" "Lineage enriched" "Detected in single" 9 "granulocytes: 2.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003505, HPA003881, CAB018768" Supported Enhanced "Nucleoplasm,Nuclear bodies,Cytosol" Nucleoplasm "Nuclear bodies, Cytosol" "CAB018768: AB_675783, HPA003505: AB_1855019, HPA003881: AB_1855020" "unprognostic (2.26e-2)" "unprognostic (1.95e-1)" "unprognostic (9.09e-2)" "unprognostic (2.14e-2)" "unprognostic (5.21e-3)" "unprognostic (6.94e-3)" "unprognostic (5.95e-2)" "unprognostic (2.49e-1)" "unprognostic (1.65e-1)" "unprognostic (2.24e-3)" "unprognostic (2.30e-1)" "unprognostic (8.81e-2)" "unprognostic (1.34e-2)" "unprognostic (2.13e-1)" "unprognostic (5.07e-2)" "unprognostic (1.11e-1)" "unprognostic (1.25e-1)" 13.2 17.3 14.9 8.3 15.0 1.4 16.4 14.1 17.4 73.4 26.3 11.2 15.9 13.6 67.2 15.3 20.8 35.1 25.8 12.6 10.9 9.7 15.4 4.2 10.4 2.3 11.6 14.6 35.2 29.4 21.3 12.4 9.6 8.1 27.6 9.3 10.2 19.6 25.1 16.8 6.0 14.6 56.8 8.0 5.1 13.9 9.7 8.7 2.7 17.4 8.5 6.6 32.2 24.7 0.0 0.1 2.9 0.0 0.3 0.2 2.5 1.1 22.3 22.1 5.9 14.9 7.2 1.3 9.3 6.1 2.5 1.8 4.3 4.0 0.0 1.9 12.7 7.8 8.6 2.4 1.0 1.1 9.3 30.5 17.9 0.0 9.8 0.0 7.8 7.1 0.0 1.6 0.7 0.1 0.0 0.0 0.6 14.7 0.0 0.1 29.9 1.1 0.0 7.3 8.9 1.8 13.3 0.8 13.1 10.8 61.6 0.0 23.4 0.0 0.1 1.3 3.1 8.7 2.7 2.8 21.1 0.0 0.1 0.0 0.1 2.9 0.0 0.5 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.7 0.3 0.0 0.1 0.0 2.5 14.9 15.0 14.1 17.4 10.9 9.7 11.6 14.6 8.1 8.7 PCM1 PTC4 ENSG00000078674 "Pericentriolar material 1" Q15154 8 17922840-18029944 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cilium biogenesis/degradation" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA023370, HPA023374, CAB058695" Enhanced Enhanced "Nuclear membrane,Centrosome,Cytosol" Centrosome "Nuclear membrane, Cytosol" "CAB058695: , HPA023370: AB_1855072, HPA023374: AB_1855073" "unprognostic (1.52e-2)" "unprognostic (1.77e-2)" "unprognostic (6.54e-3)" "unprognostic (3.35e-2)" "unprognostic (9.52e-2)" "unprognostic (1.62e-2)" "unprognostic (1.40e-1)" "unprognostic (7.74e-3)" "unprognostic (1.09e-1)" "unprognostic (2.26e-1)" "unprognostic (2.84e-1)" "unprognostic (2.83e-1)" "unprognostic (1.76e-2)" "unprognostic (2.16e-1)" "unprognostic (4.60e-1)" "unprognostic (1.34e-1)" "unprognostic (2.45e-1)" 19.6 19.0 26.2 26.7 40.4 25.1 25.1 29.2 29.0 25.0 21.1 21.6 22.8 12.4 23.3 27.3 16.4 26.4 17.8 23.0 22.9 18.4 18.8 22.0 19.1 21.1 24.5 24.9 29.1 27.0 42.0 35.8 19.8 26.4 20.2 16.3 16.2 19.4 25.3 63.1 17.6 18.3 26.7 27.2 20.8 17.9 80.0 28.0 40.2 28.2 19.1 20.4 27.0 22.6 11.5 14.9 19.9 7.5 11.2 13.0 4.3 20.3 21.7 33.4 44.2 18.9 19.7 17.3 17.2 21.2 18.4 20.8 14.7 12.2 26.7 11.9 17.1 14.8 21.3 15.8 31.4 8.8 8.2 45.8 15.4 29.8 21.1 20.0 11.8 17.1 16.9 21.3 23.7 21.1 30.9 20.8 22.4 10.2 42.9 33.2 27.5 6.3 25.9 29.9 9.5 15.2 28.3 25.6 19.3 18.4 10.1 26.4 15.9 29.3 18.8 16.8 13.7 20.5 14.5 8.9 19.6 23.9 14.2 22.1 17.1 19.9 6.0 14.4 11.5 3.8 12.0 11.1 10.4 13.0 5.9 11.5 11.6 11.6 6.4 11.2 7.5 14.9 10.3 4.3 26.2 40.4 29.2 29.0 22.9 18.4 24.5 24.9 26.4 28.0 PDCD1LG2 "B7-DC, bA574F11.2, Btdc, CD273, PD-L2, PDL2" ENSG00000197646 "Programmed cell death 1 ligand 2" Q9BQ51 9 5510570-5571254 "Cancer-related genes, CD markers, Predicted membrane proteins, Predicted secreted proteins" "Adaptive immunity, Immunity" Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "BJ: 25.4;BJ hTERT+: 39.9;HDLM-2: 30.5;TIME: 17.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA013411 Approved Approved Cytosol "Secreted - unknown location" 34000000 Cytosol "HPA013411: AB_1855102" "unprognostic (3.93e-2)" "unprognostic (1.90e-1)" "unprognostic (3.51e-3)" "unprognostic (6.68e-3)" "unprognostic (7.66e-2)" "unprognostic (6.77e-2)" "unprognostic (5.72e-2)" "unprognostic (2.91e-1)" "unprognostic (1.68e-1)" "unprognostic (4.37e-3)" "unprognostic (5.79e-2)" "unprognostic (5.29e-2)" "prognostic unfavourable (1.15e-4)" "unprognostic (5.00e-2)" "unprognostic (4.66e-2)" "unprognostic (2.01e-1)" "unprognostic (7.51e-3)" 15.2 1.8 1.2 7.7 1.4 0.2 9.5 0.7 1.2 7.0 1.9 2.3 0.0 0.8 2.9 7.2 3.9 3.8 4.0 5.8 1.2 1.3 2.5 6.4 13.3 10.8 1.6 0.5 4.1 1.8 0.5 1.1 12.9 1.9 5.0 2.5 2.4 2.9 1.7 5.5 3.6 2.5 4.6 3.7 19.5 1.9 4.2 1.2 8.1 3.5 3.5 8.1 6.0 5.4 0.5 0.9 4.1 3.6 0.0 3.0 0.7 2.0 0.0 0.0 0.0 1.7 2.0 0.0 25.4 39.9 12.3 14.9 0.0 0.1 0.0 0.0 10.3 0.2 0.0 3.4 12.2 30.5 0.0 0.0 0.0 0.0 9.9 0.0 0.0 1.8 0.0 5.7 6.7 8.0 0.0 3.0 14.7 0.0 0.0 0.0 0.0 0.0 0.0 15.2 0.2 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 17.6 8.8 0.5 4.2 7.0 0.4 0.0 0.0 5.0 0.0 1.0 4.1 0.9 0.0 1.4 3.6 1.9 0.5 2.2 0.9 0.9 0.3 0.0 1.0 2.0 0.0 0.5 0.0 3.0 0.7 1.2 1.4 0.7 1.2 1.2 1.3 1.6 0.5 1.9 1.2 PDE4DIP "CMYA2, KIAA0454, KIAA0477, MMGL" ENSG00000178104 "Phosphodiesterase 4D interacting protein" Q5VU43 1 148808181-149048286 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in all" 10 "heart muscle: 106.0;skeletal muscle: 276.2" "Cell line enhanced" "Detected in many" "ASC diff: 62.3;ASC TERT1: 50.7;K-562: 50.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA012678 Supported "Golgi apparatus" "Golgi apparatus" "HPA012678: AB_1855123" "unprognostic (2.14e-1)" "unprognostic (3.27e-1)" "unprognostic (5.31e-2)" "unprognostic (6.73e-2)" "unprognostic (7.82e-2)" "unprognostic (1.16e-2)" "unprognostic (2.17e-1)" "unprognostic (9.72e-2)" "unprognostic (7.65e-2)" "unprognostic (1.67e-1)" "unprognostic (2.23e-2)" "unprognostic (5.08e-2)" "unprognostic (1.70e-3)" "unprognostic (1.82e-1)" "unprognostic (4.14e-2)" "unprognostic (9.13e-2)" "unprognostic (2.28e-1)" 4.8 2.9 9.2 4.3 8.3 2.3 9.0 12.1 15.1 4.8 6.2 8.3 5.6 3.8 3.1 11.8 6.1 3.3 5.0 106.0 9.7 7.8 6.6 9.3 5.5 3.8 15.6 8.1 2.3 3.4 13.6 7.7 10.2 9.3 4.6 4.1 7.2 5.4 4.5 276.2 4.1 7.7 3.1 18.5 2.9 4.4 1.7 11.2 1.5 3.1 18.1 3.8 3.6 6.1 12.0 6.7 7.4 5.9 4.7 13.2 4.3 7.8 1.5 2.2 2.4 62.3 50.7 13.0 9.2 8.7 9.0 11.8 7.2 5.0 4.0 2.8 13.2 4.0 5.3 6.5 15.3 2.9 7.6 2.0 3.2 2.8 16.5 1.7 2.1 36.0 13.0 38.2 20.8 3.5 50.9 9.4 15.9 13.3 1.3 1.0 7.8 3.3 2.9 5.6 1.5 5.4 8.1 10.7 0.9 9.0 26.3 7.2 7.8 2.3 4.6 10.4 2.3 26.1 20.4 4.1 5.8 5.9 42.6 1.6 6.4 7.4 5.3 4.1 5.4 5.9 5.5 12.0 10.9 7.2 6.7 11.7 8.4 4.6 1.2 4.7 1.9 2.9 13.2 4.3 9.2 8.3 12.1 10.2 9.7 7.8 15.6 8.1 9.3 11.2 PDGFB "SIS, SSV" ENSG00000100311 "Platelet derived growth factor subunit B" P01127 22 39223359-39244751 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins" "Developmental protein, Growth factor, Mitogen" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "EFO-21: 29.1;HUVEC TERT2: 22.4;SK-BR-3: 22.2;TIME: 27.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "MAIT T-cell: 10.8" "Lineage enriched" "Detected in single" 12 "T-cells: 10.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB011604, HPA011972, CAB018341" Supported Approved Vesicles "Secreted to blood" 324500 98000 Vesicles "CAB011604: AB_2162180, CAB018341: AB_2162187, HPA011972: AB_1855134" "unprognostic (4.96e-2)" "unprognostic (8.94e-3)" "unprognostic (8.41e-2)" "unprognostic (2.66e-1)" "unprognostic (9.84e-2)" "unprognostic (4.46e-3)" "unprognostic (4.34e-1)" "prognostic unfavourable (3.67e-5)" "unprognostic (3.22e-2)" "unprognostic (2.07e-1)" "unprognostic (1.05e-1)" "unprognostic (8.68e-2)" "unprognostic (1.84e-3)" "unprognostic (5.12e-3)" "unprognostic (7.47e-2)" "unprognostic (6.50e-2)" "unprognostic (1.03e-1)" 23.5 6.4 10.4 6.4 9.3 0.6 22.5 5.7 13.0 8.3 14.3 12.4 4.2 4.7 10.8 6.5 6.5 5.6 10.8 13.8 9.7 6.1 10.9 3.8 20.8 6.1 14.7 7.3 4.0 8.3 9.2 3.5 37.3 9.6 5.8 3.7 12.1 7.9 8.6 15.2 7.5 6.7 8.9 11.4 5.6 6.2 5.2 10.3 0.8 12.6 8.6 2.3 6.9 5.0 0.0 0.9 0.1 0.4 0.0 10.8 2.3 13.3 1.0 3.5 0.0 0.0 0.0 4.1 0.0 0.1 0.0 0.0 5.3 4.2 0.0 29.1 0.0 5.0 0.2 1.2 0.0 0.0 0.1 0.3 0.4 1.9 1.9 0.0 7.5 0.0 0.1 0.0 0.2 22.4 0.5 2.5 0.8 5.5 0.0 0.0 1.3 1.4 0.0 0.1 9.0 12.1 0.0 0.1 0.0 0.2 22.2 0.1 10.1 0.0 27.8 0.0 2.7 0.0 3.0 0.0 0.1 0.1 0.0 0.6 12.9 0.0 0.0 0.0 8.1 0.1 10.8 0.0 4.7 6.1 0.0 0.0 4.1 2.2 0.1 0.0 0.4 0.9 2.4 2.3 10.4 9.3 5.7 13.0 9.7 6.1 14.7 7.3 9.6 10.3 PDGFRA "CD140a, GAS9, PDGFR2" ENSG00000134853 "Platelet derived growth factor receptor alpha" P16234 4 54229097-54298247 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "Chemotaxis, Host-virus interaction" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ovary: 81.5" "Cell line enhanced" "Detected in some" "ASC diff: 81.0;ASC TERT1: 37.9;BJ hTERT+: 47.0;fHDF/TERT166: 32.7;HHSteC: 27.4;HSkMC: 68.9" "Cancer enhanced" "Detected in all" "glioma: 30.8" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004947, CAB018143" Supported Approved "Nucleoplasm,Plasma membrane,Cell Junctions" "Intracellular and membrane" 150000 "Nucleoplasm, Plasma membrane, Cell Junctions" "CAB018143: AB_2162351, HPA004947: " "unprognostic (1.67e-1)" "unprognostic (9.35e-2)" "unprognostic (4.59e-3)" "unprognostic (1.60e-1)" "unprognostic (8.92e-2)" "prognostic favourable (9.33e-4)" "unprognostic (1.24e-1)" "unprognostic (2.00e-2)" "unprognostic (1.46e-1)" "unprognostic (2.18e-2)" "unprognostic (2.18e-1)" "unprognostic (7.01e-2)" "prognostic unfavourable (9.79e-6)" "unprognostic (9.58e-3)" "unprognostic (9.87e-2)" "unprognostic (2.16e-2)" "unprognostic (1.72e-3)" 35.0 12.4 12.6 16.1 7.6 0.9 17.2 2.4 20.1 33.2 19.1 9.2 6.4 9.6 27.6 14.6 21.9 22.5 16.2 15.3 8.9 7.4 22.8 8.4 24.1 26.9 9.2 4.0 81.5 6.8 1.6 2.1 25.1 7.2 18.6 15.2 19.2 8.5 8.3 11.9 7.0 17.4 19.7 8.8 51.6 13.6 19.0 9.3 0.5 11.3 12.8 4.3 35.9 24.6 0.9 0.4 2.5 0.4 0.3 0.8 0.3 0.0 0.0 0.2 0.1 81.0 37.9 0.1 4.2 47.0 0.0 0.1 11.2 0.0 0.1 0.1 32.7 0.1 3.2 0.0 0.0 0.4 0.1 0.1 0.1 0.2 27.4 0.0 0.0 68.9 0.0 5.3 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.2 0.6 0.1 0.1 0.0 0.0 0.0 0.3 0.1 6.6 0.0 0.1 0.0 0.1 0.0 0.1 14.8 0.5 16.2 0.0 0.0 0.0 0.1 0.4 0.0 0.3 2.5 0.4 0.2 0.5 0.2 0.2 0.6 0.8 0.4 0.0 0.9 0.7 0.4 2.3 0.3 0.3 0.4 0.2 0.3 12.6 7.6 2.4 7.3 8.9 7.4 9.2 4.0 7.2 9.3 PDGFRB "CD140b, JTK12, PDGFR, PDGFR1" ENSG00000113721 "Platelet derived growth factor receptor beta" P09619 5 150113837-150155872 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" Chemotaxis "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in some" 4 "ASC diff: 169.0;ASC TERT1: 58.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "gdT-cell: 2.9;non-classical monocyte: 4.1" "Group enriched" "Detected in many" 8 "monocytes: 4.1;T-cells: 2.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003842, CAB018144, HPA028499" Enhanced Supported "Golgi apparatus,Vesicles" 35000000 Vesicles "Golgi apparatus" "CAB003842: AB_562328, CAB018144: AB_2162497, HPA028499: AB_10602018" "unprognostic (4.75e-2)" "unprognostic (2.48e-1)" "unprognostic (5.21e-2)" "unprognostic (3.60e-2)" "unprognostic (3.27e-1)" "unprognostic (5.61e-2)" "unprognostic (1.02e-1)" "unprognostic (3.36e-2)" "unprognostic (2.12e-2)" "unprognostic (2.57e-3)" "unprognostic (6.72e-2)" "unprognostic (1.25e-1)" "prognostic unfavourable (5.87e-8)" "unprognostic (3.13e-3)" "unprognostic (1.25e-2)" "unprognostic (5.47e-2)" "prognostic unfavourable (8.11e-4)" 61.8 10.4 8.3 11.0 9.1 0.5 66.1 4.6 10.4 73.1 15.7 6.7 6.9 5.1 44.3 17.3 21.7 26.1 51.7 24.2 8.2 3.9 17.0 4.6 28.9 21.5 7.9 8.1 46.5 7.5 10.4 7.7 46.4 7.7 24.2 6.3 22.9 11.2 19.3 29.8 20.3 11.2 29.8 5.0 19.6 9.2 21.5 6.7 1.4 21.4 16.0 7.3 23.6 35.1 0.4 0.1 0.0 4.1 0.0 2.9 0.6 0.0 0.0 1.0 0.0 169.0 58.5 0.3 5.9 24.5 4.1 7.0 0.6 0.0 0.0 0.7 16.9 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.3 0.4 24.0 0.0 0.0 26.3 0.0 5.7 0.0 0.0 0.0 0.6 0.6 0.0 0.0 0.0 1.1 0.0 0.4 0.3 0.0 0.0 0.0 0.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 6.7 2.2 2.8 0.3 0.0 0.0 0.0 4.1 0.0 0.1 0.0 0.0 0.0 2.9 0.6 0.0 0.4 0.1 0.8 0.1 0.1 0.0 1.3 0.0 0.0 4.1 0.0 0.0 0.6 8.3 9.1 4.6 10.4 8.2 3.9 7.9 8.1 7.7 6.7 PER1 "PER, RIGUI" ENSG00000179094 "Period circadian regulator 1" O15534 17 8140472-8156506 "Cancer-related genes, Predicted intracellular proteins" "Biological rhythms, Transcription, Transcription regulation" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HBEC3-KT: 23.2;hTCEpi: 27.1;hTERT-HME1: 26.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA047947, HPA067064" Supported Nucleoplasm,Cytosol Cytosol Nucleoplasm "HPA047947: , HPA067064: " "unprognostic (7.64e-2)" "prognostic favourable (3.89e-4)" "unprognostic (5.54e-2)" "unprognostic (1.20e-1)" "unprognostic (2.59e-1)" "unprognostic (9.44e-2)" "prognostic favourable (2.56e-4)" "unprognostic (5.28e-2)" "unprognostic (6.67e-2)" "unprognostic (6.21e-3)" "unprognostic (6.87e-2)" "unprognostic (4.68e-2)" "unprognostic (7.09e-3)" "prognostic unfavourable (1.94e-4)" "unprognostic (2.08e-1)" "unprognostic (1.37e-1)" "unprognostic (3.34e-2)" 39.4 33.4 13.2 21.6 15.0 27.3 31.3 19.5 23.9 27.8 24.6 20.9 27.8 6.9 19.5 17.2 31.6 25.2 36.9 24.0 13.3 6.3 14.2 18.6 25.8 10.8 15.6 11.3 50.1 61.8 19.3 29.8 12.7 20.1 23.1 8.1 36.6 23.3 43.5 70.3 47.9 16.9 29.3 17.5 16.7 23.6 13.8 17.1 4.6 28.5 33.1 12.1 30.2 25.0 1.6 4.9 3.3 3.6 0.5 2.1 1.2 1.0 3.8 4.4 6.3 14.5 10.7 2.5 1.5 2.7 1.9 2.3 3.8 2.5 7.1 1.2 2.2 3.1 4.4 23.2 1.3 2.2 5.5 3.7 8.3 1.1 20.0 1.5 5.7 16.0 27.1 3.3 26.5 4.2 4.7 9.9 3.5 3.5 4.3 2.9 3.8 2.5 6.0 2.5 3.7 4.6 0.8 1.9 4.7 3.2 3.7 3.0 2.7 1.1 7.2 2.2 4.3 0.8 1.3 5.8 2.2 2.5 3.0 1.8 1.6 0.0 3.6 1.7 1.9 2.5 2.1 1.0 1.7 1.2 4.9 1.6 1.6 1.1 3.3 0.5 1.2 0.7 1.1 1.2 13.2 15.0 19.5 23.9 13.3 6.3 15.6 11.3 20.1 17.1 PICALM "CALM, CLTH" ENSG00000073921 "Phosphatidylinositol binding clathrin assembly protein" Q13492 11 85957684-86069882 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" Endocytosis "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 25.8" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019053, HPA019061" Enhanced Enhanced Vesicles 28000 Vesicles "HPA019053: AB_1855361, HPA019061: AB_1855362" "unprognostic (9.27e-3)" "unprognostic (7.29e-2)" "unprognostic (3.51e-1)" "unprognostic (6.83e-2)" "unprognostic (5.13e-2)" "unprognostic (1.93e-1)" "unprognostic (5.36e-3)" "unprognostic (9.02e-3)" "unprognostic (9.80e-2)" "unprognostic (6.27e-3)" "prognostic unfavourable (6.61e-4)" "unprognostic (4.31e-1)" "prognostic favourable (2.02e-6)" "unprognostic (1.26e-2)" "unprognostic (5.21e-3)" "unprognostic (2.52e-1)" "unprognostic (1.02e-1)" 72.9 24.2 35.6 43.1 51.4 37.1 51.3 30.2 39.7 38.7 35.9 60.0 27.7 39.6 41.6 26.0 41.3 31.5 48.1 41.4 43.7 34.2 63.9 53.8 45.1 35.2 52.0 33.5 38.2 29.7 70.6 23.8 76.7 50.7 29.9 32.0 26.7 31.8 37.0 35.5 35.0 45.3 49.9 70.7 49.5 30.7 22.9 55.1 31.0 30.8 28.5 34.8 44.0 49.2 2.1 7.1 25.8 8.5 3.9 5.3 3.1 28.9 13.8 21.9 15.3 33.6 35.3 41.4 37.3 48.5 29.5 26.1 54.4 39.5 22.6 38.5 59.8 24.0 22.9 27.2 42.7 6.7 8.2 64.2 18.8 17.3 34.3 15.0 28.9 30.6 29.5 55.3 46.1 32.0 41.1 18.7 55.5 17.0 17.6 13.8 12.0 7.9 12.2 33.2 16.0 57.3 24.5 13.3 10.8 45.8 15.5 12.3 21.0 12.2 34.6 54.6 19.0 64.4 29.7 6.7 17.5 20.7 12.9 11.9 36.8 3.6 8.5 4.2 3.9 7.2 3.3 2.1 2.9 5.3 7.1 1.4 3.0 2.7 25.8 3.9 7.2 2.5 3.8 3.1 35.6 51.4 30.2 39.7 43.7 34.2 52.0 33.5 50.7 55.1 PIM1 PIM ENSG00000137193 "Pim-1 proto-oncogene, serine/threonine kinase" P11309 6 37170203-37175426 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Apoptosis, Cell cycle" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HEL: 34.8;HMC-1: 64.9;U-698: 116.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 64.6" "Group enriched" "Detected in all" 5 "granulocytes: 64.6;T-cells: 19.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003941, CAB017040" Uncertain Supported Nucleoli,Cytosol Cytosol Nucleoli "CAB017040: , HPA003941: AB_1079618" "unprognostic (1.25e-2)" "unprognostic (4.77e-1)" "unprognostic (3.61e-2)" "prognostic unfavourable (9.73e-4)" "unprognostic (1.91e-2)" "unprognostic (1.06e-1)" "unprognostic (3.75e-1)" "unprognostic (4.64e-2)" "unprognostic (2.36e-1)" "unprognostic (1.10e-1)" "unprognostic (2.65e-2)" "unprognostic (7.32e-2)" "unprognostic (2.14e-3)" "unprognostic (8.16e-3)" "unprognostic (1.04e-1)" "unprognostic (5.26e-3)" "unprognostic (2.90e-1)" 39.3 5.4 7.4 18.5 8.9 80.9 20.1 8.1 9.9 23.0 17.9 4.7 4.2 17.9 15.4 9.8 56.3 21.6 24.7 20.8 8.2 3.7 7.5 24.5 14.5 35.7 7.4 2.2 20.0 9.6 2.0 5.6 28.7 12.7 15.6 8.8 6.9 12.8 4.5 26.5 31.3 26.1 31.6 10.7 21.4 12.1 6.8 7.6 15.0 7.2 20.1 28.8 32.6 31.2 1.7 1.4 64.6 1.7 8.4 19.0 8.5 3.0 1.2 2.0 1.1 4.6 2.4 23.5 1.0 3.3 2.2 3.6 4.5 4.2 6.0 1.7 1.2 3.5 2.0 3.2 2.0 27.5 1.3 34.8 1.3 5.8 4.7 0.6 64.9 8.3 4.0 2.0 1.3 0.6 29.9 9.8 0.3 0.7 1.9 3.1 3.7 1.9 4.6 3.6 7.1 0.6 18.4 9.7 1.9 2.3 0.2 0.6 0.5 1.0 1.1 1.3 3.9 5.8 1.3 4.6 2.4 116.6 0.5 8.8 1.3 64.6 1.7 24.4 14.7 1.6 19.0 1.7 13.1 12.9 1.4 1.3 11.9 9.0 14.1 8.4 0.9 0.4 9.4 8.5 7.4 8.9 8.1 9.9 8.2 3.7 7.4 2.2 12.7 7.6 PLAG1 ZNF912 ENSG00000181690 "PLAG1 zinc finger" Q6DJT9 8 56160904-56211324 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC diff: 13.0;ASC TERT1: 17.2;HSkMC: 12.2;hTERT-HME1: 12.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" HPA072290 Supported "Nucleoplasm,Nuclear speckles,Centrosome,Cytosol" "Nucleoplasm, Nuclear speckles" "Centrosome, Cytosol" "HPA072290: " "unprognostic (1.89e-2)" "unprognostic (1.93e-2)" "unprognostic (1.22e-3)" "unprognostic (1.63e-4)" "unprognostic (6.81e-2)" "unprognostic (1.07e-1)" "unprognostic (5.63e-3)" "unprognostic (8.56e-2)" "unprognostic (1.18e-1)" "unprognostic (7.99e-2)" "unprognostic (3.42e-2)" "unprognostic (1.97e-1)" "unprognostic (1.32e-3)" "unprognostic (2.83e-2)" "unprognostic (3.94e-1)" "unprognostic (1.21e-2)" "unprognostic (6.14e-2)" 1.9 3.6 2.4 3.5 2.9 2.1 2.5 11.0 2.7 7.6 3.8 4.1 9.0 3.4 3.4 9.8 2.0 7.5 2.1 6.8 1.9 1.8 3.7 1.2 4.6 6.7 4.8 2.1 11.6 2.2 2.1 17.8 8.0 4.6 5.1 1.6 7.9 7.5 9.2 1.4 3.4 5.5 2.5 6.3 6.2 3.0 5.2 4.5 11.7 3.5 1.5 5.2 4.8 7.0 3.5 0.2 1.1 0.5 0.7 4.6 1.0 1.5 0.0 9.5 0.1 13.0 17.2 3.0 4.2 5.5 2.0 0.9 0.6 4.9 0.2 4.1 2.3 0.3 2.6 5.6 2.0 0.1 5.8 6.0 0.5 1.4 2.7 1.9 1.8 12.2 3.1 1.1 12.6 3.7 2.5 0.1 4.2 0.0 0.5 3.6 2.7 1.4 4.7 0.7 3.7 2.6 0.5 0.1 0.0 0.1 0.0 0.3 0.1 1.8 5.6 2.9 3.8 4.7 1.0 1.5 1.1 2.2 3.3 0.7 0.8 1.1 0.1 1.1 0.3 0.1 0.2 3.5 1.0 0.6 0.1 2.0 4.6 4.3 1.0 0.7 0.5 0.2 0.2 1.0 2.4 2.9 11.0 2.7 1.9 1.8 4.8 2.1 4.6 4.5 PML "MYL, RNF71, TRIM19" ENSG00000140464 "Promyelocytic leukemia" P29590 15 73994673-74047812 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Antiviral defense, Apoptosis, Biological rhythms, Host-virus interaction, Immunity, Innate immunity, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008312, CAB010194, CAB016304" Supported Enhanced "Nuclear bodies" "Nuclear bodies" "CAB010194: AB_2166848, CAB016304: AB_628162, HPA008312: AB_1079643" "prognostic favourable (3.24e-4)" "unprognostic (4.83e-2)" "unprognostic (5.76e-2)" "unprognostic (1.58e-3)" "unprognostic (7.53e-3)" "unprognostic (1.58e-1)" "unprognostic (2.35e-2)" "unprognostic (5.30e-3)" "unprognostic (4.54e-3)" "unprognostic (1.15e-1)" "prognostic unfavourable (3.29e-4)" "unprognostic (2.67e-2)" "prognostic unfavourable (6.27e-8)" "unprognostic (1.58e-2)" "unprognostic (4.17e-2)" "unprognostic (1.02e-1)" "unprognostic (8.99e-2)" 46.2 15.4 13.5 29.9 13.0 30.0 50.0 11.4 17.2 24.7 21.9 8.3 22.1 16.9 29.4 22.1 19.3 23.0 25.6 17.6 10.7 7.5 20.5 12.9 37.2 27.3 11.9 12.4 21.2 11.0 9.6 15.0 22.4 16.1 21.2 8.7 14.6 38.0 27.7 18.7 24.2 19.6 20.1 14.3 25.9 21.4 8.7 13.1 25.3 25.9 23.3 23.0 20.7 35.6 11.8 12.9 19.1 18.2 12.7 13.2 7.8 13.8 5.2 4.6 4.4 13.2 18.7 15.9 7.2 12.8 22.3 25.8 5.5 25.0 6.2 25.4 12.9 25.5 6.3 14.4 3.2 21.7 9.7 13.4 8.2 6.0 15.3 12.7 12.3 35.1 10.4 15.1 7.9 15.5 11.3 11.1 13.1 6.5 10.4 19.9 5.0 9.6 8.1 5.5 11.6 24.9 23.1 4.0 4.4 11.5 6.3 17.1 4.9 10.7 25.8 22.6 6.2 11.2 14.3 11.6 7.3 3.0 15.6 16.2 7.2 5.4 12.7 19.1 12.4 18.0 9.6 11.8 9.9 13.2 12.9 9.8 8.1 8.2 11.0 12.7 18.2 8.3 12.9 7.8 13.5 13.0 11.4 17.2 10.7 7.5 11.9 12.4 16.1 13.1 POU2AF1 "BOB1, OBF1" ENSG00000110777 "POU class 2 associating factor 1" Q16633 11 111352252-111455630 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 21.2;lymphoid tissue: 84.0" "Cell line enhanced" "Detected in some" "Daudi: 45.4;Karpas-707: 52.0;U-266/70: 50.7;U-266/84: 22.8;U-698: 93.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Group enriched" "Detected in some" 11 "memory B-cell: 19.9;naive B-cell: 14.2" "Lineage enriched" "Detected in many" 13 "B-cells: 19.9" "Not detected" "Not detected" "Not detected" "Not detected" CAB011193 Enhanced "CAB011193: AB_532299" "prognostic favourable (1.68e-4)" "prognostic favourable (1.63e-4)" "unprognostic (1.04e-2)" "unprognostic (5.50e-3)" "unprognostic (1.88e-1)" "prognostic favourable (3.59e-4)" "unprognostic (2.09e-1)" "unprognostic (3.63e-3)" "unprognostic (7.15e-2)" "unprognostic (2.52e-2)" "unprognostic (1.34e-1)" "unprognostic (4.81e-2)" "unprognostic (8.51e-8)" "unprognostic (2.35e-1)" "unprognostic (3.90e-1)" "unprognostic (7.14e-3)" "unprognostic (1.23e-1)" 0.9 0.5 0.6 62.7 0.7 2.0 1.4 0.4 0.6 1.9 7.8 1.8 0.0 6.7 0.7 0.3 8.7 1.1 1.4 0.5 0.8 0.7 2.1 1.0 2.6 42.6 1.0 0.5 1.2 0.5 0.0 0.4 0.5 1.2 1.3 4.1 1.2 8.4 0.9 0.4 0.4 21.2 0.0 1.4 74.2 12.2 1.0 0.9 5.0 1.7 1.4 84.0 5.0 1.4 19.9 0.1 1.5 0.2 0.3 0.7 0.6 0.1 0.1 0.0 0.0 0.8 0.8 0.1 0.0 0.0 0.0 0.0 0.1 0.0 45.4 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 1.7 52.0 0.0 0.1 0.2 0.2 0.0 0.0 9.7 0.1 12.2 0.0 0.1 0.0 0.9 0.1 0.0 0.0 0.2 0.1 0.4 0.0 0.4 0.0 0.0 50.7 22.8 93.3 0.0 0.1 0.0 1.5 0.1 0.3 0.1 0.1 0.1 19.9 0.2 0.1 0.0 14.2 0.2 0.1 0.9 0.3 0.2 0.1 0.7 0.6 0.6 0.7 0.4 0.6 0.8 0.7 1.0 0.5 1.2 0.9 POU5F1 "MGC22487, OCT3, Oct4, OTF3" ENSG00000204531 "POU class 5 homeobox 1" Q01860 6 31164337-31180731 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in some" 12 "HAP1: 52.5;NTERA-2: 139.7" "Cancer enriched" "Detected in many" 34 "testis cancer: 355.9" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "CAB025600, CAB026380, HPA058267, CAB079773" Approved Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB025600: , CAB026380: , CAB079773: AB_2687916, HPA058267: " "unprognostic (3.25e-2)" "unprognostic (3.12e-1)" "unprognostic (2.87e-1)" "unprognostic (1.06e-2)" "unprognostic (3.02e-2)" "unprognostic (2.11e-2)" "unprognostic (2.62e-2)" "unprognostic (2.27e-1)" "unprognostic (2.59e-1)" "unprognostic (9.27e-2)" "unprognostic (2.27e-2)" "unprognostic (4.79e-2)" "unprognostic (1.19e-3)" "unprognostic (1.38e-1)" "unprognostic (1.35e-1)" "unprognostic (3.86e-2)" "prognostic favourable (2.04e-5)" 1.2 0.0 1.2 1.2 1.2 1.2 1.2 1.2 1.2 2.3 2.3 1.2 1.2 4.9 3.1 5.7 1.2 5.2 4.3 1.2 1.2 0.0 11.1 5.0 2.0 1.2 1.2 1.2 1.2 8.8 0.0 1.2 1.2 1.2 4.7 1.0 1.2 1.2 3.0 1.2 1.8 5.9 1.2 1.2 1.2 6.3 2.2 1.2 1.2 1.2 1.2 1.2 11.2 1.2 3.0 1.8 1.8 1.0 1.1 0.9 0.3 0.6 0.2 8.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 1.2 0.0 0.7 52.5 0.6 0.0 0.0 0.2 0.0 0.4 0.6 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.2 139.7 0.0 0.1 0.1 0.1 1.0 1.1 0.1 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.2 0.0 0.2 0.1 0.1 0.0 0.1 0.1 1.4 1.0 0.5 0.8 0.7 0.5 1.0 0.4 0.4 0.2 3.0 0.9 0.6 1.8 1.1 0.5 1.8 0.3 0.3 1.2 1.2 1.2 1.2 1.2 0.0 1.2 1.2 1.2 1.2 PPARG "NR1C3, PPARG1, PPARG2, PPARgamma" ENSG00000132170 "Peroxisome proliferator activated receptor gamma" P37231 3 12287368-12434356 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Cancer-related genes, Diabetes mellitus, Disease mutation, FDA approved drug targets, Obesity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 97.6;breast: 102.1" "Cell line enhanced" "Detected in many" "ASC diff: 47.4;ASC TERT1: 27.0;BEWO: 55.9;CAPAN-2: 25.0;HSkMC: 27.8;PC-3: 24.9;RT4: 34.1" "Cancer enhanced" "Detected in all" "urothelial cancer: 33.5" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "classical monocyte: 1.8;intermediate monocyte: 2.3" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in many" "Not detected" "Not detected" "CAB004282, HPA051239, HPA063663" Approved Enhanced Nucleoplasm,Vesicles "Nucleoplasm, Vesicles" "CAB004282: AB_628115, HPA051239: , HPA063663: " "unprognostic (7.35e-3)" "unprognostic (3.27e-2)" "unprognostic (4.05e-2)" "unprognostic (8.37e-2)" "unprognostic (2.41e-2)" "unprognostic (5.27e-3)" "prognostic unfavourable (3.41e-5)" "unprognostic (9.13e-2)" "unprognostic (2.32e-2)" "unprognostic (1.38e-1)" "unprognostic (1.02e-2)" "unprognostic (2.77e-1)" "prognostic favourable (1.59e-8)" "unprognostic (1.51e-2)" "unprognostic (1.46e-1)" "unprognostic (9.68e-3)" "prognostic favourable (5.52e-5)" 97.6 1.6 1.9 17.1 1.2 0.7 102.1 1.5 1.3 3.1 24.9 0.8 2.1 7.5 3.5 2.2 2.8 2.4 8.7 12.5 1.4 0.9 6.7 5.9 24.8 11.4 1.1 0.9 6.7 1.2 2.8 0.3 26.8 0.9 10.4 13.9 1.1 5.8 1.5 5.0 2.7 9.6 7.4 1.2 7.0 11.9 3.5 0.6 0.9 6.2 4.3 2.1 30.2 14.1 0.0 0.4 0.0 2.3 0.0 0.7 0.3 9.6 8.6 0.0 0.0 47.4 27.0 55.9 0.9 10.4 1.3 0.5 1.8 25.0 0.0 0.0 0.9 3.9 3.4 0.1 0.2 23.2 4.8 0.0 1.9 2.3 12.6 0.0 0.0 27.8 2.3 2.3 9.0 0.1 0.0 0.0 2.0 2.4 0.0 0.1 0.1 24.9 0.0 0.0 0.0 7.1 34.1 0.0 0.2 4.0 1.5 0.5 0.0 7.7 7.8 1.8 2.6 1.0 0.0 0.0 0.0 0.0 0.8 0.1 0.2 0.0 1.8 0.0 0.0 2.3 0.0 0.0 0.7 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.4 0.3 1.9 1.2 1.5 1.3 1.4 0.9 1.1 0.9 0.9 0.6 PPFIBP1 "hSGT2, hSgt2p, L2, SGT2" ENSG00000110841 "PPFIA binding protein 1" Q86W92 12 27523431-27695564 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive B-cell: 7.0" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA001924 Uncertain Approved "Plasma membrane,Cytosol" "Plasma membrane, Cytosol" "HPA001924: AB_1079665" "unprognostic (5.27e-2)" "unprognostic (5.71e-2)" "unprognostic (3.10e-2)" "prognostic unfavourable (6.29e-4)" "unprognostic (4.73e-2)" "unprognostic (6.94e-2)" "unprognostic (1.47e-1)" "prognostic unfavourable (5.11e-4)" "unprognostic (7.33e-2)" "unprognostic (3.84e-2)" "prognostic unfavourable (2.56e-4)" "unprognostic (1.92e-2)" "prognostic favourable (5.11e-7)" "unprognostic (8.54e-2)" "unprognostic (7.54e-2)" "unprognostic (2.64e-1)" "unprognostic (4.09e-2)" 21.3 17.1 15.5 8.0 16.8 2.2 22.6 4.9 25.0 18.3 15.4 13.3 13.0 7.1 28.1 9.3 17.1 16.5 12.2 43.3 17.1 9.0 23.8 15.7 25.0 7.8 13.1 16.4 53.1 13.7 12.7 22.2 34.5 15.3 15.3 11.1 8.1 14.2 18.4 13.7 17.8 10.0 20.5 11.2 16.6 15.1 7.1 13.3 6.2 23.9 14.9 6.2 17.2 18.4 7.0 2.0 1.5 0.6 0.3 1.8 0.6 4.5 9.2 7.5 6.4 12.5 34.9 13.4 16.6 18.7 9.8 14.2 24.2 13.9 3.4 19.4 33.6 11.4 4.0 15.2 17.7 7.8 2.2 7.6 7.0 3.5 5.4 2.3 4.3 27.1 10.6 28.5 29.3 33.5 4.0 3.5 34.8 3.5 2.1 0.6 13.4 7.1 3.5 18.7 1.3 14.5 10.1 0.6 3.1 8.3 4.4 23.1 5.7 3.5 32.5 27.7 9.3 15.1 16.9 0.0 0.0 0.2 30.7 3.3 43.6 1.5 0.6 0.3 0.7 0.2 1.4 0.7 1.3 0.7 0.6 7.0 1.3 1.3 1.5 0.3 0.2 2.0 1.8 0.6 15.5 16.8 4.9 25.0 17.1 9.0 13.1 16.4 15.3 13.3 PRCC RCCP1 ENSG00000143294 "Papillary renal cell carcinoma (translocation-associated)" Q92733 1 156750610-156800817 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017151, HPA019463, HPA019481" Supported Enhanced "Nuclear speckles" "Nuclear speckles" "CAB017151: , HPA019463: AB_1855672, HPA019481: AB_1855673" "unprognostic (6.12e-2)" "unprognostic (2.68e-1)" "unprognostic (2.68e-3)" "prognostic unfavourable (5.55e-4)" "unprognostic (3.19e-1)" "unprognostic (1.72e-1)" "prognostic unfavourable (8.63e-4)" "unprognostic (3.03e-1)" "unprognostic (9.16e-2)" "unprognostic (3.27e-3)" "unprognostic (1.14e-1)" "unprognostic (6.80e-2)" "prognostic unfavourable (8.99e-15)" "unprognostic (1.72e-1)" "unprognostic (2.74e-1)" "prognostic unfavourable (3.72e-4)" "unprognostic (1.02e-2)" 31.3 24.9 28.5 25.8 29.7 33.7 23.7 33.2 43.5 29.8 30.0 35.9 21.8 24.6 35.1 22.8 30.3 25.6 28.7 23.8 28.0 24.5 26.1 33.1 22.0 30.1 22.1 25.2 30.1 23.7 31.0 22.7 38.8 22.6 25.6 21.5 25.6 37.2 24.0 47.4 33.6 30.1 25.7 20.4 29.7 24.1 26.2 19.2 51.9 27.5 29.8 30.7 25.4 23.8 21.4 27.1 36.9 23.1 19.3 22.1 16.9 19.8 17.2 13.6 15.5 11.4 9.1 23.7 13.9 13.6 15.5 13.4 27.0 16.8 20.4 24.1 10.9 20.8 19.3 14.6 12.1 25.5 25.3 14.9 12.7 17.4 14.1 20.5 17.6 12.9 17.0 13.5 12.4 14.2 24.6 19.0 10.9 35.4 23.4 24.1 32.9 21.4 20.6 12.0 27.4 16.3 19.1 24.2 43.2 14.7 37.1 23.0 26.7 33.1 13.0 15.8 16.6 17.3 22.8 49.1 73.4 31.6 15.6 13.3 14.6 26.9 20.0 36.9 20.5 20.6 19.6 18.0 18.5 22.1 22.4 21.4 18.4 18.9 19.3 19.3 23.1 27.1 18.5 16.9 28.5 29.7 33.2 43.5 28.0 24.5 22.1 25.2 22.6 19.2 PRDM16 "KIAA1675, KMT8F, MEL1, MGC166915, PFM13" ENSG00000142611 "PR/SET domain 16" Q9HAZ2 1 3069168-3438621 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Transcription, Transcription regulation" "Activator, DNA-binding, Methyltransferase, Repressor, Transferase" "Cancer-related genes, Cardiomyopathy, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in some" "AN3-CA: 3.6;CACO-2: 3.4;HAP1: 3.2;HEK 293: 4.2;HHSteC: 4.9;MCF7: 3.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 13 "NK-cell: 5.4" "Lineage enriched" "Detected in single" 13 "NK-cells: 5.4" "Region enriched" "Detected in many" 5 "basal ganglia: 16.1" "Low region specificity" "Detected in many" "HPA050343, HPA060467" Supported Nucleoplasm Nucleoplasm "HPA050343: , HPA060467: " "unprognostic (2.44e-1)" "unprognostic (1.44e-1)" "unprognostic (5.31e-4)" "unprognostic (1.27e-1)" "unprognostic (1.14e-1)" "unprognostic (3.95e-2)" "unprognostic (9.15e-3)" "unprognostic (5.68e-4)" "unprognostic (2.58e-1)" "unprognostic (2.07e-2)" "unprognostic (5.21e-2)" "unprognostic (1.71e-1)" "unprognostic (7.80e-6)" "unprognostic (2.14e-1)" "unprognostic (1.73e-1)" "prognostic unfavourable (4.70e-5)" "unprognostic (4.06e-2)" 2.7 0.7 5.3 1.4 5.6 0.5 1.6 0.5 4.7 2.1 6.2 3.3 12.8 14.1 1.5 4.5 1.1 2.0 11.7 5.1 5.2 1.9 7.0 0.6 4.2 1.4 2.9 3.1 3.6 12.7 1.2 1.1 0.6 3.3 1.1 0.9 16.1 1.3 15.0 1.2 0.9 8.0 1.5 2.5 4.2 14.8 1.4 4.8 0.0 10.7 0.0 0.9 1.1 1.5 0.3 0.1 0.0 0.0 5.4 0.4 0.0 0.0 0.0 1.3 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.5 3.4 0.7 0.0 0.6 0.0 0.0 3.2 0.0 0.0 0.4 4.2 0.0 0.0 0.7 4.9 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.7 0.4 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.8 0.0 1.4 0.0 0.1 0.0 0.0 0.0 0.2 0.9 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.4 0.0 5.4 0.0 0.0 0.0 0.0 5.3 5.6 0.5 4.7 5.2 1.9 2.9 3.1 3.3 4.8 PRKACA PKACa ENSG00000072062 "Protein kinase cAMP-activated catalytic subunit alpha" P17612 19 14091688-14118084 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Cushing syndrome, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010361, HPA071185" Approved Approved Cytosol 1300000 Cytosol "CAB010361: AB_2268772, HPA071185: " "unprognostic (1.08e-1)" "prognostic favourable (6.28e-6)" "unprognostic (2.09e-2)" "prognostic unfavourable (6.26e-5)" "unprognostic (1.38e-2)" "unprognostic (2.95e-1)" "unprognostic (1.64e-1)" "unprognostic (9.36e-3)" "unprognostic (7.01e-2)" "unprognostic (3.41e-1)" "prognostic favourable (6.47e-4)" "unprognostic (2.86e-1)" "unprognostic (1.17e-1)" "unprognostic (4.68e-2)" "unprognostic (1.87e-1)" "unprognostic (3.66e-2)" "unprognostic (6.14e-3)" 25.6 43.4 19.6 17.8 22.7 9.1 34.1 29.1 39.6 20.6 17.5 16.0 16.2 13.4 19.8 15.6 20.9 18.8 16.4 91.6 20.7 29.4 14.7 34.5 16.5 28.2 21.6 27.5 47.0 15.6 20.8 24.6 15.4 26.9 16.6 16.2 18.4 15.5 24.9 92.4 13.4 14.4 29.0 16.2 28.1 13.9 24.4 11.1 15.2 15.7 26.2 14.8 21.1 17.3 1.7 2.4 8.6 5.3 0.7 1.7 1.2 25.7 15.0 34.0 40.5 30.1 32.0 6.1 27.4 25.4 39.0 35.8 18.2 9.2 11.1 22.2 43.4 16.9 23.9 26.0 37.1 20.3 12.0 20.5 28.3 17.6 25.8 12.6 21.7 30.4 12.5 31.0 10.8 32.8 19.2 29.2 39.8 38.2 28.4 9.5 12.2 33.4 25.7 31.4 25.7 19.0 16.3 26.8 17.1 24.8 15.2 11.3 21.7 12.2 25.4 46.1 12.9 61.6 25.6 20.2 20.7 16.4 30.9 19.2 17.2 0.3 3.4 0.4 1.7 5.3 0.8 1.7 0.9 1.1 2.4 1.3 1.2 1.7 8.6 0.7 4.6 1.6 0.8 1.2 19.6 22.7 29.1 39.6 20.7 29.4 21.6 27.5 26.9 11.1 PRKAR1A "CNC1, PRKAR1, TSE1" ENSG00000108946 "Protein kinase cAMP-dependent type I regulatory subunit alpha" P10644 17 68511780-68551319 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Cushing syndrome, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB019378, HPA049979" Approved Approved Cytosol 11000000 Cytosol "CAB019378: , HPA049979: " "unprognostic (8.69e-2)" "unprognostic (6.97e-2)" "unprognostic (5.34e-2)" "unprognostic (2.04e-1)" "unprognostic (1.68e-1)" "unprognostic (4.39e-2)" "unprognostic (2.61e-1)" "unprognostic (6.42e-2)" "unprognostic (2.27e-1)" "unprognostic (2.30e-1)" "unprognostic (1.19e-2)" "unprognostic (5.55e-2)" "unprognostic (8.56e-3)" "unprognostic (6.26e-2)" "unprognostic (6.92e-2)" "unprognostic (3.29e-2)" "unprognostic (1.11e-1)" 47.1 48.0 41.7 34.5 54.8 14.6 38.7 40.4 57.4 48.2 23.8 44.9 31.4 15.1 43.6 37.7 29.6 43.2 37.4 122.7 42.5 52.3 49.2 43.4 47.3 29.5 50.1 43.6 62.5 19.1 107.8 41.9 47.3 57.7 35.6 24.2 32.2 47.5 43.6 99.8 22.8 19.3 39.4 52.8 35.3 25.1 36.9 40.1 28.2 51.8 23.6 29.2 33.8 33.4 11.3 26.9 52.6 28.7 18.5 13.0 22.9 16.4 31.6 40.6 24.3 54.2 61.6 6.1 22.2 45.8 34.7 30.7 12.3 22.2 16.7 15.3 48.4 13.6 30.0 36.0 49.9 11.3 10.7 25.8 27.5 40.2 39.3 19.7 29.0 44.0 37.4 40.0 33.8 57.6 11.6 26.3 42.0 31.1 21.7 10.6 15.0 21.6 15.2 67.3 18.4 52.6 35.8 14.8 20.0 20.3 37.2 85.5 29.0 27.9 40.8 49.0 23.4 22.1 20.6 21.9 15.5 24.9 29.6 18.8 30.5 31.1 26.1 46.3 13.0 25.5 13.0 11.3 9.8 11.6 26.9 8.5 8.9 9.8 52.6 18.5 28.7 8.8 12.3 22.9 41.7 54.8 40.4 57.4 42.5 52.3 50.1 43.6 57.7 40.1 PRRX1 "PHOX1, PMX1" ENSG00000116132 "Paired related homeobox 1" P54821 1 170662728-170739419 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in some" "ASC diff: 72.3;ASC TERT1: 57.7;BJ hTERT+: 40.4;HSkMC: 29.4;U-138 MG: 28.3;U-2197: 27.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA051084, HPA063566" Uncertain Supported Nucleoplasm Nucleoplasm "HPA051084: , HPA063566: " "unprognostic (2.03e-1)" "unprognostic (2.00e-1)" "unprognostic (1.09e-1)" "unprognostic (7.00e-2)" "unprognostic (1.24e-1)" "unprognostic (4.97e-2)" "unprognostic (2.52e-2)" "unprognostic (1.88e-2)" "unprognostic (2.94e-3)" "unprognostic (1.13e-1)" "unprognostic (1.98e-2)" "unprognostic (3.29e-1)" "prognostic unfavourable (6.60e-10)" "unprognostic (4.23e-3)" "unprognostic (4.48e-2)" "unprognostic (2.68e-3)" "unprognostic (1.69e-3)" 44.8 4.4 5.2 7.2 6.3 0.0 21.0 4.0 9.2 58.5 4.1 6.7 10.6 0.4 31.4 19.4 10.8 17.9 14.5 19.5 6.8 4.5 1.8 0.7 10.4 13.0 6.1 5.3 27.6 1.9 3.4 3.1 2.7 7.7 17.3 2.5 17.4 18.4 34.1 58.6 11.9 2.2 23.0 6.6 1.0 2.3 17.6 6.8 5.0 21.7 28.7 14.9 19.4 31.2 0.0 0.6 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.0 72.3 57.7 0.0 20.5 40.4 2.9 2.9 0.0 0.0 0.0 0.0 16.8 0.0 3.5 0.0 0.9 0.0 0.0 0.0 0.3 0.0 0.2 0.0 0.0 29.4 0.0 14.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 28.3 0.5 27.0 3.1 0.0 0.0 0.0 14.9 0.0 5.7 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 5.2 6.3 4.0 3.9 6.8 4.5 6.1 5.3 7.7 6.8 PSIP1 "DFS70, LEDGF, p52, p75, PSIP2" ENSG00000164985 "PC4 and SFRS1 interacting protein 1" O75475 9 15464066-15511019 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HEL: 130.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013718, HPA019697" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB013718: , HPA019697: AB_1852779" "unprognostic (8.54e-2)" "unprognostic (3.70e-2)" "unprognostic (1.31e-1)" "unprognostic (3.29e-2)" "unprognostic (1.22e-1)" "unprognostic (2.23e-1)" "unprognostic (2.89e-3)" "unprognostic (5.10e-2)" "unprognostic (5.93e-2)" "unprognostic (2.53e-2)" "unprognostic (6.49e-3)" "unprognostic (5.49e-2)" "unprognostic (6.98e-2)" "unprognostic (2.04e-1)" "unprognostic (2.99e-1)" "unprognostic (7.14e-2)" "unprognostic (1.39e-1)" 15.1 20.3 42.7 20.8 48.8 24.9 12.2 65.3 49.4 22.6 16.1 19.0 11.5 10.8 27.9 18.2 12.9 20.0 14.9 16.0 38.7 42.7 16.1 10.5 15.6 35.4 34.1 30.2 43.6 8.1 18.8 24.9 18.7 32.4 18.3 15.3 12.3 9.0 21.1 16.3 12.3 14.2 21.3 37.7 24.6 12.5 37.2 29.3 70.4 18.1 6.5 31.9 17.0 16.1 11.4 2.6 8.5 4.3 8.0 16.4 1.9 17.6 11.7 40.0 29.2 8.6 10.5 8.9 21.3 15.2 19.2 22.8 4.9 9.2 37.6 4.9 11.2 4.9 24.8 11.5 27.8 24.7 15.0 130.0 30.7 9.1 10.5 15.1 14.4 8.8 3.4 16.0 11.8 16.7 21.4 20.9 12.4 6.4 31.3 37.7 62.0 18.2 29.3 21.8 7.6 10.7 6.2 25.4 28.0 19.0 8.4 9.9 8.5 20.4 11.8 14.0 14.1 10.4 20.1 9.0 12.6 33.9 11.1 15.3 8.0 8.5 2.1 4.2 5.5 1.6 6.7 8.4 11.0 7.6 2.4 11.4 16.4 10.1 7.2 8.0 4.3 2.6 9.8 1.9 42.7 48.8 65.3 46.6 38.7 42.7 34.1 30.2 32.4 29.3 PTPRK R-PTP-kappa ENSG00000152894 "Protein tyrosine phosphatase, receptor type K" Q15262 6 127968779-128520674 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Hydrolase, Protein phosphatase, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "memory B-cell: 2.3;naive B-cell: 4.8;naive CD8 T-cell: 1.6" "Group enriched" "Detected in many" 7 "B-cells: 4.8;T-cells: 1.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA054056, HPA054822" Uncertain Supported "Vesicles,Plasma membrane,Cell Junctions" 13000000 "Cell Junctions" "Vesicles, Plasma membrane" "HPA054056: , HPA054822: " "unprognostic (3.15e-2)" "unprognostic (1.07e-2)" "unprognostic (5.79e-3)" "unprognostic (4.95e-3)" "unprognostic (1.89e-2)" "unprognostic (7.26e-2)" "unprognostic (3.27e-1)" "unprognostic (6.06e-2)" "unprognostic (2.04e-1)" "unprognostic (1.08e-1)" "prognostic unfavourable (1.99e-4)" "unprognostic (1.46e-1)" "prognostic favourable (9.33e-5)" "unprognostic (2.10e-1)" "unprognostic (1.55e-1)" "unprognostic (2.59e-1)" "unprognostic (9.32e-2)" 12.0 5.2 18.6 10.7 20.3 1.2 20.9 4.7 24.4 12.2 21.9 25.6 11.2 25.7 12.1 10.3 9.1 13.2 29.6 11.4 17.2 12.6 13.3 23.6 17.4 5.7 20.5 19.3 15.6 25.7 11.4 12.2 17.4 14.9 16.3 23.4 3.9 18.3 17.5 9.1 13.5 27.4 14.6 17.1 6.4 24.6 2.7 23.7 15.3 10.1 6.5 7.6 18.4 15.1 4.8 0.0 0.0 0.0 0.4 1.6 0.2 4.4 4.8 2.9 0.2 6.1 8.2 2.9 12.1 23.5 5.0 4.6 8.0 3.7 0.0 3.7 11.1 12.7 3.0 9.6 7.1 13.4 4.9 0.1 7.4 11.1 7.5 0.0 0.4 6.0 8.9 10.5 14.4 13.7 0.0 0.2 12.3 9.0 6.8 0.0 3.0 6.2 24.5 6.2 0.8 12.4 9.2 15.3 0.0 12.5 14.0 0.7 3.8 0.3 23.1 7.9 5.5 15.3 10.9 0.1 1.6 0.0 10.1 0.0 8.3 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.1 0.1 0.0 4.8 0.4 1.6 0.0 0.4 0.0 0.0 0.1 0.2 18.6 20.3 4.7 24.4 17.2 12.6 20.5 19.3 14.9 23.7 QKI QK3 ENSG00000112531 "QKI, KH domain containing RNA binding" Q96PU8 6 163414000-163578596 "Cancer-related genes, Predicted intracellular proteins" "Differentiation, mRNA processing, mRNA splicing, mRNA transport, Translation regulation, Transport" "Developmental protein, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 100.3" "Cell line enhanced" "Detected in all" "AF22: 64.0" "Cancer enriched" "Detected in all" 6 "glioma: 42.0" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019123, CAB022602" Enhanced Supported Supported Nucleoplasm Nucleoplasm "CAB022602: , HPA019123: AB_1855980" "unprognostic (2.42e-1)" "unprognostic (5.81e-2)" "unprognostic (1.31e-1)" "unprognostic (1.06e-2)" "unprognostic (8.57e-2)" "unprognostic (1.65e-1)" "prognostic unfavourable (1.27e-4)" "unprognostic (1.34e-1)" "unprognostic (7.06e-2)" "unprognostic (1.76e-3)" "unprognostic (1.08e-1)" "unprognostic (5.15e-2)" "prognostic unfavourable (2.31e-5)" "prognostic unfavourable (3.69e-4)" "unprognostic (1.16e-1)" "unprognostic (3.86e-1)" "unprognostic (4.09e-2)" 32.4 12.4 37.5 16.2 63.5 27.1 14.6 15.1 100.3 14.9 12.2 83.9 3.7 4.0 14.7 4.9 16.0 12.3 15.7 64.0 43.7 18.1 11.1 18.4 24.9 11.4 72.5 31.9 18.4 7.6 7.8 4.7 23.4 46.5 7.9 8.4 7.1 10.2 11.1 59.9 12.4 7.1 21.1 68.8 16.9 8.9 20.5 74.3 5.0 10.4 10.8 11.4 15.8 17.7 1.7 7.3 10.8 8.4 7.4 3.8 1.3 4.2 18.0 64.0 21.3 19.4 21.6 14.9 11.6 27.5 19.1 23.1 12.2 3.9 5.2 9.7 29.1 6.4 33.9 12.1 31.0 10.4 10.9 20.4 9.9 13.6 23.7 10.8 6.3 25.2 5.0 20.4 32.5 26.3 29.8 12.3 12.3 8.1 7.2 2.3 8.2 9.1 11.1 39.9 10.3 10.5 13.5 1.2 7.4 12.4 6.8 5.1 2.6 17.7 26.7 13.2 11.2 14.2 21.3 7.8 9.5 6.3 11.4 9.6 31.0 3.4 8.4 3.8 2.3 5.4 3.8 1.4 1.6 2.0 4.3 1.7 1.5 2.5 10.8 7.4 5.5 7.3 1.1 1.3 37.5 63.5 15.1 41.4 43.7 18.1 72.5 31.9 46.5 74.3 RABEP1 "neurocrescin, RAB5EP, rabaptin-5, RABPT5" ENSG00000029725 "Rabaptin, RAB GTPase binding effector protein 1" Q15276 17 5282265-5385812 "Cancer-related genes, Predicted intracellular proteins" "Apoptosis, Endocytosis, Protein transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004549, HPA019669, HPA024235, HPA024691" Supported Supported Vesicles Vesicles "CAB004549: AB_628192, HPA019669: AB_1856019, HPA024235: AB_1856020, HPA024691: AB_1856021" "unprognostic (3.22e-1)" "unprognostic (2.90e-2)" "unprognostic (2.45e-1)" "unprognostic (8.75e-3)" "unprognostic (1.64e-1)" "unprognostic (8.25e-2)" "unprognostic (3.71e-2)" "unprognostic (1.20e-1)" "unprognostic (1.60e-2)" "unprognostic (7.73e-2)" "prognostic favourable (6.43e-4)" "unprognostic (1.14e-1)" "unprognostic (6.09e-3)" "unprognostic (7.67e-2)" "unprognostic (2.60e-1)" "unprognostic (1.00e-1)" "unprognostic (9.00e-3)" 19.2 16.7 29.6 18.8 31.1 10.3 31.8 24.1 32.7 16.3 14.2 19.0 12.5 10.9 18.1 18.3 12.7 12.9 15.0 27.4 29.7 25.9 16.6 21.8 13.1 21.1 36.2 24.4 15.5 12.1 38.4 16.3 20.2 31.3 22.2 14.2 10.0 14.8 16.0 41.2 11.6 13.4 20.8 35.6 17.7 15.7 11.8 29.0 21.4 17.6 13.5 25.5 14.5 13.0 37.6 14.2 12.6 19.3 9.1 11.2 6.4 17.9 22.2 23.3 13.0 24.5 24.6 12.8 23.4 17.4 24.5 23.4 19.6 7.5 37.8 19.5 23.5 14.1 34.1 19.3 34.6 24.9 31.2 23.2 27.4 14.9 23.2 15.1 15.3 19.0 13.3 23.5 30.6 21.1 19.7 18.7 21.2 12.4 25.0 12.4 10.7 10.7 23.7 28.0 12.6 12.3 16.4 10.1 15.8 20.6 20.6 19.6 37.4 7.0 18.6 21.0 9.8 21.1 27.2 11.0 12.0 20.3 16.3 24.8 14.3 4.9 9.0 8.7 11.2 9.2 9.8 30.2 8.7 10.6 9.2 37.6 11.1 9.7 12.6 9.1 19.3 14.2 8.0 6.4 29.6 31.1 24.1 32.5 29.7 25.9 36.2 24.4 31.3 29.0 RAD51B "hREC2, R51H2, RAD51L1, REC2" ENSG00000182185 "RAD51 paralog B" O15315 14 67819779-68730218 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "DNA damage, DNA recombination, DNA repair" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB016191, HPA051869" Enhanced Approved "Nucleoplasm,Nuclear bodies" "Nuclear bodies" Nucleoplasm "CAB016191: AB_2238209, HPA051869: " "unprognostic (9.10e-3)" "unprognostic (5.45e-2)" "unprognostic (4.92e-1)" "unprognostic (6.65e-2)" "unprognostic (2.38e-2)" "unprognostic (4.85e-2)" "unprognostic (6.42e-3)" "unprognostic (2.54e-2)" "unprognostic (1.06e-1)" "unprognostic (3.08e-1)" "unprognostic (6.80e-3)" "unprognostic (1.47e-1)" "unprognostic (6.25e-2)" "unprognostic (1.77e-1)" "unprognostic (2.49e-2)" "unprognostic (6.79e-2)" "unprognostic (8.13e-3)" 5.1 4.9 4.2 4.6 10.1 9.2 8.2 2.0 5.6 8.2 4.3 11.6 11.2 1.7 10.8 13.8 7.0 6.0 6.4 3.4 5.6 3.2 4.3 3.2 5.0 6.6 9.2 4.0 10.0 5.7 8.0 10.0 8.0 7.5 7.0 4.0 9.4 18.7 3.8 2.4 7.1 5.8 6.7 7.3 6.9 3.7 3.4 7.3 12.6 4.9 4.6 12.1 7.7 8.3 13.6 6.6 14.0 5.9 7.8 10.1 4.8 12.2 4.8 5.4 3.3 5.1 8.7 3.4 6.2 4.8 6.9 8.9 3.4 16.7 15.1 4.1 3.8 11.1 3.4 9.9 9.5 6.7 3.5 7.2 4.4 2.7 2.7 6.0 7.3 4.4 7.7 7.9 8.4 6.2 5.8 7.0 5.6 9.5 11.8 2.1 3.2 4.9 13.3 6.5 5.5 5.4 3.5 3.7 2.4 5.0 1.8 10.7 8.4 5.5 1.6 8.5 8.2 6.6 5.1 3.4 3.4 12.0 4.6 10.7 4.7 14.0 5.9 5.4 8.6 4.7 7.1 13.6 8.2 9.2 6.5 11.5 10.1 9.7 0.7 7.8 4.5 6.6 9.1 4.8 4.2 10.1 2.0 5.6 5.6 3.2 9.2 4.0 7.5 7.3 RAF1 "c-Raf, CRAF, Raf-1" ENSG00000132155 "Raf-1 proto-oncogene, serine/threonine kinase" P04049 3 12583601-12664226 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Cardiomyopathy, Deafness, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 53.9" "Lineage enriched" "Detected in all" 5 "granulocytes: 53.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002640, CAB019291" Approved Approved "Nuclear speckles" "Nuclear speckles" "CAB019291: , HPA002640: AB_1856047" "unprognostic (6.33e-2)" "unprognostic (1.29e-1)" "unprognostic (5.92e-2)" "unprognostic (2.17e-3)" "unprognostic (6.51e-3)" "unprognostic (7.66e-3)" "unprognostic (2.66e-3)" "unprognostic (1.53e-2)" "unprognostic (2.72e-1)" "unprognostic (7.66e-2)" "unprognostic (2.92e-2)" "unprognostic (1.29e-2)" "unprognostic (2.79e-2)" "unprognostic (1.79e-1)" "unprognostic (1.27e-1)" "unprognostic (2.64e-2)" "unprognostic (2.36e-2)" 19.5 15.6 15.1 14.7 17.1 32.2 17.5 35.2 18.9 19.9 20.3 21.1 19.6 18.4 24.9 15.7 24.6 18.6 20.2 39.3 15.3 11.0 21.7 36.2 19.7 15.7 16.0 13.4 24.9 31.3 30.7 16.9 24.8 14.3 18.8 19.2 25.0 18.3 18.4 79.7 23.9 29.6 23.7 13.8 22.1 23.7 16.7 17.8 27.7 26.9 27.9 26.1 20.5 20.4 6.6 9.3 53.9 9.9 8.5 8.6 7.7 15.1 17.4 26.6 20.5 23.1 18.7 53.5 23.1 39.2 30.6 34.8 13.6 12.5 15.9 11.1 35.8 9.7 28.0 20.5 31.9 27.7 21.9 21.4 21.0 12.6 23.4 20.8 20.3 17.2 20.7 31.5 25.6 21.9 15.5 41.8 29.5 25.9 26.7 15.3 27.0 23.7 21.6 23.4 20.0 18.3 22.9 8.3 17.5 18.9 18.3 12.3 30.4 27.5 15.7 21.1 20.1 17.6 25.7 32.6 51.8 34.2 18.2 24.3 22.4 11.3 9.7 18.4 7.4 9.9 7.5 6.6 7.3 7.2 9.3 6.3 7.5 7.6 53.9 8.5 9.6 4.2 8.6 7.7 15.1 17.1 35.2 18.9 15.3 11.0 16.0 13.4 14.3 17.8 RANBP2 "ADANE, ANE1, NUP358" ENSG00000153201 "RAN binding protein 2" P49792 2 108719481-108785811 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters" "mRNA transport, Protein transport, Translocation, Transport, Ubl conjugation pathway" "RNA-binding, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "HPA018437, HPA023960, CAB034063, HPA049497, HPA051675, HPA067564" Supported Enhanced "Nuclear membrane,Vesicles" "Nuclear membrane, Vesicles" "CAB034063: AB_2176784, HPA018437: AB_2620151, HPA023960: , HPA049497: , HPA051675: , HPA067564: " "unprognostic (2.51e-1)" "unprognostic (3.99e-2)" "unprognostic (1.22e-1)" "unprognostic (4.37e-2)" "unprognostic (1.28e-2)" "unprognostic (9.30e-2)" "unprognostic (5.47e-2)" "unprognostic (2.91e-1)" "unprognostic (4.02e-2)" "unprognostic (2.54e-1)" "unprognostic (4.23e-1)" "unprognostic (5.23e-2)" "unprognostic (1.62e-2)" "unprognostic (8.74e-2)" "unprognostic (3.08e-1)" "unprognostic (3.40e-2)" "unprognostic (2.53e-1)" 20.5 24.3 14.4 17.0 18.6 35.5 24.4 23.1 22.2 19.8 17.1 12.8 25.5 13.3 19.9 21.5 17.0 19.1 14.8 20.2 12.9 12.5 18.9 19.5 17.7 19.2 15.1 17.0 32.4 24.1 48.5 37.5 18.8 16.5 21.8 15.8 14.3 20.0 31.6 37.5 17.3 17.4 23.2 17.8 16.3 20.9 20.6 15.9 26.6 28.7 18.0 17.5 20.5 19.7 5.6 5.1 8.3 6.3 4.2 8.7 2.3 18.2 11.2 16.1 14.6 18.8 16.9 15.6 16.5 13.1 13.6 12.0 27.8 8.8 28.8 12.8 17.1 15.4 27.5 17.1 19.9 17.5 13.3 30.0 13.9 19.6 11.0 35.0 10.1 14.1 13.1 21.3 16.6 20.8 32.1 16.0 18.0 10.1 15.5 14.3 20.3 13.4 14.6 24.8 13.9 12.1 22.9 23.5 10.8 14.6 12.6 16.0 8.0 16.1 24.8 14.3 18.9 10.0 18.4 13.3 19.6 26.2 11.1 15.8 11.0 8.3 5.3 5.1 7.6 3.4 8.7 5.5 6.3 6.9 4.2 5.6 6.2 6.7 8.3 4.2 6.3 5.1 5.1 2.3 14.4 18.6 23.1 22.2 12.9 12.5 15.1 17.0 16.5 15.9 RAP1GDS1 SmgGDS ENSG00000138698 "Rap1 GTPase-GDP dissociation stimulator 1" P52306 4 98261384-98443861 "Cancer-related genes, Predicted intracellular proteins" "GTPase activation" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA019060 Approved Supported Cytosol 120000 Cytosol "HPA019060: AB_1856068" "unprognostic (8.12e-2)" "unprognostic (1.50e-1)" "unprognostic (2.69e-3)" "unprognostic (1.66e-1)" "unprognostic (9.11e-2)" "unprognostic (1.35e-2)" "unprognostic (1.57e-3)" "unprognostic (3.44e-1)" "unprognostic (6.31e-2)" "unprognostic (1.27e-1)" "unprognostic (3.15e-1)" "unprognostic (4.60e-1)" "prognostic favourable (2.00e-4)" "unprognostic (7.11e-2)" "unprognostic (3.09e-1)" "unprognostic (1.47e-1)" "unprognostic (2.76e-1)" 11.3 9.7 25.8 12.9 28.2 9.0 13.1 28.0 43.6 9.3 12.0 20.0 9.0 7.3 8.9 8.7 13.7 6.1 8.6 6.8 29.7 28.0 12.3 15.2 10.1 15.3 36.9 20.5 7.9 13.8 8.4 15.3 9.6 30.1 8.0 14.0 8.0 8.6 11.9 3.6 10.5 9.0 16.3 37.0 12.5 8.2 15.5 26.2 16.2 13.0 4.8 17.0 12.5 7.6 13.9 31.9 16.0 14.7 19.5 22.7 8.4 17.7 10.3 13.2 11.3 17.1 20.5 5.3 30.2 16.8 18.0 14.2 7.7 23.0 21.1 9.8 22.5 10.1 16.3 27.6 24.4 21.5 6.7 13.0 13.3 10.0 33.9 21.6 9.1 23.8 16.9 15.9 24.7 23.6 8.6 18.1 44.6 9.3 35.7 10.7 4.8 7.5 14.9 7.9 7.1 18.3 13.9 19.6 11.9 12.6 28.4 16.7 6.4 14.1 23.2 18.7 13.5 8.6 17.9 6.2 10.8 17.7 15.5 16.2 24.3 16.0 10.6 5.7 14.2 14.6 14.3 13.9 14.5 13.6 16.7 11.0 7.8 11.9 1.6 19.5 14.7 31.9 22.7 8.4 25.8 28.2 28.0 30.5 29.7 28.0 36.9 20.5 30.1 26.2 RARA "NR1B1, RAR" ENSG00000131759 "Retinoic acid receptor alpha" P10276 17 40309192-40357643 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "MCF7: 63.1;SK-BR-3: 40.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 26.6" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA058282 Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA058282: " "unprognostic (8.05e-3)" "unprognostic (1.89e-1)" "unprognostic (9.48e-3)" "prognostic favourable (2.60e-4)" "unprognostic (8.67e-3)" "unprognostic (4.87e-3)" "unprognostic (2.77e-1)" "unprognostic (5.73e-2)" "unprognostic (1.45e-1)" "unprognostic (3.54e-2)" "unprognostic (1.19e-1)" "unprognostic (1.79e-1)" "unprognostic (2.29e-3)" "unprognostic (1.59e-2)" "unprognostic (5.60e-2)" "unprognostic (1.60e-1)" "unprognostic (1.09e-2)" 27.6 13.5 5.0 18.6 7.6 32.3 23.7 11.5 15.2 30.2 29.6 5.0 16.8 18.0 23.8 23.9 17.3 23.3 30.2 24.3 5.9 6.1 14.6 24.0 32.0 23.4 4.6 7.8 50.0 9.3 7.4 18.1 16.6 6.5 22.9 8.5 26.8 12.1 32.7 43.1 14.3 31.6 18.6 3.7 31.1 14.3 21.8 2.9 9.7 16.3 15.4 20.2 31.5 20.3 1.0 6.1 26.6 9.3 2.5 2.6 1.9 5.0 11.9 3.6 6.0 7.0 10.8 3.6 4.2 6.3 6.2 4.0 8.2 4.4 2.7 6.6 9.4 14.9 4.1 9.9 3.5 20.2 6.1 7.7 6.0 8.0 11.3 2.7 24.4 15.1 2.9 6.5 8.3 9.1 4.8 5.9 6.9 63.1 1.7 9.4 3.1 3.8 3.6 21.1 10.2 3.6 4.0 1.5 12.2 8.9 40.1 12.2 37.8 11.1 10.6 7.7 13.2 13.5 4.5 14.2 4.7 2.3 12.9 5.5 22.8 8.7 4.2 15.7 1.6 6.9 2.6 1.0 1.7 1.7 6.1 0.9 0.8 1.3 26.6 2.5 9.3 1.8 1.4 1.9 5.0 7.6 11.5 15.2 5.9 6.1 4.6 7.8 6.5 2.9 RBM15 "OTT, OTT1" ENSG00000162775 "RNA binding motif protein 15" Q96T37 1 110338506-110346681 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction" RNA-binding "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 48.7" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB015201, HPA019824, HPA049642" Supported Enhanced Nucleoplasm Nucleoplasm "CAB015201: , HPA019824: AB_1856113, HPA049642: " "unprognostic (1.70e-1)" "unprognostic (1.63e-1)" "unprognostic (9.39e-2)" "unprognostic (7.57e-3)" "unprognostic (2.43e-1)" "unprognostic (2.11e-2)" "prognostic unfavourable (7.61e-4)" "unprognostic (1.13e-1)" "unprognostic (1.84e-2)" "unprognostic (4.91e-2)" "unprognostic (9.67e-2)" "unprognostic (2.76e-2)" "prognostic unfavourable (1.37e-4)" "prognostic favourable (7.97e-4)" "unprognostic (2.88e-1)" "unprognostic (2.46e-2)" "unprognostic (2.12e-1)" 8.5 7.6 6.3 12.2 7.6 48.7 7.9 18.6 8.3 6.6 8.8 7.6 8.3 7.3 8.5 7.2 8.0 7.3 6.6 8.8 5.2 4.3 6.3 11.0 10.5 13.7 8.3 6.0 8.6 7.5 7.1 8.1 7.1 5.9 5.7 5.7 8.1 7.4 6.4 17.2 7.2 11.3 5.5 5.0 12.5 8.3 14.0 7.9 21.8 7.0 5.3 13.4 6.5 8.6 10.5 4.8 9.8 6.9 5.0 9.9 5.5 7.0 7.7 6.9 7.1 4.4 4.6 10.9 3.7 4.9 5.9 7.8 9.4 6.5 13.3 6.0 4.2 10.0 10.8 9.4 8.8 13.8 10.0 10.8 11.7 6.8 6.2 11.7 11.5 4.2 6.6 8.2 7.7 6.3 15.2 23.4 5.9 7.2 10.5 9.2 14.8 4.3 12.5 10.5 9.1 4.8 7.1 8.4 4.2 8.2 10.3 7.9 7.2 14.1 4.3 5.7 10.2 6.1 6.8 18.0 9.1 28.9 8.5 11.8 7.0 8.2 6.9 9.4 7.0 6.0 9.9 10.5 7.7 6.0 4.8 10.0 6.8 8.2 9.8 5.0 6.4 4.7 7.5 5.5 6.3 7.6 18.6 8.3 5.2 4.3 8.3 6.0 5.9 7.9 RET "CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51" ENSG00000165731 "Ret proto-oncogene" P07949 10 43077027-43130351 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Hirschsprung disease, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "parathyroid gland: 63.9" "Cell line enhanced" "Detected in some" "MCF7: 17.6;NB-4: 11.6;SH-SY5Y: 89.7;THP-1: 26.8" "Cancer enhanced" "Detected in many" "breast cancer: 11.0" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "non-classical monocyte: 6.7" "Group enriched" "Detected in many" 13 "dendritic cells: 2.1;monocytes: 6.7" "Low region specificity" "Detected in many" "Region enriched" "Detected in many" 6 "midbrain: 95.5" "CAB002581, HPA008356, HPA008495" Approved Supported Approved "Golgi apparatus,Plasma membrane,Cytosol" 260000 "Golgi apparatus, Cytosol" "Plasma membrane" "CAB002581: AB_563673, HPA008356: AB_1847232, HPA008495: " "unprognostic (7.94e-2)" "unprognostic (3.68e-2)" "unprognostic (4.49e-1)" "prognostic unfavourable (5.02e-4)" "unprognostic (1.15e-1)" "unprognostic (9.13e-4)" "unprognostic (1.27e-2)" "unprognostic (3.62e-2)" "unprognostic (2.86e-1)" "unprognostic (2.01e-1)" "unprognostic (1.54e-3)" "unprognostic (4.43e-1)" "unprognostic (9.35e-5)" "unprognostic (1.64e-3)" "unprognostic (8.28e-2)" "unprognostic (3.67e-3)" "unprognostic (2.02e-2)" 1.8 15.2 1.1 1.8 1.3 0.7 1.2 4.1 9.0 1.9 3.1 0.9 1.1 1.5 0.9 0.6 1.2 0.7 1.0 1.2 1.5 5.8 1.0 11.7 0.7 0.8 17.5 1.2 0.8 1.3 63.9 6.3 0.8 16.8 2.2 1.5 2.8 13.6 2.0 4.5 1.1 2.6 1.1 2.8 0.6 2.1 2.0 0.0 0.1 0.8 5.1 0.6 1.9 1.4 0.2 2.1 0.0 6.7 0.0 0.3 0.4 0.0 0.1 0.0 0.5 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 17.6 0.0 11.6 2.1 0.0 0.0 0.0 0.0 0.0 0.0 1.3 89.7 0.0 0.0 0.0 1.2 26.8 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.8 0.0 0.2 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 6.7 2.1 0.3 0.4 1.1 1.3 4.1 9.0 1.5 5.8 17.5 1.2 16.8 0.0 RHOH "ARHH, RhoH, TTF" ENSG00000168421 "Ras homolog family member H" Q15669 4 40191053-40246967 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 54.8;lymphoid tissue: 94.7" "Cell line enhanced" "Detected in some" "Daudi: 35.6;HMC-1: 27.4;MOLT-4: 49.6;U-266/70: 19.2;U-266/84: 15.4;U-698: 32.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA030345, HPA061314" Uncertain Approved "Golgi apparatus,Vesicles" "Golgi apparatus, Vesicles" "HPA030345: AB_10601607, HPA061314: " "unprognostic (4.00e-2)" "unprognostic (1.83e-4)" "unprognostic (1.24e-2)" "unprognostic (2.22e-5)" "unprognostic (1.35e-1)" "unprognostic (1.32e-3)" "unprognostic (1.16e-1)" "unprognostic (2.73e-2)" "unprognostic (2.30e-2)" "unprognostic (4.30e-2)" "unprognostic (9.07e-2)" "unprognostic (1.38e-1)" "unprognostic (3.31e-6)" "unprognostic (2.96e-1)" "unprognostic (3.91e-2)" "unprognostic (4.46e-2)" "unprognostic (2.44e-2)" 1.8 0.6 0.6 33.8 1.1 21.7 5.2 0.4 0.4 1.3 2.4 0.5 0.4 1.6 2.0 0.9 2.5 1.5 4.1 1.1 0.6 0.7 1.6 1.7 4.8 43.2 0.8 0.2 0.7 0.8 0.0 0.9 0.3 0.8 2.1 2.0 1.0 7.8 0.6 0.5 1.2 15.1 0.7 1.2 33.1 2.7 0.7 0.6 94.7 1.6 1.9 41.0 5.1 1.5 41.2 4.7 32.2 0.2 12.3 54.8 21.1 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 35.6 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 5.3 0.0 0.0 0.0 5.8 27.4 0.4 0.0 0.0 0.0 0.0 0.4 0.3 0.0 0.0 49.6 3.7 0.6 0.1 5.3 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.6 0.1 0.1 0.0 0.1 0.0 0.0 19.2 15.4 32.9 0.0 1.2 0.0 32.2 0.2 29.6 21.6 0.1 19.4 30.5 34.6 29.1 0.3 41.2 54.8 43.3 1.6 12.3 0.2 4.7 47.0 21.1 0.6 1.1 0.4 0.4 0.6 0.7 0.8 0.2 0.8 0.6 RMI2 "BLAP18, C16orf75, MGC24665" ENSG00000175643 "RecQ mediated genome instability 2" Q96E14 16 11249619-11351762 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "DNA replication" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 31.7;testis: 29.6" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "memory B-cell: 6.5" "Group enriched" "Detected in many" 5 "B-cells: 6.5;T-cells: 3.0" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" HPA040995 Uncertain Supported "Nuclear speckles,Cytosol" "Nuclear speckles" Cytosol "HPA040995: AB_10795531" "unprognostic (2.76e-1)" "prognostic favourable (5.69e-5)" "unprognostic (1.17e-1)" "unprognostic (3.09e-3)" "unprognostic (1.69e-2)" "unprognostic (1.80e-3)" "prognostic unfavourable (2.77e-5)" "unprognostic (3.98e-1)" "unprognostic (1.16e-1)" "unprognostic (1.83e-1)" "unprognostic (3.44e-3)" "unprognostic (3.89e-1)" "unprognostic (2.18e-1)" "unprognostic (5.50e-2)" "unprognostic (3.68e-2)" "unprognostic (3.60e-3)" "unprognostic (1.03e-1)" 1.0 1.8 4.2 18.0 5.1 4.8 2.8 0.7 4.1 2.8 7.3 1.0 0.4 4.3 2.5 3.2 11.8 1.0 2.6 1.9 2.5 1.5 3.1 2.3 2.9 17.9 1.6 5.6 3.6 1.6 0.7 1.1 13.2 1.2 2.6 9.0 0.8 2.9 1.7 1.1 8.7 5.6 1.1 1.4 4.2 4.0 29.6 1.2 31.7 1.4 2.8 20.4 3.6 4.5 6.5 0.6 0.9 0.0 0.3 3.0 0.3 19.0 12.8 25.1 10.7 1.1 5.5 10.5 11.1 8.8 10.5 17.6 4.9 22.7 26.5 9.6 5.2 11.2 10.7 10.6 17.1 5.2 10.0 14.5 7.6 32.4 0.4 5.6 6.5 1.2 2.0 4.5 4.4 5.7 20.0 21.1 5.5 22.0 19.2 26.0 21.1 5.1 23.3 27.1 28.3 6.2 12.4 14.5 11.5 9.4 15.8 8.2 26.7 8.4 1.8 8.5 7.9 16.2 1.6 5.8 9.5 31.4 7.9 18.4 15.5 0.0 0.0 0.9 0.6 0.0 0.0 6.5 0.2 0.0 0.4 2.5 1.8 0.7 0.2 0.3 0.0 0.6 3.0 0.3 4.2 5.1 0.7 4.1 2.5 1.5 1.6 5.6 1.2 1.2 RNF213 "C17orf27, KIAA1554, KIAA1618, MYMY2, NET57" ENSG00000173821 "Ring finger protein 213" Q63HN8 17 80260866-80398786 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Angiogenesis, Ubl conjugation pathway" "Hydrolase, Transferase" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HDLM-2: 36.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003347, HPA026790" Approved Supported Cytosol Cytosol "HPA003347: AB_1079204, HPA026790: AB_10602296" "unprognostic (8.98e-2)" "unprognostic (1.60e-1)" "unprognostic (8.97e-3)" "prognostic unfavourable (4.65e-5)" "unprognostic (7.39e-2)" "unprognostic (3.99e-2)" "unprognostic (2.23e-2)" "unprognostic (1.52e-1)" "unprognostic (4.57e-2)" "unprognostic (3.85e-1)" "unprognostic (1.96e-2)" "unprognostic (1.12e-1)" "unprognostic (1.52e-3)" "unprognostic (8.92e-2)" "unprognostic (1.13e-2)" "unprognostic (1.40e-1)" "unprognostic (4.56e-2)" 17.0 15.1 7.4 16.9 10.3 22.4 10.2 4.7 7.5 11.0 12.2 15.6 14.9 8.5 16.6 13.0 13.2 9.7 12.1 8.5 7.8 7.8 17.1 11.6 15.4 17.9 10.9 5.6 11.5 9.0 41.1 11.4 15.1 10.0 11.2 8.0 12.3 11.7 12.5 9.0 8.7 14.8 13.6 14.3 17.0 10.6 5.9 8.7 24.5 15.9 7.5 18.2 13.6 15.4 7.2 13.9 37.9 9.6 11.4 12.1 1.8 16.1 28.7 2.9 2.0 10.5 16.1 2.2 4.1 8.9 18.5 15.8 3.0 7.5 1.0 3.5 8.5 9.4 3.9 5.3 6.3 36.5 1.7 2.5 11.6 5.3 4.5 2.6 2.6 8.8 3.6 10.4 4.5 14.2 4.6 6.0 6.9 3.9 10.5 1.1 2.1 6.6 7.2 6.7 1.2 5.1 14.0 2.8 3.9 9.9 21.1 7.5 4.8 3.3 18.3 10.3 8.2 6.0 4.2 2.6 2.4 2.9 7.7 3.1 3.7 6.9 9.6 4.2 12.1 8.0 8.1 6.2 8.6 9.7 2.3 7.2 6.9 8.5 37.9 11.4 6.9 13.9 6.4 1.8 7.4 10.3 4.7 7.5 7.8 7.8 10.9 5.6 10.0 8.7 ROS1 "c-ros-1, MCF3, ROS" ENSG00000047936 "ROS proto-oncogene 1, receptor tyrosine kinase" P08922 6 117288300-117425855 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "epididymis: 38.6;lung: 20.2" "Group enriched" "Detected in some" 5 "HSkMC: 9.3;hTCEpi: 19.3;LHCN-M2: 13.4" "Cancer enriched" "Detected in some" 13 "lung cancer: 6.9" "Group enriched" "Detected in some" 10 "cerebral cortex: 7.4;olfactory region: 2.5" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA049098, HPA072424" Uncertain Approved Vesicles Vesicles "HPA049098: , HPA072424: " "unprognostic (8.18e-2)" "unprognostic (4.64e-3)" "unprognostic (1.60e-1)" "unprognostic (2.37e-2)" "unprognostic (7.57e-2)" "unprognostic (2.05e-2)" "unprognostic (1.57e-1)" "unprognostic (1.79e-1)" "unprognostic (2.79e-2)" "unprognostic (1.00e-2)" "unprognostic (2.42e-1)" "unprognostic (5.20e-2)" "unprognostic (1.56e-12)" "unprognostic (1.09e-2)" "unprognostic (2.81e-1)" "unprognostic (1.91e-1)" "unprognostic (2.12e-1)" 0.3 0.2 0.2 0.0 0.4 0.0 0.2 0.2 7.4 0.2 0.4 0.0 7.9 0.0 0.2 38.6 0.2 0.2 0.0 0.2 0.2 0.2 0.4 0.2 20.2 0.0 0.2 2.5 0.2 0.2 0.0 0.3 0.7 0.0 0.2 0.3 0.0 0.2 2.3 0.2 0.7 0.3 0.0 0.2 0.2 0.3 0.7 0.0 0.0 0.2 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 9.3 19.3 0.2 1.7 0.0 0.0 0.0 13.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 0.0 0.0 0.0 1.8 0.0 2.3 1.5 0.1 1.8 0.0 0.0 0.0 1.7 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.4 0.2 7.4 0.2 0.2 0.2 2.5 0.0 0.0 RPL22 "EAP, L22" ENSG00000116251 "Ribosomal protein L22" P35268 1 6181269-6209389 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins" "Heparin-binding, Ribonucleoprotein, Ribosomal protein, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA068294 Approved Nucleoplasm,Nucleoli 320000 Nucleoli Nucleoplasm "HPA068294: " "unprognostic (3.16e-3)" "unprognostic (1.28e-1)" "unprognostic (3.13e-1)" "unprognostic (3.62e-2)" "unprognostic (2.27e-2)" "unprognostic (1.09e-1)" "unprognostic (1.29e-3)" "unprognostic (4.40e-2)" "unprognostic (7.06e-2)" "unprognostic (3.26e-1)" "unprognostic (1.48e-1)" "unprognostic (4.24e-2)" "unprognostic (1.46e-3)" "unprognostic (3.83e-1)" "unprognostic (3.88e-2)" "unprognostic (2.46e-1)" "unprognostic (1.98e-1)" 75.5 71.5 54.3 79.7 42.8 124.7 75.0 46.7 39.5 95.8 73.9 39.2 53.9 66.5 133.6 63.9 103.9 59.1 61.8 50.8 47.4 38.6 58.8 90.2 55.3 142.6 50.6 39.7 163.1 154.8 30.4 57.0 49.8 37.4 90.8 46.4 57.0 140.3 66.8 114.0 79.7 62.6 106.6 58.3 79.1 62.0 38.2 35.0 95.3 91.0 112.8 81.1 101.5 91.9 75.6 62.3 11.0 38.9 42.2 98.8 73.9 88.0 25.1 53.5 54.6 37.7 59.3 42.3 76.9 30.9 28.3 24.2 49.8 76.6 136.7 63.3 28.5 50.9 40.2 40.0 37.3 66.9 65.4 132.8 57.2 61.7 37.4 175.7 53.3 52.3 33.1 25.2 52.2 35.3 109.4 82.8 32.5 38.8 76.8 143.4 33.3 55.7 74.1 111.0 105.8 41.4 30.6 74.0 67.9 62.6 181.4 140.8 58.4 139.3 86.3 40.4 44.5 53.3 72.2 66.7 91.4 206.8 26.7 181.7 25.0 11.0 38.9 8.8 38.0 34.3 66.9 75.6 71.1 52.3 59.8 72.4 98.8 78.1 2.9 42.2 27.8 62.3 54.0 73.9 54.3 42.8 46.7 39.5 47.4 38.6 50.6 39.7 37.4 35.0 RPN1 OST1 ENSG00000163902 "Ribophorin I" P04843 3 128619970-128681075 "Cancer-related genes, Plasma proteins, Predicted membrane proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009748, HPA026828, HPA051520" Enhanced Enhanced "Endoplasmic reticulum" 8200000 "Endoplasmic reticulum" "CAB009748: AB_2182230, HPA026828: AB_10610418, HPA051520: AB_2681521" "unprognostic (4.83e-2)" "unprognostic (5.92e-2)" "unprognostic (1.10e-1)" "unprognostic (7.67e-2)" "unprognostic (2.36e-1)" "unprognostic (2.12e-2)" "prognostic unfavourable (4.80e-4)" "unprognostic (2.71e-1)" "unprognostic (2.43e-1)" "unprognostic (2.28e-2)" "unprognostic (4.58e-3)" "unprognostic (2.87e-1)" "unprognostic (7.68e-2)" "unprognostic (7.86e-2)" "unprognostic (1.52e-2)" "unprognostic (1.44e-1)" "unprognostic (9.74e-2)" 52.3 37.5 22.2 26.6 23.8 24.4 48.2 20.9 31.4 45.8 40.8 31.9 58.8 28.5 38.3 110.2 32.2 38.3 38.8 47.1 23.0 28.0 55.4 174.0 47.4 50.6 26.4 18.3 37.8 62.9 43.5 36.9 58.3 24.3 31.4 41.1 28.6 54.1 55.5 34.4 24.0 37.0 33.5 31.8 48.0 33.7 26.9 23.3 34.3 69.1 27.3 36.5 32.7 39.7 26.7 53.1 64.4 43.5 23.4 45.1 53.3 60.8 33.2 27.7 51.0 75.1 50.3 62.8 52.5 69.0 69.8 81.3 68.7 57.3 38.1 49.5 75.7 61.3 44.7 46.7 68.3 27.3 28.7 67.2 24.7 56.4 82.8 54.4 35.4 41.7 54.7 45.9 67.9 54.4 27.6 51.1 45.7 55.6 30.2 59.8 35.1 30.4 33.0 37.3 91.6 48.3 36.6 42.7 24.6 43.1 44.7 53.1 47.8 56.4 35.4 36.1 28.2 52.7 38.9 55.2 43.4 40.7 59.2 40.6 52.0 38.8 43.5 35.7 37.3 40.0 45.1 26.7 30.7 33.8 43.5 18.3 19.1 29.2 64.4 23.4 40.2 53.1 30.5 53.3 22.2 23.8 20.9 31.4 23.0 28.0 26.4 18.3 24.3 23.3 RSPO2 MGC35555 ENSG00000147655 "R-spondin 2" Q6UXX9 8 107899316-108083648 "Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins" "Sensory transduction, Wnt signaling pathway" "Developmental protein, Heparin-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 27.0;placenta: 20.1" "Cell line enhanced" "Detected in some" "HEK 293: 3.5;HEL: 3.3;NTERA-2: 2.0;U-138 MG: 3.5;U-266/70: 10.4" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 5 "intermediate monocyte: 1.6" "Lineage enriched" "Detected in single" 17 "monocytes: 1.6" "Group enriched" "Detected in some" 7 "amygdala: 8.2;cerebral cortex: 18.2;hippocampal formation: 23.2" "Group enriched" "Detected in many" 5 "amygdala: 23.3;cerebral cortex: 18.0;hippocampal formation: 24.1;midbrain: 33.2" "HPA024764, CAB025900, HPA053068" Uncertain "Secreted in other tissues" "CAB025900: , HPA024764: AB_10603236, HPA053068: " "unprognostic (1.10e-2)" "unprognostic (2.18e-1)" "unprognostic (3.97e-2)" "unprognostic (1.52e-1)" "unprognostic (2.04e-1)" "unprognostic (1.19e-1)" "unprognostic (8.33e-3)" "unprognostic (1.82e-1)" "unprognostic (9.48e-2)" "unprognostic (1.31e-1)" "unprognostic (1.40e-1)" "unprognostic (8.45e-2)" "unprognostic (1.95e-2)" "unprognostic (1.17e-2)" 0.4 0.5 3.9 1.4 6.3 0.5 0.2 1.9 27.0 3.6 12.0 4.2 3.6 5.1 0.3 3.6 8.9 0.2 4.8 0.5 5.8 10.5 0.2 1.1 9.3 0.2 15.7 5.4 1.1 0.2 0.2 2.8 20.1 2.0 11.6 10.1 15.5 0.2 3.4 0.3 0.3 5.8 0.7 1.3 0.2 8.3 2.0 1.7 0.0 0.2 0.0 0.2 2.2 1.2 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.5 3.3 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.3 0.0 0.0 0.6 0.0 0.0 0.0 0.0 2.0 0.1 0.0 0.0 1.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.2 0.0 3.5 0.2 0.1 0.0 10.4 0.0 0.0 1.0 0.4 0.0 0.0 0.3 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.9 6.3 1.9 27.0 5.8 10.5 15.7 5.4 2.0 1.7 RSPO3 "FLJ14440, THSD2" ENSG00000146374 "R-spondin 3" Q9BXY4 6 127118604-127197765 "Cancer-related genes, Predicted secreted proteins" "Sensory transduction, Wnt signaling pathway" Heparin-binding "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enriched" "Detected in some" 4 "A549: 23.4" "Low cancer specificity" "Detected in many" "Group enriched" "Detected in many" 5 "cerebellum: 5.7;hippocampal formation: 20.5" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Region enhanced" "Detected in many" "hippocampal formation: 32.5" HPA029957 Uncertain "Secreted to blood" "HPA029957: AB_10602087" "unprognostic (4.77e-2)" "unprognostic (3.95e-2)" "unprognostic (1.27e-2)" "unprognostic (2.27e-2)" "unprognostic (1.10e-1)" "unprognostic (2.99e-1)" "unprognostic (9.71e-2)" "unprognostic (1.49e-2)" "unprognostic (3.77e-2)" "unprognostic (3.21e-1)" "unprognostic (1.37e-1)" "unprognostic (3.37e-1)" "unprognostic (1.07e-3)" "unprognostic (7.94e-2)" "unprognostic (2.76e-1)" "unprognostic (1.64e-2)" "unprognostic (7.89e-3)" 18.5 10.5 2.8 12.1 0.8 0.0 40.7 5.7 2.3 12.9 8.5 0.0 23.8 1.2 50.3 32.5 23.7 14.9 7.6 4.2 20.5 1.7 3.3 4.2 3.8 10.2 0.8 2.4 13.2 1.5 0.0 2.6 24.1 0.8 10.2 4.7 8.6 3.9 15.3 19.7 2.2 6.7 34.1 0.6 1.4 10.8 12.4 0.0 0.2 2.9 2.1 0.9 9.3 39.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 23.4 0.0 0.0 1.3 0.0 0.0 0.0 4.0 0.2 0.5 0.0 0.0 0.0 0.5 0.2 0.0 0.6 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.2 0.0 0.0 0.5 0.0 0.0 0.0 2.6 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 1.2 0.0 0.0 0.0 0.0 0.0 5.2 2.0 0.7 0.0 0.0 0.0 0.0 5.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.8 0.8 5.7 2.2 20.5 1.7 0.8 2.4 0.8 0.0 RUNX1 "AML1, AMLCR1, CBFA2, PEBP2A2" ENSG00000159216 "Runt related transcription factor 1" Q01196 21 34787801-36004667 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "breast: 54.3;lymphoid tissue: 58.6" "Cell line enhanced" "Detected in many" "HEL: 65.0;HMC-1: 39.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 17.0" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" "HPA004176, HPA037912" Enhanced Enhanced Nucleoplasm,Vesicles Nucleoplasm Vesicles "HPA004176: AB_1078412, HPA037912: " "unprognostic (4.06e-3)" "unprognostic (2.35e-2)" "unprognostic (1.42e-2)" "unprognostic (1.52e-1)" "unprognostic (5.15e-3)" "unprognostic (2.62e-1)" "unprognostic (5.87e-2)" "unprognostic (1.15e-1)" "unprognostic (1.13e-1)" "unprognostic (1.12e-3)" "unprognostic (2.33e-2)" "unprognostic (3.47e-2)" "prognostic unfavourable (3.44e-15)" "unprognostic (1.48e-1)" "unprognostic (1.50e-1)" "unprognostic (6.17e-2)" "unprognostic (5.47e-2)" 11.5 3.2 5.2 14.8 7.3 29.8 54.3 1.0 4.3 12.5 4.7 3.8 4.0 3.8 2.9 7.4 6.5 4.6 12.4 7.6 6.1 2.0 4.2 6.7 17.9 13.9 8.5 1.1 6.5 5.8 1.6 5.5 6.4 6.0 9.9 5.1 3.5 29.8 8.8 14.4 8.3 5.1 6.8 12.3 10.6 12.7 2.9 6.6 58.6 4.6 5.7 14.2 11.0 9.1 3.2 3.4 17.0 3.9 1.3 4.8 2.0 13.0 1.0 0.0 0.1 3.4 4.4 8.6 7.4 7.5 4.1 3.1 0.6 10.0 6.4 0.5 6.5 11.8 0.8 8.8 6.0 9.9 1.0 65.0 2.6 3.0 6.3 7.5 39.2 8.5 5.3 12.5 12.4 2.3 4.4 3.8 8.7 2.8 30.3 11.9 0.6 3.8 30.7 22.8 3.9 5.5 5.2 0.3 0.0 7.6 1.9 2.7 3.9 17.6 9.7 6.8 8.8 10.1 11.1 12.5 5.1 6.1 8.5 16.5 9.9 17.0 3.2 6.3 3.4 1.4 3.3 3.2 3.1 3.2 0.9 3.1 4.8 3.8 3.5 1.3 3.9 3.4 4.0 2.0 5.2 7.3 1.0 4.3 6.1 2.0 8.5 1.1 6.0 6.6 RUNX1T1 "AML1T1, CBFA2T1, CDR, ETO, MTG8, ZMYND2" ENSG00000079102 "RUNX1 translocation partner 1" Q06455 8 91954967-92103286 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "brain: 57.8" "Cell line enhanced" "Detected in many" "Daudi: 12.9;fHDF/TERT166: 11.0;HEL: 23.7;HSkMC: 9.5" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in all" 4 "cerebellum: 57.8" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA049852, HPA070951" Approved Supported Nucleoplasm Nucleoplasm "HPA049852: , HPA070951: " "unprognostic (2.37e-1)" "unprognostic (1.90e-1)" "unprognostic (1.90e-1)" "unprognostic (2.35e-1)" "unprognostic (1.62e-1)" "unprognostic (3.37e-4)" "unprognostic (2.29e-4)" "unprognostic (5.56e-3)" "unprognostic (1.24e-2)" "unprognostic (1.62e-2)" "unprognostic (2.11e-2)" "unprognostic (2.37e-1)" "unprognostic (5.70e-4)" "unprognostic (8.98e-3)" "unprognostic (6.78e-2)" "unprognostic (1.51e-1)" "unprognostic (7.80e-3)" 9.6 4.6 7.7 4.5 11.5 0.4 6.9 57.8 13.0 14.0 7.8 1.1 2.0 2.0 11.8 5.9 4.1 7.7 7.8 12.3 5.8 4.0 2.5 1.3 6.0 2.0 3.6 9.6 7.7 1.8 1.7 8.6 8.7 4.2 4.2 4.0 5.3 4.7 4.1 5.5 3.6 3.6 10.3 3.0 2.9 4.2 5.6 3.7 0.0 5.2 3.3 1.8 5.7 5.9 0.0 0.1 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.3 1.3 3.5 5.1 0.0 5.1 7.8 3.4 5.3 0.0 0.0 12.9 0.0 11.0 0.0 2.7 0.3 2.3 0.0 2.1 23.7 0.0 0.0 1.4 0.0 0.0 9.5 0.0 5.7 0.2 7.3 0.1 0.0 0.8 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 7.7 4.1 0.0 0.0 0.0 0.0 0.0 0.8 0.3 0.0 0.6 0.0 2.6 0.0 4.1 0.5 0.0 1.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 7.7 11.5 57.8 13.0 5.8 4.0 3.6 9.6 4.2 3.7 SDC4 "amphiglycan, ryudocan, SYND4" ENSG00000124145 "Syndecan 4" P31431 20 45325288-45348424 "Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins, Transporters" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 141.1" "Cell line enhanced" "Detected in many" "HBEC3-KT: 73.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA005716, CAB013240" Enhanced Approved "Golgi apparatus,Plasma membrane" "Secreted to blood" "Golgi apparatus" "Plasma membrane" "CAB013240: AB_2533250, HPA005716: AB_1080160" "unprognostic (1.34e-2)" "unprognostic (1.80e-1)" "unprognostic (1.71e-2)" "unprognostic (2.16e-1)" "unprognostic (5.39e-2)" "unprognostic (6.59e-3)" "unprognostic (1.16e-1)" "unprognostic (5.93e-2)" "unprognostic (2.68e-1)" "unprognostic (2.95e-2)" "prognostic unfavourable (4.20e-4)" "unprognostic (1.97e-1)" "prognostic favourable (2.44e-7)" "unprognostic (3.00e-1)" "unprognostic (2.18e-1)" "prognostic favourable (2.67e-4)" "unprognostic (7.42e-2)" 15.9 26.2 19.9 15.7 24.3 3.5 40.5 6.9 20.1 20.4 24.8 19.2 9.0 13.3 17.6 14.7 42.4 27.4 26.2 19.5 19.8 12.1 56.6 141.1 56.7 4.8 23.5 20.5 14.7 36.6 6.2 12.5 23.0 30.9 19.5 22.3 21.8 47.6 17.5 25.5 45.5 13.8 38.7 23.0 9.0 46.9 33.7 15.7 2.0 26.5 25.2 23.5 34.4 16.4 0.7 2.8 2.0 3.1 1.4 8.1 1.2 22.6 2.9 1.6 0.1 40.4 24.9 69.8 29.0 39.6 32.8 23.6 34.5 57.9 0.0 13.0 36.4 29.4 1.1 73.7 40.0 6.5 1.0 0.7 2.4 13.4 44.1 0.1 1.2 33.5 49.4 13.5 33.1 4.3 1.1 0.0 18.9 22.5 0.0 2.0 2.9 9.1 0.0 14.6 0.0 54.0 30.2 0.6 2.3 39.8 24.7 7.1 17.9 1.3 8.1 25.1 20.9 2.5 18.6 1.2 0.9 0.1 39.5 2.3 14.9 2.0 3.1 0.7 1.3 1.1 4.1 0.6 4.1 1.6 2.8 0.7 0.9 1.1 1.6 1.4 1.1 2.5 8.1 1.2 19.9 24.3 6.9 20.1 19.8 12.1 23.5 20.5 30.9 15.7 SET "2PP2A, IPP2A2, PHAPII" ENSG00000119335 "SET nuclear proto-oncogene" Q01105 9 128683424-128696400 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction" "Chaperone, DNA-binding" "Cancer-related genes, Disease mutation, Mental retardation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "CAB005232, HPA063683" Supported Enhanced "Nucleoplasm,Lipid droplets" 880000 Nucleoplasm "Lipid droplets" "CAB005232: AB_2185634, HPA063683: " "unprognostic (1.92e-1)" "unprognostic (2.22e-1)" "unprognostic (2.31e-1)" "unprognostic (3.77e-1)" "unprognostic (7.15e-2)" "unprognostic (4.37e-3)" "prognostic unfavourable (9.41e-7)" "unprognostic (2.00e-2)" "unprognostic (1.88e-2)" "unprognostic (3.62e-1)" "unprognostic (3.78e-2)" "unprognostic (3.27e-2)" "unprognostic (1.29e-1)" "unprognostic (7.57e-2)" "unprognostic (1.91e-1)" "unprognostic (2.09e-1)" "unprognostic (1.54e-2)" 47.2 49.7 66.5 59.3 65.8 71.8 56.5 64.2 61.2 54.4 51.3 55.3 45.6 40.1 64.8 33.1 71.6 51.6 48.9 81.6 63.6 57.3 51.7 57.8 51.2 91.1 65.4 56.1 76.5 61.3 55.0 38.7 65.4 47.3 59.2 56.4 36.3 52.1 46.9 76.3 53.6 45.7 59.0 73.5 62.8 46.8 34.8 58.6 152.9 69.1 46.2 92.7 74.4 84.1 72.2 66.4 43.2 56.5 78.8 77.9 69.7 50.4 57.6 82.9 65.6 24.8 38.9 76.5 41.7 46.2 60.3 41.6 79.2 62.0 130.6 35.3 42.9 94.7 122.5 62.7 69.0 59.5 52.2 75.1 89.7 64.4 55.4 137.0 49.2 32.3 49.1 51.3 103.0 56.3 145.7 53.0 49.3 85.2 114.7 50.6 138.4 61.4 105.0 103.1 105.7 46.5 57.0 84.5 53.1 91.8 61.7 49.8 76.9 42.7 53.9 71.3 53.5 43.9 68.9 41.7 119.8 155.4 33.9 73.0 67.9 34.5 53.9 43.2 58.9 56.5 72.1 72.2 67.9 62.8 52.7 66.3 65.8 77.9 35.4 78.8 45.6 66.4 52.3 69.7 66.5 65.8 64.2 61.2 63.6 57.3 65.4 56.1 47.3 58.6 SETBP1 "KIAA0437, SEB" ENSG00000152217 "SET binding protein 1" Q9Y6X0 18 44680173-45068510 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" DNA-binding "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in many" 4 "AF22: 9.3;Karpas-707: 37.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "memory B-cell: 4.9;naive B-cell: 7.5" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA049022, HPA057259" Uncertain Supported "Nucleoplasm,Nuclear bodies,Cytosol" Nucleoplasm "Nuclear bodies, Cytosol" "HPA049022: , HPA057259: " "unprognostic (1.25e-1)" "unprognostic (1.57e-1)" "unprognostic (1.11e-1)" "unprognostic (1.97e-2)" "unprognostic (4.63e-2)" "unprognostic (1.80e-1)" "unprognostic (1.91e-1)" "unprognostic (3.57e-2)" "unprognostic (3.49e-1)" "unprognostic (2.01e-2)" "unprognostic (2.71e-3)" "unprognostic (6.52e-2)" "prognostic favourable (6.34e-8)" "unprognostic (2.18e-2)" "unprognostic (2.29e-1)" "unprognostic (6.06e-2)" "unprognostic (7.81e-5)" 10.6 2.9 3.8 13.2 8.7 2.1 9.8 16.0 12.6 16.9 14.6 4.2 19.9 2.5 14.0 17.5 6.6 11.0 7.9 6.8 3.6 3.5 15.0 7.2 9.8 7.0 2.9 7.4 12.8 8.2 9.1 5.1 10.2 3.2 12.2 5.3 14.0 6.9 21.3 14.5 6.6 6.9 19.9 3.7 5.9 9.1 5.5 1.2 3.4 8.4 8.7 8.8 11.9 13.3 7.5 4.3 0.2 1.6 0.0 0.6 0.2 0.0 1.6 9.3 0.0 2.7 0.7 0.6 0.7 1.7 0.9 0.7 0.1 0.0 0.5 0.3 1.0 2.7 1.0 2.9 0.6 0.8 0.4 0.0 1.0 0.6 0.0 0.0 0.0 2.2 1.1 0.0 1.8 0.3 0.0 37.1 0.2 0.5 0.0 0.0 1.3 0.6 3.0 0.0 3.2 3.1 2.1 4.7 2.5 0.0 0.0 0.5 1.3 0.0 0.0 5.5 2.1 0.0 4.3 4.9 0.3 0.0 3.3 0.1 3.1 0.2 0.0 0.0 0.6 1.1 0.0 4.9 0.1 0.5 0.1 7.5 0.0 0.2 0.0 0.0 1.6 4.3 0.0 0.2 3.8 8.7 16.0 12.6 3.6 3.5 2.9 7.4 3.2 1.2 SFPQ "PPP1R140, PSF" ENSG00000116560 "Splicing factor proline and glutamine rich" P23246 1 35176378-35193148 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Biological rhythms, DNA damage, DNA recombination, DNA repair, Immunity, Innate immunity, mRNA processing, mRNA splicing, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009886, HPA047513, HPA054689" Enhanced Enhanced Nucleoplasm 280000 Nucleoplasm "CAB009886: AB_2186937, HPA047513: AB_2680073, HPA054689: AB_2682574" "prognostic favourable (9.56e-5)" "unprognostic (1.01e-1)" "unprognostic (1.02e-3)" "unprognostic (1.99e-1)" "unprognostic (5.53e-2)" "unprognostic (1.86e-2)" "prognostic unfavourable (7.91e-13)" "unprognostic (3.10e-1)" "unprognostic (4.00e-3)" "unprognostic (3.85e-2)" "unprognostic (2.20e-2)" "unprognostic (8.03e-3)" "unprognostic (1.25e-3)" "unprognostic (1.16e-2)" "unprognostic (3.97e-3)" "unprognostic (3.07e-1)" "unprognostic (3.77e-3)" 40.5 35.7 31.5 39.4 31.4 122.5 48.3 53.0 38.5 39.0 31.4 37.8 32.9 30.0 45.3 36.5 45.5 43.0 28.1 34.0 29.1 24.6 36.4 34.2 47.6 48.8 26.3 32.6 59.9 40.2 45.8 46.3 35.5 31.9 35.5 38.0 35.7 39.6 38.0 44.9 42.9 34.1 36.5 32.8 42.4 35.5 37.5 32.9 95.2 35.3 24.1 60.6 35.9 38.6 6.9 11.2 4.4 8.8 4.9 8.9 3.3 36.1 30.2 52.8 29.8 13.0 19.6 49.6 19.8 20.2 33.9 24.8 32.9 26.2 66.1 27.6 22.9 33.1 57.4 38.8 46.3 35.2 38.1 49.7 32.6 39.0 17.6 51.6 29.6 15.6 15.1 29.4 14.3 29.5 56.1 31.6 32.9 31.5 60.4 44.3 62.9 29.3 61.4 35.9 43.0 32.7 44.0 38.1 42.4 28.6 22.3 28.7 26.1 36.8 31.3 27.2 40.0 17.8 42.4 36.2 30.7 67.3 19.4 34.2 38.6 2.6 6.5 4.4 7.7 8.8 8.9 6.2 7.6 6.1 5.8 6.9 7.2 7.9 3.4 4.9 6.4 11.2 8.2 3.3 31.5 31.4 53.0 38.5 29.1 24.6 26.3 32.6 31.9 32.9 SH3GL1 "CNSA1, EEN, MGC111371, SH3D2B, SH3P8" ENSG00000141985 "SH3 domain containing GRB2 like 1, endophilin A2" Q99961 19 4360370-4400547 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" Endocytosis "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA021485 Approved Enhanced Cytosol Cytosol "HPA021485: AB_1856816" "unprognostic (1.32e-1)" "prognostic favourable (1.50e-4)" "unprognostic (6.85e-2)" "prognostic favourable (1.86e-4)" "unprognostic (1.84e-1)" "unprognostic (1.02e-1)" "prognostic unfavourable (1.10e-4)" "unprognostic (1.92e-2)" "unprognostic (1.21e-1)" "unprognostic (1.42e-2)" "unprognostic (1.32e-1)" "unprognostic (1.54e-1)" "prognostic unfavourable (9.36e-8)" "unprognostic (5.48e-3)" "unprognostic (2.45e-1)" "unprognostic (1.02e-3)" "unprognostic (4.10e-2)" 20.5 22.4 12.8 17.7 14.5 28.9 17.5 19.1 25.9 21.6 18.7 13.3 11.9 25.4 16.9 12.1 66.0 15.0 16.1 13.2 13.0 8.0 13.8 19.7 14.8 13.0 11.4 13.0 23.5 20.5 5.6 17.3 33.9 9.4 17.1 6.2 14.9 22.1 16.8 8.6 40.4 29.8 18.8 9.0 19.5 16.4 13.7 11.3 10.1 14.2 19.1 33.0 22.2 30.0 6.1 6.5 9.7 5.1 3.8 7.4 3.4 31.7 14.4 15.0 19.8 17.6 27.5 27.7 27.7 23.9 24.7 24.6 22.4 16.8 7.2 11.7 27.4 26.3 10.6 30.4 6.6 9.5 17.7 8.6 19.8 29.3 25.4 7.7 9.8 23.0 21.2 20.8 12.8 29.0 22.3 16.4 19.8 26.6 7.5 8.1 37.6 16.1 5.9 20.9 12.5 19.5 28.1 14.8 22.8 24.4 24.4 17.3 16.8 12.3 43.7 23.8 17.4 49.8 28.0 10.5 6.4 7.6 34.3 20.1 32.6 1.0 3.8 4.8 5.0 1.9 4.8 6.1 7.4 6.9 5.0 4.5 4.2 4.5 9.7 3.8 5.1 6.5 6.6 3.4 12.8 14.5 19.1 25.9 13.0 8.0 11.4 13.0 9.4 11.3 SLC34A2 NAPI-3B ENSG00000157765 "Solute carrier family 34 member 2" O95436 4 25648011-25678748 "Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters" "Ion transport, Sodium transport, Symport, Transport" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "lung: 259.9;seminal vesicle: 69.1" "Group enriched" "Detected in some" 81 "BEWO: 12.3;EFO-21: 46.6;RPTEC TERT1: 33.6" "Cancer enhanced" "Detected in many" "thyroid cancer: 585.2" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "basophil: 1.9" "Low lineage specificity" "Detected in single" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA037989 Enhanced Supported "Nucleoplasm,Golgi apparatus,Plasma membrane,Cytosol" "Plasma membrane, Cytosol" "Nucleoplasm, Golgi apparatus" "HPA037989: AB_10670536" "unprognostic (1.60e-2)" "unprognostic (1.12e-1)" "unprognostic (1.38e-1)" "unprognostic (4.25e-2)" "unprognostic (7.33e-2)" "unprognostic (9.83e-2)" "unprognostic (2.37e-2)" "unprognostic (6.60e-3)" "unprognostic (6.27e-2)" "unprognostic (1.89e-2)" "unprognostic (5.77e-2)" "unprognostic (2.24e-1)" "unprognostic (7.08e-3)" "unprognostic (3.25e-1)" "unprognostic (6.75e-2)" "unprognostic (2.57e-2)" "unprognostic (1.93e-1)" 0.1 0.1 0.1 0.0 0.1 0.0 3.2 0.2 0.1 13.0 0.1 0.0 24.7 2.9 6.9 2.1 0.5 13.0 3.4 0.1 0.1 0.1 10.8 0.5 259.9 0.0 0.1 0.0 2.9 4.4 0.0 0.6 2.6 0.8 0.3 0.0 1.6 27.4 69.1 0.1 0.7 2.1 0.0 0.1 0.1 0.4 0.5 0.0 0.4 27.9 0.1 1.9 0.0 0.1 0.4 0.2 1.9 0.5 0.4 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.3 0.0 0.0 0.0 0.0 0.1 0.0 0.1 46.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.0 0.0 0.0 0.0 33.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.0 0.2 0.1 0.1 0.0 0.0 0.0 1.9 0.5 0.2 0.3 0.3 0.1 0.2 0.1 0.1 0.0 0.4 0.3 0.2 1.5 0.4 0.1 0.2 0.0 0.0 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.8 0.0 SLC45A3 "IPCA-2, IPCA-6, IPCA-8, PCANAP2, PCANAP6, PCANAP8, prostein" ENSG00000158715 "Solute carrier family 45 member 3" Q96JT2 1 205657851-205680459 "Cancer-related genes, Predicted membrane proteins, Transporters" Transport "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "prostate: 115.0" "Cell line enriched" "Detected in some" 30 "HMC-1: 138.2" "Cancer enriched" "Detected in all" 49 "prostate cancer: 539.9" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 226 "basophil: 22.6" "Lineage enriched" "Detected in single" 226 "granulocytes: 22.6" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA019073, HPA019075" Enhanced Approved Nucleoplasm,Vesicles Vesicles Nucleoplasm "HPA019073: AB_1857177, HPA019075: AB_1857179" "unprognostic (1.80e-1)" "unprognostic (1.08e-3)" "unprognostic (3.13e-2)" "prognostic unfavourable (4.04e-5)" "unprognostic (6.93e-2)" "unprognostic (2.36e-2)" "unprognostic (1.15e-1)" "unprognostic (1.50e-1)" "unprognostic (1.84e-1)" "unprognostic (1.10e-1)" "unprognostic (2.90e-2)" "unprognostic (1.18e-1)" "unprognostic (3.03e-2)" "unprognostic (3.16e-1)" "unprognostic (1.55e-1)" "unprognostic (1.96e-1)" "prognostic favourable (7.33e-5)" 0.8 1.5 2.5 1.5 6.2 0.7 0.8 0.4 5.8 1.9 2.1 19.0 0.0 2.1 0.9 0.6 0.9 1.1 1.8 0.7 4.2 2.0 1.1 4.0 1.7 1.6 13.2 1.6 1.0 0.7 0.5 1.9 0.6 7.2 115.0 1.6 0.2 0.9 0.7 2.2 0.9 2.1 0.8 12.4 5.0 6.4 1.4 11.1 0.0 0.5 0.7 0.7 1.5 0.4 0.0 0.0 22.6 0.0 0.0 0.0 0.2 1.5 0.4 0.4 0.4 0.0 0.0 0.3 0.2 0.0 0.5 0.4 1.1 2.9 0.4 0.7 0.0 0.5 0.2 0.5 0.0 0.6 0.4 4.6 0.1 0.3 0.3 0.7 138.2 0.0 0.1 0.3 0.0 1.5 0.7 0.2 0.2 0.3 0.1 1.3 2.0 1.7 0.1 0.6 0.2 0.6 2.1 0.2 0.4 0.2 3.4 0.6 0.7 0.2 1.5 0.2 1.5 0.5 1.1 0.0 0.1 0.0 0.3 0.2 1.1 22.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 2.5 6.2 0.4 5.8 4.2 2.0 13.2 1.6 7.2 11.1 SND1 "p100, TDRD11" ENSG00000197157 "Staphylococcal nuclease and tudor domain containing 1" Q7KZF4 7 127652180-128092609 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, Transcription, Transcription regulation" "Endonuclease, Hydrolase, Nuclease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002529, HPA002632, CAB019323" Enhanced Enhanced Cytosol 1200000 Cytosol "CAB019323: , HPA002529: AB_1857317, HPA002632: AB_1857316" "unprognostic (2.06e-1)" "unprognostic (8.27e-3)" "unprognostic (2.21e-1)" "prognostic favourable (1.95e-4)" "unprognostic (5.10e-3)" "unprognostic (6.83e-2)" "unprognostic (1.17e-2)" "unprognostic (2.91e-2)" "unprognostic (4.22e-2)" "unprognostic (3.81e-2)" "unprognostic (1.56e-1)" "unprognostic (2.30e-1)" "unprognostic (1.36e-2)" "unprognostic (9.96e-2)" "unprognostic (1.99e-1)" "unprognostic (3.42e-2)" "unprognostic (2.26e-3)" 21.5 29.8 25.3 25.3 19.8 22.5 45.4 28.1 28.1 33.3 20.0 13.0 57.7 21.3 36.1 38.4 24.8 26.7 25.3 28.3 20.9 16.6 17.3 39.6 38.8 64.2 20.2 19.0 39.7 130.3 22.2 30.3 33.7 27.6 24.5 20.2 13.9 37.5 66.7 20.5 21.5 19.2 41.0 40.1 24.9 30.8 37.0 18.0 22.3 26.6 13.5 24.9 26.5 24.2 28.1 34.9 16.1 30.0 21.0 30.9 28.5 27.9 25.4 19.5 35.3 29.5 30.9 26.7 33.0 39.0 30.2 34.0 32.8 24.3 37.2 16.7 40.4 23.5 27.4 35.8 29.6 20.3 23.2 20.5 30.4 31.4 53.8 31.7 20.2 45.5 39.9 25.8 43.3 37.5 22.7 37.4 30.1 20.9 34.5 23.8 21.8 31.7 24.1 17.4 83.2 23.7 19.8 24.5 26.5 23.9 111.1 38.2 13.9 22.6 37.2 24.6 16.1 44.6 25.6 46.1 17.3 39.1 49.4 27.4 44.5 16.1 30.0 5.9 26.1 28.1 30.9 28.1 19.8 21.0 32.3 16.2 14.3 15.8 2.2 21.0 22.8 34.9 15.8 28.5 25.3 19.8 28.1 28.1 20.9 16.6 20.2 19.0 27.6 18.0 SRSF3 "SFRS3, SRp20" ENSG00000112081 "Serine and arginine rich splicing factor 3" P84103 6 36594353-36605600 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "mRNA processing, mRNA splicing, mRNA transport, Transport" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB012986, HPA056981" Supported Supported Nucleoplasm 1600000 Nucleoplasm "CAB012986: AB_2533150, HPA056981: " "unprognostic (3.25e-1)" "unprognostic (1.08e-3)" "prognostic favourable (2.56e-4)" "unprognostic (8.19e-2)" "unprognostic (2.06e-2)" "unprognostic (2.77e-2)" "prognostic unfavourable (6.22e-5)" "unprognostic (2.92e-2)" "prognostic unfavourable (1.95e-4)" "prognostic favourable (1.37e-4)" "unprognostic (9.61e-2)" "unprognostic (1.21e-1)" "prognostic unfavourable (2.02e-4)" "unprognostic (9.88e-2)" "unprognostic (3.33e-2)" "unprognostic (8.33e-2)" "unprognostic (1.06e-2)" 45.3 27.4 37.4 42.1 38.3 69.5 43.5 42.6 39.1 36.4 41.7 32.9 34.0 25.5 37.2 31.8 42.9 40.8 27.4 37.5 33.0 28.1 34.3 36.9 32.3 51.8 35.8 27.0 53.9 31.3 22.4 47.2 37.4 38.1 40.1 46.6 30.1 30.2 33.0 29.2 36.2 35.8 43.1 31.9 36.4 35.2 27.2 36.7 67.5 35.9 46.7 67.0 49.6 38.6 28.0 73.9 12.9 38.0 37.6 37.6 53.9 51.7 34.6 61.1 46.6 23.6 18.5 37.7 37.1 31.1 62.5 48.2 40.6 37.2 87.1 26.7 40.5 41.1 80.1 59.0 66.8 40.6 49.3 52.2 27.5 45.7 28.9 70.1 44.2 16.4 20.1 40.7 45.5 47.4 62.9 36.9 45.3 40.4 86.1 66.4 64.3 36.4 76.8 58.5 52.1 44.2 43.1 47.2 44.7 41.2 40.4 56.0 41.0 75.4 30.9 32.0 46.7 32.0 55.6 36.5 53.9 119.3 27.4 65.2 44.3 12.9 38.0 11.5 32.9 36.2 37.1 28.0 31.1 34.5 73.9 24.0 31.4 32.3 3.7 37.6 24.4 43.7 37.6 53.9 37.4 38.3 42.6 39.1 33.0 28.1 35.8 27.0 38.1 36.7 SS18 "SSXT, SYT" ENSG00000141380 "SS18, nBAF chromatin remodeling complex subunit" Q15532 18 26016253-26091217 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" Activator "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA055741, HPA059539" Supported Approved Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA055741: , HPA059539: " "unprognostic (2.03e-2)" "unprognostic (1.76e-1)" "unprognostic (1.48e-2)" "unprognostic (1.95e-2)" "unprognostic (3.39e-1)" "unprognostic (8.74e-2)" "unprognostic (4.59e-2)" "unprognostic (1.53e-2)" "unprognostic (1.63e-2)" "unprognostic (1.45e-2)" "unprognostic (1.04e-1)" "unprognostic (2.47e-1)" "prognostic favourable (4.86e-4)" "unprognostic (1.03e-1)" "unprognostic (3.50e-2)" "unprognostic (1.40e-2)" "unprognostic (1.30e-1)" 26.1 40.5 18.7 30.4 26.4 15.5 26.6 17.6 20.2 24.8 21.4 31.8 32.1 14.0 31.7 32.7 29.8 27.2 23.4 22.4 21.6 16.1 30.0 30.9 21.9 25.8 32.6 16.3 39.4 20.6 39.4 41.8 43.2 25.3 28.6 18.7 26.1 26.0 33.5 10.3 31.3 22.6 31.0 23.7 24.7 22.5 28.3 32.6 27.8 35.6 24.7 35.2 25.5 25.9 15.9 13.1 19.9 17.1 20.7 17.6 13.1 19.0 13.8 33.9 16.6 27.0 24.5 17.1 23.4 21.3 20.7 19.8 9.0 15.8 33.2 18.7 27.4 24.9 18.4 22.7 25.6 21.2 8.8 16.4 20.3 14.6 21.4 25.2 25.5 31.4 26.8 26.0 28.5 15.5 12.0 17.1 28.6 19.1 10.3 14.6 6.4 13.4 12.0 26.4 15.9 21.9 22.5 14.5 21.9 35.8 16.6 10.1 16.9 14.9 17.7 43.6 8.7 10.0 22.9 30.8 20.6 24.0 20.4 17.5 23.1 19.9 11.7 16.5 15.1 17.1 17.6 15.9 14.6 15.7 13.1 13.0 15.5 17.4 5.6 20.7 16.7 7.4 15.7 13.1 18.7 26.4 17.6 20.2 21.6 16.1 32.6 16.3 25.3 32.6 SS18L1 "CREST, KIAA0693" ENSG00000184402 "SS18L1, nBAF chromatin remodeling complex subunit" O75177 20 62143795-62182484 "Cancer-related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, Chromatin regulator" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB011827, HPA059046" Approved Supported Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "CAB011827: AB_778216, HPA059046: " "unprognostic (4.12e-2)" "unprognostic (5.82e-2)" "unprognostic (1.54e-1)" "unprognostic (3.03e-2)" "unprognostic (6.57e-2)" "prognostic favourable (8.00e-5)" "unprognostic (1.39e-1)" "prognostic favourable (3.74e-4)" "unprognostic (1.01e-1)" "unprognostic (1.87e-1)" "unprognostic (2.47e-3)" "unprognostic (6.43e-2)" "unprognostic (2.42e-1)" "unprognostic (1.06e-1)" "unprognostic (2.66e-1)" "unprognostic (1.01e-1)" "unprognostic (9.94e-3)" 6.6 8.9 11.9 7.7 12.7 7.7 8.6 35.9 15.8 7.0 7.0 9.9 12.2 9.5 9.7 10.9 9.3 6.9 7.2 6.4 11.5 10.9 11.5 33.3 8.2 7.4 11.2 14.5 10.0 10.4 8.4 10.7 8.8 13.1 8.7 7.8 7.4 8.6 11.8 19.2 23.7 9.0 7.7 9.9 9.2 8.8 10.7 10.9 6.0 8.3 6.7 7.1 6.8 8.6 3.6 1.3 2.5 2.7 1.6 2.8 0.5 6.4 7.7 10.7 9.7 4.8 5.6 7.8 6.1 2.4 10.2 5.1 26.3 6.0 3.9 8.1 3.4 16.7 6.6 5.8 9.3 2.7 4.3 17.5 16.1 13.6 3.6 6.3 15.6 3.4 12.8 5.2 4.4 4.6 11.7 7.6 5.7 7.6 9.6 9.9 4.3 8.8 10.7 13.9 4.4 7.6 8.2 20.4 11.3 10.9 13.3 9.1 12.5 10.2 5.4 19.5 11.8 7.2 8.5 8.5 7.6 3.5 9.7 6.3 6.4 0.3 1.6 0.6 1.7 1.1 1.1 0.7 0.9 1.4 1.3 3.6 2.8 0.9 2.5 1.6 2.7 0.8 0.8 0.5 11.9 12.7 35.9 15.8 11.5 10.9 11.2 14.5 13.1 10.9 SSX1 CT5.1 ENSG00000126752 "SSX family member 1" Q16384 X 48255317-48267444 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 14 "testis: 12.6" "Cell line enhanced" "Detected in some" "Daudi: 28.1;Karpas-707: 40.8;U-2197: 9.5" "Cancer enhanced" "Detected in many" "liver cancer: 7.9" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA045683 Supported Approved Nucleoplasm,Nucleoli "Nucleoplasm, Nucleoli" "HPA045683: " "unprognostic (2.25e-1)" "unprognostic (3.51e-3)" "unprognostic (2.36e-1)" "unprognostic (4.32e-3)" "unprognostic (3.38e-1)" "unprognostic (5.41e-2)" "unprognostic (6.94e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 12.6 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.1 0.2 0.9 0.4 0.5 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 28.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 40.8 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 9.5 0.0 0.0 2.0 0.0 2.3 0.0 0.0 0.9 0.4 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.3 0.5 0.5 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 SSX2 "CT5.2a, HD21, HOM-MEL-40, MGC119055, MGC15364, MGC3884, SSX" ENSG00000241476 "SSX family member 2" Q16385 X 52696896-52707189 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 57 "testis: 24.1" "Cell line enhanced" "Detected in some" "PC-3: 3.1;U-2197: 1.9" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA045683, CAB046020" Enhanced Approved Nucleoplasm,Nucleoli "Nucleoplasm, Nucleoli" "CAB046020: AB_2194010, HPA045683: " 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 24.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.5 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.3 0.3 0.0 0.0 0.0 0.2 3.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.9 0.0 0.6 0.1 0.6 1.9 0.0 0.0 0.3 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 SSX4 CT5.4 ENSG00000268009 "SSX family member 4" O60224 X 48383516-48393347 "Cancer-related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Tissue enriched" "Detected in single" 14 "testis: 6.8" "Group enriched" "Detected in some" 10 "BEWO: 3.5;Karpas-707: 8.6;U-266/70: 5.1;U-266/84: 9.3" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA045683 Approved Approved Nucleoplasm,Nucleoli "Nucleoplasm, Nucleoli" "HPA045683: " 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.4 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 6.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.0 0.0 0.0 0.1 0.6 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.5 8.6 0.0 0.0 0.0 0.0 0.3 0.3 0.6 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 5.1 9.3 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 STAT5B ENSG00000173757 "Signal transducer and activator of transcription 5B" P51692 17 42199168-42276707 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Disease mutation, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HDLM-2: 43.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004298, HPA042128, HPA049883, HPA051156" Approved 170000 "CAB004298: AB_2197067, HPA042128: , HPA049883: , HPA051156: " "unprognostic (1.49e-1)" "unprognostic (3.60e-2)" "unprognostic (4.06e-2)" "prognostic favourable (9.37e-4)" "unprognostic (2.68e-1)" "unprognostic (4.29e-1)" "unprognostic (2.23e-1)" "unprognostic (1.03e-1)" "unprognostic (3.06e-2)" "unprognostic (7.98e-2)" "prognostic favourable (1.63e-4)" "unprognostic (1.36e-1)" "prognostic favourable (2.39e-5)" "unprognostic (9.19e-2)" "unprognostic (2.95e-1)" "unprognostic (1.54e-1)" "unprognostic (2.13e-1)" 25.7 24.0 13.5 19.5 16.3 21.8 26.2 32.1 15.9 21.6 21.0 13.7 16.3 8.6 31.9 12.0 11.6 24.5 18.1 12.8 11.9 20.1 12.4 13.5 15.8 24.6 16.0 13.9 34.4 12.1 12.0 22.6 55.4 17.2 20.8 10.3 16.4 12.9 21.7 38.3 12.2 14.8 33.1 10.6 22.1 14.4 13.2 15.7 21.7 15.4 9.6 19.8 21.5 33.1 2.5 2.4 18.8 2.8 3.5 8.3 3.8 5.2 8.2 12.3 3.3 15.4 7.8 5.9 5.4 9.7 7.8 6.8 3.6 4.5 17.1 8.1 6.2 6.8 7.2 4.7 6.2 43.1 8.4 16.7 15.5 5.5 8.5 7.3 27.0 9.5 7.2 5.8 7.4 12.2 30.1 3.7 3.2 5.1 34.5 19.3 3.0 0.0 14.9 7.7 5.9 4.9 8.4 9.1 5.3 9.9 12.6 7.6 8.9 8.7 9.4 10.9 3.8 5.6 7.5 7.4 3.4 8.5 4.3 7.8 5.6 8.8 2.8 4.6 5.9 2.5 6.4 2.5 8.3 6.7 2.4 2.5 5.9 5.0 18.8 3.5 2.8 1.8 6.9 3.8 13.5 16.3 32.1 15.9 11.9 20.1 16.0 13.9 17.2 15.7 STAT6 "D12S1644, IL-4-STAT" ENSG00000166888 "Signal transducer and activator of transcription 6" P42226 12 57095408-57132139 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001861 Approved Supported Nucleoplasm,Cytosol Cytosol Nucleoplasm "HPA001861: AB_1080106" "unprognostic (3.43e-3)" "unprognostic (1.87e-1)" "unprognostic (1.37e-1)" "prognostic favourable (1.69e-4)" "unprognostic (4.14e-2)" "unprognostic (2.51e-1)" "unprognostic (2.22e-1)" "unprognostic (6.70e-2)" "unprognostic (1.88e-2)" "unprognostic (3.65e-1)" "unprognostic (5.39e-2)" "unprognostic (1.00e-2)" "unprognostic (2.81e-2)" "unprognostic (1.67e-1)" "unprognostic (1.55e-1)" "prognostic favourable (7.76e-4)" "prognostic favourable (1.14e-4)" 33.6 34.9 10.4 35.9 12.8 12.8 27.9 4.6 11.6 37.8 47.3 6.2 28.4 23.9 44.5 26.6 40.8 31.8 33.8 20.9 10.2 3.9 35.0 31.0 34.9 25.2 13.3 12.0 41.9 21.2 18.1 9.2 22.0 9.8 42.3 26.2 23.3 30.1 26.5 11.4 39.1 59.4 43.8 12.2 48.4 32.1 13.3 7.9 29.3 31.1 24.4 42.8 43.1 34.0 6.2 9.6 27.6 13.0 4.7 5.9 14.0 16.8 16.8 4.1 6.8 41.0 39.8 11.9 13.4 29.5 14.9 10.9 7.6 22.9 40.4 21.0 29.7 23.5 5.1 26.0 11.0 18.1 1.9 9.3 17.9 9.4 24.5 10.7 30.5 55.4 21.5 18.1 16.1 26.3 6.5 5.7 19.2 5.7 11.7 12.0 6.3 3.4 13.6 0.3 13.7 25.8 28.1 0.1 0.4 12.5 10.5 12.6 15.6 24.7 21.8 0.3 8.8 15.5 0.2 0.1 0.4 10.1 13.5 10.5 17.9 9.8 12.5 6.8 5.9 13.0 5.2 6.2 4.8 4.8 9.6 6.2 4.7 4.3 27.6 4.7 11.0 4.6 4.9 14.0 10.4 12.8 4.6 11.6 10.2 3.9 13.3 12.0 9.8 7.9 STIL "MCPH7, SIL" ENSG00000123473 "STIL, centriolar assembly protein" Q15468 1 47250139-47314147 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Developmental protein" "Cancer-related genes, Disease mutation, Mental retardation, Primary microcephaly, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 36.0;testis: 23.8" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" HPA046543 Approved "Plasma membrane,Cytosol" "Plasma membrane, Cytosol" "HPA046543: " "unprognostic (2.07e-1)" "unprognostic (6.29e-2)" "unprognostic (5.54e-3)" "unprognostic (2.67e-3)" "unprognostic (1.76e-1)" "unprognostic (1.56e-2)" "unprognostic (2.90e-5)" "unprognostic (7.35e-3)" "unprognostic (4.04e-3)" "unprognostic (1.41e-1)" "prognostic unfavourable (1.33e-4)" "unprognostic (5.81e-2)" "unprognostic (3.36e-14)" "unprognostic (5.76e-3)" "unprognostic (2.58e-1)" "unprognostic (1.64e-1)" "unprognostic (2.28e-1)" 1.2 1.4 1.3 10.8 2.4 11.0 2.9 1.4 2.2 1.2 4.1 0.9 2.5 3.6 1.5 2.2 5.8 0.9 1.7 2.0 1.4 1.2 1.5 1.6 1.7 5.0 1.3 1.5 1.2 1.5 0.9 0.9 5.5 1.1 1.7 6.4 0.8 3.6 0.5 0.8 4.2 4.0 1.3 1.2 3.4 2.2 23.8 1.0 36.0 1.1 3.5 7.1 1.3 2.1 1.9 1.6 5.4 0.7 3.3 1.2 0.5 16.9 9.1 13.1 11.7 0.9 2.3 8.3 15.0 7.2 16.8 17.7 9.8 8.4 20.0 7.1 7.4 11.3 15.3 7.8 18.1 14.9 6.9 22.5 11.3 8.6 0.5 18.1 11.5 0.8 1.3 14.4 9.4 11.1 15.9 19.0 12.6 7.7 17.6 5.7 15.8 7.5 11.5 21.3 9.6 4.7 10.2 11.7 7.0 16.1 11.9 7.7 7.7 10.4 6.5 15.8 16.1 11.4 20.2 6.3 13.0 19.6 7.4 13.9 14.7 4.3 0.7 1.1 1.1 0.4 0.5 1.7 1.2 1.0 0.5 1.9 0.8 0.8 5.4 3.3 0.3 1.6 1.1 0.5 1.3 2.4 1.4 2.2 1.4 1.2 1.3 1.5 1.1 1.0 STRN "PPP2R6A, STRN1" ENSG00000115808 Striatin O43815 2 36843640-36966472 "Cancer-related genes, Predicted intracellular proteins" Calmodulin-binding "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA017286 Approved Approved Nucleoplasm,Cytosol 11000 Cytosol Nucleoplasm "HPA017286: AB_1857618" "unprognostic (1.65e-1)" "unprognostic (1.65e-1)" "unprognostic (3.57e-3)" "unprognostic (2.23e-2)" "unprognostic (3.25e-1)" "unprognostic (1.53e-1)" "unprognostic (1.63e-3)" "unprognostic (7.37e-2)" "unprognostic (1.25e-1)" "unprognostic (2.42e-1)" "unprognostic (1.77e-3)" "unprognostic (1.33e-1)" "prognostic favourable (2.27e-4)" "unprognostic (1.13e-1)" "unprognostic (6.43e-2)" "unprognostic (2.11e-1)" "unprognostic (3.43e-2)" 11.8 8.1 11.4 11.0 22.1 17.4 13.3 16.4 14.2 11.2 14.0 10.9 8.9 10.1 8.6 7.1 25.9 6.8 8.4 25.7 16.2 10.2 11.6 10.2 10.3 9.6 16.9 9.4 9.9 7.1 11.3 6.3 12.6 10.5 8.1 13.7 5.6 16.2 6.9 16.0 16.1 13.2 11.1 34.3 10.9 11.4 9.8 14.8 18.6 8.1 15.5 16.7 11.3 14.4 1.5 0.8 3.7 1.5 0.5 2.1 0.4 23.0 11.7 15.6 6.6 8.6 12.0 15.7 9.3 8.8 9.1 8.4 11.9 7.5 15.3 7.5 11.8 11.0 13.1 10.3 11.3 17.3 10.1 24.8 10.3 6.1 8.2 14.9 13.9 7.2 9.0 14.5 11.5 11.6 18.5 12.2 11.2 6.6 14.7 6.5 12.5 5.9 9.6 24.7 6.7 7.5 19.1 2.9 9.5 14.0 10.8 8.8 7.7 5.8 15.4 16.4 16.5 10.1 12.2 12.3 18.6 13.5 8.3 14.9 11.3 3.4 0.8 1.4 2.1 1.5 0.7 1.5 1.5 1.3 0.4 0.9 0.8 0.9 3.7 0.5 1.4 0.8 0.3 0.4 11.4 22.1 16.4 13.0 16.2 10.2 16.9 9.4 10.5 14.8 SUZ12 "CHET9, JJAZ1, KIAA0160" ENSG00000178691 "SUZ12 polycomb repressive complex 2 subunit" Q15022 17 31937018-32001045 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Repressor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA057436 Approved Supported "Nucleoplasm,Nucleoli,Nuclear bodies" "Nucleoplasm, Nucleoli, Nuclear bodies" "HPA057436: " "unprognostic (1.23e-1)" "unprognostic (1.11e-1)" "unprognostic (3.65e-3)" "unprognostic (1.23e-1)" "unprognostic (2.49e-1)" "unprognostic (7.31e-2)" "unprognostic (2.66e-3)" "unprognostic (8.05e-2)" "unprognostic (7.27e-2)" "unprognostic (3.06e-2)" "unprognostic (6.29e-2)" "unprognostic (8.70e-2)" "unprognostic (3.28e-2)" "unprognostic (2.25e-1)" "unprognostic (1.28e-1)" "unprognostic (5.91e-2)" "unprognostic (1.31e-1)" 10.1 10.8 13.4 15.4 10.4 25.5 33.5 16.0 13.8 11.2 11.4 7.5 13.6 10.1 12.5 8.1 12.3 9.8 7.7 9.7 9.1 7.6 10.9 11.5 10.6 19.9 9.3 9.9 10.0 10.1 15.5 10.4 15.3 9.5 10.7 10.9 6.9 10.1 9.6 8.7 9.9 12.2 9.6 7.7 15.2 10.7 17.1 12.5 31.8 12.0 6.5 18.9 10.8 19.5 5.5 4.6 4.1 2.6 4.4 5.5 1.2 14.0 12.5 11.8 13.5 6.8 8.8 12.1 13.7 12.1 16.9 20.5 9.4 7.9 30.8 10.6 8.5 12.5 17.5 7.9 27.5 10.8 17.0 21.3 10.6 6.8 8.0 33.5 21.9 6.1 8.9 16.8 12.9 10.3 20.5 42.8 14.5 4.9 39.8 19.5 6.7 7.6 23.8 30.2 24.9 9.9 13.8 15.1 11.8 22.1 7.2 13.2 20.8 28.0 7.6 13.4 12.2 16.1 21.1 23.4 29.1 38.1 9.8 20.7 12.1 1.4 1.9 3.8 3.8 2.6 3.0 5.5 4.1 4.0 1.4 4.4 3.9 5.5 4.1 4.4 1.8 4.6 4.2 1.2 13.4 10.4 16.0 13.8 9.1 7.6 9.3 9.9 9.5 12.5 SYK ENSG00000165025 "Spleen associated tyrosine kinase" P43405 9 90801787-90898549 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Adaptive immunity, Angiogenesis, Host-virus interaction, Immunity, Innate immunity" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 38.5" "Cell line enhanced" "Detected in many" "Daudi: 38.7;HEL: 22.3;HL-60: 30.8;HMC-1: 20.5;REH: 25.8;THP-1: 23.7;U-698: 18.3;U-937: 21.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 15 "classical monocyte: 21.4;eosinophil: 23.3;intermediate monocyte: 19.0;memory B-cell: 23.1;myeloid DC: 24.9;naive B-cell: 17.5;neutrophil: 32.8;NK-cell: 8.7;non-classical monocyte: 16.4;plasmacytoid DC: 18.5" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA001384, CAB007773" Enhanced Approved "Vesicles,Plasma membrane,Cytosol" 1000000 "Plasma membrane, Cytosol" Vesicles "CAB007773: AB_562232, HPA001384: AB_1080144" "unprognostic (1.01e-1)" "unprognostic (5.45e-2)" "unprognostic (2.10e-1)" "unprognostic (2.69e-2)" "unprognostic (2.31e-1)" "unprognostic (7.92e-2)" "unprognostic (1.06e-1)" "unprognostic (1.34e-1)" "unprognostic (6.41e-2)" "unprognostic (1.78e-2)" "unprognostic (7.20e-2)" "unprognostic (9.93e-2)" "unprognostic (2.55e-3)" "unprognostic (8.77e-2)" "unprognostic (5.36e-3)" "unprognostic (3.41e-2)" "unprognostic (1.06e-2)" 7.2 3.3 6.0 38.1 9.6 18.2 6.7 1.1 4.5 3.7 10.3 6.7 1.5 12.3 2.3 6.7 16.2 6.9 6.6 5.5 7.2 3.2 8.6 2.5 13.7 36.4 9.1 2.5 2.1 8.9 25.9 3.1 5.0 6.1 4.1 8.3 2.8 8.9 1.8 1.4 8.3 22.2 3.5 11.3 38.5 7.4 5.5 7.9 30.5 18.1 7.8 32.2 8.6 7.5 23.1 24.9 32.8 21.4 8.7 0.1 10.2 6.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.5 38.7 1.1 0.0 6.0 0.8 3.2 0.0 0.0 5.3 22.3 0.0 0.0 0.0 30.8 20.5 0.0 4.4 0.0 0.4 0.0 0.6 3.1 0.0 4.7 0.0 13.5 0.2 0.0 25.8 0.0 10.6 0.8 5.8 2.0 1.8 0.0 2.7 0.0 2.5 23.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 18.3 0.0 21.7 0.0 1.4 21.4 23.3 0.1 19.0 0.1 23.1 0.0 0.0 24.9 17.5 0.0 0.0 32.8 8.7 16.4 18.5 0.0 10.2 6.0 9.6 1.1 4.5 7.2 3.2 9.1 2.5 6.1 7.9 TAF15 "hTAFII68, Npl3, RBP56, TAF2N" ENSG00000270647 "TATA-box binding protein associated factor 15" Q92804 17 35713791-35864615 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "DNA-binding, RNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA052059, HPA063647" Supported Enhanced Nucleoplasm Nucleoplasm "HPA052059: , HPA063647: " "unprognostic (1.26e-1)" "unprognostic (2.66e-3)" "unprognostic (1.10e-1)" "unprognostic (1.63e-2)" "unprognostic (1.82e-1)" "unprognostic (1.27e-1)" "unprognostic (8.48e-3)" "unprognostic (4.75e-2)" "unprognostic (8.06e-3)" "unprognostic (2.08e-2)" "unprognostic (2.33e-1)" "unprognostic (1.44e-2)" "unprognostic (1.79e-2)" "unprognostic (1.39e-2)" "unprognostic (5.41e-2)" "unprognostic (3.35e-2)" "unprognostic (2.99e-1)" 14.0 12.9 12.7 15.3 16.2 13.9 11.0 13.7 14.1 10.5 11.7 15.0 13.2 12.7 10.2 11.0 12.6 8.0 11.5 13.1 11.8 9.8 15.0 8.9 19.4 14.7 8.3 10.7 11.3 14.6 18.1 11.1 11.1 11.4 10.1 9.2 9.8 15.3 26.9 14.7 13.4 17.5 15.9 12.7 11.0 11.3 15.5 21.1 9.4 12.8 15.8 12.0 9.8 3.7 3.2 3.8 3.6 4.7 7.2 2.2 28.7 47.3 25.3 24.5 20.3 11.5 16.6 32.9 11.2 15.0 14.7 31.6 20.8 57.2 23.7 21.3 30.6 33.6 33.1 21.7 16.1 43.9 32.9 34.4 33.1 20.0 53.1 22.1 18.3 17.4 22.7 35.7 20.2 30.8 23.7 16.9 34.3 57.9 12.9 15.6 13.6 34.6 37.6 21.4 19.0 51.7 19.2 18.9 41.0 12.4 13.0 29.0 18.3 27.3 11.6 25.3 16.7 39.5 22.4 27.3 41.7 22.9 26.2 19.0 3.8 3.5 3.5 4.9 3.4 7.2 3.0 3.5 3.8 2.5 3.7 3.3 3.7 2.0 4.7 3.6 3.2 3.9 2.2 TAL1 "bHLHa17, SCL, TCL5" ENSG00000162367 "TAL bHLH transcription factor 1, erythroid differentiation factor" P17542 1 47216290-47232220 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 33.1" "Cell line enhanced" "Detected in some" "HEL: 52.8;HMC-1: 25.4;HUVEC TERT2: 11.0;K-562: 16.5;MOLT-4: 8.8;TIME: 12.0" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 5 "basophil: 3.2;neutrophil: 1.2" "Lineage enriched" "Detected in single" 7 "granulocytes: 3.2" "Region enriched" "Detected in some" 5 "midbrain: 17.1" "Low region specificity" "Detected in many" "CAB017805, HPA047866, HPA073983" Approved Enhanced Nucleoplasm Nucleoplasm "CAB017805: , HPA047866: , HPA073983: " "unprognostic (2.63e-1)" "unprognostic (2.62e-2)" "unprognostic (1.22e-1)" "unprognostic (2.40e-2)" "unprognostic (1.59e-1)" "unprognostic (8.80e-3)" "unprognostic (3.95e-3)" "unprognostic (1.33e-1)" "unprognostic (4.15e-2)" "unprognostic (1.99e-2)" "unprognostic (5.42e-3)" "unprognostic (3.68e-1)" "unprognostic (1.02e-2)" "unprognostic (2.76e-2)" "unprognostic (2.19e-1)" "unprognostic (1.51e-1)" "unprognostic (1.18e-2)" 9.1 2.7 7.0 1.8 5.7 33.1 7.1 1.6 6.9 3.3 2.4 12.0 2.3 1.6 3.7 3.3 2.5 4.1 4.2 3.9 8.8 3.5 4.5 2.4 14.6 2.2 11.1 4.4 1.5 1.3 2.2 2.1 9.8 7.3 2.4 2.4 2.1 1.4 3.0 3.1 2.0 3.3 4.4 9.4 8.5 2.1 1.8 9.2 0.0 6.7 4.1 1.5 2.5 5.5 0.3 0.1 3.2 0.3 0.4 0.4 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 3.7 0.0 0.0 0.0 0.0 52.8 0.0 0.0 0.0 0.0 25.4 0.0 0.0 0.0 0.0 11.0 16.5 0.0 0.0 0.0 8.8 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 12.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.2 0.1 0.2 0.1 0.3 0.1 0.1 0.1 0.1 0.0 0.3 0.4 0.1 1.2 0.4 0.1 0.1 0.1 2.2 7.0 5.7 1.6 6.9 8.8 3.5 11.1 4.4 7.3 9.2 TAL2 bHLHa19 ENSG00000186051 "TAL bHLH transcription factor 2" Q16559 9 105662457-105663112 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 11 "blood: 8.8;kidney: 4.6;skeletal muscle: 17.3" "Cell line enhanced" "Detected in some" "HAP1: 4.8;K-562: 12.6" "Cancer enhanced" "Detected in some" "renal cancer: 1.6" "Group enriched" "Detected in some" 21 "memory B-cell: 8.8;naive B-cell: 7.9;plasmacytoid DC: 2.2" "Group enriched" "Detected in many" 18 "B-cells: 8.8;dendritic cells: 2.2" "Low region specificity" "Detected in single" "Not detected" "Not detected" HPA030886 Uncertain Approved Cytosol Cytosol "HPA030886: AB_10601596" "unprognostic (3.89e-2)" "unprognostic (1.45e-1)" "unprognostic (8.51e-2)" "unprognostic (5.54e-2)" "unprognostic (2.24e-1)" "unprognostic (9.06e-2)" "unprognostic (4.98e-2)" "unprognostic (1.03e-1)" "unprognostic (2.70e-3)" "unprognostic (2.63e-1)" "unprognostic (7.00e-4)" "unprognostic (2.84e-2)" "prognostic favourable (2.69e-4)" "unprognostic (2.70e-2)" "unprognostic (1.24e-1)" "unprognostic (1.29e-1)" "unprognostic (7.39e-2)" 0.1 0.3 0.5 0.1 0.7 0.0 0.0 0.3 0.6 0.2 0.0 0.0 0.2 0.9 0.1 0.2 0.0 0.3 0.4 0.5 4.6 0.3 0.0 0.2 0.7 0.3 0.1 0.0 0.8 0.1 0.1 0.1 0.0 0.2 17.3 0.1 0.1 0.0 0.8 0.3 0.0 0.6 0.1 0.4 0.1 0.0 8.8 2.2 0.0 0.0 0.3 0.0 0.1 0.0 0.6 2.5 0.7 0.3 0.0 0.3 0.1 0.3 0.1 0.4 3.3 0.2 0.1 0.2 0.0 0.1 4.8 0.0 0.1 0.6 0.5 1.1 0.0 0.0 0.2 0.5 1.8 0.2 0.5 0.1 0.2 0.0 12.6 0.3 0.4 0.3 0.8 0.7 0.2 0.2 0.1 0.1 0.0 0.0 0.0 2.8 1.1 0.2 0.2 0.2 0.2 2.0 0.5 0.3 0.8 0.7 1.0 0.9 1.9 0.1 0.2 2.3 0.8 0.0 0.0 0.0 0.0 0.0 0.0 8.8 0.0 0.0 0.0 7.9 0.0 0.0 0.0 0.3 0.0 2.2 0.0 0.1 TCEA1 "GTF2S, SII, TCEA, TF2S, TFIIS" ENSG00000187735 "Transcription elongation factor A1" P23193 8 53966552-54022529 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA043786 Approved Supported Nucleoplasm,Nucleoli Nucleoplasm Nucleoli "HPA043786: AB_10959468" "unprognostic (5.35e-2)" "unprognostic (9.90e-2)" "unprognostic (2.39e-1)" "unprognostic (2.11e-3)" "unprognostic (3.34e-2)" "unprognostic (1.17e-1)" "unprognostic (3.72e-2)" "unprognostic (1.77e-1)" "unprognostic (4.14e-2)" "unprognostic (1.00e-2)" "unprognostic (1.56e-2)" "unprognostic (1.25e-1)" "prognostic unfavourable (3.75e-5)" "unprognostic (3.80e-3)" "unprognostic (1.10e-1)" "unprognostic (1.13e-1)" "unprognostic (3.05e-2)" 26.7 25.3 30.7 40.5 31.5 29.6 31.1 26.1 27.4 26.0 28.3 21.9 26.6 20.3 27.3 20.9 27.5 23.6 24.7 21.4 27.8 24.2 26.5 56.8 22.3 39.2 29.7 17.6 28.5 38.4 32.2 28.7 21.1 27.1 31.3 22.5 20.6 25.4 25.4 21.8 22.8 22.4 38.9 36.8 30.0 26.1 17.3 31.3 39.9 54.6 18.6 46.9 39.6 37.3 60.0 31.9 20.5 17.8 25.2 40.1 17.8 26.8 27.2 24.3 25.0 17.3 21.5 17.4 21.3 25.0 25.2 28.2 15.5 22.5 65.9 24.3 24.4 20.7 30.7 19.5 36.8 37.7 15.4 49.8 13.3 22.9 54.3 19.5 21.5 15.4 52.8 23.7 104.8 21.5 31.6 57.3 22.9 12.7 40.4 13.7 39.6 8.1 31.3 8.5 11.8 34.8 18.3 22.8 16.6 17.6 15.5 57.2 22.4 21.9 19.0 18.6 17.1 20.8 19.1 35.4 22.1 44.7 32.7 22.4 26.1 18.1 17.8 20.5 30.1 16.8 28.6 60.0 31.4 27.7 22.1 44.4 28.0 29.1 6.4 25.2 15.6 31.9 40.1 17.8 30.7 31.5 26.1 27.4 27.8 24.2 29.7 17.6 27.1 31.3 TCF12 "bHLHb20, HEB, HsT17266, HTF4" ENSG00000140262 "Transcription factor 12" Q99081 15 56918623-57299281 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Neurogenesis, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Craniosynostosis, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 89.4" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004432, HPA065827" Approved Supported "Nucleoplasm,Nuclear speckles" "Nucleoplasm, Nuclear speckles" "CAB004432: AB_671267, HPA065827: " "unprognostic (1.19e-1)" "unprognostic (1.11e-1)" "unprognostic (8.26e-2)" "unprognostic (1.65e-1)" "unprognostic (2.07e-3)" "unprognostic (1.11e-1)" "unprognostic (6.63e-2)" "unprognostic (1.85e-1)" "prognostic unfavourable (8.89e-4)" "unprognostic (7.83e-2)" "unprognostic (7.26e-3)" "unprognostic (5.57e-3)" "prognostic unfavourable (5.24e-5)" "unprognostic (2.03e-1)" "unprognostic (2.93e-1)" "unprognostic (3.15e-2)" "unprognostic (1.41e-1)" 20.9 14.3 24.9 12.6 37.5 10.9 18.4 32.7 41.8 48.2 16.5 33.6 14.0 16.0 28.1 15.0 14.8 28.2 21.4 15.7 28.4 16.4 17.0 14.4 17.3 13.7 33.9 15.3 26.2 12.5 29.2 15.7 19.1 27.9 26.3 17.9 14.7 20.1 17.5 18.1 16.0 15.8 25.8 25.3 13.6 17.3 14.7 41.3 89.4 17.0 9.6 15.8 23.3 21.2 11.8 15.9 16.0 19.3 12.2 17.6 10.2 6.5 12.3 54.2 17.5 24.7 21.7 9.5 13.5 23.8 12.0 16.0 8.0 5.3 9.0 11.1 20.4 7.9 21.2 9.7 15.4 11.8 7.9 18.1 13.4 9.5 17.1 11.3 9.5 19.1 17.6 11.0 29.2 21.4 20.2 11.4 16.3 2.2 26.7 6.3 14.6 5.3 36.6 63.0 8.4 16.5 12.2 11.1 32.1 14.6 5.3 13.1 8.2 22.3 16.5 19.4 14.8 8.2 19.7 6.5 11.6 15.0 10.8 22.1 23.1 16.0 11.2 8.7 15.0 14.3 12.4 10.8 12.2 13.6 15.9 11.8 14.1 12.7 1.3 12.2 19.3 6.6 17.6 10.2 24.9 37.5 32.7 26.9 28.4 16.4 33.9 15.3 27.9 41.3 TCF3 "bHLHb21, E2A, E47, ITF1, MGC129647, MGC129648, VDIR" ENSG00000071564 "Transcription factor 3" P15923 19 1609290-1652605 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Differentiation, Neurogenesis, Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-698: 95.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB018351, HPA049808, HPA062476" Approved Enhanced Nucleoplasm Nucleoplasm "CAB018351: AB_675504, HPA049808: , HPA062476: " "unprognostic (8.82e-2)" "unprognostic (4.74e-2)" "unprognostic (1.26e-2)" "unprognostic (1.25e-1)" "unprognostic (1.91e-2)" "unprognostic (8.25e-3)" "prognostic unfavourable (2.46e-4)" "unprognostic (2.07e-2)" "unprognostic (7.99e-2)" "unprognostic (2.35e-1)" "unprognostic (2.42e-1)" "unprognostic (9.29e-3)" "prognostic unfavourable (1.53e-4)" "unprognostic (4.87e-3)" "unprognostic (1.88e-1)" "unprognostic (3.07e-1)" "unprognostic (8.05e-2)" 13.0 8.8 12.8 31.6 9.8 33.2 17.4 8.3 11.9 15.5 16.2 11.9 9.4 18.1 16.6 11.3 16.7 12.1 19.0 9.4 11.2 6.2 11.9 8.9 13.2 42.0 10.7 6.0 18.2 13.5 6.3 13.9 10.8 11.0 17.1 9.7 12.4 13.6 6.9 11.2 16.7 23.0 8.8 10.4 33.1 14.9 36.0 11.2 63.2 15.9 11.6 38.0 15.2 13.9 11.3 12.1 2.9 2.8 2.3 4.2 1.6 15.7 8.1 22.3 19.9 3.2 8.5 9.9 9.8 7.7 11.2 10.0 15.9 12.4 75.4 11.1 8.0 16.3 13.6 10.6 6.6 45.6 9.0 7.1 10.2 17.4 7.3 17.3 10.0 5.4 12.3 8.8 6.8 13.5 29.1 26.1 7.1 27.7 47.8 16.9 30.9 8.5 75.0 10.2 17.0 7.5 13.8 21.2 29.8 9.2 9.2 11.3 11.6 30.9 16.2 14.8 17.5 18.2 16.6 63.8 31.1 95.0 9.6 22.1 13.2 2.9 1.3 0.9 3.5 1.4 3.7 10.8 2.2 3.2 2.7 11.3 3.2 4.2 0.4 2.3 2.8 12.1 2.1 1.6 12.8 9.8 8.3 11.9 11.2 6.2 10.7 6.0 11.0 11.2 TCF7L2 "TCF-4, TCF4" ENSG00000148737 "Transcription factor 7 like 2" Q9NQB0 10 112950250-113167678 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation, Wnt signaling pathway" "Activator, DNA-binding, Repressor" "Cancer-related genes, Diabetes mellitus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 9 "intermediate monocyte: 12.1;non-classical monocyte: 33.1" "Lineage enriched" "Detected in many" 13 "monocytes: 33.1" "Group enriched" "Detected in many" 8 "midbrain: 84.5;thalamus: 98.3" "Group enriched" "Detected in all" 5 "midbrain: 190.1;pons and medulla: 104.8;thalamus: 169.1" "CAB013535, HPA038800" Supported Approved "Nucleoplasm,Nuclear bodies,Cytosol" Nucleoplasm "Nuclear bodies, Cytosol" "CAB013535: AB_2533167, HPA038800: " "unprognostic (1.79e-2)" "unprognostic (3.36e-1)" "unprognostic (1.11e-1)" "unprognostic (2.31e-2)" "unprognostic (4.59e-3)" "unprognostic (1.72e-1)" "unprognostic (2.09e-1)" "unprognostic (9.84e-2)" "unprognostic (5.09e-1)" "unprognostic (7.10e-2)" "unprognostic (6.10e-3)" "unprognostic (3.46e-2)" "unprognostic (7.25e-3)" "unprognostic (1.60e-1)" "unprognostic (1.55e-1)" "unprognostic (3.64e-1)" "unprognostic (7.36e-3)" 27.4 10.3 8.7 18.7 10.0 7.3 46.4 5.4 10.3 27.4 34.2 15.4 28.1 21.0 26.6 14.9 12.6 18.2 15.3 13.5 8.1 17.9 10.2 22.9 26.9 13.9 8.5 9.0 25.6 13.9 16.5 17.9 24.0 10.2 14.4 23.7 13.9 14.9 52.8 13.7 17.6 40.4 18.0 13.9 27.3 24.0 10.6 10.1 6.6 14.3 9.3 7.0 21.5 16.3 0.0 1.7 2.5 33.1 0.0 0.6 1.1 7.0 18.5 20.3 19.6 10.6 7.1 24.2 5.0 9.8 3.5 4.3 12.2 21.5 0.0 5.7 9.4 5.0 6.9 8.7 4.5 0.8 6.4 5.0 12.3 11.3 11.3 1.9 1.8 12.5 3.2 5.5 9.3 5.9 5.1 0.3 4.1 13.8 3.1 1.2 14.6 10.7 8.9 14.9 3.2 7.6 9.9 0.4 6.2 7.6 7.6 8.1 4.9 1.0 13.6 3.3 9.6 8.4 10.3 1.3 0.1 0.1 3.3 4.2 7.4 0.1 1.8 0.1 0.6 12.1 0.4 0.0 0.1 0.5 1.7 0.0 0.1 0.3 2.5 0.0 33.1 0.0 0.0 1.1 8.7 10.0 5.4 10.3 8.1 17.9 8.5 9.0 10.2 10.1 TCL1A TCL1 ENSG00000100721 "T cell leukemia/lymphoma 1A" P56279 14 95709967-95714196 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 12 "blood: 179.4;lymphoid tissue: 63.7" "Group enriched" "Detected in some" 157 "Daudi: 69.4;REH: 90.3;U-698: 92.2" "Cancer enriched" "Detected in many" 18 "testis cancer: 64.4" "Not detected" "Not detected" "Group enriched" "Detected in some" 381 "memory B-cell: 45.6;naive B-cell: 179.4;plasmacytoid DC: 79.8" "Group enriched" "Detected in many" 487 "B-cells: 179.4;dendritic cells: 79.8" "Not detected" "Not detected" "CAB004045, HPA016604" Enhanced Enhanced "Nucleoplasm,Endoplasmic reticulum,Cytosol" "Endoplasmic reticulum, Cytosol" Nucleoplasm "CAB004045: AB_2179419, HPA016604: AB_1857859" "unprognostic (1.27e-3)" "unprognostic (3.12e-4)" "unprognostic (2.61e-4)" "unprognostic (2.01e-2)" "unprognostic (1.27e-1)" "unprognostic (4.75e-4)" "unprognostic (7.70e-2)" "unprognostic (9.67e-3)" "unprognostic (1.03e-1)" "unprognostic (3.35e-1)" "unprognostic (1.14e-1)" "unprognostic (2.14e-2)" "unprognostic (2.64e-2)" "unprognostic (1.87e-1)" "unprognostic (3.94e-1)" "unprognostic (2.06e-1)" "unprognostic (4.55e-1)" 0.4 0.2 0.2 53.4 0.2 4.8 0.3 0.2 0.2 0.2 0.9 0.0 0.2 0.0 0.3 0.0 0.8 0.3 0.6 0.3 0.2 0.2 1.1 0.4 3.2 63.7 0.2 0.0 0.3 0.2 0.0 0.2 0.6 0.0 0.4 0.2 0.1 2.9 0.0 0.2 0.2 10.4 0.1 0.2 33.5 0.5 5.3 0.0 4.7 0.8 1.2 53.6 3.6 0.3 179.4 79.8 0.2 0.1 0.0 0.1 6.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 69.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 90.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.4 0.0 0.0 0.0 0.5 92.2 0.0 0.0 0.0 0.2 0.1 0.1 0.0 0.0 0.1 45.6 0.0 0.0 0.1 179.4 0.1 0.0 0.2 0.0 0.1 79.8 0.0 6.0 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.0 0.0 0.0 TET1 "bA119F7.1, CXXC6, KIAA1676, LCX" ENSG00000138336 "Tet methylcytosine dioxygenase 1" Q8NFU7 10 68560656-68694482 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Chromatin regulator, Dioxygenase, DNA-binding, Oxidoreductase, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "BEWO: 15.1;HAP1: 17.2;K-562: 9.6;NTERA-2: 10.1" "Cancer enriched" "Detected in some" 15 "testis cancer: 10.4" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019032, HPA057273" Supported "Nucleoplasm,Nuclear membrane" Nucleoplasm "Nuclear membrane" "HPA019032: AB_1847363, HPA057273: " "unprognostic (1.60e-1)" "unprognostic (8.30e-2)" "unprognostic (9.85e-2)" "unprognostic (1.67e-2)" "unprognostic (1.27e-1)" "unprognostic (8.15e-2)" "unprognostic (3.60e-3)" "unprognostic (1.12e-1)" "unprognostic (2.00e-1)" "unprognostic (7.90e-3)" "unprognostic (1.83e-1)" "unprognostic (1.71e-1)" "unprognostic (1.18e-3)" "unprognostic (2.88e-4)" "unprognostic (4.02e-2)" "unprognostic (2.54e-1)" "unprognostic (9.52e-3)" 4.4 1.6 3.3 4.3 2.6 1.6 3.1 4.4 4.3 5.1 2.4 5.8 3.2 1.2 6.0 3.4 2.4 2.9 3.5 2.4 3.5 2.3 1.8 1.5 1.6 1.7 2.5 2.6 6.1 1.6 7.4 2.2 5.8 2.9 3.2 2.0 8.1 15.9 4.8 4.0 2.2 1.8 6.5 3.6 1.7 2.2 1.4 5.9 1.2 3.2 3.2 1.8 5.1 5.4 1.3 1.1 1.0 0.0 0.9 2.3 0.2 0.6 0.7 6.8 7.7 0.7 0.6 15.1 0.3 0.8 0.6 1.1 4.6 0.2 0.0 0.2 0.7 0.0 17.2 0.0 0.7 0.2 2.7 1.8 0.0 4.0 1.0 1.5 0.9 0.9 0.1 0.4 0.0 0.1 9.6 1.2 0.6 0.5 2.7 1.2 10.1 0.9 2.6 2.2 0.2 0.3 0.7 1.9 3.0 0.3 0.4 1.4 0.9 1.2 0.2 0.6 1.4 0.0 0.5 0.5 0.5 2.7 0.1 0.0 0.1 0.0 0.0 1.0 1.5 0.0 2.0 1.3 0.8 1.3 0.2 0.5 1.4 1.1 0.0 0.9 0.0 1.1 2.3 0.2 3.3 2.6 4.4 2.6 3.5 2.3 2.5 2.6 2.9 5.9 TFE3 "bHLHe33, TFEA" ENSG00000068323 "Transcription factor binding to IGHM enhancer 3" P19532 X 49028726-49043486 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Adaptive immunity, Immunity, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 10.5" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA023881 Approved Supported Nucleoplasm,Cytosol "Nucleoplasm, Cytosol" "HPA023881: AB_1857931" "unprognostic (2.68e-2)" "unprognostic (2.89e-3)" "unprognostic (2.40e-2)" "unprognostic (5.36e-2)" "unprognostic (2.71e-2)" "unprognostic (1.81e-1)" "prognostic unfavourable (6.03e-5)" "unprognostic (2.40e-1)" "unprognostic (1.26e-1)" "unprognostic (4.32e-2)" "unprognostic (5.41e-2)" "unprognostic (1.16e-1)" "prognostic unfavourable (2.19e-8)" "unprognostic (1.93e-1)" "unprognostic (8.77e-2)" "unprognostic (4.19e-2)" "unprognostic (6.25e-1)" 31.3 20.9 12.6 18.2 14.4 22.6 53.1 16.5 18.1 22.6 17.7 16.6 30.0 9.9 22.8 21.9 20.5 18.8 16.4 15.1 11.3 11.8 21.6 14.1 22.8 10.3 13.2 9.4 24.4 15.9 16.5 16.3 22.0 15.9 21.2 10.4 15.7 12.6 30.6 13.6 14.1 13.5 21.2 14.8 23.0 14.7 10.4 15.2 4.2 21.7 10.8 10.5 28.6 20.5 1.2 1.9 10.5 4.4 0.4 1.4 1.6 11.9 15.3 5.1 14.8 16.7 15.1 5.1 15.7 18.2 16.1 13.8 9.4 9.5 4.5 6.7 23.1 9.8 9.7 14.2 13.0 9.8 5.2 4.1 11.4 8.7 22.5 4.3 10.2 13.1 9.2 26.3 18.9 7.7 7.9 19.7 13.7 7.0 2.8 4.0 13.9 13.8 4.3 8.9 10.2 10.2 5.5 4.9 4.9 16.8 7.2 5.5 10.3 3.9 16.3 17.6 18.9 17.6 8.6 12.1 11.4 3.7 21.0 5.3 12.0 0.0 3.5 1.6 0.5 4.3 0.9 0.6 0.9 0.5 1.9 1.2 0.6 0.4 10.5 0.4 4.4 0.4 1.4 1.6 12.6 14.4 16.5 14.9 11.3 11.8 13.2 9.4 15.9 15.2 TFEB "bHLHe35, TCFEB" ENSG00000112561 "Transcription factor EB" P19484 6 41683978-41736259 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Adaptive immunity, Autophagy, Immunity, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "BEWO: 30.9;Daudi: 19.6;HDLM-2: 17.9;U-698: 28.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 29.0" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA049532 Supported Nucleoplasm Nucleoplasm "HPA049532: " "unprognostic (3.63e-3)" "unprognostic (1.51e-3)" "unprognostic (1.75e-2)" "unprognostic (4.48e-3)" "unprognostic (1.95e-1)" "unprognostic (1.05e-1)" "unprognostic (1.64e-1)" "unprognostic (4.22e-3)" "unprognostic (1.39e-2)" "unprognostic (4.13e-2)" "prognostic favourable (4.77e-4)" "unprognostic (2.12e-2)" "prognostic favourable (1.06e-5)" "unprognostic (1.44e-1)" "unprognostic (3.51e-2)" "unprognostic (2.46e-1)" "unprognostic (1.31e-2)" 8.6 6.4 10.2 16.8 20.7 8.9 6.8 8.6 15.0 6.4 10.5 34.4 8.2 6.8 7.1 4.3 9.3 7.2 9.1 19.3 14.6 8.2 12.2 5.0 8.3 24.1 30.0 6.8 6.7 11.4 26.1 14.9 18.5 16.2 10.7 5.3 6.9 18.0 8.6 45.2 7.9 15.5 8.4 27.4 27.3 7.9 2.5 24.0 2.8 11.1 10.9 18.3 10.8 11.1 22.2 8.5 29.0 9.6 0.8 2.6 4.4 1.7 1.8 0.4 7.2 2.4 1.4 30.9 2.8 5.6 2.5 1.9 4.1 2.1 19.6 3.8 2.9 5.0 1.1 2.8 0.6 17.9 2.0 0.0 7.1 7.5 4.8 0.5 2.6 0.5 5.5 2.9 1.9 1.9 2.3 4.8 0.9 1.3 1.1 1.5 0.1 0.9 12.9 0.2 2.7 4.4 1.4 8.1 2.3 2.4 5.0 0.6 1.4 9.8 3.8 0.9 2.0 0.1 2.0 12.6 2.0 28.9 1.5 8.3 1.0 0.1 9.6 8.8 2.6 9.3 0.4 22.2 0.7 1.0 8.5 15.1 0.2 0.9 29.0 0.8 6.5 1.7 0.4 4.4 10.2 20.7 8.6 15.0 14.6 8.2 30.0 6.8 16.2 24.0 TFG "FLJ36137, SPG57, TF6" ENSG00000114354 "TRK-fused gene" Q92734 3 100709331-100748966 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "ER-Golgi transport, Transport" "Cancer-related genes, Disease mutation, Hereditary spastic paraplegia, Neurodegeneration, Neuropathy, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019473, HPA052206" Approved Supported Vesicles,Cytosol Vesicles Cytosol "HPA019473: AB_1857936, HPA052206: " "unprognostic (1.14e-1)" "unprognostic (3.58e-2)" "unprognostic (1.46e-1)" "unprognostic (2.94e-2)" "unprognostic (1.46e-1)" "unprognostic (4.14e-2)" "prognostic unfavourable (5.48e-4)" "unprognostic (3.31e-3)" "unprognostic (1.42e-1)" "unprognostic (3.73e-2)" "prognostic unfavourable (1.50e-4)" "unprognostic (4.58e-3)" "unprognostic (3.72e-2)" "unprognostic (2.82e-1)" "unprognostic (8.55e-2)" "unprognostic (3.33e-1)" "unprognostic (8.45e-2)" 36.4 40.3 27.2 21.9 33.8 29.7 31.0 28.1 40.5 31.2 34.7 33.3 44.2 52.5 31.2 45.8 46.7 29.0 40.8 46.2 28.1 30.7 44.6 68.6 29.9 25.4 28.2 21.5 33.5 49.2 52.3 45.1 63.3 33.7 27.5 40.7 31.9 39.6 45.8 38.6 31.0 67.1 37.5 31.7 28.3 28.9 33.5 23.0 27.6 43.6 42.9 41.2 29.5 30.1 25.8 27.8 43.2 28.4 27.7 26.8 21.8 48.4 26.4 32.9 20.9 41.6 47.2 40.7 35.1 47.3 45.9 54.8 33.3 24.2 6.5 25.8 43.6 36.4 35.4 40.1 54.7 29.8 20.8 24.4 20.3 30.9 46.5 18.0 14.6 38.6 54.1 27.5 48.5 40.6 17.5 18.1 47.4 33.9 15.8 14.3 31.3 39.8 14.0 19.3 21.1 55.7 32.7 26.0 23.8 23.1 30.1 40.9 35.4 24.4 27.1 27.8 33.6 12.8 25.4 15.4 15.5 23.3 44.4 19.7 32.6 43.2 28.3 27.0 21.8 28.4 26.4 25.8 22.6 24.4 27.8 22.9 21.6 21.6 18.7 27.7 26.4 19.4 26.8 21.8 27.2 33.8 28.1 40.5 28.1 30.7 28.2 21.5 33.7 23.0 TLX1 "HOX11, TCL3" ENSG00000107807 "T cell leukemia homeobox 1" P31314 10 101130505-101137789 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Developmental protein, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "lymphoid tissue: 59.5;salivary gland: 19.5" "Cell line enhanced" "Detected in some" "HAP1: 5.3;HEK 293: 3.0;K-562: 15.0;SCLC-21H: 2.5;SH-SY5Y: 3.7;SiHa: 2.5" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in single" 13 "pons and medulla: 0.5" "Region enriched" "Detected in single" 20 "pons and medulla: 0.5" HPA053185 Supported Nucleoplasm Nucleoplasm "HPA053185: " "unprognostic (8.67e-2)" "unprognostic (2.23e-1)" "prognostic unfavourable (7.32e-4)" "unprognostic (1.06e-5)" "unprognostic (1.06e-1)" "unprognostic (1.60e-1)" "unprognostic (5.07e-1)" "unprognostic (1.57e-2)" "unprognostic (2.12e-2)" "unprognostic (2.69e-2)" "unprognostic (2.52e-3)" "unprognostic (1.81e-1)" "unprognostic (2.63e-1)" "unprognostic (3.26e-1)" "unprognostic (3.06e-1)" "unprognostic (7.35e-2)" 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.1 0.1 0.0 0.8 0.0 0.0 0.1 0.0 0.0 0.2 0.4 0.0 0.0 0.5 0.1 0.0 0.0 0.0 0.0 0.1 0.5 0.0 0.1 0.1 0.2 0.0 0.0 19.5 0.0 0.1 0.0 0.6 0.0 0.0 59.5 0.0 0.1 0.1 0.0 0.0 4.8 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.8 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 5.3 0.0 0.0 0.0 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 2.5 3.7 2.5 0.0 0.0 0.1 0.4 0.2 0.0 1.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.0 0.0 0.1 0.1 TLX3 "HOX11L2, RNX" ENSG00000164438 "T cell leukemia homeobox 3" O43711 5 171309284-171312134 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 59 "brain: 46.6" "Cell line enriched" "Detected in some" 5 "SH-SY5Y: 24.0" "Cancer enhanced" "Detected in some" "cervical cancer: 1.7" "Region enriched" "Detected in some" 22 "cerebellum: 46.6" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in single" 7 "cerebellum: 2.5" "Region enriched" "Detected in some" 11 "cerebellum: 48.1" "HPA030504, HPA060957, HPA069359" Enhanced Enhanced Nucleoplasm Nucleoplasm "HPA030504: , HPA060957: , HPA069359: " "unprognostic (3.52e-2)" "unprognostic (2.43e-2)" "unprognostic (2.09e-1)" "unprognostic (3.11e-1)" "unprognostic (9.80e-2)" "unprognostic (2.76e-2)" "unprognostic (4.48e-2)" 0.4 0.5 0.0 0.0 0.0 0.0 0.0 46.6 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.4 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 1.6 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.4 0.0 0.0 0.2 0.0 0.0 0.0 1.3 0.0 4.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.2 0.0 0.0 24.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 46.6 0.0 0.0 0.0 0.0 0.0 2.0 0.0 TMPRSS2 PRSS10 ENSG00000184012 "Transmembrane serine protease 2" O15393 21 41464551-41531116 "Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins" "Hydrolase, Protease, Serine protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 75.6;pancreas: 64.5;prostate: 68.2" "Cell line enhanced" "Detected in some" "CACO-2: 14.6;MCF7: 6.3;RT4: 35.2;SK-BR-3: 7.2;T-47d: 5.4" "Cancer enriched" "Detected in many" 7 "prostate cancer: 250.6" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA034493, HPA035787" Enhanced Supported "Nucleoplasm,Cell Junctions" "Intracellular and membrane" "Cell Junctions" Nucleoplasm "HPA034493: , HPA035787: AB_2674782" "unprognostic (4.80e-3)" "unprognostic (3.49e-1)" "unprognostic (2.16e-1)" "prognostic favourable (2.56e-4)" "unprognostic (1.72e-1)" "unprognostic (1.05e-2)" "unprognostic (4.28e-2)" "unprognostic (1.51e-3)" "unprognostic (9.43e-2)" "unprognostic (9.02e-3)" "unprognostic (6.24e-2)" "unprognostic (6.43e-2)" "prognostic favourable (7.86e-6)" "unprognostic (2.00e-2)" "unprognostic (1.68e-1)" "unprognostic (1.41e-1)" "unprognostic (2.15e-2)" 0.2 0.1 0.2 15.5 0.4 0.0 6.1 0.2 0.5 1.3 38.7 0.4 24.4 17.5 0.5 0.9 10.7 2.2 17.3 0.2 0.3 0.1 19.4 18.4 20.7 0.2 0.2 0.2 0.7 64.5 0.0 1.3 1.0 0.4 68.2 18.5 0.3 52.3 35.7 0.2 2.1 75.6 0.9 0.2 0.3 36.7 0.8 0.3 0.5 19.9 3.9 10.2 5.9 4.3 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 14.6 1.9 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.3 0.1 0.5 1.3 0.0 0.0 0.0 1.4 0.6 35.2 0.0 0.4 0.0 7.2 0.1 5.4 0.0 0.0 0.0 0.3 0.3 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.2 0.4 0.2 0.5 0.3 0.1 0.2 0.2 0.4 0.3 TNFRSF17 "BCM, BCMA, CD269, TNFRSF13A" ENSG00000048462 "TNF receptor superfamily member 17" Q02223 16 11965107-11968068 "Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 34.1;intestine: 17.8;lymphoid tissue: 28.8" "Cell line enhanced" "Detected in some" "Karpas-707: 25.3;RPMI-8226: 39.9;U-266/70: 118.6;U-266/84: 58.9" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in some" 59 "memory B-cell: 34.1;naive B-cell: 26.9;plasmacytoid DC: 27.9" "Group enriched" "Detected in many" 62 "B-cells: 34.1;dendritic cells: 27.9" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" 2200000 "prognostic favourable (1.35e-5)" "unprognostic (3.41e-2)" "unprognostic (4.00e-3)" "unprognostic (1.41e-2)" "unprognostic (6.47e-2)" "prognostic favourable (1.58e-6)" "unprognostic (9.75e-3)" "unprognostic (5.93e-2)" "unprognostic (2.13e-2)" "unprognostic (7.96e-3)" "unprognostic (2.46e-1)" "unprognostic (2.58e-1)" "unprognostic (2.85e-6)" "unprognostic (2.06e-1)" "unprognostic (2.48e-1)" "unprognostic (3.54e-2)" "unprognostic (1.10e-1)" 0.6 0.4 0.4 24.0 0.9 0.3 5.4 0.5 0.4 1.5 17.8 0.2 0.2 12.3 0.5 0.2 3.7 1.1 4.9 0.7 0.4 0.4 1.3 0.8 3.0 22.4 0.4 0.2 0.9 3.1 0.0 0.5 0.3 0.2 1.0 9.4 0.6 14.2 0.2 0.4 0.4 11.7 0.2 0.4 22.2 9.4 2.2 0.3 3.1 1.1 1.4 28.8 7.6 0.7 34.1 27.9 0.5 0.1 0.2 0.1 3.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 6.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 25.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 39.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 118.6 58.9 9.2 0.1 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.1 34.1 0.0 0.0 0.0 26.9 0.0 0.0 0.5 0.2 0.0 27.9 0.0 3.7 0.4 0.9 0.5 0.4 0.4 0.4 0.4 0.2 0.2 0.3 TOP1 ENSG00000198900 "DNA topoisomerase I" P11387 20 41028818-41124487 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Biological rhythms, Host-virus interaction" "DNA-binding, Isomerase, Topoisomerase" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009058, HPA019039" Supported Supported "Nucleoplasm,Nucleoli fibrillar center" "Nucleoplasm, Nucleoli fibrillar center" "CAB009058: AB_2303554, HPA019039: AB_1858187" "unprognostic (1.46e-1)" "unprognostic (8.65e-2)" "unprognostic (1.33e-2)" "unprognostic (1.92e-3)" "unprognostic (5.05e-2)" "unprognostic (1.49e-3)" "prognostic unfavourable (6.42e-4)" "unprognostic (5.86e-2)" "unprognostic (1.51e-1)" "unprognostic (4.60e-2)" "unprognostic (3.74e-3)" "unprognostic (6.51e-2)" "unprognostic (8.65e-2)" "unprognostic (4.70e-2)" "unprognostic (5.14e-1)" "unprognostic (3.64e-1)" "unprognostic (1.29e-1)" 26.6 31.0 24.6 46.3 25.3 55.3 37.4 39.6 31.1 21.3 30.0 11.1 26.7 29.7 22.9 22.5 36.0 20.5 29.2 21.0 23.0 18.3 31.8 32.7 37.9 38.6 21.9 20.9 25.5 22.5 22.2 39.9 43.9 25.2 23.3 27.2 13.6 25.3 34.3 26.2 24.6 48.4 23.1 27.4 36.9 26.7 14.2 24.2 54.2 31.5 25.1 40.6 25.2 41.7 9.0 17.2 18.4 11.1 5.8 8.2 4.6 21.5 15.1 28.3 23.1 11.5 13.7 28.0 19.5 17.2 22.7 20.7 39.6 27.2 61.5 20.9 10.1 21.0 33.9 31.2 33.3 13.3 17.3 78.4 12.1 28.1 29.9 33.8 27.0 15.5 16.7 22.1 36.4 23.7 34.0 21.4 25.6 47.9 47.7 21.4 22.8 28.1 40.8 26.6 32.7 24.2 20.1 23.5 16.3 30.6 19.0 19.8 21.1 30.3 23.2 18.4 15.6 17.0 20.9 13.6 15.2 71.7 24.7 19.0 17.4 9.1 9.2 14.3 6.5 9.2 8.2 9.0 7.2 6.8 8.6 8.7 7.7 6.9 18.4 5.8 11.1 17.2 7.9 4.6 24.6 25.3 39.6 31.1 23.0 18.3 21.9 20.9 25.2 24.2 TP53 "LFS1, p53" ENSG00000141510 "Tumor protein p53" P04637 17 7661779-7687550 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors, Transporters" "Apoptosis, Biological rhythms, Cell cycle, Host-virus interaction, Necrosis, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Li-Fraumeni syndrome, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 102.6" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002973, CAB039238, CAB039239, HPA051244, HPA063532, CAB072876" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB002973: AB_2206626, CAB039238: , CAB039239: , CAB072876: , HPA051244: , HPA063532: " "unprognostic (2.29e-2)" "unprognostic (8.83e-3)" "unprognostic (1.26e-2)" "prognostic favourable (1.35e-4)" "unprognostic (9.95e-2)" "unprognostic (4.00e-2)" "unprognostic (2.79e-3)" "unprognostic (4.99e-2)" "unprognostic (2.75e-2)" "unprognostic (2.55e-1)" "unprognostic (1.30e-1)" "prognostic unfavourable (5.01e-4)" "unprognostic (1.86e-3)" "unprognostic (7.89e-3)" "unprognostic (8.05e-2)" "unprognostic (2.74e-1)" "unprognostic (1.08e-1)" 18.5 11.1 6.0 28.6 6.8 9.0 17.5 2.5 7.3 18.5 14.6 6.8 8.3 9.7 20.3 15.0 25.3 16.7 22.6 8.1 5.0 3.8 10.6 20.8 11.2 26.0 6.6 3.1 33.8 13.8 4.9 6.0 22.8 6.9 16.5 14.5 9.9 15.3 16.1 12.5 24.6 14.0 12.8 6.2 24.2 12.0 14.1 6.9 102.6 13.2 23.5 31.2 16.9 15.0 15.2 19.6 2.2 14.1 11.0 11.3 8.2 19.2 35.6 19.4 14.0 9.1 10.8 20.6 6.9 15.6 19.2 24.3 1.0 9.9 45.3 31.5 13.6 42.5 28.2 19.1 18.0 10.1 18.9 18.3 20.0 16.9 27.4 0.4 9.5 13.7 22.2 9.3 25.7 18.8 0.9 1.7 9.8 34.2 30.7 22.4 19.6 0.7 59.7 13.7 15.7 14.3 21.3 11.6 20.0 22.8 15.4 5.9 26.7 1.7 24.3 23.0 7.6 0.3 11.6 11.9 8.7 19.5 6.0 2.3 19.4 0.8 13.3 2.2 9.1 14.1 11.1 15.2 9.4 10.2 19.6 14.5 9.9 10.8 1.7 11.0 11.9 17.9 11.3 8.2 6.0 6.8 2.5 6.4 5.0 3.8 6.6 3.1 6.9 6.9 TP63 "EEC3, KET, NBP, OFC8, p51, p53CP, p63, p73H, p73L, SHFM4, TP53CP, TP53L, TP73L" ENSG00000073282 "Tumor protein p63" Q9H3D4 3 189631416-189897279 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Apoptosis, Notch signaling pathway, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation, Ectodermal dysplasia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skeletal muscle: 83.2;skin 1: 54.2" "Group enriched" "Detected in some" 5 "HaCaT: 23.3;HBEC3-KT: 44.6;hTCEpi: 33.8;hTERT-HME1: 32.3;RT4: 49.0" "Group enriched" "Detected in many" 11 "cervical cancer: 37.9;head and neck cancer: 73.3;lung cancer: 37.3;urothelial cancer: 21.2" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected" "Not detected" "CAB000083, HPA006288, HPA006289, HPA007009, HPA007010" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB000083: AB_2207187, HPA006288: AB_1080334, HPA006289: , HPA007009: , HPA007010: AB_1080336" "prognostic favourable (1.07e-4)" "unprognostic (1.30e-1)" "unprognostic (1.44e-1)" "unprognostic (3.02e-1)" "unprognostic (4.38e-2)" "unprognostic (3.50e-1)" "unprognostic (1.29e-1)" "unprognostic (5.17e-2)" "unprognostic (2.78e-1)" "unprognostic (5.37e-2)" "unprognostic (2.09e-3)" "unprognostic (1.54e-1)" "unprognostic (1.87e-5)" "unprognostic (1.86e-1)" "unprognostic (1.05e-1)" "unprognostic (1.62e-1)" "unprognostic (2.74e-3)" 2.9 0.1 0.2 0.7 0.1 0.0 7.2 0.1 0.2 9.5 0.1 0.1 5.7 0.0 0.3 8.0 33.7 0.3 0.0 0.2 0.1 0.1 0.4 0.1 1.2 0.2 0.1 0.2 0.1 0.1 0.0 0.3 7.8 0.8 9.6 0.0 0.3 9.0 7.8 83.2 54.2 0.1 2.7 0.6 0.1 0.1 1.2 0.0 9.0 0.4 36.7 26.1 9.6 19.2 3.7 1.3 3.0 0.9 1.2 1.2 0.2 0.6 1.2 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 4.3 0.1 0.0 23.3 0.0 44.6 0.0 0.3 0.0 0.5 0.3 0.1 0.0 0.0 0.1 0.0 33.8 0.0 32.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 49.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 6.8 0.1 0.3 0.1 0.0 0.2 2.0 0.4 1.1 0.9 0.5 0.7 3.7 1.2 1.0 0.4 1.7 0.8 0.7 3.0 1.2 0.9 1.3 0.8 0.2 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.8 0.0 TPM3 "NEM1, TRK" ENSG00000143549 "Tropomyosin 3" P06753 1 154155304-154194648 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Actin-binding, Muscle protein" "Cancer-related genes, Disease mutation, Nemaline myopathy, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 738.4;tongue: 203.6" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000261, HPA009066, HPA047089, HPA053624" Approved Approved "Actin filaments,Cytosol" 410000000 "Actin filaments" Cytosol "HPA000261: AB_1080339, HPA009066: AB_1080342, HPA047089: , HPA053624: " "unprognostic (1.64e-1)" "unprognostic (2.11e-2)" "unprognostic (3.01e-3)" "unprognostic (1.07e-1)" "unprognostic (2.39e-1)" "unprognostic (2.69e-3)" "prognostic unfavourable (6.73e-6)" "prognostic unfavourable (4.01e-4)" "unprognostic (2.80e-1)" "prognostic favourable (2.39e-5)" "prognostic unfavourable (3.65e-4)" "unprognostic (3.31e-2)" "prognostic unfavourable (3.12e-5)" "unprognostic (3.52e-2)" "unprognostic (1.67e-1)" "unprognostic (1.98e-2)" "unprognostic (1.00e-2)" 10.1 7.3 10.8 10.8 10.5 26.5 6.2 6.4 11.2 4.6 9.6 3.9 3.2 7.9 4.1 27.9 18.3 4.4 6.7 29.7 7.7 8.1 7.2 6.8 9.6 12.9 8.9 5.8 4.8 23.2 3.6 3.2 6.7 5.0 5.7 10.7 4.4 20.5 2.5 738.4 5.9 8.2 5.2 7.7 11.7 6.9 5.4 4.4 6.7 9.3 203.6 28.6 6.8 4.9 38.9 72.6 154.8 95.9 35.4 54.4 146.1 67.5 33.7 43.2 28.3 36.6 47.8 43.5 58.1 53.7 77.1 58.2 62.8 63.4 50.9 47.3 65.5 62.6 42.8 61.1 82.2 35.2 23.3 62.6 32.9 42.2 29.1 91.6 83.2 36.0 33.5 67.9 52.3 118.6 47.0 54.7 95.1 40.5 71.3 94.6 97.2 73.3 61.1 30.0 72.1 55.6 51.6 30.3 56.9 44.1 58.8 57.6 82.0 109.5 88.6 67.5 48.9 64.7 91.0 46.6 76.5 68.0 61.0 69.0 106.6 70.8 64.7 154.8 54.4 87.8 48.6 38.9 48.5 51.1 72.6 30.1 36.6 47.3 74.9 35.4 95.9 36.0 52.1 146.1 10.8 10.5 6.4 11.2 7.7 8.1 8.9 5.8 5.0 4.4 TPM4 ENSG00000167460 "Tropomyosin 4" P67936 19 16067021-16103005 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Actin-binding, Muscle protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "U-2197: 225.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004685, HPA047089, HPA053624" Approved Approved "Actin filaments,Cytosol" 950000000 "Actin filaments" Cytosol "CAB004685: AB_425723, HPA047089: , HPA053624: " "unprognostic (1.27e-1)" "unprognostic (1.53e-2)" "unprognostic (3.62e-3)" "unprognostic (7.38e-3)" "unprognostic (3.80e-1)" "unprognostic (2.40e-2)" "unprognostic (3.11e-2)" "unprognostic (2.75e-3)" "unprognostic (1.38e-2)" "unprognostic (3.61e-1)" "prognostic unfavourable (3.07e-4)" "unprognostic (1.03e-1)" "prognostic unfavourable (1.26e-10)" "unprognostic (3.85e-2)" "unprognostic (2.25e-1)" "unprognostic (1.48e-1)" "unprognostic (1.78e-1)" 66.2 17.9 13.3 60.0 13.7 10.8 47.4 46.2 11.5 90.2 40.5 14.6 56.4 17.4 87.1 63.3 149.3 49.4 108.4 39.2 14.5 12.4 32.4 12.2 69.7 27.1 16.0 10.5 102.4 15.4 8.4 16.2 65.0 19.7 84.1 31.8 18.6 47.6 64.6 29.9 39.0 25.2 127.2 22.5 99.7 37.5 30.6 11.7 11.5 20.0 92.2 60.1 177.3 70.5 22.2 35.0 40.7 32.7 24.7 52.5 48.6 58.7 23.3 45.1 27.5 104.9 156.3 56.6 82.3 99.9 69.8 72.0 24.2 61.4 2.7 64.3 102.7 31.7 18.8 47.2 91.3 38.7 10.8 29.6 33.5 19.4 57.7 5.3 70.8 96.7 15.3 57.0 65.6 79.7 3.4 37.3 96.3 20.0 15.9 18.6 23.6 28.4 21.8 38.8 12.7 16.1 50.4 8.2 25.8 55.3 24.8 29.2 0.5 8.2 93.4 121.6 15.4 225.9 76.1 6.5 15.3 13.1 84.3 15.6 41.1 40.7 30.1 2.2 34.8 32.7 26.3 22.2 26.9 31.2 35.0 18.8 7.8 18.3 35.2 24.7 16.2 27.4 52.5 48.6 13.3 13.7 46.2 11.5 14.5 12.4 16.0 10.5 19.7 11.7 TPR ENSG00000047410 "Translocated promoter region, nuclear basket protein" P12270 1 186311652-186375693 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters" "Cell cycle, Cell division, Mitosis, mRNA transport, Protein transport, Translocation, Transport" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019661, HPA019663, HPA024336" Enhanced Enhanced "Nuclear membrane" "Nuclear membrane" "HPA019661: AB_1858215, HPA019663: AB_1858216, HPA024336: AB_1858217" "unprognostic (4.51e-2)" "unprognostic (9.87e-3)" "unprognostic (2.48e-1)" "unprognostic (7.56e-2)" "unprognostic (9.88e-3)" "prognostic favourable (4.71e-4)" "prognostic unfavourable (1.06e-4)" "unprognostic (1.71e-1)" "unprognostic (3.71e-2)" "unprognostic (1.14e-1)" "unprognostic (1.45e-2)" "unprognostic (3.63e-2)" "unprognostic (1.31e-3)" "unprognostic (3.75e-1)" "unprognostic (4.19e-2)" "unprognostic (5.06e-2)" "unprognostic (1.98e-2)" 21.5 17.3 14.3 26.7 21.3 21.6 19.0 24.4 17.1 21.7 24.2 7.3 27.1 12.9 20.8 23.5 18.5 16.9 16.8 28.3 13.8 10.5 18.7 20.6 17.9 20.4 14.1 16.6 24.7 17.8 44.2 29.1 29.7 15.1 22.2 17.7 9.1 20.2 30.1 33.1 20.5 21.1 21.2 16.4 26.1 18.8 35.0 17.8 39.5 21.7 19.7 21.4 25.1 19.1 19.1 19.8 50.3 15.2 10.7 16.9 5.2 22.0 19.1 28.7 16.6 23.0 20.6 30.2 25.4 17.0 18.0 16.8 28.7 18.9 25.9 19.7 17.2 29.0 21.6 17.4 22.2 19.4 23.6 34.5 30.9 20.1 12.4 36.8 22.6 15.7 10.6 27.1 21.1 21.2 41.5 23.4 19.1 19.1 18.2 9.8 31.6 6.7 21.7 22.5 22.4 14.7 26.6 15.6 24.8 29.6 19.7 15.9 21.9 23.5 29.7 18.0 17.1 19.8 30.7 25.7 30.0 23.7 11.5 18.8 16.1 29.5 12.0 21.9 15.8 10.0 13.3 15.2 13.8 12.7 6.8 19.1 16.9 11.7 50.3 10.7 15.2 19.8 15.3 5.2 14.3 21.3 24.4 17.1 13.8 10.5 14.1 16.6 15.1 17.8 TRIM24 "hTIF1, RNF82, TIF1, Tif1a" ENSG00000122779 "Tripartite motif containing 24" O15164 7 138460334-138589993 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation, Ubl conjugation pathway" "DNA-binding, Repressor, Transferase" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "AF22: 42.7;HMC-1: 57.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA043495, HPA061717" Approved Enhanced Nucleoplasm "Intracellular and membrane" Nucleoplasm "HPA043495: AB_10962915, HPA061717: AB_2684592" "unprognostic (2.40e-1)" "unprognostic (9.52e-3)" "unprognostic (2.23e-1)" "unprognostic (3.96e-2)" "unprognostic (1.20e-1)" "unprognostic (1.15e-1)" "prognostic unfavourable (9.94e-4)" "prognostic favourable (6.57e-4)" "unprognostic (4.01e-2)" "unprognostic (8.93e-2)" "unprognostic (2.53e-1)" "unprognostic (2.02e-1)" "unprognostic (4.62e-2)" "unprognostic (1.62e-1)" "unprognostic (2.25e-2)" "unprognostic (5.54e-2)" "unprognostic (6.34e-2)" 10.3 31.4 10.4 11.2 10.6 8.8 8.8 8.5 10.7 9.4 9.2 14.6 5.7 9.4 9.0 8.5 11.3 7.0 10.3 9.7 8.4 8.5 9.6 21.5 10.7 8.5 10.5 8.0 29.9 11.6 20.7 7.3 13.5 8.4 13.6 9.1 7.5 10.1 7.1 16.0 9.8 14.1 9.4 8.0 8.5 10.8 24.1 11.3 34.8 8.8 9.2 8.9 11.3 11.2 1.3 1.9 3.7 2.5 2.2 2.7 0.8 4.1 5.1 42.7 12.3 2.9 2.6 3.3 3.9 4.1 3.0 3.0 8.1 3.9 8.0 3.9 3.7 2.2 20.7 3.2 4.5 6.1 5.1 17.7 3.8 24.9 3.9 13.7 57.8 2.3 3.4 2.5 4.1 7.2 20.0 4.9 3.6 8.1 23.4 12.5 16.3 4.6 18.6 5.0 6.8 6.8 12.5 8.9 20.2 7.3 6.5 2.1 4.5 9.1 3.0 3.5 2.9 6.2 5.3 4.6 4.9 13.7 5.9 9.1 5.2 1.1 2.3 3.6 2.2 2.5 0.4 0.9 1.9 1.2 1.9 1.3 1.8 2.0 3.7 2.2 1.1 1.4 2.7 0.8 10.4 10.6 8.5 9.7 8.4 8.5 10.5 8.0 8.4 11.3 TRIM27 "RFP, RNF76" ENSG00000204713 "Tripartite motif containing 27" P14373 6 28903002-28923989 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation, Transport, Ubl conjugation pathway" "DNA-binding, Repressor, Transferase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA048684, HPA053408" Approved Approved Nucleoplasm,Nucleoli Nucleoli Nucleoplasm "HPA048684: , HPA053408: " "unprognostic (1.57e-1)" "unprognostic (1.48e-2)" "unprognostic (2.36e-1)" "unprognostic (1.14e-2)" "unprognostic (1.70e-2)" "unprognostic (2.56e-1)" "unprognostic (2.00e-3)" "unprognostic (1.17e-2)" "unprognostic (1.01e-2)" "unprognostic (1.12e-3)" "unprognostic (4.76e-3)" "unprognostic (1.16e-2)" "prognostic unfavourable (3.50e-6)" "unprognostic (1.27e-1)" "unprognostic (1.41e-1)" "unprognostic (1.47e-1)" "prognostic favourable (2.71e-4)" 11.5 10.6 8.8 25.5 9.7 7.9 9.3 10.1 12.2 11.2 10.2 8.7 20.2 23.8 12.1 13.2 7.8 12.1 11.4 8.1 8.2 9.6 10.1 22.5 10.4 17.4 12.6 8.3 14.7 31.0 7.4 13.9 13.7 10.6 13.7 4.6 7.7 17.0 25.2 12.2 9.7 19.4 9.2 8.4 18.6 18.5 9.2 9.2 16.7 12.5 7.9 12.1 9.9 11.8 12.5 12.5 13.8 13.9 11.2 15.9 13.8 3.3 2.3 0.9 6.0 0.8 1.7 0.6 4.6 1.1 1.4 1.7 1.7 1.4 7.7 7.9 1.3 7.4 1.1 2.7 0.1 3.0 12.9 10.8 0.5 2.3 1.3 4.5 1.7 1.3 1.6 1.2 0.5 1.2 10.5 3.3 0.4 1.3 6.3 2.4 0.0 7.3 9.0 6.9 14.2 1.1 1.1 3.2 12.9 5.5 3.4 7.3 3.3 3.5 3.9 3.4 7.1 6.2 2.7 12.0 14.4 12.0 1.8 11.5 5.2 12.6 13.8 8.8 12.7 13.9 15.9 12.5 12.6 14.4 12.5 10.5 11.8 12.1 13.8 11.2 12.1 9.8 10.4 13.8 8.8 9.7 10.1 12.2 8.2 9.6 12.6 8.3 10.6 9.2 TRIM33 "FLJ11429, KIAA1113, PTC7, RFG7, TF1G, TIF1G, TIF1GAMMA, TIFGAMMA" ENSG00000197323 "Tripartite motif containing 33" Q9UPN9 1 114392777-114511160 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation, Ubl conjugation pathway" "DNA-binding, Repressor, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "MCF7: 48.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA004345 Supported Approved Nucleoplasm,Vesicles Vesicles Nucleoplasm "HPA004345: AB_1858287" "unprognostic (8.90e-2)" "unprognostic (5.86e-2)" "prognostic favourable (6.20e-4)" "unprognostic (1.09e-2)" "unprognostic (8.42e-3)" "prognostic favourable (8.93e-4)" "unprognostic (1.34e-2)" "unprognostic (1.83e-1)" "unprognostic (6.75e-2)" "unprognostic (4.58e-2)" "unprognostic (2.14e-1)" "unprognostic (1.08e-1)" "unprognostic (2.27e-2)" "unprognostic (4.84e-2)" "unprognostic (1.99e-1)" "unprognostic (1.40e-1)" "unprognostic (1.68e-1)" 15.2 12.8 16.9 18.4 19.9 27.1 17.1 38.3 21.8 16.9 14.3 11.0 21.9 10.9 19.8 38.3 16.4 15.0 15.6 10.8 18.1 12.5 17.3 15.0 14.3 15.2 12.1 18.0 19.8 15.7 21.8 22.4 27.2 15.2 16.5 13.0 10.7 16.4 19.1 14.3 19.5 14.8 20.2 12.9 14.9 14.1 29.0 16.3 20.5 17.9 9.8 16.6 17.9 28.7 3.4 4.0 12.2 2.8 4.7 4.4 1.0 12.9 7.0 13.2 9.9 5.6 5.9 22.5 6.6 7.0 9.2 9.8 7.9 5.5 13.8 6.8 7.7 7.5 12.0 7.7 12.7 10.4 7.1 13.3 9.2 9.1 6.2 16.8 11.1 5.6 5.7 10.9 11.2 7.7 16.6 9.8 8.8 48.5 16.9 7.1 17.8 7.1 14.6 20.2 4.5 6.6 20.4 9.2 9.7 12.5 15.1 11.9 6.9 9.2 8.6 6.4 10.5 14.8 9.2 6.9 6.4 14.5 9.1 9.8 18.2 12.2 1.6 7.4 3.5 1.8 3.1 3.4 3.7 3.7 2.0 2.2 2.9 4.4 4.8 4.7 2.8 4.0 2.0 1.0 16.9 19.9 38.3 21.8 18.1 12.5 12.1 18.0 15.2 16.3 TRIP11 "CEV14, GMAP-210, GMAP210, Trip230" ENSG00000100815 "Thyroid hormone receptor interactor 11" Q15643 14 91965991-92040896 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Disease mutation, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002570, HPA070684" Supported Enhanced "Nucleoplasm,Golgi apparatus" "Golgi apparatus" Nucleoplasm "HPA002570: AB_1078995, HPA070684: " "unprognostic (1.65e-1)" "unprognostic (2.81e-2)" "unprognostic (7.14e-2)" "unprognostic (1.12e-1)" "unprognostic (6.89e-2)" "unprognostic (1.39e-1)" "unprognostic (3.49e-3)" "unprognostic (1.60e-1)" "unprognostic (1.46e-1)" "unprognostic (7.33e-3)" "unprognostic (2.04e-1)" "unprognostic (1.21e-1)" "prognostic favourable (1.78e-6)" "unprognostic (1.78e-1)" "unprognostic (5.08e-1)" "unprognostic (7.74e-2)" "unprognostic (5.55e-2)" 13.0 15.0 10.5 10.8 12.5 7.7 12.1 18.5 14.1 17.4 13.0 8.8 15.2 11.1 13.3 12.7 14.7 11.4 11.2 12.9 9.2 6.7 15.5 16.1 10.6 9.4 12.2 11.1 16.0 27.1 27.1 34.9 24.4 15.2 14.5 11.0 9.4 15.1 15.3 24.0 12.4 15.9 11.2 10.7 15.2 16.2 14.0 13.5 16.4 18.4 11.1 11.9 15.8 12.5 20.0 12.7 17.0 13.0 12.1 14.1 3.9 12.4 12.6 8.2 8.6 14.5 22.5 12.5 19.8 15.2 9.8 11.3 7.6 20.3 8.7 14.6 17.4 16.4 10.8 9.6 21.5 13.2 3.3 9.8 11.4 7.2 11.1 11.5 9.8 8.6 11.8 17.3 14.9 15.6 6.4 10.1 15.3 17.4 6.5 2.8 3.7 9.0 8.1 15.7 4.3 8.8 20.4 6.0 5.4 16.0 9.4 6.1 20.5 5.8 20.6 11.4 8.1 11.9 8.9 9.0 13.8 7.8 13.4 6.5 14.3 8.2 8.8 17.0 13.3 8.0 12.8 11.8 14.1 12.1 6.9 20.0 13.5 14.1 8.7 12.1 13.0 12.7 12.2 3.9 10.5 12.5 18.5 14.1 9.2 6.7 12.2 11.1 15.2 13.5 USP6 "HRP1, Tre-2, TRE17, Tre2, TRESMCR" ENSG00000129204 "Ubiquitin specific peptidase 6" P35125 17 5116438-5175034 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Ubl conjugation pathway" "Calmodulin-binding, Hydrolase, Protease, Thiol protease" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 9 "skeletal muscle: 18.2;testis: 29.0" "Low cell line specificity" "Detected in many" "Cancer enriched" "Detected in single" 14 "testis cancer: 2.8" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" HPA046969 Uncertain Vesicles Vesicles "HPA046969: " "unprognostic (3.89e-2)" "unprognostic (3.79e-3)" "unprognostic (2.50e-1)" "unprognostic (1.85e-1)" "unprognostic (9.32e-2)" "unprognostic (3.50e-3)" "unprognostic (1.29e-1)" "unprognostic (1.67e-2)" "unprognostic (3.45e-2)" "unprognostic (2.46e-2)" "unprognostic (7.91e-4)" "unprognostic (6.28e-3)" "unprognostic (3.24e-4)" "unprognostic (3.75e-2)" "unprognostic (3.13e-1)" "unprognostic (2.71e-1)" "unprognostic (7.09e-4)" 0.3 0.3 0.3 0.3 0.6 0.2 0.4 0.5 0.5 0.3 0.5 0.3 1.2 0.0 0.6 0.6 0.3 0.5 0.4 0.3 0.3 0.1 0.3 0.3 0.3 0.3 0.3 0.3 2.6 0.3 0.0 0.4 0.4 0.3 0.4 0.1 0.3 0.3 0.3 18.2 0.6 0.7 0.9 0.3 0.3 0.0 29.0 0.3 0.3 0.4 0.3 0.3 0.3 0.3 0.9 1.2 1.9 1.0 0.2 0.4 0.1 2.2 1.0 2.2 1.7 0.4 0.2 2.3 1.9 0.1 0.6 0.4 0.8 1.1 2.2 1.7 1.3 1.0 0.7 0.8 0.5 1.6 1.3 1.7 1.3 0.9 1.2 0.5 2.9 1.1 0.5 0.1 0.2 0.3 0.5 0.3 0.5 2.5 1.9 0.7 1.6 0.1 1.4 2.0 0.2 0.5 0.7 0.9 2.2 1.0 0.1 3.3 2.2 2.2 1.2 1.0 3.3 2.1 1.4 2.0 1.7 1.5 0.0 0.1 2.7 0.1 0.4 0.9 0.4 0.3 0.2 0.6 0.3 0.3 0.3 0.9 0.3 0.4 1.9 0.2 1.0 1.2 0.1 0.1 0.3 0.6 0.5 0.3 0.3 0.1 0.3 0.3 0.3 0.3 WDCP "C2orf44, FLJ21945" ENSG00000163026 "WD repeat and coiled coil containing" Q9H6R7 2 24029340-24049575 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA041054 Approved Approved Nucleoli,Cytosol Nucleoli Cytosol "HPA041054: AB_10796566" "unprognostic (1.07e-1)" "unprognostic (3.19e-2)" "unprognostic (3.36e-1)" "prognostic unfavourable (6.53e-4)" "unprognostic (1.32e-1)" "unprognostic (1.35e-1)" "prognostic unfavourable (5.14e-8)" "unprognostic (7.69e-2)" "unprognostic (9.01e-3)" "unprognostic (2.05e-1)" "unprognostic (1.07e-1)" "unprognostic (5.19e-2)" "unprognostic (2.76e-3)" "unprognostic (1.85e-1)" "unprognostic (1.97e-1)" "unprognostic (7.76e-2)" "unprognostic (3.00e-1)" 11.7 9.6 8.3 7.6 9.4 2.4 9.2 14.6 9.8 9.6 9.3 11.5 8.4 5.3 10.7 8.0 7.4 7.2 5.6 6.8 7.1 6.9 7.5 8.9 5.4 12.4 8.3 4.8 11.6 7.7 11.2 9.4 8.5 8.7 8.7 6.2 7.8 7.1 12.9 13.8 5.9 7.5 7.4 8.0 9.4 7.0 12.5 9.2 17.9 8.9 5.5 13.7 9.4 6.4 4.9 4.3 1.5 3.8 5.0 7.8 4.2 7.2 11.1 12.3 8.5 8.5 6.8 4.4 8.8 4.7 9.2 8.8 10.1 3.3 19.0 3.8 4.5 5.3 17.4 6.0 9.6 11.4 10.0 11.5 5.5 10.5 5.8 10.5 8.0 4.0 4.7 9.4 4.7 8.7 16.0 5.3 9.6 3.3 13.7 6.3 14.8 8.7 15.1 20.8 7.6 4.3 3.6 9.5 13.1 4.3 4.2 5.4 3.3 4.7 8.2 7.4 8.2 4.4 8.0 8.7 10.9 26.8 4.8 11.3 5.7 0.0 2.4 1.5 7.5 3.8 7.8 4.9 5.0 5.5 4.3 4.7 6.8 7.5 0.7 5.0 2.6 1.6 7.1 4.2 8.3 9.4 14.6 9.8 7.1 6.9 8.3 4.8 8.7 9.2 WIF1 ENSG00000156076 "WNT inhibitory factor 1" Q9Y5W5 12 65050626-65121566 "Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins" "Wnt signaling pathway" "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 35.2;lung: 67.7;retina: 29.6" "Cell line enhanced" "Detected in some" "HEK 293: 5.2;LHCN-M2: 2.4;NTERA-2: 6.8;SCLC-21H: 1.5" "Cancer enhanced" "Detected in many" "endometrial cancer: 16.9" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in some" "Secreted to extracellular matrix" "unprognostic (5.96e-3)" "unprognostic (2.00e-1)" "unprognostic (4.29e-3)" "unprognostic (3.26e-3)" "unprognostic (9.66e-2)" "unprognostic (1.91e-1)" "unprognostic (1.26e-2)" "unprognostic (7.94e-2)" "unprognostic (2.44e-1)" "unprognostic (2.92e-2)" "unprognostic (3.17e-1)" "unprognostic (2.30e-5)" "unprognostic (3.02e-1)" "unprognostic (2.02e-1)" "unprognostic (1.22e-1)" "unprognostic (7.24e-3)" 0.9 2.4 23.3 0.8 35.2 0.6 14.2 1.6 20.6 1.6 0.8 1.0 1.9 0.6 5.5 14.5 3.4 1.5 0.6 0.7 10.4 3.9 1.0 0.6 67.7 0.7 1.4 8.2 0.8 0.8 0.6 21.4 0.6 0.4 9.5 0.8 29.6 24.8 2.3 0.6 4.2 1.8 1.2 0.7 0.7 0.9 1.0 3.5 0.0 0.6 3.6 0.6 0.8 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 5.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 2.4 0.1 0.0 0.9 6.8 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.2 0.0 0.4 0.0 0.2 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 23.3 35.2 1.6 20.6 10.4 3.9 1.4 8.2 0.4 3.5 WT1 "AWT1, GUD, NPHS4, WAGR, WIT-2" ENSG00000184937 "Wilms tumor 1" P19544 11 32387775-32435630 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, RNA-binding" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "endometrium 1: 69.0;fallopian tube: 34.5;ovary: 53.4" "Cell line enhanced" "Detected in some" "HEL: 13.2;HMC-1: 17.0;K-562: 11.9;NB-4: 31.9;THP-1: 15.3" "Cancer enriched" "Detected in many" 14 "ovarian cancer: 55.2" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Region enhanced" "Detected in single" "pons and medulla: 0.5" "Low region specificity" "Detected in single" "CAB000327, HPA035717, HPA053848" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB000327: AB_2304486, HPA035717: , HPA053848: " "unprognostic (3.09e-3)" "unprognostic (9.97e-4)" "unprognostic (3.32e-1)" "unprognostic (8.24e-3)" "unprognostic (5.20e-2)" "unprognostic (1.98e-3)" "unprognostic (2.94e-2)" "unprognostic (1.59e-2)" "unprognostic (1.23e-2)" "unprognostic (4.15e-2)" "unprognostic (1.86e-2)" "unprognostic (1.36e-1)" "unprognostic (1.31e-10)" "unprognostic (2.65e-3)" "unprognostic (1.87e-1)" "unprognostic (1.96e-3)" "unprognostic (1.30e-2)" 10.3 0.0 0.2 1.8 0.6 0.0 0.2 0.2 0.5 20.3 1.5 0.2 3.7 0.0 69.0 9.3 0.4 34.5 0.8 2.1 0.9 0.0 5.3 0.2 0.8 0.5 0.2 0.2 53.4 0.2 0.0 0.2 6.9 0.3 0.9 0.0 0.2 0.2 4.2 0.2 0.0 0.4 23.7 0.2 14.6 0.0 24.5 0.2 0.2 0.3 0.2 0.2 1.3 4.1 0.1 0.0 0.0 0.4 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.3 0.0 0.1 0.1 0.0 0.0 6.1 0.0 0.0 0.0 4.6 13.2 0.0 1.1 3.7 8.8 17.0 0.0 0.0 2.7 0.0 0.0 11.9 0.1 2.7 0.0 7.7 31.9 0.7 3.7 1.1 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 15.3 0.1 0.0 2.3 0.0 0.3 0.0 0.0 0.0 0.1 2.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.2 0.6 0.2 0.5 0.9 0.0 0.2 0.2 0.3 0.2 WWTR1 "DKFZp586I1419, TAZ" ENSG00000018408 "WW domain containing transcription regulator 1" Q9GZV5 3 149517235-149736714 "Cancer-related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" Activator "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "EFO-21: 59.8;SK-MEL-30: 41.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "gdT-cell: 2.6;memory CD8 T-cell: 2.8" "Lineage enriched" "Detected in single" 4 "T-cells: 2.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA007415, CAB017483, CAB068248" Enhanced Supported "Nucleoplasm,Nuclear bodies,Cytosol" "Nucleoplasm, Nuclear bodies" Cytosol "CAB017483: AB_2216639, CAB068248: , HPA007415: AB_1080602" "unprognostic (1.85e-2)" "unprognostic (2.24e-2)" "unprognostic (3.41e-3)" "unprognostic (1.33e-2)" "unprognostic (7.94e-2)" "unprognostic (1.37e-1)" "unprognostic (2.41e-2)" "unprognostic (2.22e-1)" "unprognostic (1.74e-2)" "unprognostic (2.34e-1)" "unprognostic (1.63e-2)" "unprognostic (3.32e-1)" "unprognostic (1.17e-3)" "unprognostic (2.76e-2)" "unprognostic (2.53e-1)" "unprognostic (3.98e-2)" "unprognostic (1.01e-3)" 25.1 9.9 9.3 16.0 18.6 0.2 20.4 7.7 10.5 27.2 38.5 18.4 15.0 5.6 27.2 17.6 41.2 16.4 25.8 20.6 14.7 9.0 31.0 13.1 29.8 6.2 15.2 5.6 30.9 21.7 10.4 8.5 29.0 20.7 34.6 9.1 29.4 15.8 22.4 12.1 13.4 11.7 81.5 25.8 13.8 20.8 12.0 16.4 0.7 18.2 13.2 7.1 68.4 31.0 0.2 0.1 0.6 0.1 0.1 2.8 0.4 16.5 19.7 10.5 13.9 12.5 22.4 11.0 9.6 14.1 4.4 4.6 11.0 14.0 0.0 59.8 10.8 9.8 6.8 7.0 4.3 4.6 5.2 0.0 5.1 9.1 7.1 0.0 0.0 11.8 1.8 15.2 6.6 33.9 0.0 0.0 15.1 2.2 0.0 0.0 2.4 24.9 0.0 14.0 0.1 37.2 2.4 0.0 0.1 6.3 4.5 41.3 7.6 0.3 27.6 8.6 4.1 6.9 18.8 0.1 0.1 0.2 18.4 0.0 21.8 0.4 0.1 0.1 2.6 0.0 0.0 0.0 0.3 2.8 0.0 0.2 0.1 1.3 0.6 0.1 0.0 0.1 1.9 0.4 9.3 18.6 7.7 10.5 14.7 9.0 15.2 5.6 20.7 16.4 YWHAE FLJ45465 ENSG00000108953 "Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon" P62258 17 1344272-1400378 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008445, CAB016200, CAB021109, CAB047350, HPA061603" Approved Supported Nucleoplasm,Nucleoli,Cytosol 160000000 Cytosol "Nucleoplasm, Nucleoli" "CAB016200: AB_626619, CAB021109: AB_10060396, CAB047350: , HPA008445: AB_1844336, HPA061603: " "unprognostic (1.29e-1)" "unprognostic (1.50e-1)" "unprognostic (3.99e-2)" "prognostic favourable (6.48e-6)" "unprognostic (1.59e-1)" "unprognostic (2.91e-2)" "unprognostic (2.73e-2)" "unprognostic (4.77e-3)" "unprognostic (4.53e-2)" "unprognostic (5.14e-2)" "unprognostic (1.59e-1)" "unprognostic (2.73e-1)" "unprognostic (1.92e-3)" "unprognostic (8.33e-2)" "unprognostic (2.57e-1)" "unprognostic (3.24e-2)" "unprognostic (8.94e-2)" 55.2 54.3 107.5 35.3 87.1 32.7 37.3 71.5 118.4 28.4 40.2 60.9 23.8 40.2 35.9 54.1 43.1 44.2 23.4 57.7 92.3 81.9 64.5 50.9 32.8 25.4 94.1 77.9 40.2 40.2 41.0 37.9 45.1 73.7 35.0 42.5 27.9 42.4 27.7 135.9 36.8 36.2 32.2 101.1 26.2 38.5 46.0 53.6 30.9 47.5 36.5 37.2 31.6 32.1 19.2 41.5 17.2 36.2 15.0 23.3 31.5 77.8 58.2 70.5 59.3 31.2 36.1 67.8 50.4 29.7 45.0 34.9 104.0 32.0 52.9 59.2 41.7 54.1 59.7 50.9 63.8 36.5 111.3 36.9 48.6 44.5 37.3 35.3 37.8 32.7 37.6 45.0 69.0 54.1 42.3 38.2 57.8 37.9 46.7 28.2 64.6 37.8 56.8 33.3 37.5 45.8 45.1 39.3 59.7 60.6 24.9 39.4 47.2 32.7 51.1 43.7 37.1 55.1 88.9 24.0 44.3 44.4 52.4 42.3 63.1 17.2 31.8 8.6 12.4 36.2 15.6 19.2 18.7 13.9 41.5 16.1 17.0 14.3 10.8 15.0 30.9 28.8 23.3 31.5 107.5 87.1 71.5 90.2 92.3 81.9 94.1 77.9 73.7 53.6 ZBTB16 "PLZF, ZNF145" ENSG00000109906 "Zinc finger and BTB domain containing 16" Q05516 11 114059593-114250676 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation, Ubl conjugation pathway" "DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Mental retardation, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in some" "ASC diff: 29.9;ASC TERT1: 17.3;HEL: 17.8;HHSteC: 12.9;HSkMC: 13.8;hTCEpi: 12.8;hTERT-HME1: 11.2" "Cancer enhanced" "Detected in many" "prostate cancer: 5.2" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "gdT-cell: 13.7;MAIT T-cell: 23.5" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001499, CAB004540" Uncertain "CAB004540: AB_2218941, HPA001499: AB_1079640" "unprognostic (2.21e-1)" "unprognostic (2.17e-1)" "unprognostic (7.30e-2)" "unprognostic (1.18e-1)" "unprognostic (2.53e-1)" "unprognostic (3.05e-1)" "unprognostic (1.25e-2)" "unprognostic (1.40e-1)" "unprognostic (1.09e-1)" "unprognostic (8.79e-4)" "unprognostic (1.68e-1)" "unprognostic (1.18e-1)" "prognostic favourable (2.21e-4)" "unprognostic (2.57e-3)" "unprognostic (2.67e-1)" "unprognostic (1.00e-1)" "unprognostic (5.90e-2)" 38.0 16.0 10.0 6.3 14.6 6.3 20.5 18.0 22.8 18.7 14.9 6.7 15.7 1.8 19.6 8.5 24.0 17.3 11.8 25.5 11.8 4.5 8.3 9.3 17.3 6.2 16.1 8.9 41.6 51.5 14.5 9.5 8.3 12.6 10.0 3.0 7.8 10.4 15.1 58.8 17.5 10.4 15.1 10.8 11.1 12.8 4.6 14.2 0.0 24.1 10.9 2.5 21.9 27.5 6.9 0.0 0.6 2.4 5.5 23.5 2.7 0.0 0.0 6.1 0.0 29.9 17.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.2 17.8 0.0 0.0 12.9 0.3 0.2 13.8 12.8 0.0 11.2 2.1 0.0 0.0 0.1 0.0 1.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 4.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 2.4 0.6 13.7 0.6 23.5 0.1 0.6 2.0 0.0 6.9 0.8 0.4 0.2 5.5 0.5 0.0 0.2 2.7 10.0 14.6 18.0 22.8 11.8 4.5 16.1 8.9 12.6 14.2 ZMYM2 "FIM, MYM, RAMP, ZNF198" ENSG00000121741 "Zinc finger MYM-type containing 2" Q9UBW7 13 19958670-20091829 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA031765 Approved Approved "Nucleoplasm,Endoplasmic reticulum" "Nucleoplasm, Endoplasmic reticulum" "HPA031765: AB_10601927" "unprognostic (2.96e-1)" "unprognostic (3.42e-3)" "unprognostic (1.85e-1)" "unprognostic (1.69e-1)" "unprognostic (7.71e-2)" "unprognostic (2.33e-1)" "unprognostic (2.66e-3)" "unprognostic (1.16e-1)" "unprognostic (6.78e-2)" "unprognostic (5.88e-2)" "unprognostic (4.60e-2)" "unprognostic (2.80e-2)" "unprognostic (6.65e-3)" "unprognostic (2.05e-1)" "unprognostic (8.74e-2)" "unprognostic (1.06e-1)" "prognostic favourable (6.07e-4)" 15.0 17.3 15.9 18.1 23.3 22.2 16.1 23.9 26.8 18.3 16.8 14.0 13.7 13.3 20.0 14.0 18.5 16.1 15.7 17.1 14.4 12.0 17.3 13.7 15.4 14.2 12.9 20.2 21.7 16.2 17.1 32.1 14.0 23.2 19.4 13.8 13.8 18.2 17.6 19.7 18.3 14.5 15.3 16.2 16.3 16.0 44.5 16.5 38.0 24.3 10.4 19.7 19.5 17.2 5.5 6.3 7.4 5.9 5.4 7.9 3.5 6.3 5.7 22.0 9.5 9.7 10.5 10.5 6.6 10.6 8.6 10.3 8.8 13.1 15.2 6.1 9.3 10.2 16.2 7.1 11.7 6.1 4.6 26.9 8.6 4.4 9.8 22.7 8.2 10.3 13.3 6.8 7.1 14.6 10.2 10.8 11.8 9.0 21.9 6.4 20.4 3.6 24.5 24.0 7.1 6.7 9.3 25.8 25.7 12.8 9.2 12.0 12.2 16.2 8.5 4.3 6.8 5.2 3.5 8.6 6.7 15.7 3.6 5.3 10.2 0.2 5.2 4.0 5.5 5.9 6.7 5.5 7.5 5.6 6.1 4.5 7.9 6.9 7.4 5.4 4.9 6.3 5.4 3.5 15.9 23.3 23.9 26.8 14.4 12.0 12.9 20.2 23.2 16.5 ZNF331 "RITA, ZNF361, ZNF463" ENSG00000130844 "Zinc finger protein 331" Q9NQX6 19 53520981-53580269 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "adrenal gland: 66.4;ovary: 86.4" "Cell line enhanced" "Detected in many" "HEK 293: 36.6;RT4: 28.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA063157 Approved Nucleoplasm Nucleoplasm "HPA063157: " "unprognostic (2.19e-1)" "unprognostic (1.79e-1)" "unprognostic (5.18e-2)" "unprognostic (1.55e-2)" "unprognostic (4.24e-1)" "unprognostic (8.16e-2)" "unprognostic (7.62e-3)" "unprognostic (3.25e-2)" "unprognostic (1.84e-2)" "unprognostic (4.40e-2)" "unprognostic (5.68e-3)" "unprognostic (2.69e-1)" "unprognostic (4.73e-2)" "prognostic unfavourable (4.79e-4)" "unprognostic (2.08e-1)" "prognostic unfavourable (7.43e-4)" "unprognostic (6.74e-2)" 19.1 66.4 6.8 9.0 8.2 18.6 10.5 11.4 9.5 9.4 5.3 8.4 8.9 2.1 9.5 11.6 4.9 19.5 23.8 15.5 5.1 7.7 6.6 6.1 15.6 4.0 6.8 5.5 86.4 9.9 11.3 29.0 23.3 7.2 10.2 4.2 9.9 4.7 31.5 6.3 5.2 4.8 8.5 9.1 4.5 6.3 8.1 6.0 3.8 7.8 4.4 4.8 25.7 9.2 8.1 4.1 6.5 7.4 4.6 14.7 5.2 0.1 5.1 10.3 11.9 8.0 6.0 17.3 7.4 6.5 5.6 10.3 5.5 2.6 4.1 1.9 4.3 3.0 7.5 5.5 10.1 0.0 36.6 5.2 8.7 3.4 5.9 3.2 7.2 6.0 3.6 6.2 3.0 2.5 0.2 1.6 5.5 3.6 7.3 6.8 4.6 7.7 9.0 6.5 4.2 3.4 28.0 7.4 7.5 3.5 9.7 2.4 1.7 2.9 2.6 7.9 7.0 4.6 4.8 20.4 13.3 7.8 0.1 0.4 6.2 0.5 4.9 6.5 8.7 3.8 13.4 8.1 9.4 8.8 3.6 8.1 14.7 9.7 0.7 4.6 7.4 4.1 9.4 5.2 6.8 8.2 11.4 9.5 5.1 7.7 6.8 5.5 7.2 6.0 ZNF384 "CAGH1A, CIZ, NMP4, NP, TNRC1" ENSG00000126746 "Zinc finger protein 384" Q8TF68 12 6666477-6689572 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA004051 Supported Approved Nucleoplasm Nucleoplasm "HPA004051: AB_1859228" "unprognostic (1.90e-1)" "unprognostic (5.11e-3)" "unprognostic (1.76e-1)" "unprognostic (6.16e-2)" "unprognostic (1.79e-1)" "unprognostic (3.04e-2)" "unprognostic (1.87e-2)" "unprognostic (9.94e-2)" "unprognostic (1.35e-2)" "unprognostic (2.57e-2)" "unprognostic (3.51e-2)" "unprognostic (4.25e-1)" "unprognostic (1.24e-2)" "unprognostic (1.01e-1)" "unprognostic (2.22e-1)" "unprognostic (2.06e-1)" "unprognostic (8.13e-2)" 20.5 22.8 18.9 30.9 19.9 33.4 22.1 36.1 23.0 23.2 23.3 19.5 16.8 22.1 29.8 17.6 21.1 24.2 25.3 16.1 16.0 10.8 20.7 19.9 19.7 21.9 19.7 17.7 31.3 25.8 25.8 20.5 23.9 14.8 22.7 21.4 18.6 22.4 20.6 22.7 24.1 29.4 24.8 14.2 33.6 21.3 20.5 18.7 39.7 27.0 17.5 29.7 25.2 28.9 10.2 11.1 14.2 13.3 15.6 17.3 7.3 10.6 20.5 25.3 16.9 17.9 12.7 34.0 15.5 14.5 15.0 16.1 22.5 22.9 25.3 5.9 17.4 14.5 18.6 14.2 17.2 45.6 16.9 28.9 27.2 11.7 12.6 27.4 21.4 13.9 13.8 18.5 28.9 13.0 15.0 8.7 16.4 16.6 24.6 17.6 48.9 9.0 24.5 27.1 9.7 13.3 28.8 7.9 25.6 16.0 21.5 13.8 5.6 22.7 16.0 16.5 23.2 12.9 18.2 12.2 11.6 46.1 16.3 9.9 18.7 3.3 8.0 14.2 17.3 9.7 13.8 10.2 11.0 13.6 11.1 8.8 10.8 12.1 14.2 15.6 13.3 7.4 13.2 7.3 18.9 19.9 36.1 23.0 16.0 10.8 19.7 17.7 14.8 18.7 ZNF521 "EHZF, Evi3" ENSG00000198795 "Zinc finger protein 521" Q96K83 18 25061926-25352190 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding, Repressor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 69.1" "Cell line enhanced" "Detected in many" "AF22: 31.4;fHDF/TERT166: 14.7;HUVEC TERT2: 21.5;THP-1: 17.5" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in all" 6 "cerebellum: 69.1" "Group enriched" "Detected in some" 5 "basophil: 8.8;plasmacytoid DC: 9.8" "Group enriched" "Detected in many" 5 "dendritic cells: 9.8;granulocytes: 8.8" "Low region specificity" "Detected in all" "Region enriched" "Detected in all" 6 "cerebellum: 105.4" "HPA023056, HPA023849" Enhanced Approved Nucleoplasm Nucleoplasm "HPA023056: AB_1859315, HPA023849: AB_1859316" "unprognostic (8.80e-3)" "unprognostic (9.68e-2)" "unprognostic (2.05e-1)" "unprognostic (3.40e-2)" "unprognostic (5.43e-2)" "unprognostic (3.73e-3)" "unprognostic (1.52e-3)" "unprognostic (6.17e-2)" "unprognostic (1.72e-1)" "unprognostic (1.57e-1)" "unprognostic (8.18e-2)" "unprognostic (1.83e-1)" "unprognostic (1.19e-3)" "unprognostic (1.16e-3)" "unprognostic (2.43e-1)" "unprognostic (2.52e-3)" "unprognostic (7.82e-4)" 9.2 11.3 5.2 2.8 7.0 1.9 9.1 69.1 11.5 11.0 3.4 9.1 4.7 1.7 19.8 5.9 3.8 9.0 10.0 7.0 5.8 5.1 3.1 1.2 6.4 4.0 8.4 2.8 20.5 1.4 1.4 16.8 8.0 12.2 4.4 3.5 6.7 8.7 3.0 3.8 4.6 3.2 13.3 12.2 18.5 2.4 3.4 8.9 0.5 5.3 6.9 2.6 7.4 5.4 0.0 9.8 8.8 0.1 1.7 0.0 0.1 0.0 0.0 31.4 0.0 5.0 8.8 0.1 4.5 6.6 1.6 1.0 0.0 0.0 0.0 0.0 14.7 0.1 0.0 0.0 1.3 0.0 1.8 6.2 0.3 0.2 0.9 0.0 9.4 10.9 0.0 0.1 0.0 21.5 0.1 0.0 2.8 0.0 4.0 0.0 2.1 0.0 0.0 7.1 0.5 0.0 0.0 4.1 2.6 0.4 0.0 0.0 0.0 17.5 12.2 12.5 1.0 3.6 0.6 0.0 0.0 0.1 4.7 0.0 10.2 8.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.1 9.8 0.0 0.1 5.2 7.0 69.1 4.3 5.8 5.1 8.4 2.8 12.2 8.9